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Long-term glucocorticoid use leads to glucocorticoid-induced osteoporosis 
(GIOP) and fractures which require proper management.  Little is known about the 
“real-world,” long-term costs and effectiveness of anti-osteoporotic treatments.  A 
retrospective analysis of data from the 1996-2004 Medical Expenditure Panel Survey was 
conducted to evaluate the “real-world” outcomes.  Markov modeling with Monte Carlo 
simulations was used to yield long-term estimates of these outcomes.   
A total of 5,461 subjects met the study criteria for long-term glucocorticoid users 
(LTGS, average prednisone-equivalent dose=11.0 mg/day, average length=237 days), 
which represents 2.3% of the non-institutional U.S. population.  The study subjects 
tended to be middle-aged (49.7 years old), female (61.4%) and white (86.2%).  Overall, 
 vii
22.4% of LTGS users reported use of any anti-osteoporotic agent.  Hormone 
replacement therapy (HRT) was the most frequently used in women followed by 
bisphosphonates, while bisphosphonates and calcitonin were used by men.  Analyses of 
variance indicated some significant differences in characteristics of LTGS users among 
treatment groups which suggest a selection bias.  Female LTGS users had higher 
prevalence rates (6.8%) of osteoporosis than males (1.0%), but the prevalence rates of 
osteoporotic fractures were similar (3.0%).  The logistic regression analyses indicated 
that the use of oral glucocorticoid tablets does not significantly change the odds of 
osteoporotic fractures in study subjects (relative risk (RR)=1.146, 95% confidence 
interval (CI) 0.901-1.458 for subjects in the WELL state; RR=0.55, 95% CI 0.188-1.621 
for subjects in the GIOP state; RR=1.241, 95% CI 0.532-2.893 for subjects in the GIFX 
state).   
The estimated 10-year and lifetime incremental cost per osteoporotic fracture 
avoided are $27,253-$35,692 (10-year) and $84,942-$91,075 (lifetime) in hypothetical 
female glucocorticoid users.  HRT is the most cost-effective option for hypothetical 
females except that calcitonin is preferred for 65-year-old females receiving lifetime 
treatments.  When HRT is excluded, calcitonin is the next most cost-effective option 
except that raloxifene is preferred for 30- and 50-year-old females receiving 10-year 
treatments.  Calcitonin is the most cost-effective option for male glucocorticoid users.  
Bisphosphonates are less cost-effective which may be due to selection bias.  
Anti-osteoporotic treatments are recommended for all long-term glucocorticoid users, but 
the preferred option depends on gender, age, length of treatments and budgets. 
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Because of significant anti-inflammatory and immunosuppressive properties, 
glucocorticoid steroids (GS) are widely used to treat various conditions (such as 
pulmonary disorders, rheumatic diseases, skin problems and organ transplantations), 
many of which are chronic and require prolonged therapy.  Patients with these chronic 
conditions are frequently prescribed glucocorticoid steroids for a long period of time.  
An important complication of long-term glucocorticoid treatment is the loss of bone 
mass.0F1  If this condition is not prevented or treated properly, long-term glucocorticoid 
users may develop glucocorticoid-induced osteoporosis (GIOP) with increased risks of 
osteoporotic fractures and mortality.1F2  Because some osteoporotic fractures are strongly 
associated with permanent disability and premature death, proper interventions are highly 
recommended for those receiving extended glucocorticoid therapy to avoid severe 
consequences.   
Currently available interventions include: (1) lifestyle modification (e.g., smoking 
cessation, reduced consumption of alcohol, sufficient nutrition for calcium from dairy 
products and other food, increased physical/weight-bearing exercise); (2) 
over-the-counter (OTC) medications (calcium and vitamin D supplements); and (3) 
prescribed medications (such as anti-resorptive agents and anabolic agents).2F3  Prescribed 
                                                 
1 Cushing, H. W. (1932). The basophile adenomas of the pituitary body and their clinical manifestations. 
Bulletin of the Johns Hopkins Hospital 50: 137-195.  
2 van Staa, T. P. et al. (2001). Public health impact of adverse bone effects of oral corticosteroids. British 
Journal of Clinical Pharmacology 51(6): 601-607.  
3 National Osteoporosis Foundation. (2003). Physician's guide to prevent and treatment of osteoporosis. 
National Osteoporosis Foundation; Washington, D.C. 37 pages. 
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medications are the main focus of this study.  These medications have demonstrated 
increased bone mineral density (BMD) and a decreased risk of osteoporotic fractures in 
randomized clinical trials (RCTs).3F4, 4F5  The findings of RCTs for calcium/vitamin D and 
prescribed medication will be discussed and summarized in Chapter Two.  Brief 
highlights are as follows.   
 
 OTC medications   
In many osteoporosis studies, calcium/vitamin D supplements were used as a 
baseline treatment for all study groups.  Because patients with bone loss are losing 
calcium, an intuitive approach is to provide calcium and vitamin D supplements.  There 
are many subtypes of vitamin D, among which vitamin D3 and its derivatives (e.g., 
alfacalcidol, calcitriol, cholescalciferol) have received much attention in studies related to 
glucocorticoid-induced osteoporosis.5F6, 6F7, 7F8, 8F9, 9F10  Combined use of calcium and vitamin 
D supplements has demonstrated evidence of slowing the rate of bone loss, but not to 
                                                 
4 American College of Rheumatology. (1996). Recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on osteoporosis 
guidelines. Arthritis and Rheumatism 39(11): 1791-1801. 
5 American College of Rheumatology. (2001). Recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee 
on glucocorticoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503. 
6 Ringe, J. D. et al. (2004). Superiority of alfacalcidol over plain vitamin D in the treatment of 
glucocorticoid-induced osteoporosis. Rheumatology International 24(2): 63-70.  
7 Barthel, H. R. & Vieth, R. (2004). Lack of generalizable evidence of the superiority of alfacalcidol over 
plain vitamin D in the treatment of glucocorticoid-induced osteoporosis: comment on the article by Ringe 
et al. Rheumatology International 24(4): 250-251.  
8 Gram, J. et al. (1998). Effects of short-term treatment with prednisolone and calcitriol on bone and 
mineral metabolism in normal men. Bone 23(3): 297-302.  
9 McDonald, C. F. et al. (2006). Calcitriol does not prevent bone loss in patients with asthma receiving 
corticosteroid therapy: a double-blind placebo-controlled trial. Osteoporosis international 17(10): 
1546-1551.  
10 de Nijs, R. N. J. et al. (2004). Prevention and treatment of glucocorticoid-induced osteoporosis with 
active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ 
transplantation studies. Osteoporosis International 15(8): 589-602. 
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reduce risks of some osteoporotic fractures.10F11, 11F12  A daily supplementation of 1,500 
milligrams (mg) of calcium and 400 International Units (IU) of vitamin D is 
recommended for glucocorticoid-induced osteoporosis.12F13   
 
 Prescribed medications   
Anti-resorptive agents include bisphosphonates, agents for replacement of 
gonadal sex hormones, selective estrogen receptor modulators (SERMs) and calcitonin.  
Bisphosphonates (e.g., alendronate and risedronate) show significant efficacy regarding 
the prevention and the treatment of glucocorticoid-induced osteoporosis and 
postmenopausal osteoporosis. 13F14, 14F15, 15F16, 16F17  Bisphosphonates increase bone density at 
most vulnerable sites of bone and reduce risks of osteoporotic fractures, so they are 
usually the first choice for preventing and treating all types of osteoporosis.  Hormone 
replacement therapy (HRT, e.g., estrogens and testosterone) shows a risk reduction of 
                                                 
11 Meunier, P. J. (1999). Calcium, vitamin D and vitamin K in the prevention of fractures due to 
osteoporosis. Osteoporosis International 9(suppl. 1): S48-S52.  
12 Porthouse, J. et al. (2005). Randomised controlled trial of calcium and supplementation with 
cholecalciferol (vitamin D3) for prevention of fractures in primary care. British Medical Journal 330(7498): 
1003-1008.  
13 American College of Rheumatology. (1996). Recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on osteoporosis 
guidelines. Arthritis and Rheumatism 39(11): 1791-1801. 
14 Saag, K. G. et al. (1998). Alendronate for the prevention and treatment of glucocorticoid-induced 
osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. New England Journal of 
Medicine 339(5): 292-299.  
15 Adachi, J. D. et al. (2001). Two-year effects of alendronate on bone mineral density and vertebral 
fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension 
trial. Arthritis and Rheumatism 44(1): 202-211.  
16 Lems, W. F. et al. (2006). Positive effect of alendronate on bone minieal density and makers of bone 
turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a 
randomized, double-blind, placebo-controlled trial. Osteoporosis International 17: 716-723. 
17 Reid, D. M. et al. (2000). Efficacy and safety of daily risedronate in the treatment of 
corticosteroid-induced osteoporosis in men and women: a randomized trial. Journal of Bone and Mineral 
Research 15(6): 1006-1013. 
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osteoporotic fractures and was once widely used among postmenopausal women. 17F18  
After the discovery of increased risks of cardiovascular diseases, thromboembolism and 
breast cancer since 2002, HRT is generally not recommended for osteoporosis anymore. 
18F
19, 19F20  Raloxifene which is the only SERM currently used for osteoporosis, decreases the 
risks of vertebral fractures and breast cancer, and could be used for osteoporosis in 
postmenopausal women. 20F 21   Calcitonin, which is a peptide derived from salmon 
proteins, moderately increases the values of BMD, but does not significantly reduce the 
risk of vertebral fractures. 21F22   Although calcitonin shows relatively weak efficacy, it 
still serves as the second-line agent for osteoporosis because of its pain management 
potential with vertebral fractures. 22F23, 23F24  Calcitonin is also frequently used when a patient 
with osteoporosis has a contraindication with bisphosphonates.24F25  Teriparatide, which is 
a human parathyroid segment (PTH 1-34), is an anabolic agent and is currently the only 
approved prescribed medicine which increases the process of bone formation.  
                                                 
18 Geusens, P. (2000). Hormonal replacement therapy in the prevention and treatment of 
glucocorticoid-induced osteoporosis. Clinical and Experimental Rheumatology 18(suppl. 21): S57-S59.  
19 Kleerekoper, M. (2002). Lessons from the skeleton: was the Women's Health Initiative (WHI) a 
primary prevention trial? Osteoporosis International 13(9): 685-687.  
20 Majumdar, S. R. et al. (2004). Promotion and prescribing of hormone therapy after report of harm by 
the Women's Health Initiative. Journal of the American Medical Association 292(16): 1983-1988.  
21 Seeman, E. et al. (2006). Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis 
International 17(2): 313-316.  
22 Healey, J. H. et al. (1996). A randomized controlled trial of salmon calcitonin to prevent bone loss in 
corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcified Tissue International 58(2): 
73-80.  
23 Coyle, D. et al. (2001). Cost effectiveness of nasal calcitonin in postmenopausal women: use of 
Cochrane collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 19(5): 
565-575.  
24 Knopp, J. et al. (2005). Calcitonin for treating acute pain of osteoporotic vertebral compression 
fractures: a systematic review of randomized, controlled trials. Osteoporosis International 16(10): 
1281-1290.  
25 American College of Rheumatology (ACR) (2001). Recommendations for the prevention and treatment 
of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc 
Committee on glucocoritcoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503.  
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Teriparatide has demonstrated risk reduction of both vertebral and non-vertebral fractures 
in two-year RCTs, 25F26, but the efficacy beyond two years is not established.  Among all of 
these agents, alendronate (Fosamax＠) and risedronate (Actonel＠) are the only prescribed 
medicines which were approved by the U.S. Food and Drug Administration (FDA) for 
the prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).  
Nevertheless, other anti-osteoporotic agents which were approved for other types of 
osteoporosis may still be used clinically for glucocorticoid-induced osteoporosis.   
 
 Guidelines for Glucocorticoid-Induced Osteoporosis 
There are three types of osteoporosis.  Postmenopausal osteoporosis (Type 1) is 
mostly due to hypogonadism.  Senile osteoporosis (Type 2), associated with decreased 
bone formation, occurs with an increased age.  Glucocorticoid-induced osteoporosis is 
the leading cause of secondary osteoporosis (Type 3), which refers to osteoporosis caused 
by or associated with diseases or pharmacotherapy.  The pathogenic mechanism of 
glucocorticoid-induced osteoporosis should not be confused with those of other types of 
osteoporosis. 26F27,  An agent that is good for treating one type of osteoporosis may not 
have the same efficacy for treating glucocorticoid-induced osteoporosis.   
In the past decade, glucocorticoid-induced osteoporosis has been receiving more 
attention globally.  Since 1996, many guidelines or consensus reports have been 
developed for glucocorticoid-induced osteoporosis.  The American College of 
Rheumatology Ad Hoc Committee on glucocoritcoid-induced osteoporosis and the 
                                                 
26 Lane, N. E. et al. (2000). Bone mass continues to increase at the hip after parathyroid hormone 
treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled 
clinical trial. Journal of Bone and Mineral Research 15(5): 944-951.  
27 Canalis, E. (2003). Mechanisms of glucocorticoid-induced osteoporosis. Current Opinion in 
Rheumatology 15(4): 454-457.  
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American Medical Association (AMA) provided recommendations to physicians in the 
United States.27F28, 28F29, 29F30  It is suggested that patients receiving long-term glucocorticoid 
therapy (≧ 5 mg/day, ≧ three months) modify lifestyle, initiate weight-bearing 
physical exercise, measure bone mineral density (BMD) at lumbar spine and/or hip every 
one year or as frequent as six months, and should be provided supplementation with 
calcium and vitamin D (plain or activated form) at a dosage of 800 IU/day.  
Bisphosphonates should be prescribed in all men and postmenopausal women when 
BMD is below normal (e.g., T-score < -1), and calcitonin should be considered as a 
second-line agent if patients do not tolerate or have contraindication to bisphosphonate 
therapy.  However, it was emphasized that these recommendations are not mandated, 
and that final decisions on management of glucocorticoid-induced osteoporosis should 
consider patients’ individual needs.  
A similar guideline published in 2003 was specifically designed for American 
veterans.30F31  Weight-bearing exercise, prevention of falls and calcium plus vitamin D 
therapy are recommended to all patients receiving glucocorticoid therapy for at least three 
months, followed by careful monitoring of urinary calcium.  Bisphosphonates are 
recommended to patients with prior fractures and to those receiving ≧ 5 mg/day of 
prednisone with abnormal BMD.  Hormone replacement therapy or raloxifene is an 
                                                 
28 American College of Rheumatology (1996). Recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on osteoporosis 
guidelines. Arthritis and Rheumatism 39(11): 1791-1801.  
29 American College of Rheumatology (2001). Recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee 
on glucocoritcoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503.  
30 American Medical Association (1999). Managing osteoporosis. Part 2: glucocorticoid-induced 
osteoporosis-AMA continuing medical education program for primary care physicians; 23 pages.  
31 Adler, R. A. & Hochberg, M. C. (2003). Suggested guidelines for evaluation and treatment of 
glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Archives of Internal Medicine 
163(21): 2619-2624.  
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alternative for postmenopausal women.  If gonadal status is low, estrogen or 
testosterone replacement therapy is an alternative for premenopausal women and men.  
In 1998, a management algorithm for glucocorticoid-induced osteoporosis was 
published by a consensus group in the United Kingdom.31F32  This UK consensus report 
suggested that oral glucocorticoid users receiving 7.5 mg/day for at least six months 
incorporate lifestyle modifications, take calcium and vitamin D supplementation if 
deficient in the normal diet, discuss glucocorticoid regimens and alternative with 
physicians, and measure BMD if available.  Diagnostic tests and assessment of 
hypogonadism should be performed if an abnormal BMD (T-score < -1.5) is found.  
Hormone replacement therapy (HRT) should be used for all postmenopausal women, and 
bisphosphonates are the first-line treatment in men and for women who are unwilling to 
take HRT.  Assessment of response to treatments should be followed after one year, and 
treatments should be adjusted accordingly.  It should be noted that the management 
algorithm has not been evaluated by formal economic modeling nor has the diagnostic 
assessment, so future pharmacoeconomic research is needed.   
Another consensus report on prevention of glucocorticoid-induced osteoporosis 
was provided by the Dutch Society for Rheumatology.32F 33  The main difference in 
diagnostic and therapeutic steps from U.S. and U.K. recommendations is that 
bisphosphonates should be provided “immediately in patients at high risk” (e.g., all 
patient receiving ≧ 15 mg/day of glucocorticoids or prevalence fracture or 
postmenopausal women and elderly men receciving ≧ 7.5 mg of glucocorticoids).  In 
2004, the Japanese Society for Bone and Mineral Reseach also proposed a guideline for 
                                                 
32 Eastell, R. et al. (1998). A UK consensus group on management of glucocorticoid-induced 
osteoporosis: an update. Journal of Internal Medicine 244(4): 271-292.  
33 Geusens, P. et al. (2004). Prevention of glucocorticoid osteoporosis: a consensus document of the 
Dutch Society for Rheumatology. Annals of the Rheumatic Diseases 63(3): 324-325. 
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glucocorticoid-induced osteoporosis based on research conducted by subcommittee 
members.33F 34   Bisphosphonates (e.g., etidronate, alendronate and risedronate) are 
recommended as first-line treatment.  Specially, vitamin D3 and vitamin K2 are 
recommended as the second-line treatment because the latter was found to have a 
preventive effect on fractures in a longitudinal study in Japan.34F35   
Recently, a consensus guideline on prevention and treatment of 
glucocorticoid-induced osteoporosis was reported by the Belgian Bone Club.35F 36  It 
emphasized that all glucocorticoid users are threatened with osteoporosis, so all 
postmenopausal women as well as men and premenopausal women who expect to receive 
7.5 mg/day of prednisolone for at least three months should attempt to prevent 
glucocorticoid-induced osteoporosis.  Non-pharmacological interventions are 
recommended to all patients.  Supplementation with 500-1,000 mg of calcium and 
800-1,000 IU of vitamin D is the first-line treatment.  Bisphosphonates could be used as 
the second-line treatment to all patients at risk.  Other alternatives include hormone 
replacement therapy which could be used in young postmenopausal women on 
glucocorticoid therapy and men with low androgen levels, and calcitonin which could be 
considered in postmenopausal women.  No data were found to support the use of 
raloxifene and combination therapy other than calcium plus vitamin D in glucocorticoid 
users.   
                                                 
34 Soen, S. & Tanaka, Y. (2005). Glucocorticoid-induced osteoporosis: skeletal manifestations of 
glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its 
management. Modern Rheumatology 15(3): 163-168.  
35 Tanaka, I. & Oshima, H. (2003). A longitudinal study of diagnosis and treatment for 
glucocorticoid-induced osteoporosis. Osteoporosis Japan 11: 11-14.  
36 Devogelaer, J. P. et al. (2006). Evidence-based guidelines for the prevention and treatment of 
glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis 
International 17(1): 8-19.  
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Many papers and reviews have also discussed the importance of the prevention 
and treatment of glucocorticoid-induced osteoporosis.36F37, 37F38, 38F39, 39F40, 40F41, 41F42, 42F43, 43F44, 44F45, 45F46, 46F47, 47F48, 48F49, 
49F
50 , 50F 51 , 51F 52 , 52F 53 , 53F 54 , 54F 55 , 55F 56 , 56F 57 , 57F 58 , 58F 59 , 59F 60   These articles provided an overview of 
                                                 
37 Adachi, J. D. & Ioannidis, G. (2000). glucocorticoid-induced osteoporosis. Drug Development 
Research 49: 120-134.  
38 Bijlsma, J. W. J. (1997). Prevention of glucocorticoid induced osteoporosis. Annals of the Rheumatic 
Diseases 56(9): 507-509.  
39 Boulos, P. et al. (2000). Glucocorticoid-induced osteoporosis. Current Rheumatology Reports 2(1): 
53-61.  
40 Buckley, L. M. (1997). Importance of guidelines on glucocorticoid-induced osteoporosis: comment on 
the American College of Rheumatology recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis. Arthritis and Rheumatism 40(8): 1547.  
41 Clowes, J. A. et al. (2001). Glucocorticoid-induced osteoporosis. Current Opinion in Rheumatology 
13(4): 326-332.  
42 Eggelmeijer, F. (1998). Prevention and treatment of glucocorticoid-induced osteoporosis. Pharmacy 
World and Science 20(5): 193-197.  
43 Koval, P. G. et al. (2002). What are effective strategies for reducing the risk of steroid-induced 
osteoporosis? Journal of Family Practice 51(12): 1076.  
44 Lane, N. E. et al. (1995). Prevention and management of glucocorticoid-induced osteoporosis. Bulletin 
on the Rheumatic Diseases 44(5): 1-4.  
45 Lane, N. E. (2001). An update on glucocorticoid-induced osteoporosis. Rheumatic Diseases Clinics of 
North America 27(1): 235-253.  
46 Lips, P. (1999). Prevention of corticosteroid induced osteoporosis: should be easier if doctors follow the 
recent guidelines. British Medical Journal 318(7195): 1366-1367.  
47 Manelli, F. & Giustina, A. (2000). Glucocorticoid-induced osteoporosis. Trends in Endocrinology and 
Metabolism 11(3): 79-85. 
48 Meunier, P. J. (1993). Is steroid-induced osteoporosis preventable? New England Journal of Medicine 
328(24): 1781-1782.  
49 Niewoehner, C. B. & Niewoehner, D. E. (1987). Steroid-induced osteoporosis. Are your asthmatic 
patients at risk? Postgraduate Medicine 105(3): 79-83.  
50 O'Mahony, D. (1999). Prevention of corticosteroid-induced osteoporosis and fractures. Journal of 
Clinical Pharmacy and Therapeutics 24(2): 83-85.  
51 Peat, I. D. et al. (1995). Steroid induced osteoporosis: an opportunity for prevention? Annals of the 
Rheumatic Diseases 54(1): 66-68.  
52 Ramsey-Goldman, R. (2002). Missed opportunities in physician management of glucocorticoid-induced 
osteoporosis? Arthritis and Rheumatism 46(12): 3115-3120.  
53 Reid, I. R. (1997). Preventing glucocorticoid-induced osteoporosis. New England Journal of Medicine 
337(6): 419-421.  
54 Ringe, J. D. (1989). Glucocorticoid-induced osteoporosis. Clinical Rheumatology 8(suppl. 2): 109-115.  
55 Saag, K. G. (2003). Glucocorticoid-induced osteoporosis. Endocrinology and Metabolism Clinics of 
North America 32(1): 135-157.  
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glucocorticoid-induced osteoporosis.  These papers also discuss some pharmaceutical 
options based on evidence of protective effects on bone loss and fractures in the 
literature.  Bisphosphonates show promising protective effects on 
glucocorticoid-induced bone loss, but evidence of other pharmaceutical options do not 
support a similar degree of protective effects.  More research is needed.   
 
 Efficacy vs. Effectiveness 
Most of the guidelines, concensus reports and papers which were mentioned 
previously were based on evidence from randomized controlled trials (RCTs) in the 
literature.  In addition to gender and age, some common exclusion criteria of these 
RCTs are comorbidity, prior anti-osteoporotic treatments and use of glucocorticoid 
steroids, anticoagulants and anticonvulsants.  However, research has discovered that a 
significantly large percentage (>80%) of patients who were diagnosed with osteoporosis 
and being considered for RCTs for osteoporosis were excluded as a result of exclusion 
criteria.60F 61  From the perspective of managed care, study results from RCTs (i.e., 
efficacy) may not be applicable to these patients who often consume the largest portion of 
medical sources and encounter significant amounts of direct medical costs.  
Additionally, the sample size in most RCTs is too small to yield enough statistical power 
                                                                                                                                                 
56 Sambrook, P. N. (2005). How to prevent steroid induced osteoporosis. Annals of the Rheumatic 
Diseases 64(2): 176-178.  
57 Tamura, Y. et al. (2004). Glucocorticoid-induced osteoporosis. Biomedicine and Pharmacotherapy 
58(9): 500-504.  
58 Tan, T. T. et al. (1997). Steroid-induced osteoporosis-a cause for concern? Malaysian Journal of 
Pathology 19(1): 27-33.  
59 Weinstein, R. S. (2001). Glucocorticoid-induced osteoporosis. Reviews in Endocrine and Metabolic 
Disorders 2(1): 65-73.  
60 Ziegler, R. & Kasperk, C. (1998). Glucocorticoid-induced osteoporosis: prevention and treatment. 
Steroids 63(5-6): 344-348.   
61 Dowd, R. et al. (2000) Study subjects and ordinary patients. Osteoporosis International 11(6): 533-536. 
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for detection of significant differences in fracture rates between treatments.61F 62  
Therefore, efficacy from RCTs should be interpreted with caution in managed care 
settings. 
Effectiveness, on the other hand, reflects the “real-world” conditions and has 
received more and more attention from the perspective of managed care. 62F 63  
Effectiveness and “real-world” data can be obtained from existing databases and 
retrospective analyses. 63F64   Compared to RCTs, retrospective database analyses feature 
relatively inexpensive and assessable data, quick study results, more realistic time-frame, 
large sample sizes and inclusion of study subjects in multiple regions, health plans, 
treatment groups and physician specialties.64F 65 , 65F 66   However, retrospective database 
analyses also carry some limitations which include no control over variables of interest 
(such as calcium and vitamin D as over-the-counter medications), errors in data coding, 
problems of causal linkage and selection bias.66F67, 67F68   
It has been estimated that less than one percent of the general population used 
glucocorticoid steroids for at least three months.68F69, 69F70  The incidence of osteoporotic 
                                                 
62 Brixner, D. (2006). Assessment of the prevalence and costs of osteoporosis treatment options in a 
real-world setting. The American Journal of Managed Care, 12(7 Supple.): S191-S198. 
63 Arnold, R. G. et al. (1999). Panel 3: Methodological issues in conducting pharmacoeconomic 
evaluations-retrospective and claims database studies. Value in Health 2(2): 82-87. 
64 Yood, R. A. et al. (2001). Prevention of glucocorticoid-induced osteoporosis. Archive Internal 
Medicine 161: 1322-1327. 
65 Arnold, R. G. et al. (1999). Panel 3: Methodological issues in conducting pharmacoeconomic 
evaluations-retrospective and claims database studies. Value in Health 2(2): 82-87.  
66 Brixner, D. (2006). Assessment of the prevalence and costs of osteoporosis treatment options in a 
real-world setting. The American Journal of Managed Care, 12(7 Supple.): S191-S198. 
67 Ibid. 
68 Motheral, B et al. (2003) A checklist for retrospective database studies-report of the ISPOR Task Force 
on retrospective databases. Value in Health 6(2): 90-97.  
69 Gudbjornsson, B. et al. (2002). Prevalence of long term steroid treatment and the frequency of decision 
making to prevent steroid induced osteoporosis in daily clinical practice. Annals of the Rheumatic Diseases 
61(1): 32-36.  
70 van Staa, T. P. et al. (2000). Use of oral corticosteroids in the United Kingdom. QJM 93(2): 105-111.  
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fractures is generally too low to be detected in studies with a small sample size.70F71  
Research on glucocorticoid-induced osteoporosis should include study samples in 
thousands or tens of thousands in order to reach enough statistical power to detect 
significant differences in fracture rates between anti-osteoporotic treatments.  
Additionally, it has been noted that “fracture risk is not directly linked to BMD,”71F72 
which is often the primary outcome measured in most RCTs.  A large database should 
include records for osteoporotic fractures, with the ability to link medical records to 
pharmacy data for retrospective analyses.  Therefore, retrospective database analyses 
which yield costs and effectiveness data served as the best option for this study.   
 
1.2 STUDY GOALS AND RATIONALE 
This study aims to reach two goals.  The first study goal is to raise awareness of 
glucocorticoid-induced bone loss and related fractures in the U.S.  The study provides 
U.S.-based epidemiological estimates of osteoporosis and osteoporotic fractures.  The 
second study goal is to aid decision-making on use of preventive anti-osteoporotic 
treatments for glucocorticoid users, and to suggest preferable options.  This goal can be 
reached by providing “real-world” information on short-term and long-term costs and 
effectiveness of anti-osteoporotic treatments.   
When patients take glucocorticoid medications for a prolonged period of time 
(e.g., at a daily dosage of more than 5 mg for more than three months), an important 
potential side effect is bone mass loss, which increases risks of (glucocorticoid-induced) 
                                                 
71 Barrington, C. et al. (2006). Managing osteoporosis in a managed care population. The American 
Journal of Managed Care 12(7) S199-202.   
72 Ibid.   
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osteoporosis and osteoporotic fractures.72F73  If long-term glucocorticoid therapy is not 
discontinued and preventive interventions are not implemented, the risks of 
glucocorticoid-induced bone loss remains and could worsen as time passes.  
Glucocorticoid-induced bone loss should be properly managed.   
Many anti-osteoporotic agents have shown protective efficacy on bone loss in 
RCTs, and two bisphosphonates have been specifically approved by the FDA for the 
prevention and treatment of glucocorticoid-induced osteoporosis.  Studies and 
guidelines have suggested that long-term glucocorticoid users should receive preventive 
treatment for future bone loss and osteoporotic fractures.73F74  However, a relatively large 
portion of these users still do not receive any anti-osteoporotic agents. 74F75, 75F76, 76F77, 77F78  
Possible reasons may include, but are not limited to: (1) lack of significant awareness of 
risks of glucocorticoid-induced osteoporosis and osteoporotic fractures in the population 
at risk; (2) unconvincing evidence on long-term effectiveness of prevention or treatment 
of glucocorticoid-induced osteoporosis; and (3) concerns of unaffordable costs for 
anti-osteoporotic treatments.78F79   
Providing appropriate information on threats of glucocorticoid-induced bone loss 
and fractures is one approach to raise awareness in glucocorticoid users.  No 
                                                 
73 American College of Rheumatology (2001). Recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee 
on glucocoritcoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503. 
74 See references 26 to 34. 
75 Walsh, L. J. et al. (1996). Use of oral corticosteroids in the community and the prevention of secondary 
osteoporosis: a cross sectional study. British Medical Journal 313(7053): 344-346.  
76 van Staa, T. P. et al. (2000). Use of oral corticosteroids in the United Kingdom. QJM 93(2): 105-111.  
77 Aagaard, E. M. et al. (1999). Prevention of glucocorticoid-induced osteoporosis: provider practice at an 
urban county hospital. American Journal of Medicine 107(5): 456-460.  
78 Hart, S. R. & Green, B. (2002). Osteoporosis prophylaxis during corticosteroid treatment: failure to 
prescribe. Postgraduate Medical Journal 78(918): 242-243.  
79 Bijlsma, J. W. J. (1997). Prevention of glucocorticoid induced osteoporosis. Annals of the Rheumatic 
Diseases 56(9): 507-509.  
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information was found in the literature on prevalence and incidence of 
glucocorticoid-induced osteoporosis and related osteoporotic fractures in the U.S. 
population.  This study estimates the average annual prevalence and incidence of 
glucocorticoid-induced osteoporosis and related osteoporotic fractures in the U.S.  A 
cross-sectional analysis of nationally representative data provides current epidemiological 
estimates (i.e., prevalence and incidence of glucocorticoid-induced osteoporosis and 
osteoporotic fractures).   
Patients, clinicians and payers may have difficulty in deciding whether it is better 
to spend money in advance to use anti-osteoporotic agents for the prevention of 
glucocorticoid-induced bone loss and osteoporotic fractures for long-term glucocorticoid 
users, or just treat glucocorticoid-induced osteoporosis and osteoporotic fractures when 
they occur.  The simultaneous considerations of costs and effectiveness of 
anti-osteoporotic treatments are important in decisions regarding whether 
anti-osteoporosis medications should be recommended for long-term glucocorticoid 
users.  An evaluation technique called cost-effectiveness analysis (CEA) could be used 
to facilitate the decisions on which approach is preferable by considering both the clinical 
(e.g., effectiveness of fracture prevention) and economic outcomes (e.g., direct medical 
costs) together.  Glucocorticoid-induced osteoporosis occurs as early as three months 
after the initiation of glucocorticoid therapy, yet it progresses throughout an individual’s 
lifetime.  Therefore, both pieces of information regarding short-term and long-term 
clinical and economic evaluations of pharmacotherapy for the prevention and treatment 
of glucocorticoid-induced osteoporosis are equally important.   
Information on long-term costs and effectiveness of anti-osteoporosis treatments 
is of specific interest for these decisions, but the literature is incomplete.  Most 
cost-effectiveness studies targeting anti-osteoporotic agents in the literature were 
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designed for postmenopausal osteoporosis.  Three studies which evaluated 
cost-effectiveness of anti-osteoporotic treatments for osteoporosis and osteoporotic 
fractures in glucocorticoid users were identified in the literature.  However, the 
projected long-term estimates of cost-effectiveness of anti-osteoporotic agents were 
based on short-term efficacy data (“ideal” information) from the randomized clinical 
trials.  It has been generally accepted that effectiveness data (“real-world” information) 
are more meaningful to the actual management of glucocorticoid-induced bone loss than 
efficacy data.  Therefore, there is a need of “real-world” cost-effectiveness data of 
anti-osteoporotic treatments for long-term glucocorticoid users.   
Long-term “real-world” cost-effectiveness information on anti-osteoporotic 
agents can be obtained from studies or databases that follow glucocorticoid users 
longitudinally.  A longitudinal study on long-term cost-effectiveness of 
anti-osteoporotic treatments is currently not available in the literature, so long-term 
“real-world” cost-effectiveness estimates can be projected from short-term “real-world” 
data by using another technique called Markov modeling.  To our knowledge, there is 
no study in the literature that has used actual expenditures as inputs in a Markov model to 
estimate the long-term cost-effectiveness of medications for glucocorticoid-induced 
osteoporosis.   
This study generates both short-term and long-term estimates of average direct 
medical costs and effectiveness for prevention and treatment of osteoporosis and 
osteoporotic fractures in long-term glucocorticoid users.  The short-term data should 
also reflect “real-world” situations as closely as possible, so this study uses data from the 
Medical Expenditure Panel Survey (MEPS), which provides nationally representative 
information on medical utilization and related expenses.  The long-term estimates of 
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costs and effectiveness in glucocorticoid users who received any of anti-osteoporotic 
treatments will be compared with those who did not.   
In short, this study provides information on: (1) descriptive statistics of 
glucocorticoid and anti-osteoporotic medication use, and characteristics of glucocorticoid 
users in the U.S.; (2) nationally representative estimates of prevalence and incidence of 
osteoporosis and osteoporotic fractures in glucocorticoid users; (3) nationally 
representative estimates of average medical costs for evaluation of osteoporosis, 
treatment of osteoporotic fractures and treatments by using anti-osteoporotic agents; (4) 
Markov models for estimations of long-term costs and effectiveness; (5) long-term 
estimates of costs and effectiveness of anti-osteoporotic treatment; (6) a summary and 
useful plots of cost-effectiveness and acceptability curves for comparisons among 
anti-osteoporotic options in glucocorticoid users.  These study results should provide 
information which will facilitate clinical decisions for management of osteoporosis and 
osteoporotic fractures in glucocorticoid users in the U.S. 
 
1.3 ABOUT THIS DISSERTATION 
This dissertation consists of five chapters and appendices.  This chapter provides 
a brief overview for this study.  Chapter Two will elaborate on the existing evidence 
regarding glucocorticoid-induced osteoporosis and related osteoporotic fractures, and 
identify research questions from gaps or issues in the literature.  Chapter Three will 
describe the study methodology and highlight some concepts, theories and issues 
regarding cost-effectiveness analysis and Markov modeling.  Chapter Four will present 
study findings.  Chapter Five will discuss study findings, and make recommendations 
for the management of osteoporotic fractures in glucocorticoid users.  Appendices show 
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additional information on institutional review board’s letter of approval, and additional 
tables of incidence rates of osteoporosis and osteoporotic fractures by gender, type of 
treatment and age groups.  A bibliography for this study follows.  A brief vita about the 
author is provided at the end of this dissertation. 
 
1.4 SUMMARY OF CHAPTER ONE 
Long-term glucocorticoid users have a significantly increased risk of developing 
glucocorticoid-induced osteoporosis and fractures, but interventions to prevent these 
conditions have received little attention.  The lack of use of agents for proper 
management of glucocorticoid-induced osteoporosis and fractures may occur for many 
reasons, such as uncertainty of long-term effectiveness and financial burden of long-term 
costs of anti-osteoporotic treatments.  Both short-term and long-term “real-world” 
cost-effectiveness information regarding expenditures and effectiveness associated with 
anti-osteoporotic agents will help decision-makers determine whether it is beneficial to 
use anti-osteoporotic agents in advance for the prevention of glucocorticoid-induced 
osteoporosis and related fractures.  If the use of these preventive medications is 
warranted, the information may also help in choosing preferable options for long-term, 
high-risk glucocorticoid users.   
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CHAPTER TWO-LITERATURE REVIEW 
 
This chapter reviews what is known about glucocorticoid-induced osteoporosis 
(GIOP) and osteoporotic fractures in the literature, identifies possible research questions, 
and describes study objectives and hypotheses.  First, the possible pathogenic 
mechanism of glucocorticoid-induced osteoporosis is presented to help with the 
understanding of its clinical features and pharmacotherapeutic options.  The 
epidemiology of glucocorticoid-induced osteoporosis is then reviewed to demonstrate the 
magnitude of this problem.  Emphasis is placed on the clinical and economic outcomes 
of each therapeutic option.  Gaps in the literature and possible research questions are 
then identified.  Study objectives and hypotheses are listed at the end of this chapter. 
First of all, osteoporosis needs to be clearly defined.  Osteoporosis is “a disease 
characterized by low bone mass and structural deterioration of bone tissue, leading to 
bone fragility and an increased susceptibility to fractures, especially of the hip, spine, and 
wrist, although any bone can be affected.”79F80  In 1994, the World Health Organization 
(WHO) defined diagnostic criteria for osteoporosis on the basis of measurement of bone 
mineral density (BMD) and a comparison to the mean BMD value in young healthy 
adults of the same gender.80F81  Osteoporosis is defined as a BMD value less than 2.5 
standard deviations (SD) below the mean BMD in young healthy adults of the same 
gender (T-score < -2.5).  Similarly, osteopenia is defined as a BMD value between 2.5 
and 1 SD below the same reference BMD (-2.5 < T-score < -1).  Normal BMD is 
                                                 
80 National Osteoporosis Foundation (2004). America's bone health: the state of osteoporosis and low 
bone mass. 2002. National Osteoporosis Foundation. Washington, DC. 22 Pages. 
81 Kanis, J. A. (1994). Assessment of fracture risk and its application to screening for postmenopausal 
osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis International 4(6): 368-381.  
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defined as a BMD value greater than 1 SD below the reference BMD (T-score >-1).  
Most guidelines and consensus reports suggest using the same criteria for BMD 
measurements to define the abnormality due to the use of glucocorticoid steroids. 
 
2.1 MECHANISM OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 
The problem of glucocorticoid-associated bone loss was first noted over 70 years 
ago,81F82 yet the pathogenic mechanisms are not fully understood.  It is known that human 
bones periodically undergo a remodeling cycle, which involves coupled processes called 
bone resorption and bone formation.  During a normal bone remodeling cycle, the bone 
mass is resorbed in the first few weeks, which is called bone resorption.  Then, new 
bone mass is restored which lasts for a few months; this is called bone formation.  
Glucocorticoid steroids moderately increase the process of bone resorption and 
significantly decrease the process of bone formation.   
The evidence of glucocorticoid effects on bone resorption is controversial at the 
bio-molecular level because the roles and pathways of mediators are not fully established.  
Some common observations associated with glucocorticoid steroid use include inhibited 
pituitary gonadotropin production (e.g., decreased levels of estrogen and testosterone), 
stimulated osteoclastogenesis, an increased life-span of osteoclasts (cells responsible for 
bone resorption), reduced function and number of osteoblasts (bone forming cells), and 
decreased osteoblastic signals.  The effects of glucocorticoid steroids are more 
significant on bone formation than on bone resorption.  Evidence includes reduced 
numbers of both osteoblasts and osteoclasts, inhibition of osteoblastogenesis, low rates of 
mineral apposition and suppressed osteoblast matrix synthesis.  Clinically, excess 
                                                 
82 Cushing, H. W. (1932). The basophile adenomas of the pituitary body and their clinical manifestations. 
Bulletin of the Johns Hopkins Hospital 50: 137-195.  
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exposure to glucocorticoid steroids is associated with a decreased absorption of calcium 
in the gastrointestinal system, an increased excretion of urinary calcium, a decreased 
level of serum osteocalcin and alkaline phosphonates, and an increased serum level and 
activity of parathyroid hormone (PTH).82F83, 83F84, 84F85, 85F86, 86F87, 87F88  Accordingly, some treatments 
target problems associated with these clinical observations.  
It is important to know that pathogenic mechanisms of glucocorticoid-induced 
osteoporosis in men and women are similar.  It should be noted that mechanisms of 
glucocorticoid-induced osteoporosis actually differ from those mechanisms of 
postmenopausal osteoporosis, senile osteoporosis and other secondary osteoporosis.  
Studies or guidelines on populations with other types of osteoporosis do not directly 
apply to glucocorticoid users.88F89, 89F90  Therefore, this review primarily focuses on the 
studies for glucocorticoid users and glucocorticoid-induced osteoporosis.  However, for 
reference purposes, information on postmenopausal osteoporosis is provided if no 
information was found for glucocorticoid-induced osteoporosis.  The next section 
reviews some important GIOP-related clinical features. 
 
                                                 
83 Canalis, E. (1996). Clinical review 83: mechanisms of glucocorticoid action in bone: implications to 
glucocorticoid-induced osteoporosis. Journal of Clinical Endocrinology and Metabolism 81(10): 
3441-3447.  
84 Canalis, E. & Giustina, A. (2001). Glucocorticoid-induced osteoporosis: summary of a workshop. 
Journal of Clinical Endocrinology and Metabolism 86(12): 5681-5685.  
85 Canalis, E. & Delany, A. M. (2002). Mechanisms of glucocorticoid action in bone. Annals of the New 
York Academy of Sciences 966: 73-81.  
86 Canalis, E. (2003). Mechanisms of glucocorticoid-induced osteoporosis. Current Opinion in 
Rheumatology 15(4): 454-457.  
87 Jilka, R. L. (2003). Biology of the basic multicellular unit and the pathophysiology of osteoporosis. 
Medical and Pediatric Oncology 41: 182-185.  
88 Patschan, D. et al. (2001). Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29(6): 
498-505.  
89 Canalis, E. et al. (2004). Perspectives on glucocorticoid-induced osteoporosis. Bone 34(4): 593-598. . 
90 Clowes, J. A. et al. (2001). Glucocorticoid-induced osteoporosis. Current Opinion in Rheumatology 
13(4): 326-332.  
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2.2 CLINICAL FEATURES OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 
Risk factors for bone loss include daily and accumulated dose of oral 
glucocorticoid steroids, prior osteoporotic fractures, older age, vitamin D deficiency, 
malnutrition, minimal physical (especially weight-bearing) activity and underlying 
diseases.  Compared with the risk factors for other types of osteoporosis, glucocorticoid 
doses and the underlying diseases are two important factors in glucocorticoid-induced 
osteoporosis.  Therefore, they are reviewed as follows. 
 
2.2.1 Glucocorticoid Doses, Forms and Affected Sites 
Significant bone loss may be found as early as one month after the initiation of 
glucocorticoid therapy even at a relatively low daily dose (i.e., less than 5 mg per day) of 
prednisone or equivalents.90F91, 91F92, 92F93 The quick bone loss is probably due to the quickly 
increased bone resorption.  A dose-dependent relationship was found between 
glucocorticoid doses and bone loss; however, intermittent use of oral glucocorticoid 
steroids does not reduce the risk of bone loss.93F94  The cumulative dose is more important 
to bone loss than the average dose or duration of therapy.94F95  Some researchers argue that 
no dose of oral glucocorticoid steroids is safe, and recommend that interventions which 
prevent glucocorticoid-induced bone loss should be used for all glucocorticoid users at 
                                                 
91 Buckley, L. M. (2000). Clinical and diagnostic features of glucocorticoid-induced osteoporosis. 
Clinical and Experimental Dermatology 18(suppl. 21): S41-S43.  
92 Natsui, K. et al. (2006). High-dose glucocorticoid treatment induces rapid loss of trabecular bone 
mineral density and lean body mass. Osteoporosis International 17(1): 105-108.  
93 van Staa, T. P. et al. (2001). Public health impact of adverse bone effects of oral corticosteroids. British 
Journal of Clinical Pharmacology 51(6): 601-607.  
94 Canalis, E. (2003). Mechanisms of glucocorticoid-induced osteoporosis. Current Opinion in 
Rheumatology 15(4): 454-457.  
95 van Staa, T. P. et al. (2000). Oral corticosteroids and fracture risk: relationship to daily and cumulative 
doses. Rheumatology 39(12): 1383-1389.  
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any dose.95F96, 96F97, 97F98  Therefore, this study targets glucocorticoid user who receive at least 
three months of glucocorticoid therapy, with a additional consideration for high-risk users 
who receive a higher cumulative glucocorticoid dose. 
Different forms of glucocorticoid steroids have different impacts on bone loss.  
The oral form is the frequently used form which has a systemic effect.  Research 
compared the risk of osteoporotic fractures among different glucocorticoid forms, and 
showed that the use of oral glucocorticoid steroid has higher increased risks than other 
forms.98F99  The topical or inhaled forms of glucocorticoid steroids seem to have less effect 
on bone loss than the oral form.99F100 , 100F101, 101F102   
Glucocorticoid steroids affect bones at the spine, hip and wrist, but the risk of 
vertebral fractures is higher than that of non-vertebral fractures in glucocorticoid users.  
For example, a study indicated that about 72% of all vertebral fractures and 47% of all 
hip fractures were associated with use of glucocorticoid steroid.102F 103  
Glucocorticoid-induced bone loss occurs faster in trabecular bone (primarily in the spine 
and ribs) than in cortical bone (e.g., hip and long bones).  The rate of bone loss in 
trabecular bone in glucocorticoid users is about 10-20% in the first three to six months of 
glucocorticoid therapy and about two percent per year thereafter; bone loss at the femoral 
                                                 
96 Adachi, J. D. & Ioannidis, G. (2000). Glucocorticoid-induced osteoporosis. Drug Development 
Research 49: 120-134.  
97 Buckley, L. M. (2000). Clinical and diagnostic features of glucocorticoid-induced osteoporosis. 
Clinical and Experimental Dermatology 18(suppl. 21): S41-S43.  
98 Clowes, J. A. et al. (2001). Glucocorticoid-induced osteoporosis. Current Opinion in Rheumatology 
13(4): 326-332.  
99 Steinbuch, M. et al. (2004). Oral glucocorticoid use is associated with an increased risk of fracture. 
Osteoporosis International, 15(4): 323-328. 
100 Ibid. 
101 van Staa, T. P. et al. (2001). Use of inhaled corticosteroids and risk of fractures. Journal of Bone and 
Mineral Research 16(3): 581-588.  
102 Allen, D. B. (2002). Safety of inhaled corticosteroids in children. Pediatric Pulmonology 33: 208-220.  
103 van Staa, T. P. et al. (2001). Public health impact of adverse bone effects of oral corticosteroids. 
British Journal of Clinical Pharmacology 51(6): 601-607.  
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neck remains constant over time (2-3% per year).103F104  When glucocorticoid therapy is 
discontinued, the bone loss caused by using glucocorticoid steroids is unlikely to be 
completely recovered, but the rate of bone loss and the risk of osteoporotic fractures 
could be decreased.104F105   
 
2.2.2 Underlying Diseases in Glucocorticoid Users 
The underlying diseases, for which glucocorticoid steroids were prescribed, have 
a confounding effect on bone loss.  Both glucocorticoid use and the underlying 
condition(s) contribute to the bone loss, so the net effect of glucocorticoid use on bones is 
not easily singled out.105F 106   Therefore, direct comparisons among studies of 
glucocorticoid use with different diseases should be made with caution.  Two reviews 
summarized various risks of developing glucocorticoid-induced osteoporosis, vertebral 
fractures and hip fractures in glucocorticoid users with different underlying diseases106F107, 
107F
108  Musculoskeletal (e.g., 67.1% of subjects of all studies in van Staa’s review) and 
pulmonary diseases (15.7%) account for the major categories of underlying conditions in 
the samples of many studies.  They are followed by organ transplantations, 
gastrointestinal, renal and hepatic diseases.   
Glucocorticoid dosing and use patterns and the comorbidities of glucocorticoid 
users are factors to be considered in studies for glucocorticoid-induced osteoporosis.  
                                                 
104 Buckley, L. M. (2000). Clinical and diagnostic features of glucocorticoid-induced osteoporosis. 
Clinical and Experimental Dermatology 18(suppl. 21): S41-S43.  
105 Ibid. 
106 van Staa, T. P. et al. (2001). Public health impact of adverse bone effects of oral corticosteroids. 
British Journal of Clinical Pharmacology 51(6): 601-607. 
107 Boling, E. P. (2004). Secondary osteoporosis: underlying disease and the risk for 
glucocorticoid-induced osteoporosis. Clinical Therapeutics 26(1): 1-14.  
108 van Staa, T. P. et al. (2002). The epidemiology of corticosteroid-induced osteoporosis: a 
meta-analysis. Osteoporosis International 13(10): 777-787.  
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The next question is: Why should we care about glucocorticoid-induced osteoporosis?  
The following section highlights the magnitude of this condition. 
 
2.3 MAGNITUDE OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRACTURES 
Epidemiological data show the importance of the effects of glucocorticoid steroid 
use.  An important consequence of glucocorticoid-induced osteoporosis is the 
development of fractures, which result in increased risks of immobility or death.  In this 
section, a review of GIOP-related epidemiology, including incidence, fracture risks, 
disability and mortality, is provided.   
 
2.3.1 Prevalence 
There is no current estimate of the number of long-term glucocorticoid users in 
the United States.  However, recent estimates indicate that about 0.7% of the general 
population in Iceland took glucocorticoid steroids for at least three months, and that 0.9% 
of the general population in the U.K. had received oral glucocorticoid therapy.108F109, 109F110  If 
these percentages are projected to the population in the United States, the number of 
Americans receiving long-term glucocorticoid therapy could be 2.04 to 2.62 million, 
based on the total U.S. population of 290.85 million in 2003.   
Although the size of the vulnerable population seems relatively small, the 
magnitude of threats caused by glucocorticoid steroids is relatively large.  The most 
common threat after the development of bone loss is osteoporotic fracture.  In the 
                                                 
109 Gudbjornsson, B. et al. (2002). Prevalence of long term steroid treatment and the frequency of 
decision making to prevent steroid induced osteoporosis in daily clinical practice. Annals of the Rheumatic 
Diseases 61(1): 32-36.  
110 van Staa, T. P. et al. (2000). Use of oral corticosteroids in the United Kingdom. QJM 93(2): 105-111.  
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cross-sectional study in Iceland, 20% of long-term steroid users had osteoporosis or 
osteopenia (low bone mass), and 26% had fragility fractures.110F 111   In France, the 
incidence rates of all osteoporotic fractures during 2001 were 7,567 (95% CI 
7,519-7,615) and 2,312 (95% CI 2,283-2,341) per one million women and men aged over 
45 years, respectively.111F112  Based on these estimates, there would be approximately 0.41 
to 0.52 million Americans with GIOP and 0.53 to 0.68 million with osteoporotic 
fractures.  Next, the relative risks of osteoporotic fracture are reviewed.   
 
2.3.2 Fracture Risks 
Oral glucocorticoid use increases risks of osteoporotic fractures.  Many studies 
have estimated the relative risks (RRs) of various osteoporotic fractures in glucocorticoid 
users.  Steinbuch et al. evaluated fracture risks in patients exposed to oral glucocorticoid 
steroids by using an administrative claims database.112F113  The adjusted relative risks (RR) 
are 1.87 (95% CI 1.2-2.9) for hip fractures, 2.92 (95% CI 2.0-4.3) for vertebral fractures, 
1.03 (95% CI 0.8-1.4) for wrist/forearm fractures, 1.68 (95% CI 1.5-1.9) for 
non-vertebral fractures or 1.75 (95% CI 1.6-1.9) for any fractures.  The same study also 
reported the relative risks of any fracture by gender and age groups.  Overall, the 
relative risks of any fracture are 1.50 for men (95% CI 1.28-1.75) and 2.21 for women 
(95% CI 1.94-2.51).  The relative risks increase with increased age overall: 1.59 (95% 
CI 1.18-2.14) for subjects aged 18-30 years old, 1.86 (95% CI 1.51-2.28) for subjects 
                                                 
111 Gudbjornsson, B. et al. (2002). Prevalence of long term steroid treatment and the frequency of 
decision making to prevent steroid induced osteoporosis in daily clinical practice. Annals of the Rheumatic 
Diseases 61(1): 32-36.  
112 Maravic, M. et al. (2005). Incidence and cost of osteoporotic fractures in France during 2001. a 
methodological approach by the national hospital database. Osteoporosis International 16(12): 1475-1480.  
113 Steinbuch, M. et al. (2004). Oral glucocorticoid use is associated with an increased risk of fracture. 
Osteoporosis International, 15(4): 323-328. 
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aged 31-44 years old, 1.89 (95% CI 1.58-2.27) for subjects aged 45-54 years old and 2.02 
(95% CI 1.71-2.40) for subjects aged 55-64 years old.   
The increased relative risks are dependent on glucocorticoid doses.  A 
case-control study (cases=124,655 controls=373,962) was conducted in Denmark to 
investigate relative risks associated with use of glucocorticoid steroids in any formulation 
and administration.113F 114   With respect to oral glucocorticoid steroids, compared to 
background-matched non-glucocorticoid users, the overall adjusted odds ratios (OR) 
were 0.97 (95% CI 0.93-1.01) for subjects using less than 2.5 mg of prednisone (or its 
equivalents) per day, 1.15 (95% CI 1.09-1.22) for subjects using prednisone between 2.5 
mg and 7.49 mg per day, and 1.59 (95% CI 1.49-1.70) for subjects using more than 7.5 
mg of prednisone per day.  Among fractures at different sites, vertebral fractures have 
the highest increased OR (2.08, 95% CI 1.54-2.79 in subjects using more than 7.5 mg of 
prednisone, for example), followed by hip fractures (1.45 95% CI 1.25-1.69 in the 7.5 mg 
group) and wrist fractures (1.19 95% CI 0.99-1.43 in the 7.5 mg group).   
The study with the largest sample size included 244,235 oral glucocorticoid users 
and 244,235 controls from the U.K. General Practice Research Database (GPRD).114F115  
The relative risk of all fractures was 1.33 (95% confidence interval [CI] 1.29-1.38); 
specifically, the relative risks of vertebral, hip or wrist fractures were 2.60 (95% CI 
2.31-2.92), 1.61 (95% CI 1.47-1.76) and 1.09 (95% CI 1.01-1.17), respectively.  A 
meta-analysis was conducted to provide the pooled relative risks of osteoporotic fractures 
in a total of 66 studies involving 2,891 glucocorticoid users.115F116  The pooled RRs were 
                                                 
114 Vestergaard, P. et al. (2003). Corticosteroid use and risk of hip fracture: a population-based 
case-control study in Denmark. Journal of Internal Medcine 254: 486-493. 
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Mineral Research 15(6): 993-1000.  
116 van Staa, T. P. et al. (2002). The epidemiology of corticosteroid-induced osteoporosis: a 
meta-analysis. Osteoporosis International 13(10): 777-787. . 
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1.91 (95% CI 1.68-2.15) for all fractures, 2.86 (95% CI 2.56-3.16) at the spine, 2.01 
(95% CI 1.74-2.29) at hip and 1.13 (95% CI 0.66-1.59) at wrist.  The pooled RRs are 
larger than those in the U.K. study; this may have resulted from a smaller sample size in 
the meta-analyses, different sample characteristics, or different criteria for recruiting 
samples.  Compared to non-glucocorticoid users, glucocorticoid users have a two-to 
three-times higher risk of vertebral fractures, about two-times higher risk of hip fractures 
and an increased risk of other fractures.   
Kanis, Johnell and colleagues also reported 10-year probabilities of osteoporotic 
fractures in the Swedish population by age and BMD t-scores.116F117  The risks of fractures 
are different by gender, age, affected sites and BMD t-scores.  The probabilities of 
fractures in women are higher than those in men.  The average 10-year probabilities of 
any osteoporotic fracture ranging from 2.6% to 13.1% in men with increasing age from 
45 years old to 85 years old, and ranging from 3.8% to 27.0% in women with increasing 
age from 45 years old to 85 years old.  As expected, those with lower BMD t-scores 
have higher probabilities than those with higher BMD t-scores at the same gender and 
age.  Compared to subjects with normal BMD (t-score =0), subjects with BMD t-scores 
below 2.5 have approximately a three-fold increased risk of any fractures.   
Vertebral fractures are often under-diagnosed, unless significant clinical 
symptoms (e.g., back pain) are observed.117F 118   As mentioned in Section 2.2.1, 
glucocorticoid use induces more bone loss at trabecular bone than other sites within the 
first year of glucocorticoid therapy.  The actual risk of vertebral fractures in 
                                                 
117 Kanis, J. A. et al. (2001). Ten Year Probabilities of Osteoporotic Fractures According to BMD and 
Diagnostic Thresholds. Osteoporosis International, 989-995. 
118 Melton, L. J. III et al. (1993). Prevalence and incidence of vertebral deformities. Osteoporosis 
International 3(3): 113-119.  
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glucocorticoid users could be higher than reported values in the literature.  Similarly, it 
has been argued that the lifetime risks of hip fractures are also under-estimated.118F119   
 
2.3.3 Disability and Mortality 
Osteoporosis was found to be associated with disability.119F 120  The estimated 
global prevalence of hip fractures with disability was 4.48 million in 1990.120F121  Evidence 
shows that mortality rates after fractures were significantly higher in patients with 
osteoporosis than in the general population.   
A few studies were found to specifically address mortality in glucocorticoid users. 
However, various underlying diseases may have a confounding attribution to deaths 
caused by osteoporotic fractures, so it is difficult to compare mortality rates among 
glucocorticoid steroid users with different disease conditions.  Nevertheless, the trends 
of post-fracture mortality in other types of osteoporosis may, to some extent, help with 
projection of mortality due to glucocorticoid-induced osteoporosis.   
Glucocorticoid users have an increased risk of mortality compared to 
non-glucocorticoid users, and the increases are dose-dependent.  Schols et al. compared 
mortality rates among severe chronic pulmonary disease (COPD) patients who used oral 
glucocorticoid steroids to the rates of those who did not.121F 122   Compared to 
non-glucocorticoid users, the relative risks (RR) of mortality are: 2.279 (95% CI 
                                                 
119 Oden, A. et al. (1998). Lifetime risk of hip fracture is underestimated. Osteoporosis International 
8(6): 599-603.  
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121 Johnell, O. & Kanis, J. A. (2004). An estimate of the worldwide prevalence, mortality and disability 
associated with hip fracture. Osteoporosis International 15(11): 897-902.  
122 Schols, A. M. W. J. et al. (2001). Dose dependent increased mortality risk in COPD patients treated 
with oral glucocorticoids. European Respiratory Journal 17(3): 337-342. 
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0.902-5.762) for 5 mg oral steroid users, 2.340 (95% CI 1.235-4.435) for 10 mg oral 
steroid users and 4.031 (95% CI 1.994-8.149) for 15 mg oral steroid users.  Sihvonen et 
al. evaluated mortality in patients with rheumatoid arthritis who used low dose oral 
glucocorticoid steroids.122F123  Compared to non-glucocorticoid users, the RR of mortality 
in oral glucocorticoid users are 1.14 (95% CI 0.98-1.27, p=0.057) for one-year treatment, 
and 1.69 (95% CI 1.12-2.56, p=0.011) for treatment over 10 years.   
The mortality rates after osteoporotic fractures vary by affected sites.  The 
mortality of vertebral fractures is usually the highest, followed by hip and then wrist 
fractures.  For example, Johnell, Kanis and colleagues reported that the one-year 
survival rates after osteoporotic fractures in Sweden were 72% for vertebral fractures, 
78% for hip fractures and 94% for wrist fractures.123F124  Jonell’s study also indicated that 
mortality rates increase with increased age and number of years after fractures.  Another 
study showed that the relative risks of age-adjusted mortality following fractures were 
8.64 (95% CI 4.45-16.74) for vertebral fractures, 6.68 (95% CI 3.08-14.52) for hip 
fractures and 2.15 (95% CI 1.36-3.42) for all fractures.124F125   
The role of gender in mortality rates is unclear.  Both unadjusted and 
age-adjusted excess post-fracture mortality rates in men are usually higher than those in 
                                                 
123 Sihvohen, S. et al. (2006). Mortality in patients with rheumatoid arthritis treated with low-dose oral 
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women in two studies.125F126, 126F127  However, after adjustment for gender-specific population 
risks, Johnell et al. found no difference in mortality between males and females.127F128   
No study was found for investigation of differences in mortality rates between 
anti-osteoporotic treatments and non-treatment in glucocorticoid users.  However, Cree 
et al. conducted a study which investigated mortality and morbidity associated with 
osteoporotic treatments after hip fractures in the general population of Alberta.128F129  The 
study used administrative claims data, data for emergency room visits and the morbidity 
database in Alberta, and divided subjects into one of six treatment groups: hormones, 
bisphosphonates (including Didronel® and Fosamax®, but excluding Actonel®), 
calcitonin, vitamin D3, raloxifene and no treatment.  Similar incidence rates of hip 
fracture and rates of hospitalization were found between treated and untreated patients.  
Overall, subjects in the treatment groups had a significant lower mortality rate than 
untreated patients (OR=0.34 95% CI 0.17-0.70).   
Given the epidemiological data related to glucocorticoid-induced osteoporosis, 
the consequences of using glucocorticoid steroids are potentially severe.  Therefore, 
glucocorticoid users should receive proper intervention to manage bone loss and 
associated consequences.  In the next section, results from randomized clinical trials 
(RCTs) of each medication used for glucocorticoid-induced osteoporosis are reviewed.  
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2.4 CLINICAL EVALUATION OF PHARMACOTHERAPY 
Pharmaceutical agents frequently used for osteoporosis are often classified into 
seven groups: (1) calcium, vitamin D and their combinations; (2) bisphosphonates (BP); 
(3) hormone replacement therapy (HRT); (4) selective estrogen receptor modulators 
(SERMs); (5) calcitonin; (6) anabolic agents; and (7) combination therapy.  For each 
medication, the clinical outcomes in randomized clinical trials (RCTs) are highlighted.  
Clinical outcomes are limited to differences in bone mineral density (BMD) and fracture 
risks between study arms in glucocorticoid users in this review.   
 
2.4.1 Calcium, Vitamin D and Their Combinations  
Daily calcium plus vitamin D supplements are frequently recommended by many 
studies, guidelines or textbooks for people who are vulnerable to bone loss and 
osteoporotic fractures.  The calcium element in supplements is commonly provided in 
the carbonate or citrate form; some brand name products include Tums®, Caltrate®, 
Citracal® and Solgar®.  Vitamin D helps the body absorb calcium from the intestines 
and prevents its excessive excretion in the urine.  Vitamin D contains a range of 
compounds, including vitamin D1 (calciferol), vitamin D2 (ergocalciferol), vitamin D3 
(cholecalciferol), vitamin D4, vitamin D5, vitamin Dc, and vitamin Dm.  The term “plain” 
or “inactivated” vitamin D usually refers to vitamin D2 (ergocalciferol), which is derived 
from plants or yeasts, or vitamin D3 (cholecalciferol), which is derived from animal 
sources.  The “plain” vitamin D has to be activated to 1, 25-dihydroxy vitamin D 
(activated forms) by enzymes in the liver and kidneys.  Alfacalcidol 
(1-alpha-hydroxycholecalciferol), calcitriol (Rocaltrol®) and calcifediol (Calderol®) are 
examples of analogues of active vitamin D3 metabolites.   
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 Calcium, Vitamin D and their Combinations for osteoporosis 
A review indicated that using calcium decreases further bone loss, but does not 
reduce fracture risks, and also indicated that vitamin D reduces fracture risks slightly but 
does not affect BMD.129F130  It suggests that the combination of calcium and vitamin D 
may have a protective effect regarding both BMD and fractures in the elderly.  
However, in a recent trial recruiting 811 men and 4,481 women aged more than 70 years 
old who were followed for 24 to 62 months, there were no significant differences in 
hazard ratios among groups receiving 800 IU of vitamin D3 alone, 1,000 mg of calcium 
alone, the combination of calcium/vitamin D, or placebo.130F131  In another RCT recruiting 
3,314 women aged 70 years or over with at least one risk factor for hip fractures, subjects 
were provided a combination of 800 IU of vitamin D3 (cholecalciferol)/1,000 mg of 
calcium with an information leaflet (the study group) or an information leaflet alone (the 
control group).131F132  No significant differences in risk of all fractures and quality of life 
measures were found between groups.  Because of the non-significant results and some 
adverse outcomes observed, this study did not support the use of daily calcium and plain 
vitamin D3 (alone or in combination) in independent elderly people.  These studies 
targeted osteoporosis in general and the results are not necessarily applicable to 
glucocorticoid-induced osteoporosis.   
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 Calcium, Vitamin D and their Combinations for glucocorticoid-induced 
osteoporosis 
Alfacalcidol and calcitriol, which are vitamin D3 analogues, have received much 
attention recently in studies involving glucocorticoid users.  Ringe et al. reviewed some 
early RCTs for alfacalcidol and calcitriol, and suggested that activated vitamin D3 should 
be recommended for the prevention and treatment of glucocorticoid-induced 
osteoporosis.132F133  Ringe et al. also conducted a three-year prospective matched study 
recruiting long-term glucocorticoid users who received 500 mg of calcium, and they 
found that the group who received one microgram (mcg) of alfacalcidol showed a small 
but significant increase in spine BMD and a significant reduction of back pain in 
comparison with the control group who received 1,000 IU of plain vitamin D.133F134  
Similarly, a subsequent expanded study by Ringe et al. suggested that the groups 
receiving one mcg of alfacalcidol and 500 mg of calcium had significant increases in 
BMD values at the spine and femoral neck, had significant reductions of vertebral (RR 
=0.61, 95% CI 0.24-0.81) and non-vertebral fractures (RR =0.41, 95% CI 0.06-0.68), and 
showed a significant reduction in back pain when compared to the control group who 
received 1,000 IU of plain vitamin D with 500 mg of calcium.134F 135  Ringe et al. 
concluded that alfacalcidol is “superior” for glucocorticoid-induced osteoporosis to other 
vitamin D derivatives.  However, Barthel et al. argued that the comparisons in Ringe’s 
studies were unfair because they compared a maximal dose of alfacalcidol with the dose 
                                                 
133 Ringe, J. D. (1997). Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcified 
Tissue International 60(1):124-127.  
134 Ringe, J. D. et al. (1999). Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium 
versus vitamin D/calcium. Calcified Tissue International 65(4): 337-340.  
135 Ringe, J. D. et al. (2004). Superiority of alfacalcidol over plain vitamin D in the treatment of 
glucocorticoid-induced osteoporosis. Rheumatology International 24(2): 63-70.  
 34
of vitamin D that is too small to show a significant effect on glucocorticoid-induced 
osteoporosis.135F136   
In a 28-day RCT for calcitriol, 48 normally healthy male volunteers aged 21 to 54 
years randomly received calcitriol alone, prednisolone alone, a combination or placebo in 
turns.136F 137   The results suggested a partial prevention effect of calcitriol on 
glucocorticoid-induced osteoporosis.  However, in a recent two-year RCT recruiting 108 
patients with moderate asthma who took inhaled glucocorticoid steroids, no significant 
difference in BMD values at the lumbar spine and femoral neck was found between the 
calcitriol (0.25 mg) group and the matched placebo group.137F138   
Amin et al. conducted a meta-analysis comparing the efficacy of vitamin D, 
active vitamin D3 and its analogues with calcium alone or bisphosphonates in RCTs (for 
at least six months) for the prevention and/or treatment of glucocorticoid-induced 
osteoporosis, and they concluded that vitamin D plus calcium combination was better 
than calcium alone or no treatment, but “inferior” to bisphosphonates.138F139  Barthel et al. 
argued that four out of six studies in that meta-analysis also included vitamin D in the 
bisphosphonate group, so the authors’ conclusion is “unsupported.”139F 140   Recently, 
another meta-analysis was conducted to compare the efficacy of vitamin D3 preparations 
with other anti-osteoporosis therapies for glucocorticoid-induced osteoporosis by 
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including more RCTs.140F141  The pooled relative risk for vertebral fractures of active 
vitamin D3 analogues was 0.56 (95% CI 0.34-0.92), compared with placebo, plain 
vitamin D and/or calcium, or 1.20 (95% CI 0.32-4.55), compared with bisphosphonates.  
However, the authors inappropriately concluded that the efficacy of vitamin D3 analogues 
is less than that of bisphosphonates.  The efficacy of active vitamin D3 and its analogues 
for glucocorticoid-induced bone loss is inconclusive.   
Overall, evidence on calcium, vitamin D (plain or active forms or analogues) and 
the combination shows no or minimal protective effects on bone loss and fracture risks in 
glucocorticoid users.  It is generally believed that the addition of anti-osteoporotic 
agents to calcium and vitamin D (or their combination) should result in an additional 
benefit for the management of osteoporosis.  A daily supplementation of 1,500 
milligrams (mg) of calcium and 400 International Units (IU) of vitamin D is 
recommended for glucocorticoid-induced osteoporosis.141F142   
However, in many studies, the reported outcomes of an anti-osteoporotic agent 
actually reflect the synergistic effects of calcium/vitamin D and the anti-osteoporotic 
agent.  Additionally, the dosage regimens of calcium/vitamin D vary across studies.  
Therefore, the efficacy and/or effectiveness of an anti-osteoporotic agent should be 
interpreted or compared with special caution.  The next few sections review the efficacy 
of other anti-osteoporotic agents on glucocorticoid-induced osteoporosis.   
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2.4.2 Bisphosphonates (BP)  
 
 Alendronate 
Alendronate has been shown to increase the BMD and reduce risks of 
osteoporotic fractures in studies of glucocorticoid users with various underlying diseases.  
In an RCT recruiting 43 men and premenopausal women with sarcoidosis, 15 patients 
(the glucocorticoid group) were treated by glucocorticoid therapy for six to 12 months, 15 
patients (the alendronate/glucocorticoid group) were simultaneously prescribed 
glucocorticoid and 5 mg of alendronate daily and 13 patients received no treatment 
(controls).  The alendronate/glucocorticoid group had significant increases in BMD in 
comparison with the glucocorticoid group (+0.8%) and the control group (+4.5%).142F143  In 
a six-month RCT recruiting 25 heart transplant recipients, those who received 10 mg of 
alendronate per day (starting two months after transplantation) had a significant increase 
in BMD (at total body, hip and spine) compared to those who had no alendronate 
therapy.143F144  Similarly, in a two-year RCT recruiting 58 renal transplant recipients, 29 
patients (with relatively low BMD values) had a significant increase in BMD compared 
to their previous values after one year of alendronate treatment at a dose of 10 mg per 
day; yet a significant increase was not found in the control group.144F145   
In a 48-week multi-center, multi-country RCT recruiting 477 patients with 
long-term glucocorticoid use and taking 800-1,000 mg of calcium and 250-500 IU of 
vitamin D per day, those who used alendronate (5-10 mg daily) had significant increases 
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in BMD at the spine, hip and wrist in comparison with the placebo controls.145F146  The 
incidence rates of fractures after one-year alendronate treatments were 3.0% (2.7% in 
men and 4.4% in women) in treatment groups and 5.9% (2.1% in men and 13% in 
women) in the placebo group.  It is likely that alendronate increases BMD but fails to 
reduce the incidence rates of vertebral fractures in glucocorticoid users. 
The same research group conducted a one-year extended RCT by using the same 
design, and recruited 66 male and 142 female glucocorticoid users who were enrolled in 
the previous study.146F 147   Study subjects who received alendronate still showed 
significantly increased BMD at the spine when compared with the control groups.  
Evidence indicates the reduction in BMD occurred as early as three months after 
initiation of alendronate therapy. A reduction of vertebral fractures was also observed in 
comparison of alendronate group to the controls.  After one-year alendronate treatments, 
the incidence rates of vertebral fractures were 0.7% in the treatment group and 6.8% in 
the control group (p=0.026).  After two years of alendronate treatment, no vertebral 
fracture was found in the treatment group.147F148   
Lems et al. conducted an RCT to investigate the efficacy of alendronate in 
patients with rheumatoid arthritis who used low-dose prednisone.148F149  No significant 
difference in prevalence rates of vertebral fractures was found between the two 
comparison groups (54% in alendronate group and 39% in the placebo group) after 
                                                 
146 Saag, K. G. et al. (1998). Alendronate for the prevention and treatment of glucocorticoid-induced 
osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. New England Journal of 
Medicine 339(5): 292-299.  
147 Adachi, J. D. et al. (2001). Two-year effects of alendronate on bone mineral density and vertebral 
fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension 
trial. Arthritis and Rheumatism 44(1): 202-211.  
148 Ibid. 
149 Lems, W. F. et al. (2006). Positive effect of alendronate on bone minieal density and makers of bone 
turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a 
randomized, double-blind, placebo-controlled trial. Osteoporosis International 17: 716-723. 
 38
one-year follow-up.  There was also no significant difference in incidence rates of 
vertebral fractures between the two comparison groups (13% in alendronate group and 
4% in the placebo group).  Although the differences are not significant, it is noted that 
both rates for alendronate group are higher than those for the placebo group.   
In a three-year RCT recruiting 2,027 postmenopausal women with prior vertebral 
fractures, those who received 5 mg of alendronate daily for two years and then 10 mg of 
alendronate daily for one additional year had significantly lower risks of new fractures 
(any fracture RR =0.72, 95% CI 0.58-0.90; vertebral RR =0.53, 95% CI 0.41-0.68; hip 
RR =0.49, 95% CI =0.23-0.99; wrist RR =0.52, 95% CI 0.31-0.87) than those in the 
placebo control group.149F150  An important RCT for postmenopausal osteoporosis is the 
Fracture Intervention Trial (FIT),150F151, 151F152, 152F153, 153F154, 154F155 and the conclusions were similar to 
those in studies for glucocorticoid-induced osteoporosis.   
 
 Risedronate 
Risedronate also shows protective effects similar to those of alendronate.  In a 
one-year multi-center, double-blind RCT recruiting 224 men and women who received 
500 mg of calcium daily and long-term glucocorticoid therapy, risedronate groups 
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showed a significantly higher BMD (both 2.5-mg and 5-mg groups) and a significantly 
lower incidence of vertebral fractures (5-mg group only) in comparison with controls.155F156  
The incidence rates of vertebral fractures after one-year risedronate treatments were 5.7% 
in the treatment group and 17.3% in the placebo group.  Another one-year RCT in 23 
sites in Europe recruited men and women aged 18 to 85 years old who received 
glucocorticoid therapy at a minimum daily dose of 7.5 mg of prednisone for more than 
six months.156F157  Significant differences in BMD were found at lumbar spine (p<0.001), 
femoral neck (p=0.004) and trochanter (p=0.010) between risedronate and the placebo 
groups).  The incidence rates of vertebral fractures were 5% in each of two groups 
receiving 2.5-mg and 5-mg of risedronate, respectively, for one year, and 15% in the 
placebo group; however, the differences are not significant (p=0.125).  If these two 
risedronate groups are combined, the reduction of vertebral fractures (70%) in the 
combined risedronate group is significant (p=0.042).   
Because the sample size in each of the risedronate groups was relatively small, it 
may result in insufficient statistical power to detect differences in incidence rates of 
vertebral fractures between comparison groups.  In studies investigating the efficacy of 
risedronate for postmenopausal osteoporosis, similar patterns emerged.157F158  The findings 
of studies for postmenopausal osteoporosis may still serve as a reference.  The notable 
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corticosteroid-induced osteoporosis in men and women: a randomized trial. Journal of Bone and Mineral 
Research 15(6): 1006-1013. 
158 Reginster, J.-Y. et al. (2000). Randomized trial of the effects of risedronate on vertebral fractures in 
women with established postmenopausal osteoporosis. Osteoporosis International 11(1): 83-91.  
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RCT that evaluated efficacy of risedronate for postmenopausal osteoporosis is the 
Vertebral Efficacy with Risedronate Therapy (VERT) Study.158F159, 159F160   
 
 Other bisphosphonates 
Three RCTs evaluating other bisphosphonates for glucocorticoid-induced 
osteoporosis were found.  Adachi et al. conducted a one-year RCT of intermittent 
etidronate in 141 men and women aged 19 to 87 years old who recently received 
high-dose glucocorticoid therapy.  Each subject in the etidronate group received four 
cycles of intermittent treatments; in each cycle, subjects were provided 400 mg of 
etidronate per day for 14 days and then 500 mg of calcium per day for 76 days.  
Significant differences in BMD were found between etidronate and the placebo groups at 
lumbar spine (p=0.02) and at trochanter (p=0.02), but not at femoral neck (not 
significant).  Among post-menopausal female subjects, a reduction (85%) in incidence 
rates of vertebral fractures was found between etidronate and placebo groups (p=0.05).   
In another one-year RCT recruiting glucocorticoid users who received 800 mg of 
calcium daily, 14 patients receiving intermittent intravenous pamidronate (30 mg every 
three months) had a significant increase in BMD compared to the 13 control subjects.160F161  
In a four-year double-blind RCT recruiting patients with arthritis and osteoporosis who 
received 1,000 mg of calcium and 800 IU of vitamin D supplements daily, 84 patients 
who received 100 mg of intramuscular clodronate once per week had a significant 
                                                 
159 Harris, S. T. et al. (1999). Effects of risedronate treatment on vertebral and nonvertebral fractures in 
women with postmenopausal osteoporosis: a randomized controlled trial, the Vertebral Efficacy With 
Risedronate Therapy (VERT) Study Group. Journal of the American Medical Association 282(14): 
1344-1352.  
160 Reginster, J.-Y. et al. (2000). Randomized trial of the effects of risedronate on vertebral fractures in 
women with established postmenopausal osteoporosis. Osteoporosis International 11(1): 83-91.  
161 Boutsen, Y. et al. (1997). Primary prevention of glucocorticoid-induced osteoporosis with intermittent 
intravenous pamidronate: a randomized trial. Calcified Tissue International 61(4): 266-271.  
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reduction of vertebral fractures (RR =0.63, 95% CI 0.35-0.98 for vertebral; RR =0.25, 
95% CI 0.15-0.91 for multiple vertebral) compared to the 79 control subjects.161F162   
Currently, alendronate and risedronate are the only prescription medications 
approved by the FDA for the prevention and treatment of glucocorticoid-induced 
osteoporosis.  Alendronate (Fosamax® by Merck) is available in tablets (5, 10, 35, 40 
and 70 mg), solution (75 ml equivalent to 70 mg) and a tablet combined with 
cholecalciferol (Fosamax plus D®).  Risedronate (Actonel® by Procter and Gamble) is 
available in a tablet form (5, 30 and 35 mg).  Etidronate (Didronel® by Procter and 
Gamble) was approved by the FDA for treating Paget’s disease (but not for osteoporosis); 
it is available for the treatment of bone pain due to osteoporosis in Canada and Europe.  
Table 2.1 shows the dosing regimens, indications and approval dates for FDA-approved 
bisphosphonates.   
In conclusion, the protective effects of alendronate and risedronate for 
glucocorticoid-induced osteoporosis have been supported.  The efficacy of other 
bisphosphonates for glucocorticoid-induced osteoporosis is still under evaluation, but 
positive results are expected.  Although bisphosphonates have shown significant 
protective effects on bone loss and fracture risks, estrogens or hormone replacement 
therapy (HRT) had been used widely for preventing osteoporosis, especially in 
postmenopausal women.  The next section reviews the efficacy of HRT for 
osteoporosis.   
 
                                                 
162 Frediani, B. et al. (2003). Effects of 4-year treatment with once-weekly clodronate on prevention of 
corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray 
absorptiometry and quantitative ultrasound. Bone 33(4): 575-581.  
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2.4.3 Hormone Replacement Therapy (HRT) 
Hormone replacement therapy (HRT) was frequently used to manage 
osteoporosis.  Only a few small prospective studies were found that evaluated the 
efficacy of HRT in glucocorticoid users.  The efficacy of HRT was evaluated in 
postmenopausal women with rheumatoid arthritis who used or did not use low-dose 
glucocorticoid steroids.162F163  One hundred subjects received HRT (the HRT groups) and 
another 100 subjects received daily 400 mg calcium supplementation (the calcium 
group).  Twenty-one subjects in each group received glucocorticoid steroids (GS).  
Overall, a significant difference in BMD were found at lumber spine between the HRT 
and calcium groups after two-year treatments (HRT: +2.22%, 95% CI +0.72% to 
+3.72%; calcium -1.19%, 95% CI -2.29% to -0.09%, p<0.001).  Subjects in the 
GS-HRT group had a significant increase in BMD at lumber spine (+3.75%, 95% CI 
+0.72% to +6.78%) after two-year treatments; however, no significant difference in 
BMD was found between GS-HRT and GS-calcium groups.   
 
                                                 
163 Hall, G. M. et al. (1994) Effect of hormone replacement therapy on bone mass in rheumatoid arthritis 
patients treated with and without steroids. Arthritis and Rheumatism 37(10): 1499-1505.  
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Table 2.1 Dosing regimens, indications and approval dates for approved bisphosphonates 
Brand name (generic name) and manufacturer 
 Dosing regimen Indication§ Approval date†
Fosamax® (alendronate sodium) by Merck 
















 35 mg oral tablet/week PMO-prevention 10/20/2000 
 40 mg oral tablet/day for 6 months Paget’s disease 06/08/1999 












    
Fosamax plus D® (alendronate sodium and cholecalciferol) by Merck 




    
Actonel® (risedronate sodium) by Procter and Gamble 








 30 mg oral tablet/day for 2 months Paget’s disease 03/07/1998 




    
Actonel with Calcium® (risedronate sodium and calcium carbonate, co-packaged) by Procter and Gamble
 35 mg oral tablets/week & 1,250 mg calcium 





    
Didronel® (etidronate disodium) by Procter and Gamble 
 200 mg oral tablet or 400 mg oral tablet at 
5-10 mg/kg/day < 6 months or 
11-20 mg/kg/day < 3 months 
Paget’s disease 09/01/1977 
 
 
    
Etidronate disodium by Genpharm 
 200 or 400 mg oral tablet 
 
Paget’s disease 01/24/2003 
§ PMO-postmenopausal osteoporosis; GIOP-Glucocorticoid-induced osteoporosis; OP/men-osteoporosis in men. 
†Approval date by the U.S. Food and Drug Administration (FDA). 
References: searchable Drug@FDA websites for FDA approved drug products, URL: 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm 
HRT= hormone replacement therapy. 
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A review summarized the findings of some RCTs, and concluded that using HRT 
has a small protective effect on vertebral fractures but not on hip fractures.163F164  However, 
the results of the Women Health Initiative (WHI) study, in which partial results were first 
released in 2002, changed the way that HRT has been used.164F165, 165F166  In the WHI Study, 
which recruited 16,608 postmenopausal women who received 0.625 mg of conjugated 
estrogen plus 2.5 mg of medroxyprogesterone acetate daily, a protective effect on 
fractures was found (RR =0.61, 95% CI 0.41-0.91 for hip fractures; RR =0.62, 95% CI 
0.34-1.13 for vertebral fractures; RR =0.70, 95% CI 0.63-0.79 for total fractures), but the 
risks of stroke (RR =1.39, 95% CI 1.10-1.77) and total cardiovascular diseases (RR 
=1.12, 95% CI 1.01-1.24) were increased.166F 167 , 167F 168 , 168F 169   Although HRT showed a 
protective effect on osteoporotic fractures, its risks associated with other conditions 
outweighed the beneficial effects.  Therefore, HRT is currently not recommended for 
the management of osteoporosis, and HRT should be used cautiously with appropriate 
monitoring.169F170   
                                                 
164 Geusens, P. (2000). Hormonal replacement therapy in the prevention and treatment of 
glucocorticoid-induced osteoporosis. Clinical and Experimental Rheumatology 18(suppl. 21): S57-S59.  
165 Kleerekoper, M. (2002). Lessons from the skeleton: was the Women's Health Initiative (WHI) a 
primary prevention trial? Osteoporosis International 13(9): 685-687.  
166 Majumdar, S. R. et al. (2004). Promotion and prescribing of hormone therapy after report of harm by 
the Women's Health Initiative. Journal of the American Medical Association 292(16): 1983-1988.  
167 Anderson, G. L. et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with 
hysterectomy: the Women's Health Initiative randomized controlled trial. Journal of the American Medical 
Association 291(14): 1701-1712.  
168 Manson, J. E. et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. New 
England Journal of Medicine 349(6): 523-534.  
169 Wassertheil-Smoller, S. et al. (2003). Effect of estrogen plus progestin on stroke in postmenopausal 
women: the Women's Health Initiative: a randomized trial. Journal of the American Medical Association 
289(20): 2673-2684.  
170 American College of Rheumatology (ACR) (2001). Recommendations for the prevention and 
treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad 
Hoc Committee on glucocoritcoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503.  
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In short, HRT was widely used for preventing bone loss at spine or reducing risks 
of vertebral fractures before 2002.  The use of HRT for osteoporosis is not 
recommended given its risks for cardiovascular conditions.  Other estrogen-related 
agents, the selective estrogen receptor modulators (SERMs), have fewer risks of adverse 
reactions compared to HRT.  The SERMs are potentially used as anti-osteoporotic 
agents.  The next section reviews the efficacy of SERMs on bone loss. 
 
2.4.4 Selective Estrogen Receptor Modulators (SERMs) 
Among Selective Estrogen Receptor Modulators (SERMs), only raloxifene has 
been evaluated and approved for the treatment of postmenopausal osteoporosis.  
Raloxifene (Evista＠ by Eli Lilly) was approved by the FDA for the treatment of 
postmenopausal osteoporosis on December 9, 1997, and is available in 60 mg tablets.  
No published study of raloxifene for glucocorticoid-induced osteoporosis was found.  
Nevertheless, raloxifene may be used clinically as an intervention for 
glucocorticoid-induced osteoporosis in postmenopausal women.  It may be helpful to 
review these raloxifene trials.   
In a series of large double-blind RCTs, the Multiple Outcomes of Raloxifene 
Evaluation (MORE) study recruited 7,705 women diagnosed with postmenopausal 
osteoporosis and followed them for three years. A total of 2,576 women receiving 
raloxifene had significant reductions of the incidence of vertebral fracture (RR =0.7, 95% 
CI 0.5-0.8 for 60 mg; RR =0.5, 95% CI 0.4-0.7 for 100 mg) and had a protective effect 
on breast cancer (RR =0.1, 95% CI 0.04-0.24) but had an increased risk of endometrial 
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cancer (RR =3.1, 95% CI 1.5-6.2) compared with placebo control subjects.170F171, 171F172  The 
prevention of vertebral fracture was supported in a recent meta-analysis (pooled RR =0.6, 
95% CI 0.49-0.74).172F173   
Raloxifene could be potentially useful in postmenopausal women for 
glucocorticoid-induced osteoporosis.  However, more studies are needed to evaluate the 
relative risks of endometrial cancer from raloxifene use.  Another type of anti-resorptive 
agent is calcitonin, and its efficacy is reviewed in the following section.   
 
2.4.5 Calcitonin 
Calcitonin is recommended as the second-line alternative for post-menopausal 
osteoporosis when other anti-osteoporosis medications are contraindicated.173F 174  
Compared with calcium and vitamin D combination, calcitonin shows similar efficacy in 
increasing BMD or reducing risks of osteoporotic fractures in glucocorticoid users.  In a 
two-year double-blind RCT recruiting 25 patients with temporal arteritis or polymyalgia, 
those who received 100 IU of salmon calcitonin had no significant difference in BMD 
values and incidence of vertebral fracture when compared with the control group who 
                                                 
171 Cummings, S. R. et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal 
women: results from the MORE randomized trial. Journal of the American Medical Association 281(23): 
2189-2197.  
172 Ettinger, B. et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with 
osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Journal of the 
American Medical Association 282(7): 637-645.  
173 Seeman, E. et al. (2006). Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis 
International 17(2): 313-316.  
174 American College of Rheumatology (ACR) (2001). Recommendations for the prevention and 
treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad 
Hoc Committee on glucocoritcoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503.  
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took 1,500 mg of calcium and 400 IU of vitamin D supplements daily.174F175  However, 
calcitonin is used clinically for managing pain caused by vertebral fractures.  A 
meta-analysis concluded that calcitonin has a significant effect on relieving acute pain 
after recent vertebral fractures.175F176  A recent systematic review of related RCTs supports 
the pain management effect of calcitonin.176F177  The first salmon calcitonin product is 
Calcimar® (an injectable form by Rhone-Poulenc Rorer) which was approved by the FDA 
in 1975.  Miacalcin® (salmon calcitonin by Novartis) is approved by the FDA only for 
postmenopausal women who cannot tolerate estrogen, or for whom estrogen is not an 
option.  Miacalcin® is currently available in two forms: 200 IU/ml injection (approved 
on March 29, 1991) and 200 IU metered nasal spray (approved on August 17, 1995). 
Calcitonin-salmon recombinant (rDNA origin, Fortical® by Unigene) was approved for 
the treatment of postmenopausal osteoporosis on August 12, 2005, and is currently 
available as 200 IU metered nasal spray.   
Anti-resorptive agents are widely used to treat glucocorticoid-induced 
osteoporosis as well as other types of osteoporosis.  The efficacy of each anti-resorptive 
agent for glucocorticoid-induced osteoporosis varies; bisphosphonates showed the most 
promising results.  Other treatments include anabolic agents which target the process of 
bone formation.  The next section reviews the efficacy of anabolic agents for 
glucocorticoid-induced osteoporosis. 
                                                 
175 Healey, J. H. et al. (1996). A randomized controlled trial of salmon calcitonin to prevent bone loss in 
corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcified Tissue International 58(2): 
73-80.  
176 Coyle, D. et al. (2001). Cost effectiveness of nasal calcitonin in postmenopausal women: use of 
Cochrane collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 19(5): 
565-575.  
177 Knopp, J. et al. (2005). Calcitonin for treating acute pain of osteoporotic vertebral compression 




2.4.6 Anabolic Agents 
Fluoride and parathyroid hormone are the two most common anabolic agents 
which have been evaluated for osteoporosis.  In a two-year RCT recruiting 47 
glucocorticoid users with established osteoporosis who received 500 mg of calcium per 
day, 0.2 mg of dihydrotachysterol per day and eight cycles of intermittent cyclical 
etidronate (one cycle =200 mg twice daily for 2 weeks and stop etidronate for 11 weeks), 
23 patients receiving 25 mg of sodium fluoride twice daily had a significant increase in 
BMD at the spine (+8.9%, p<0.01) compared to 24 controls (placebo/etidronate); no 
significant change in BMD at hip nor in fracture rates was found between two groups.177F178  
Because the sample size of this study was relatively small, the efficacy of fluoride for 
glucocorticoid-induced osteoporosis is not conclusive.   
The human parathyroid hormone 1-34 (hPTH 1-34) is a fragment of the intact 
parathyroid hormone 1-84.  PTH (1-34) significantly increases BMD in the spine and 
hip in glucocorticoid users.  In a one-year RCT recruiting women with postmenopausal 
osteoporosis who received glucocorticoid steroids, PTH (1-34) had a significant increase 
in BMD at the lumber spine within six months in comparison with those who received 
HRT.178F179  The PTH treatment was discontinued six months after the initiation of therapy 
in this one-year trial.  The effect of PTH on spine BMD remains for an additional year 
after the termination of therapy; however, the effect on hip BMD, which was not found 
                                                 
178 Lems, W. F. et al. (1997). Is the addition of sodium fluoride to cyclical etidronate beneficial in the 
treatment of corticosteroid-induced osteoporosis? Annals of Rheumatic Diseases 56: 357-63.  
179 Lane, N. E. et al. (1998). Parathyroid hormone treatment can reverse corticosteroid-induced 
osteoporosis: results of a randomized controlled clinical trial. Journal of Clinical Investigation 102(8): 
1627-1633.  
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during the first six months of the treatment, appeared six months after the termination.179F180, 
180F
181  This suggested that the onset time for PTH (1-34) effects on hip BMD may be 
relatively long.  Teriparatide (Forteo＠ by Eli Lilly), a recombinant hPTH 1-34, was 
approved by the FDA for the treatment of postmenopausal osteoporosis on Nov 26, 2002, 
and is available in subcutaneous injection (0.25 mg/ml).  Table 2.2 shows the dosing 
regimens, indications and approval dates for non-bisphosphonate agents. 
 
Table 2.2 Dosing regimens, indications and approval dates for non-bisphosphonate agents 
Brand name (generic name) and manufacturer 
 Dosing regimen Indication‡ Approval date† 
Evista® (raloxifene hydrochloride) by Eli Lilly 





    
Miacalcin® (calcitonin-salmon) by Novartis 





 200 IU/metered nasal spray/day  08/17/1995 
   
Fortical® (calcitonin-salmon recombinant, rDNA origin) by Unigene 
 200 IU/metered nasal spray/day Alternating nostrils daily 
PMO-treatment 08/12/2005 
 
   
Forteo® (teriparatide recombinant human, rDNA origin) by Lilly 
 









‡PMO-postmenopausal osteoporosis; OP/men-osteoporosis in men. 
†Approval date by the U.S. Food and Drug Administration (FDA). 




                                                 
180 Lane, N. E. et al. (2000). Bone mass continues to increase at the hip after parathyroid hormone 
treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled 
clinical trial. Journal of Bone and Mineral Research 15(5): 944-951.  
181 Lane, N. E. et al. (2000). Short-term increases in bone turnover markers predict parathyroid 
hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced 
osteoporosis. Osteoporosis International 11(5): 434-442.  
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2.4.7 Combination Therapy 
The efficacy of combination therapy for postmenopausal osteoporosis has been 
reviewed.181F 182   Combination therapy (e.g., BP-HRT, BP-raloxifene, calcitonin-HRT, 
PTH-HRT, etc.) generally shows increased BMD values and decreased risks of 
osteoporotic fractures when compared with monotherapy.  Compared to monotherapy of 
BP or HRT, the BP-HRT combination shows reduced relative risks of osteoporotic 
fractures in an observational study.182F183  However, the additive protective effects are 
generally small.  Additionally, the chance of adverse reactions increases; adherence and 
tolerance are usually decreased.  The benefit of using combination therapy may not 
outweigh potential adverse drug reactions; therefore, combination therapy is currently not 
recommended.  More studies are needed to evaluate the efficacy, safety and adherence 
of combination therapy for osteoporosis in at least three areas: (1) exclusion of HRT as 
an option; (2) an adjustment of dose regimens for each option; and (3) an extended study 
period.   
 
2.4.8 Effectiveness and Efficacy 
In a cohort study using an electronic administrative and clinical database from a 
large health maintenance organization (HMO) plan covering 450,000 lives, a total of 
3,031 glucocorticoid users were identified between 2000 and 2001, and 90% of the 
population were non-Hispanic white.183F184  A total of 575 subjects were excluded because 
                                                 
182 Compston, J. E. & Watts, N. B. (2002). Combination therapy for postmenopausal osteoporosis. 
Clinical Endocrinology 56(5): 565-569.  
183 Tiller, W. (2004). Alendronate and hormone replacement therapy in the prevention of osteoporotic 
fracture: A pharmacoeconomic analysis employing a net-benefit regression method of cost-effectiveness. 
Dissertation. The University of Texas at Austin, Austin, TX, U.S. A.; 325 pages. 
184 Feldstein, A. C. et al. (2005). Practice patterns in patients at risk for glucocorticoid-induced 
osteoporosis. Osteoporosis International 16(12): 2168-2174. 
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of ineligibility of the HMO plan.  Of 1,827 female glucocorticoid users, 46.4% received 
HRT and 18.3% received other anti-osteoporotic medications, including bisphosphonates, 
calcitonin and raloxifene. Of 1,204 male glucocorticoid users, 8.9% received either 
bisphosphonates or calcitonin.   
Given the efficacy of anti-osteoporotic agents for glucocorticoid-induced 
osteoporosis, bisphosphonates are usually the first-line choice.  However, 
bisphosphonates may not always be the best option for every patient.  The “efficacy” of 
a medication shown in an RCT usually shows the ideal results among study subjects with 
relatively restricted criteria, so it usually does not reflect the “effectiveness” in patients 
who actually use that medication in the “real world.”  Combined with complex 
considerations (e.g., co-morbidities, social or economic issues), effectiveness is more 
meaningful to patients, healthcare providers, payers or policy makers than is efficacy. 
 
2.4.8 Summary of Pharmacotherapy for Glucocorticoid-Induced Osteoporosis 
This concludes the review of clinical outcomes of RCTs for 
glucocorticoid-induced osteoporosis.  Calcium, vitamin D supplementation or the 
combination is the basic intervention for glucocorticoid-induced osteoporosis in most 
studies.  Bisphosphonates showed the greatest efficacy for glucocorticoid-induced 
osteoporosis compared to other agents, so bisphosphonates are considered first-line 
agents.  HRT was widely used as an intervention for osteoporosis, but is no longer 
recommended because of the risks of cardiovascular diseases.  Instead, raloxifene may 
be the choice of postmenopausal women for managing osteoporosis, but more studies are 
needed to evaluate the risks of endometrial cancer.  Calcitonin showed a relatively weak 
efficacy for osteoporosis, but it is used clinically for the management of pain associated 
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with vertebral fractures and it is the second-line agent.  Teriparatide (PTH 1-34) is 
another potential agent for glucocorticoid-induced osteoporosis.  The next section will 
focus on the evaluation of the economic burden of glucocorticoid-induced osteoporosis 
and its treatments, especially targeting cost-effectiveness studies. 
 
2.5 ECONOMIC EVALUATIONS 
Given limited resources, attention is focused on costs and utilization of 
medications.  Cost-effectiveness analyses (CEA) can be helpful in addressing these 
issues because they integrate both economic and clinical outcomes, and compare the 
outcomes of potential alternatives with those of the reference (standard) treatment.  
Based on individual needs and information provided by the cost-effectiveness analyses, 
patients (along with their healthcare providers) may select the best approach to manage 
their conditions.  The following two sections review the economic burden of 
glucocorticoid-induced osteoporosis and the cost-effectiveness of medications used for 
the prevention and/or the treatment of glucocorticoid-induced osteoporosis.  It is noted 
that most studies included only direct medical costs.   
 
2.5.1 Burden of Osteoporosis and Osteoporotic Fractures 
Most studies of osteoporosis focused on osteoporotic vertebral and/or hip 
fractures.  The vertebral fracture is the most common type, and the hip fracture usually 
accounts for the largest portion of the total direct and indirect medical costs.  The 
estimated costs of osteoporosis or osteoporotic fractures vary in different settings and 
countries.  No cost-of-illness or disease-burden study specifically targeting 
glucocorticoid users was found.  However, the costs associated with all osteoporotic 
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fractures may give a hint of costs related to glucocorticoid-induced osteoporosis.  Those 
studies conducted in European countries will be summarized first, followed by those in 
the U.S.   
 
2.5.1.1 Hospital costs of osteoporotic fractures outside the U.S. 
(1) Fractures at all sites.  In Switzerland, the costs of hospitalizations for 
osteoporotic fractures in 2000 were $18,227 Swiss Francs (CHF) for hip fractures, 
$11,644 CHF for vertebral fractures and $6,260 CHF for forearm fractures,184F 185 or 
$10,356, $6,616 and $3,557 USD, respectively ($1 USD ≈  $1.76 CHF in 2000).185F186  Of 
62,535 hospitalized fractures, osteoporotic fractures accounted for 51% in women and 
24% in men; about a half of all osteoporotic fractures involved the hip.  In the U.K., the 
estimated direct medical costs of hip, spine, wrist and other osteoporotic fractures in 
women aged 50 years or more in 1998 were about ₤12,000, ₤479, ₤468 and ₤1,338 per 
fracture, respectively (in 1998 ₤),186F 187   or $19,800, $790, $772 and $2,208 USD 
(1₤=$1.65 in 1998).187F188.   
(2) Hip fractures.  The total inpatient cost for fractures at proximal humerus, 
distal radius/ulna and proximal hip in 2001 in France was estimated to range between 
€714 million and €762 million (2001 €),188F189 or $643 and $656 million (€1≈  $0.90 
                                                 
185 Lippuner, K. et al. (2005). Epidemiology and direct medical costs of osteoporotic fractures in men and 
women in Switzerland. Osteoporosis International 16(Suppl 02): S8-S17.  
186  URL: http://www.itu.int/aboutitu/annual_report/2000/financial_situation.html  Accessed July 12, 
2007.  
187 Dolan, P. & Torgerson, D. J. (1998). The cost of treating osteoporosis fractures in the United 
Kingdom female population. Osteoporosis International 8(6): 611-617.  
188  1₤=$1.6120-1.7255 in 1998, URL: http://www.taxfreegold.co.uk/1998forexrates.html  Accessed 
July 12, 2007. 
189 Maravic, M. et al. (2005). Incidence and cost of osteoporotic fractures in France during 2001. a 
methodological approach by the national hospital database. Osteoporosis International 16(12): 1475-1480.  
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USD).189F190  Another study reported that the total hospital costs for osteoporotic fractures 
in Sweden was about 351 million Swedish Kronors (SEK) in 1996190F191 (or $52.4 million, 
1 SEK=$0.1493 USD in 1996),191F192 and that hip fractures accounted for 63% in men and 
72% in women of the hospital admissions for osteoporotic fractures.   
A survey recruiting 7,983 men and women aged 55 years or over in the 
Netherlands found that the estimated average incremental direct medical costs of hip 
fractures were about U.S. $10,000 within one year after fracture, and about an additional 
U.S. $1,000 in the second year, compared with matched participants without osteoporotic 
fractures in the study period (1990-1993).192F193  These costs were not adjusted to the dollar 
values in the same year.  It was also estimated in another study that the average cost per 
hip fracture in 2,374 Belgium patients aged 60 years or over in 1996 was U.S. $8,977 for 
the first year and U.S. $752 within one year after the fracture (1996 dollars).193F194  In 
Belgium, the estimated direct medical cost of hospital stays for hip fracture among 159 
female patients aged 50 years or more was €8,667, and its additional direct medical cost 
within one year after the fracture was €6,636 in 1996 (adjusted to 1998 €),194F195 or $10,314 
and $7,897, respectively (€1≈$1.19 USD on January 4, 1999).195F196   
                                                 
190 1Euro=$0.84-0.96 USD in 2001. URL: http://www.taxfreegold.co.uk/2001forexrates.html Accessed 
July 12, 2007.   
191 Johnell, O. et al. (2005). The burden of hospitalised fractures in Sweden. Osteoporosis International 
16(2): 222-228.  
192 On average, $1 USD=6.7 SEK in 1996.  URL: 
http://www.astrazeneca.com/sites/7/archive/Investors/Financial%20Reports/1995-1998/zeneca-1995-1997-
basis-of-preparation.pdf  Accessed July 12, 2007.   
193 De Laet, C. E. D. H. et al. (1999). Incremental cost of medical care after hip fracture and first 
vertebral fracture: the Rotterdam study. Osteoporosis International 10(1): 66-72.  
194 Reginster, J.-Y. et al. (1999). Direct costs of hip fractures in patients over 60 years of age in Belgium. 
Pharmacoeconomics 15(5): 507-514.  
195 Autier, P. et al. (2000). Costs induced by hip fractures: a prospective controlled study in Belgium. 
Osteoporosis International 11(5): 373-380.  
196 $1 USD =0.84219 Euro, as of Jan. 4, 1999.  URL: 
http://www.geocities.com/eureka/concourse/8751/tabl-er2.htm  Accessed July 12, 2007.  
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(3) Vertebral fractures.  A study surveyed the Ministries and Departments of 
Health in 15 European countries, and found that the total hospital cost of osteoporotic 
vertebral fractures for patients aged over 50 years in these countries was about €377 
million per year (average €3,892 per fracture, 2001 €), or 339 million per year and 
average $3,505 per fracture (€1≈  $0.90 USD),196F197 which was 63% of the average cost 
per hip fracture (€6,178 or $5,560 USD).197F198   
 
2.5.1.2 Direct and indirect costs of osteoporotic fractures outside the U.S. 
In Sweden, the estimated (direct and indirect combined) costs of vertebral, hip 
and wrist fractures within one year after the fracture among 635 male and female patients 
aged 50 years or more were €12,544, €14,221 and €2,147 (2004 €), 198F199 respectively, or 
$16,558, $18,772 and $2,834, respectively (€1≈  $1.32 USD in 2004).199F200  The indirect 
costs include opportunity cost (work loss per day), and costs for special living 
arrangements (e.g., nursing home, group living, home help), transportation and informal 
care (value of lost leisure time).   
 
2.5.1.3 Direct medical costs of osteoporotic fractures in the U.S. 
Four studies were found for estimation of costs of fractures in the U.S.  In 
California, the 1998 Medicare expenditure for the direct medical costs of osteoporosis 
                                                 
197 1Euro=$0.84-0.96 USD in 2001. URL: http://www.taxfreegold.co.uk/2001forexrates.html Accessed 
July 12, 2007.   
198 Finnern, H. W. & Sykes, D. P. (2003). The hospital cost of vertebral fractures in the EU: estimates 
using national datasets. Osteoporosis International 14(5): 429-436.  
199 Borgstrom, F. et al. (2006). Costs and quality of life associated with osteoporosis-related fractures in 
Sweden. Osteoporosis International 17(5): 637-650.  
200 1 Euro=$1.32 in December 2004. URL: http://www.molon.de/travelogues/Singapore/2004/#Money 
Accessed July 12, 2007.   
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and related conditions was over $2.4 billion; 59% of which was for nursing home care.200F201  
In 600 women aged 45 years or more who enrolled in a U.S. health maintenance 
organization (HMO) between 1998 and 1999, the total direct medical cost for 
osteoporosis or osteoporotic fractures was $411,684 (average $686 per person).201F202  The 
disease-specific costs were $645 per patient per year (PPPY) for osteoporosis and $939 
PPPY for osteoporotic fractures.  The estimated cost (including inpatient, outpatient and 
long-term care) in Florida was over $1.2 billion for 86,428 osteoporotic fractures in 2000, 
and it was projected to reach $2.1 billion for 151,622 osteoporotic fractures in 2025.202F203  
The direct medical costs of follow-ups after osteoporotic fractures were reported.  The 
median incremental costs of hip, vertebral and wrist fractures in one year after fracture 
were $10,338, $1,255 and $1,496, respectively (1995 dollars) in 1,263 Minnesota patients 
aged 50 years or more.203F204   
 
Trends for costs of osteoporotic fractures 
Table 2.3 summarizes direct medical costs of osteoporotic fractures reported in 
previous studies.  Regardless of region, the economic burden of osteoporosis or 
osteoporotic fractures is significant.  The burden of osteoporotic fractures is mostly due 
to the hospital costs.  The first-year expense for hip fractures is about $10,000 per 
patient, and it accounts for the largest portion of direct medical expenses for osteoporotic 
fractures.  Although there is no information on costs of glucocorticoid-induced 
                                                 
201 Max, W. et al. (2002). The burden of osteoporosis in California, 1998. Osteoporosis International 
13(6): 493-500.  
202 Desai, S. S. et al. (2003). The cost of treating osteoporosis in a managed health care organization. 
Journal of Managed Care Pharmacy 9(2): 142-149.  
203 Burge, R. T. et al. (2003). Methodology for estimating current and future burden of osteoporosis in 
state populations: application to Florida in 2000 through 2025. Value in Health 6(5): 574-583.  
204 Gabriel, S. E. et al. (2002). Direct medical costs attributable to osteoporosis fractures. Osteoporosis 
International 13(4): 323-330.  
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osteoporosis and osteoporotic fractures, the burden of osteoporosis and osteoporotic 
fractures in glucocorticoid users may be significant, if glucocorticoid-induced bone loss 
is left untreated.  Osteoporosis and osteoporotic fractures need to be managed from the 
perspectives of both clinical and economic considerations.  The next question is: What 
is the most cost effective option to manage glucocorticoid-induced osteoporosis?  The 
following section summarizes some findings from the CEAs, which may help answer this 
question.   
 
2.5.2 Costs and Effectiveness of Agents for Glucocorticoid-Induced Osteoporosis 
Most outcomes research for anti-osteoporotic agents in the literature focused on 
management of postmenopausal osteoporosis.  Two articles were found to review 
cost-effectiveness, cost-utility and cost-minimization analyses of anti-osteoporotic 
treatments in the literature.  Cranney, Coyle and colleagues reviewed 19 
cost-effectiveness studies from 1983 to 1998,204F205, 205F206 and Fleurence et al. provided a 
review of 42 studies which were published by December 2004.206F207  A total of 71% of the 
42 studies in Fleurence’s review were conducted in Sweden, the U.K. or the U.S.; 88% 
included females only; 38% addressed hip fracture only; and the major intervention 
groups were HRT (27%), bisphosphonates (17%) and calcium and/or vitamin D (16%).  
As indicated previously, research in postmenopausal osteoporosis may not be applicable 
to research in glucocorticoid-induced osteoporosis. 
                                                 
205 Cranney, A. et al. (1999). A review of economic evaluation in osteoporosis. Arthritis Care and 
Research 12(6): 425-434.  
206 Coyle, D. et al. (2000). Cost-effectiveness research in osteoporosis. Drug Development Research 
49(3): 135-140.  
207 Fleurence, R. L. et al. (2006). Economic evaluations of interventions for the prevention and treatment 
of osteoporosis: a structured review of the literature. Osteoporosis International 17(1): 29-40.  
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Table 2.3 Direct medical costs of osteoporotic fractures reported by previous studies 





Lippuner et al.a Switzerland Administrative & medical 
claims, 2000 













U.K. Census data & surveys & 
national databases, 1998 









De Laet et al.c Netherlands Survey, 1990-1993 7,983 men & women ≧ 55 
years old 




Reginster et al.d Belgium National databases, 1996 2,374 hospitalized men & 
women ≧ 60 years old 




Autier et al.e Belgium 1-year perspective study, 
1995-1996 
170 hospitalized women ≧ 






Surveys on Ministries of 
Health, national statistics, 
2001 








Desai et al.g U.S. HMO Claims data, 
1998-1999 
600 women ≧ 45 years 
old 
all $939 /yr $1,281 /yr











HMO=health maintenance organization; yr=year 
† CHF=Swiss Francs; ₤ =UK Pound; €=Euro 
§ Converted to 2005 USD based on average foreign exchange rates at that year and U.S. Consumer Price Index (CPI) medical component;  
a. Lippuner et al. (2005). Osteoporosis International 16(Suppl 02): S8-S17. 
b. Dolan & Torgerson (1998). Osteoporosis International 8(6): 611-617. 
c. De Laet et al. (1999). Osteoporosis International 10(1): 66-72. 
d. Reginster et al. (1999). Pharmacoeconomics 15(5): 507-514. 
e. Autier et al. (2000). Osteoporosis International 11(5): 373-380. 
f. Finnern. & Sykes. (2003). Osteoporosis International 14(5): 429-436. 
g. Desai et al. (2003). Journal of Managed Care Pharmacy 9(2): 142-149. 
h. Gabriel et al. (2002). Osteoporosis International 13(4): 323-330. 
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Three cost-effectiveness studies were found in the literature to compare long-term 
outcomes of treatment options for glucocorticoid-induced osteoporosis.  Long-term 
outcomes of anti-osteoporotic treatments were estimated by Markov models in these 
three studies.  The first study was presented as a poster on November 11, 1998 at the 
annual meeting of the American College of Rheumatology.207F208  Homik et al. modeled 
the 10-year cost-effectiveness of bisphosphonates in the prevention of 
glucocorticoid-induced osteoporosis for hypothetical young women treated with 
glucocorticoid steroids.  The reported annual costs per patient for “no prophylaxis,” 
“conditional prophylaxis” and “universal prophylaxis” were $75, $170 and $780, 
respectively.  Compared with “no prophylaxis,” the incremental costs per vertebral 
fracture avoided were $2,000 for “conditional prophylaxis” and $9,000 for “universal 
prophylaxis.”   
The second study was conducted by Solomon and Kuntz who used a Markov 
model with simulations to estimate the long-term costs and quality-adjusted life years 
(QALYs) of three strategies involving alendronate use in the prevention of 
glucocorticoid-induced osteoporosis.208F209  The three strategies were “watchful waiting” 
(no screening, treated only when a fracture occurs), “screen and treat” (screening but 
treated only when the T-score of BMD is below -1.0) and “treat all” (treated without any 
screening).  The hypothetical cohorts were postmenopausal women aged 55 who were 
diagnosed with rheumatoid arthritis and about to initiate glucocorticoid therapy.  
Compared to the “watchful waiting” group, the incremental cost per QALY gained was 
                                                 
208 Homik, J. E. et al. (1998). Cost-effectiveness of bisphosphonates in the prevention of 
corticosteroid-induced osteoporosis. Arthritis and Rheumatism 4(Suppl. 9): S303.  
209 Solomon, D. H. & Kuntz, K. M. (2000). Should postmenopausal women with rheumatoid arthritis who 
are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis 
and Rheumatism 43(9): 1967-1975.  
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$93,150 for the “screen and treat” group and $100,000 for the “treat all” group.  The 
authors indicated that the results of modeling were still limited because the model used 
the efficacy data derived from the literature with few studies specifically targeting 
glucocorticoid users.  In a study for postmenopausal osteoporosis, for example, a range 
of $18,000 to $77,000 per quality adjusted life year (QALY) gained was reported to 
detect prevalent vertebral deformity in osteopenic postmenopausal women receiving 
alendronate therapy compared to no drug therapy.209F210   
The third study was conducted by Buckley and Hillner who used a Markov model 
to estimate the 10-year and lifetime costs and effectiveness of calcium and vitamin D 
supplements, cyclic etidronate, and alendronate in the prevention of vertebral fractures 
among four hypothetical cohorts of Caucasian women receiving one-year glucocorticoid 
therapy.210F211  The cohorts were 30-year-old women with normal BMD (T-score =0), 
50-year-old women with borderline bone loss (T-score =-1), 60-year-old women with 
moderate bone loss (T-score =-1.5) and 70-year-old women with severe bone loss 
(T-score =-2).  The incremental costs per vertebral fracture avoided ranged from $800 to 
$8,923 (10-year) or $800 to $1,944 (lifetime) for etidronate treatment, and ranged from 
$2,318 to $25,429 (10-year) or $2,318 to $2,728 (lifetime) for alendronate treatment 
compared to calcium/vitamin D treatment.  The combination of calcium and vitamin D 
supplements was the most cost-effective option for most comparisons.   
Table 2.4 summarizes important results of these three cost-effectiveness analyses 
of bisphosphonate treatment for prevention of glucocorticoid-induced osteoporosis.  
                                                 
210 Schousbue, J. T. et al. (2006). Cost-effectiveness of vertebral fracture assessment to detect prevalent 
vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate 
therapy: a modeling study. Journal of Clinical Densitomatry 9(2): 133-143.   
211 Buckley, L.M. & Hillner, B. E. (2003). A cost effectiveness analysis of calcium and vitamin D 
supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with 
glucocorticoids. Journal of Rheumatology 2003 30(1): 132-138.  
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Subjects of these studies were hypothetical women, and long-term estimations were 
based on Markov modeling.  The cost-effectiveness (CE) ratios of comparisons provide 
limited information for the management of glucocorticoid-induced osteoporosis.  
Compared to no treatment, Buckley et al. estimated a range of $838 to $121,125 and 
Homik et al. reported a range of $2,000 to $9,000 as the incremental costs per vertebral 
fracture avoided for bisphosphonate therapy in glucocorticoid users; Solomon et al. 
reported a range of $93,150 to $100,000 as the incremental cost per QALY gained for 
bisphosphonates in glucocorticoid users.  Some studies suggested that interventions 
should be implemented in glucocorticoid users for preventing or treating bone loss.  
Nevertheless, physicians seem reluctant to prescribe them.  The next section elaborates 
on some barriers to glucocorticoid-induced osteoporosis management in daily practice.   
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Table 2.4 Previous cost-effectiveness studies of bisphosphonate treatments for prevention 
of glucocorticoid-induced osteoporosis 













$2,000 d - 
   universal 
prophylaxis
$9,000 d - 
     
Solomon 
& Kuntzb 







   Treat all $100,000e 
     
Etidronate - $1,944dBuckley  
& Hillnerc 
Hypothetical 30 y/o women  
BMD T score=0 
 
Calcium 
+ vit D Alendronate - $2,728d
Etidronate $8,923d $1,563d Hypothetical 50 y/o women  




Etidronate $7,281d $1,169d Hypothetical 60 y/o women  




Etidronate $800d $800d Hypothetical 70 y/o women  
BMD T score=-2 
 
Alendronate $2,318d $2,318d
ICER=incremental cost-effectiveness ratio; RA=rheumatoid arthiritis; y/o=years old; 
a. Homik et al. (1998). Arthritis and Rheumatism 4(Suppl. 9): S303. 
b. “watchful waiting” (no screening, treated only when a fracture occurs), “screen & treat” (screening but 
treated only when the T-score of BMD is below -1.0), “treat all” (treated without any screening); Solomon 
& Kuntz (2000). Arthritis and Rheumatism 43(9): 1967-1975. 
c. ICERs were recalculated by using calcium/vit D as the reference group from tables in this reference. 
Buckley & Hillner (2003). Journal of Rheumatology 30(1): 132-138. 
d. Cost per vertebral fracture avoided. 
e. Cost per quality-adjusted life year (QALY) gained. 
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2.6 BARRIERS TO THE MANAGEMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 
Glucocorticoid-induced osteoporosis is undertreated.  A relatively low 
percentage of glucocorticoid users receive proper interventions for 
glucocorticoid-induced osteoporosis.  A population-based, retrospective study of British 
patients in general practices indicated that only 14% (41/303) of long-term (for at least 3 
months) oral glucocorticoid users aged 12-94 years had received preventive medication 
in the past four years.211F212  A total of 244,235 adult glucocorticoid users who registered 
with the U.K. General Practice Research Database (GPRD) before December 1997 
received at least one oral glucocorticoid prescription (mean =6.8 prescriptions, median =2 
prescriptions); about 4% to 5.5% of them used calcium/vitamin D, bisphosphonates, 
estrogens or calcitonin during oral glucocorticoid therapy.212F213  Of 215 adult outpatients 
who had received at least 5 mg of prednisone (or its equivalent) daily for at least one 
month at the San Francisco General Hospital from March 1996 to February 1997, 58% 
also received calcium, vitamin D, calcium/vitamin D combination or HRT.213F214  In a 
prospective study conducted in a district general hospital in the U.K. from January to 
September of 1999, 92 glucocorticoid users were identified and 51 of them were qualified 
for the prevention of glucocorticoid-induced osteoporosis.214F215  Of these 51 inpatients, 18 
(35.3%) received effective prophylaxis for glucocorticoid-induced osteoporosis (11 with 
bisphosphonates, seven with HRT), 10 received inadequate prophylaxis (five with 
calcium only, two with vitamin D only and three with calcium/vitamin D combination); 
                                                 
212 Walsh, L. J. et al. (1996). Use of oral corticosteroids in the community and the prevention of 
secondary osteoporosis: a cross sectional study. British Medical Journal 313(7053): 344-346.  
213 van Staa, T. P. et al. (2000). Use of oral corticosteroids in the United Kingdom. QJM 93(2): 105-111.  
214 Aagaard, E. M. et al. (1999). Prevention of glucocorticoid-induced osteoporosis: provider practice at 
an urban county hospital. American Journal of Medicine 107(5): 456-460.  
215 Hart, S. R. & Green, B. (2002). Osteoporosis prophylaxis during corticosteroid treatment: failure to 
prescribe. Postgraduate Medical Journal 78(918): 242-243.  
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three had previously used bisphosphonates but discontinued (due to poor compliance or 
intolerance) without taking another anti-osteoporotic agent; and 20 did not have any 
treatment for glucocorticoid-induced osteoporosis.   
Patients with osteoporotic fractures are also undertreated for further bone loss in 
general.  A study which surveyed hip fracture patients aged 65 or more in Canada 
showed that only 81 of 356 patients (23%) were treated with bisphosphonates, HRT, 
calcitonin or vitamin D3 after fractures.215F216  Bisphosphonates include alendronate and 
etidronate; risedronate was not available during the study.  Among these 81 patients, 74 
received bisphosphonates and 12 received HRT; 10 females received two different types 
of anti-osteoporotic agents during the post-fracture period; one female received three 
different drugs; and none received SERMs.   
The pattern of prevention also varies with different types of clinicians.  For 
example, rheumatologists and pulmonologists were more likely to prescribe medications 
for prevention of glucocorticoid-induced osteoporosis in comparison with other 
specialists.  Compared to internists, the odds ratios (ORs) of performing screenings for 
osteoporosis were 0.49 (95% CI 0.28-0.86) for gastroenterologists, 0.56 (95% CI 
0.30-1.04) for primary care physicians and 1.48 (95% CI 1.06-2.08) for rheumatologists 
in a study of 6,281 glucocorticoid users.216F217  Few gastrointestinal conditions require 
long-term glucocorticoid therapy, so gastroenterologists are less likely to screen for 
osteoporosis.  Many rheumatic diseases require chronic glucocorticoid therapy, so 
rheumatologists are more likely to order a check of bone mass.   
                                                 
216 Cree, M. W. et al. (2003). Mortality and morbidity associated with osteoporosis drug treatment 
following hip fracture. Osteoporosis International 14(9): 722-727.  
217 Curtis, J. R. et al. (2005). Longitudinal patterns in the prevention of osteoporosis in 
glucocorticoid-treated patients. Arthritis and Rheumatism 52(8): 2485-2494. 
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Some possible reasons have been noted in the literature for the insufficient 
treatment of glucocorticoid-induced osteoporosis: (1) physicians may not be convinced of 
the clinical importance of GIOP management; (2) the risk factors for different subgroups 
(gender, age, etc.) are unclear; and (3) there is a lack of supportive evidence for the 
efficacy or selection of therapeutic agents.217F218  Potential barriers to the treatment of 
postmenopausal osteoporosis were also noted: (1) “virtually silent” symptoms for 
osteoporosis; (2) lack of acceptance of the therapy; and (3) lack of adherence to 
long-term therapy for osteoporosis.218F 219   These points may be applicable to the 
management of glucocorticoid-induced osteoporosis.  From the perspective of primary 
care practice, the barriers to management of glucocorticoid-induced osteoporosis include: 
(1) the chance of developing glucocorticoid-induced osteoporosis or related osteoporotic 
fractures is relatively low in the general population; (2) not all individuals at risk develop 
osteoporosis; it is difficult to identify individual patients at risk; (3) even if osteoporosis 
and osteoporotic fractures occur, osteoporosis and vertebral fractures are silent unless 
there are symptomatic presentations (e.g., reduced height, back pain).  Therefore, some 
physicians are not convinced of the need for prevention of glucocorticoid-induced 
osteoporosis.   
Additionally, even if interventions are provided, bone loss cannot be completely 
recovered.  Many interventions effectively increase bone mineral density (BMD), but a 
patient’s BMD usually does not reach the original level.  Although the risk of 
osteoporotic fractures is decreased after interventions, some patients still develop 
osteoporotic fractures.  For example, 18 out of 38 patients who had received 
                                                 
218 Bijlsma, J. W. J. (1997). Prevention of glucocorticoid induced osteoporosis. Annals of the Rheumatic 
Diseases 56(9): 507-509.  
219 Cuddihy, M. T. (2003). Barriers to postfracture osteoporosis care in postmenopausal women: 
challenges and opportunities. Journal of General Internal Medicine 18(1): 70-71.  
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bisphosphonates, HRT, calcitonin or vitamin D3 (prior to fracture) still developed hip 
fractures in the study surveying 449 hip fracture patients aged 65 or more in Canada.219F220  
However, the dosage regimens and duration of the therapy were not reported in this 
study; it is unclear whether proper interventions were selected for these patients.   
Compliance and tolerance are important issues to be considered when long-term 
therapy for osteoporosis is planned.  Patients who receive long-term glucocorticoid 
therapy also require long-term interventions for preventing further 
glucocorticoid-induced bone loss.  The selection of the best therapy for 
glucocorticoid-induced osteoporosis should consider patients’ acceptance.  If 
compliance is low, then the therapeutic effects are reduced.  Low compliance may result 
from side effects of anti-osteoporosis therapy.   
Moreover, patients may have unequal access to care.  Even if patients have 
access to care, their willingness to pay for long-term, costly treatments varies.  All of the 
above reasons result in under-diagnosis and under-treatment of glucocorticoid-induced 
osteoporosis and related osteoporotic fractures.  Therefore, there is a need for studies 
which address these concerns and provide information regarding the management of 
glucocorticoid-induced osteoporosis.  The next section lists some of the areas that have 
not been addressed in the literature.   
 
2.7 GAPS IN THE LITERATURE AND POSSIBLE RESEARCH QUESTIONS 
Four missing pieces of information in the literature are identified.  First, the 
prevalence and incidence of glucocorticoid-induced osteoporosis and 
glucocorticoid-induced osteoporotic fractures in the U.S. have not been estimated.  
                                                 
220 Cree, M. W. et al. (2003). Mortality and morbidity associated with osteoporosis drug treatment 
following hip fracture. Osteoporosis International 14(9): 722-727.  
 67
More epidemiologic information allows for more accurate estimations of risks and 
economic burden of glucocorticoid-induced osteoporosis and glucocorticoid-induced 
osteoporotic fractures.  To estimate the prevalence and incidence rates in the U.S., the 
population at risk must be described.  No national estimates are currently available 
regarding background characteristics of glucocorticoid users in the U.S.  Some 
important characteristics (such as gender, age and glucocorticoid user) which may have 
an impact on outcomes should be assessed.   
The second missing piece of information in the literature is “real-world” 
outcomes of anti-osteoporotic treatments in glucocorticoid users.  Information regarding 
effectiveness (i.e., “real-world” use) of anti-osteoporotic agents is usually more 
meaningful than “ideal” drug efficacy data.  Although published studies have shown 
efficacy and effectiveness data for each therapeutic option for osteoporosis, most studies 
were not specifically designed for glucocorticoid users.  Therefore, results from these 
studies may not be applicable to glucocorticoid users.  Even if some studies targeted 
glucocorticoid users, there are many limitations including small sample sizes (which 
limits the study power), short observation periods for anti-osteoporosis interventions, and 
confounding issues (including underlying conditions).  Additionally, differences in 
study criteria may generate unfair comparisons across studies.  A study simultaneously 
comparing therapeutic options for glucocorticoid-induced osteoporosis is needed.  
Furthermore, glucocorticoid-induced bone loss may occur within three months, so there 
is a need for cost-effectiveness analyses to evaluate “short-term,” “real-world” outcomes 
of anti-osteoporotic agents.   
The third missing piece of information in the literature is long-term outcomes of 
anti-osteoporotic treatments in glucocorticoid users  Long-term glucocorticoid users 
require long-term preventive treatments to decrease the risk of glucocorticoid-induced 
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bone loss.  There is a need to evaluate long-term outcomes of these preventive 
treatments in glucocorticoid users.  No study was found to measure long-term outcomes 
of anti-osteoporotic treatments in glucocorticoid users.  Three studies used modeling 
techniques to estimate long-term outcomes related to osteoporosis and fractures for 
glucocorticoid users.  However, as described previously, the inputs of Markov models in 
these studies were derived from efficacy data instead of effectiveness data.  Use of 
effectiveness data as model inputs should yield long-term estimates which more likely 
reflect the real long-term outcomes.   
The fourth missing piece of information in the literature is the lack of 
comparisons among all anti-osteoporotic treatments for glucocorticoid users 
simultaneously.  It is difficult to synthesize study results and compare outcomes of 
anti-osteoporotic treatments across different studies which have different sets of study 
criteria, methodology and populations at risk.  A study is needed to make a fair 
comparison of outcomes among all anti-osteoporotic treatments for glucocorticoid users.   
These pieces of information, which include both short-term and long-term 
“real-world” cost-effectiveness outcomes of anti-osteoporotic treatments, will assist the 
decision-makers in selecting strategies which may manage glucocorticoid-induced 
osteoporosis and fractures in glucocorticoid users in a more proper way.  There is a need 
for a study which integrates all pieces of information, and provides an overall 
recommendation.   
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 Research Questions 
The following six research questions address issues relating to the above gaps in 
the literature.  The long-term users of oral glucocorticoid tablets in the U.S. were the 
main focus of this study.  Anti-osteoporotic treatments considered in this study include 
bisphosphosnates, calcitonin, hormone replacement therapy (HRT), raloxifene, the 
combination of HRT and bisphosphonates, teriparatide and no treatment. 
(1) How were anti-osteoporotic agents used in glucocorticoid users in the U.S.?  What 
are the characteristics of these users?  In order to make a fair comparison, can some 
confounding factors, which may have an impact on study outcomes, be explained or 
measured, or at least be partially controlled?  
(2) What are the prevalence and incidence rates of glucocorticoid-induced osteoporosis 
and related osteoporotic fractures in glucocorticoid users in the U.S.?   
(3) What are the average direct medical costs for evaluation of osteoporosis and for 
treatment of osteoporotic fractures in glucocorticoid users in the U.S.?   
(4) What are the average direct medical costs associated with anti-osteoporotic treatments 
in glucocorticoid users in the U.S.?   
(5) What are the long-term estimates of costs and osteoporotic fracture rates based on 
actual data from glucocorticoid users who used anti-osteoporotic agents and for those 
who did not?   
(6) What is the most cost-effective option among anti-osteoporotic treatments for the 
prevention of glucocorticoid-induced fractures for glucocorticoid users in the U.S.?  
The next sections describe the study goals, objectives and hypotheses which address 
these research questions.   
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2.8 STUDY OBJECTIVES  
Six study objectives were established to match the six research questions.  These 
study objectives are:  
(1) To describe and compare background characteristics of oral glucocorticoid tablet 
users using different anti-osteoporotic treatments in the U.S.  Anti-osteoporotic 
treatments include bisphosphonate therapy (BP), calcitonin therapy (CN), hormone 
replacement therapy (HT), a combination of HT & BP (HB), raloxifene therapy (RF) 
and “watching and waiting” strategy (control group, CT).  These characteristics 
include gender, age and glucocorticoid use;  
(2) To estimate the national annual prevalence and incidence rates of 
glucocorticoid-induced osteoporosis and related fractures in oral glucocorticoid 
tablet users in the U.S.; 
(3) To estimate national average direct medical costs associated with evaluation of 
osteoporosis and treatments of osteoporotic fractures in oral glucocorticoid tablet 
users in the U.S.;   
(4) To estimate and compare national average direct medical costs associated with 
preventive anti-osteoporotic treatments in oral glucocorticoid tablet users in the U.S.;   
(5) To develop a Markov model that projects two-year, 10-year and lifetime estimates of 
costs and effectiveness of anti-osteoporotic treatments for oral glucocorticoid tablet 
users in the U.S.; and  
(6) To suggest the best cost-effective option for the prevention and management of 
glucocorticoid-induced fractures in oral glucocorticoid tablet users in the U.S.   
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2.9 STUDY HYPOTHESES 
This section describes the hypotheses that were developed for four of the six 
study objectives.  Study subjects were categorized into subgroups by gender, type of 
glucocorticoid use, and type of anti-osteoporotic treatments.  Two types of 
glucocorticoid use include long-term glucocorticoid use (LTGS) for subjects who 
received oral glucocorticoid tablets for a minimal period of 90 days, and high-risk 
glucocorticoid use (HRGS) for subjects who received a minimal cumulative dose of 450 
mg of oral prednisone tablets (or its equivalent).  It is noted that LTGS and HRGS are 
not mutually exclusive to each other; some subjects are categorized into both types.  
Anti-osteoporotic treatments include bisphosphonate therapy (BP), calcitonin therapy 
(CN), hormone replacement therapy (HT), a combination of HT & BP (HB), raloxifene 
therapy (RF) and “watching and waiting” strategy (control group, CT).  Four sets of 
hypotheses are described in detail as follows. 
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2.9.1 Hypotheses for Objective One 
Average ages, average cumulative glucocorticoid doses, average cumulative 
quantity of glucocorticoid tablets and average glucocorticoid doses per tablet are 
compared among subgroups.  The hypotheses for the first objective are: 
 
 Average age 
Ho1A1: AgeLTGS-F(BP) =AgeLTGS-F(CN) =AgeLTGS-F(HB) =AgeLTGS-F(HT) =AgeLTGS-F(RF)  
=AgeCTL-F 
There is no significant difference in average ages among female long-term glucocorticoid 
users (LTGS) who received different anti-osteoporotic treatments.   
 
Ho1A2: AgeLTGS-M(BP) =AgeLTGS-M(CN) =AgeCTL-M 
There is no significant difference in average ages among male long-term glucocorticoid 
users (LTGS) who received different anti-osteoporotic treatments.   
 
Ho1A3: AgeHRGS-F(BP) =AgeHRGS-F(CN) =AgeHRGS-F(HB) =AgeHRGS-F(HT) =AgeHRGS-F(RF)  
=AgeCTL-F 
There is no significant difference in average ages among female high-risk glucocorticoid 
users (HRGS) who received different anti-osteoporotic treatments.   
 
Ho1A4: AgeHRGS-M(BP) =AgeHRGS-M(CN) =AgeCTL-M 
There is no significant difference in average ages among male high-risk glucocorticoid 
users (HRGS) who received different anti-osteoporotic treatments.   
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 Average cumulative glucocorticoid dose (CGSD) 
Ho1B1: CGSDLTGS-F(BP) =CGSDLTGS-F(CN) =CGSDLTGS-F(HB) =CGSDLTGS-F(HT)  
=CGSDLTGS-F(RF) =CGSDCTL-F 
There is no significant difference in average cumulative glucocorticoid doses (CGSD) 
among female long-term glucocorticoid users (LTGS) who received different 
anti-osteoporotic treatments.   
 
Ho1B2: CGSDLTGS-M(BP) =CGSDLTGS-M(CN) =CGSDCTL-M 
There is no significant difference in average cumulative glucocorticoid doses (CGSD) 
among male long-term glucocorticoid users (LTGS) who received different 
anti-osteoporotic treatments.   
 
Ho1B3: CGSDHRGS-F(BP) =CGSDHRGS-F(CN) =CGSDHRGS-F(HB) =CGSDHRGS-F(HT)  
=CGSDHRGS-F(RF) =CGSDCTL-F 
There is no significant difference in average cumulative glucocorticoid doses (CGSD) 
among female high-risk glucocorticoid users (HRGS) who received different 
anti-osteoporotic treatments.   
 
Ho1B4: CGSDHRGS-M(BP) =CGSDHRGS-M(CN) =CGSDCTL-M 
There is no significant difference in average cumulative glucocorticoid doses (CGSD) 
among male high-risk glucocorticoid users (HRGS) who received different 
anti-osteoporotic treatments.   
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 Average cumulative quantity of oral glucocorticoid tablets (CGSQ) 
Ho1C1: CGSQLTGS-F(BP) =CGSQLTGS-F(CN) =CGSQLTGS-F(HB) =CGSQLTGS-F(HT)  
=CGSQLTGS-F(RF) =CGSQCTL-F 
There is no significant difference in average cumulative quantity of oral glucocorticoid 
tablets (CGSQ) among female long-term glucocorticoid users (LTGS) who received 
different anti-osteoporotic treatments.   
 
Ho1C2: CGSQLTGS-M(BP) =CGSQLTGS-M(CN) =CGSQCTL-M 
There is no significant difference in average cumulative quantity of oral glucocorticoid 
tablets (CGSQ) among male long-term glucocorticoid users (LTGS) who received 
different anti-osteoporotic treatments.   
 
Ho1C3: CGSQHRGS-F(BP) =CGSQHRGS-F(CN) =CGSQHRGS-F(HB) =CGSQHRGS-F(HT)  
=CGSQHRGS-F(RF) =CGSQCTL-F 
There is no significant difference in average cumulative quantity of oral glucocorticoid 
tablets (CGSQ) among female high-risk glucocorticoid users (HRGS) who received 
different anti-osteoporotic treatments.   
 
Ho1C4: CGSQHRGS-M(BP) =CGSQHRGS-M(CN) =CGSQCTL-M 
There is no significant difference in average cumulative quantity of oral glucocorticoid 
tablets (CGSQ) among male high-risk glucocorticoid users (HRGS) who received 
different anti-osteoporotic treatments.   
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 Average glucocorticoid dose per tablet (DGSD) 
Ho1D1: DGSDLTGS-F(BP) =DGSDLTGS-F(CN) =DGSDLTGS-F(HB) =DGSDLTGS-F(HT)  
=DGSDLTGS-F(RF) =DGSDCTL-F 
There is no significant difference in average glucocorticoid dose per tablet (DGSD) 
among female long-term glucocorticoid users (LTGS) who received different 
anti-osteoporotic treatments.   
 
Ho1D2: DGSDLTGS-M(BP) =DGSDLTGS-M(CN) =DGSDCTL-M 
There is no significant difference in average glucocorticoid dose per tablet (DGSD) 
among male long-term glucocorticoid users (LTGS) who received different 
anti-osteoporotic treatments.   
 
Ho1D3: DGSDHRGS-F(BP) =DGSDHRGS-F(CN) =DGSDHRGS-F(HB) =DGSDHRGS-F(HT)  
=DGSDHRGS-F(RF) =DGSDCTL-F 
There is no significant difference in average glucocorticoid dose per tablet (DGSD) 
among female high-risk glucocorticoid users (HRGS) who received different 
anti-osteoporotic treatments.   
 
Ho1D4: DGSDHRGS-M(BP) =DGSDHRGS-M(CN) =DGSDCTL-M 
There is no significant difference in average glucocorticoid dose per tablet (DGSD) 
among male high-risk glucocorticoid users (HRGS) who received different 




2.9.2 Hypotheses for Objective Two 
Annual prevalence and incidence rates of glucocorticoid-induced osteoporosis and 
related fractures in glucocorticoid tablet users in the U.S. are estimated.  These rates are 
separately calculated for men and women and for long-term glucocorticoid users (LTGS) 
and high-risk glucocorticoid users (HRGS).  However, no hypothesis is needed for the 
second objective.   
 
2.9.3 Hypotheses for Objective Three 
Average direct medical costs associated with evaluation of osteoporosis and 
treatments of osteoporotic fractures in glucocorticoid tablet users in the U.S. are 
calculated.  These costs will be defined and methods of calculations will be described in 
Section 3.2.5.  Briefly, costs of evaluation of osteoporosis exclude costs of 
pharmacotherapy, and costs of fracture treatment include pharmacotherapy and surgery.  
It is assumed that these costs will be the same for all glucocorticoid users in the U.S. 
(Section 3.2.5) so only descriptive statistics will be presented.  No hypothesis is needed 
for the third objective.   
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2.9.4 Hypotheses for Objective Four 
Average direct medical costs of preventive anti-osteoporotic treatments (CTX) for 
glucocorticoid tablet users in the U.S. are calculated and compared.  Subjects using 
preventive anti-osteoporotic treatments are those who did not have prior osteoporotic 
fractures.  These costs are categorized by gender and type of glucocorticoid use.  For 
the fourth study objective, the hypotheses are: 
 
Ho4A1: CTXLTGS-F(BP) =CTXLTGS-F(CN) =CTXLTGS-F(HB) =CTXLTGS-F(HT) =CTXLTGS-F(RF)  
=CTXCTL-F 
There is no significant difference in average direct medical costs of preventive 
anti-osteoporotic treatments for female long-term glucocorticoid users (LTGS).   
 
Ho4A2: CTXLTGS-M(BP) =CTXLTGS-M(CN) =CTXCTL-M 
There is no significant difference in average direct medical costs of preventive 
anti-osteoporotic treatments for male long-term glucocorticoid users (LTGS).   
 
Ho4B1: CTXHRGS-F(BP) =CTXHRGS-F(CN) =CTXHRGS-F(HB) =CTXHRGS-F(HT) =CTXHRGS-F(RF) 
=CTXCTL-F 
There is no significant difference in average direct medical costs of preventive 
anti-osteoporotic treatments for female high-risk glucocorticoid users (HRGS).   
 
Ho4B2: CTXHRGS-M(BP) =CTXHRGS-M(CN) =CTXCTL-M 
There is no significant difference in average direct medical costs of preventive 
anti-osteoporotic treatments for male high-risk glucocorticoid users (HRGS).   
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2.9.5 Hypotheses for Objective Five 
Model-estimated average total direct medical costs and average effectiveness 
(fracture avoided) of 10-year or lifetime anti-osteoporotic treatments for glucocorticoid 
tablet users in the U.S. are compared.  For the fifth study objective, the hypotheses are:  
 
 Average costs of anti-osteoporotic treatments (COST) 
Ho5A1: COST10YR-F(BP) =COST10YR-F(CN) =COST10YR-F(HB) =COST10YR-F(HT)  
=COST10YR-F(RF) =COST10YR-F (CT) 
There is no significant difference in average direct medical costs of 10-year 
anti-osteoporotic treatments for female glucocorticoid tablet users.   
 
Ho5A2: COST10YR -M(BP) =COST10YR -M(CN) =COST10YR -M(CT) 
There is no significant difference in average direct medical costs of 10-year 
anti-osteoporotic treatments for male glucocorticoid tablet users.   
 
Ho5B1: COSTLIFE-F(BP) =COSTLIFE-F(CN) =COSTLIFE-F(HB) =COSTLIFE-F(HT)  
=COSTLIFE-F(RF) =COSTLIFE-F (CT) 
There is no significant difference in average direct medical costs of lifetime 
anti-osteoporotic treatments for female glucocorticoid tablet users.   
 
Ho5B2: COSTLIFE -M(BP) =COSTLIFE -M(CN) =COSTLIFE -M(CT) 
There is no significant difference in average direct medical costs of lifetime 
anti-osteoporotic treatments for male glucocorticoid tablet users.   
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 Average effectiveness of anti-osteoporotic treatments (EFF) 
Ho5C1: EFF10YR-F(BP) =EFF10YR-F(CN) =EFF10YR-F(HB) =EFF10YR-F(HT) =EFF10YR-F(RF)  
=EFF10YR-F (CT) 
There is no significant difference in average effectiveness of 10-year anti-osteoporotic 
treatments for female glucocorticoid tablet users.   
 
Ho5C2: EFF10YR -M(BP) =EFF10YR -M(CN) =EFF10YR -M(CT) 
There is no significant difference in average effectiveness of 10-year anti-osteoporotic 
treatments for male glucocorticoid tablet users.   
 
Ho5D1: EFFLIFE-F(BP) =EFFLIFE-F(CN) =EFFLIFE-F(HB) =EFFLIFE-F(HT) =EFFLIFE-F(RF)  
=EFFLIFE-F (CT) 
There is no significant difference in average effectiveness of lifetime anti-osteoporotic 
treatments for female glucocorticoid tablet users.   
 
Ho5D2: EFFLIFE -M(BP) =EFFLIFE -M(CN) =EFFLIFE -M(CT) 
There is no significant difference in average effectiveness of lifetime anti-osteoporotic 
treatments for male glucocorticoid tablet users.   
 
 80
2.9.6 Hypotheses for Objective Six 
Because of budget constrains, payers often establish a threshold cost-effectiveness 
value called the ceiling cost ratio (Rc).  The Rc for this study implies the maximum 
willingness-to-pay (WTP) to avoid an additional incidence of osteoporotic fractures.  
Compared to no treatment, Buckley et al. reported a range of $838 to $121,125 and 
Homik et al. reported a range of $2,000 to $9,000 as the incremental costs per vertebral 
fracture avoided for bisphosphonates.220F221, 221F222  Therefore, three arbitrary values of Rc are 
assumed for the purpose of testing hypotheses: $1,000, $10,000 and $100,000 per 
fracture avoided.  Long-term costs and effectiveness (fracture avoided) are compared 
between an anti-osteoporotic treatment and the control group.  Compared to the control 
group, the difference in model-estimated cost divided by the difference in 
model-estimated effectiveness for an anti-osteoporotic treatment is called the incremental 
cost-effectiveness ratio (ICER).  For the sixth study objective, the hypotheses are: 
 
Ho6A1: ICER10YR-F(BP) =ICER10YR-F(CN) =ICER10YR-F(HB) =ICER10YR-F(HT)  
=ICER10YR-F(RF) ≦Rc 
The incremental cost-effectiveness ratios (ICERs) of a 10-year anti-osteoporotic 
treatment for female glucocorticoid tablet users, compared to those who do not use any 
anti-osteoporotic agent, are less than or equal to the ceiling cost (Rc).  
 
 
                                                 
221 Buckley, L. M. et al. (2003). A cost effectiveness analysis of calcium and vitamin D supplementation, 
etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. 
Journal of Rheumatology 2003 30(1): 132-138.  
222 Homik, J. E. et al. (1998). Cost-effectiveness of bisphosphonates in the prevention of corticosteroid- 
induced osteoporosis. Arthritis and Rheumatism 4(Suppl. 9): S303.  
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Ho6A2: ICER10YR-M(BP) =ICER10YR-M(CN) ≦Rc 
The incremental cost-effectiveness ratios (ICERs) of a 10-year anti-osteoporotic 
treatment for male glucocorticoid tablet users, compared to those who do not use any 
anti-osteoporotic agent, are less than or equal to the ceiling cost (Rc).  
 
Ho6B1: ICERLIFE-F(BP) =ICERLIFE-F(CN) =ICERLIFE-F(HB) =ICERLIFE-F(HT)  
=ICERLIFE-F(RF) ≦Rc 
The incremental cost-effectiveness ratios (ICERs) of a lifetime anti-osteoporotic 
treatment for female glucocorticoid tablet users, compared to those who do not use any 
anti-osteoporotic agent, are less than or equal to the ceiling cost (Rc).  
 
Ho6B2: ICERLIFE-M(BP) =ICERLIFE-M(CN) ≦Rc 
The incremental cost-effectiveness ratios (ICERs) of a lifetime anti-osteoporotic 
treatment for male glucocorticoid tablet users, compared to those who do not use any 
anti-osteoporotic agent, are less than or equal to the ceiling cost (Rc).  
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2.10 SUMMARY OF CHAPTER TWO 
Literature reviews indicate that bisphosphonates, calcitonin, teriparatide and 
vitamin D3 have shown evidence of increasing bone mineral density (BMD) in 
glucocorticoid users in randomized controlled clinical trials (RCTs), and that only 
bisphosphonates have demonstrated preventive effects of reduction of osteoporotic 
fracture risks.  Nevertheless, bisphosphonates may not always be the best option for 
every patient because an RCT usually shows the “ideal” results (efficacy) and does not 
reflect the “real-world” conditions (effectiveness).  Other anti-osteoporotic agents may 
also reduce risk of osteoporotic fractures in long-term glucocorticoid users.  In addition, 
costs related to glucocorticoid-induced osteoporosis, osteoporotic fractures and 
anti-osteoporotic treatments in long-term glucocorticoid users were not previously 
reported in the literature.  More information is needed for proper management of 
glucocorticoid-induced osteoporosis and fractures.   
Limited information was found in the literature about long-term cost-effectiveness 
of anti-osteoporotic treatments.  Previous studies used Markov models to estimate these 
long-term outcomes, and the model inputs of these studies were derived from efficacy 
data.  However, these study results may not reflect treatment realities.  A study using 
“real-world” data as model inputs is needed.   
Based on gaps in the literature and research questions identified in this chapter, 
six study objectives were established.  Accordingly, study hypotheses were proposed 





This chapter describes the study methodology with brief reviews of the theoretical 
framework for cost-effectiveness analyses and Markov modeling.  There are six sections 
in this chapter.  The first section discusses the selection of study datasets, and describes 
the characteristics and structures of the study datasets.  The second section defines the 
target population, inclusion and exclusion criteria, clinical outcomes and economic 
outcomes for study subjects.   
The third section describes a cross-sectional analysis of the study groups.  The 
descriptive analyses not only provide background information about study samples, but 
also estimate annual prevalence and incidence rates of glucocorticoid-induced 
osteoporosis and osteoporotic fractures and average direct medical costs associated with 
evaluation of osteoporosis, treatment of osteoporotic fractures and anti-osteoporosis 
treatments.  The results of the descriptive analyses will address the first four study 
objectives, and these empirical statistics were used as inputs in the Markov model for this 
study.   
The fourth section describes the theoretical framework for economic evaluations, 
which is the foundation of cost-effectiveness analyses.  Some basic concepts and terms 
used in this study will be covered.  The fifth section reviews the technique of modeling 
in economic evaluation, and describes specifications of the Markov model for this study.  
The longitudinal projections by using Markov modeling will address the fifth study 
objective.  The long-term estimates of costs and fracture rates are also used in the 
cost-effectiveness analyses.   
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The sixth section highlights cost-effectiveness analyses (CEA) for this study by 
comparing costs and effectiveness simultaneously across anti-osteoporotic treatment 
options.  Compared to the cost and effectiveness in the control group, the incremental 
cost-effectiveness ratio (ICER) of each anti-osteoporotic treatment will be calculated and 
reported.  The results of cost-effectiveness analyses address the sixth study objective.  
A second-order Monte Carlo simulation is the method for probabilistic sensitivity 
analysis, and a one-way sensitivity analysis on annual discount rates was performed; 
sensitivity analyses help address parameter uncertainty in this study.  Plots for 
cost-effectiveness and acceptability curves of treatment options for male and female 
glucocorticoid users are provided.   
 
3.1 STUDY DATASETS 
Information presented in Chapter Two suggests the use of empirical data for 
analyses in glucocorticoid users for management of glucocorticoid-induced osteoporosis 
and osteoporotic fractures.  Even though previous studies have estimated costs and 
effectiveness of some anti-osteoporosis treatments, the use of hypothetical cohorts and 
efficacy data from randomized clinical trials yields hypothetical results, which may not 
reflect actual use of anti-osteoporotic treatments.  The uniqueness of this study is the use 
of “real-world,” nationally representative data to generate national estimates of costs and 
annual prevalence and incidence rates of osteoporosis and osteoporotic fractures in 
glucocorticoid tablet users.  Because this information is derived from “real-world” 
empirical data, the study results can more appropriately facilitate decisions regarding the 
use of anti-osteoporotic treatments than information derived from hypotheticalal data.  
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The appropriateness of data is one of the keys in this study, so the first part of this section 
discusses potential data sources and the selection of study datasets.   
 
3.1.1 Selection of Datasets 
The best dataset would be the one which is designed and collected specifically for 
this study, such as primary data from a new large-scale, longitudinal follow-up 
observational study.  However, because of budget and time constrains, the use of 
secondary data is more feasible for this study.  Some possible, available secondary 
dataset candidates include Medicare datasets, Medicaid datasets, the Veterans 
Administration (VA) datasets, private claims datasets from insurers, hospitals, consultant 
firms or health systems, and data obtained from national surveys.   
Some ideal features of secondary datasets for this study include: (1) 
representation of actual glucocorticoid users in the U.S.; (2) availability of needed 
economic and clinical outcomes; (3) availability of longitudinal information; and (4) easy 
and free accessibility.  The goal of data selection is to find datasets which meet as many 
of these features as possible.  The advantages and disadvantages of each type of datasets 
will be evaluated based on these features.   
Medicare datasets include national, longitudinal data and information about 
economic and clinical outcomes, and they are accessible.  However, the major covered 
lives in Medicare are the elderly aged 65 years old and over.  This population may 
account for a significant percentage of population at risk for osteoporosis, but do not 
represent population at risk for glucocorticoid-induced osteoporosis.   
Medicaid datasets include longitudinal data and information about economic and 
clinical outcomes.  The Texas Medicaid datasets are easily accessible from the study 
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site.  However, the major covered lives in Medicaid are the low-income or disabled 
people, who do not represent all glucocorticoid users.  Additionally, Texas Medicaid 
data are regional which do not provide national information.   
The Veterans Administration datasets also include longitudinal data and 
information about economic and clinical outcomes.  The Texas VA datasets are 
accessible with authorization from the regional offices in Texas.  However, the majority 
of covered lives in state VA datasets are men.  It is generally believed that women 
account for the majority of population at risk for all types of osteoporosis.  Further 
more, glucocorticoid-induced osteoporosis affects both men and women at any age who 
use prolonged glucocorticoid therapy so an ideal dataset should include both men and 
women at any age.  Therefore, Medicare, Medicaid and the VA datasets do not fit most 
needs for this study.   
Private claims datasets from insurers, hospitals, consultant firms or health systems 
usually contain data for men and women at all ages.  However, the covered lives in 
private claims datasets are frequently limited to the regions where services or plans are 
available.  Specially, claims datasets from hospitals likely include patients with more 
severe conditions than the general public.  Most importantly, the acquisition of private 
claims datasets is usually costly.  Therefore, private claims datasets do not fit the needs 
for this study.   
There are many national surveys, including the Medical Expenditure Panel 
Survey (MEPS).  MEPS is designed to generate nationally representative estimates of 
medical expenditures for the general public in the U.S. including men, women and 
children from newborns to 90 years old.  The MEPS public datasets are free and easy to 
access.  Most specifically, MEPS is designed for studies and projections of health and 
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economic outcomes in managed care.222F223  MEPS datasets contain economic and clinical 
information needed for this study.  One disadvantage of MEPS is the lack of laboratory 
data; specifically, the values of bone mineral density (BMD) would be an indicator of 
bone loss.  Although having information on BMD for this study would be useful, 
osteoporotic fractures are the main outcomes for this study.  A potential limitation is 
noted that subjects in MEPS were followed up for a period of two years, which may limit 
the generalizability of short-term outcomes for longitudinal projections.  Overall, the 
features of good national representation, surveys designed for cost-effectiveness analyses 
and free access qualify MEPS as the data source which best fits the study needs among 
all available sources.  Detailed features and the structure of MEPS datasets will be 
described below.   
 
3.1.2 Medical Expenditure Panel Survey (MEPS) 
3.1.2.1 Brief History of MEPS 
The Medical Expenditure Panel Survey (MEPS) is a set of nationwide surveys 
conducted by the Agency for Healthcare Research and Quality (AHRQ) and the National 
Center for Health Statistics (NCHS), the U.S. Department of Health and Human Services 
(DHHS).  Prior to MEPS, AHRQ had conducted two series of national surveys on costs 
and use of health care services in the U.S.: the National Medical Care Expenditure 
Survey (NMCES) since 1977 and the National Medical Expenditure Survey (NMES) 
since 1987.  After modification of the survey design aiming to “capture the changing 
                                                 
223 AHRQ (2004). Overview of the Medical Expenditure Panel Survey. Rockville, MD. URL: 
http://www.meps.ahrq.gov/WhatIsMEPS/Overview.HTM (Accessed July 31, 2006).. 
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dynamics of the health care delivery and insurance system,”223F224 beginning in March 
1996, MEPS has been collecting data and providing timely, “real-world,” nationally 
representative estimates of health care utilization, expenditures, sources of payments and 
health insurance coverage over time in the United States.   
 
3.1.2.2 Four Components 
MEPS consists of four component surveys: the Household Component (HC), the 
Medical Provider Component (MPC), the Insurance Component (IC), and the Nursing 
Home Component (NHC).  The target population of MEPS-HC is the U.S. civilian 
non-institutionalized population, and Hispanic Americans and Black Americans are 
over-sampled.224F 225   The sample design of the MEPS-HC includes stratification, 
clustering, multiple stages of selection and disproportionate sampling.  The unit of 
survey sampling is a household, and data are collected at both household and personal 
levels.  Sampled households were drawn from a nationally representative subsample of 
households who participated in the prior year’s National Health Interview Survey 
(NHIS), conducted by the National Center for Health Statistics (NCHS).  For example, 
the households sampled in the 1996 MEPS-HC came from approximately one-fourth of 
the households sampled in the 1995 NHIS.225F226   
The HC is the core survey which provides information on demographic 
characteristics, health conditions and status, health care utilization, charges and 
payments, access to care, satisfaction with care and health insurance coverage.  The HC 
                                                 
224 Cohen, S. B. (2000). Sample design of the 1997 Medical Expenditure Panel Survey Household 
Component. AHRQ Pub. No. 01-0001: MEPS Methodology Report 11:1-18. 
225 Cohen, S. B. (2000). Sample design of the 1997 Medical Expenditure Panel Survey Household 
Component. AHRQ Pub. No. 01-0001: MEPS Methodology Report 11:1-18. 
226 Ibid.  
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employs an overlapping panel design.  Each individual within the selected household 
participates in five interviews over a two-year period in one panel.  For example, 
participants in Panel 1 had two interviews in 1996 and three interviews in 1997; 
participants in Panel 2 had three interviews in 1997 and two interviews in 1998 (see 
Table 3.1).  Only selected core questions, such as health status, medical use, hospital 
admissions and purchase of medicines, were repeated.  The medical care events reported 
by participants in the HC survey are further validated by contacting hospitals, physicians, 
home health agencies and pharmacies identified by participants.   
The sum of subjects in all full-year consolidation files is 272,277, which consists 
of 22,601 (in 1996), 34,551 (in 1997), 24,072 (in 1998), 24,618 (in 1999), 25,096 (in 
2000), 33,556 (in 2001), 39,165 (in 2002), 34,215 (in 2003) and 34,403 (2004) 
observations, respectively (Table 3.1).  As mentioned earlier, a participant may have 
information for up to two years.  The total number of participants identified in 
consolidated files from 1996 to 2004 is 151,864.  The MEPS-HC overall response rates 
for public use files (PUFs) were 70.7% (in 1996), 66.8% (in 1997), 67.4% (in 1998), 
66.0% (in 1999), 65.8% (in 2000), 66.3% (in 2001), 64.7% (2002), 64.5% (2003) and 
63.1% (2004).226F227  
The MPC samples comprise contacts of medical providers and pharmacies 
identified by participants.  The MPC collects information on: (1) charges, payments and 
reasons for differences between the two; (2) diagnoses which are coded by ICD-9-CM 
(the International Classification of Disease, the ninth edition, Clinical Modification) and 
DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, the fourth version) 
                                                 
227 MEPS (2007) MEPS-HC Response Rates by Panel . URL: 
http://www.meps.ahrq.gov/mepsweb/survey_comp/hc_response_rate.jsp. Page last revisesd on April 22, 
2007; last accessed on July 7, 2007. 
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codes; (3) physician procedures which are classified by CPT-4 (Current Procedural 
Terminology, the fourth version) codes; (4) inpatient stays which are coded by DRG 
(diagnosis-related group) codes; and (5) prescribed medicines (medication names, 
national drug codes (NDC), strengths, quantity, dosages and dose forms, etc.).  The 
MPC data are only used to supplement household expenditure data and to facilitate 
matching, but not to replace household data.  Because of reasons such as lack of a 
participant’s consent or a medical provider’s cooperation, MPC data are not available for 
all reported events.   
 
Table 3.1 The MEPS panel design and the numbers of subjects in each full-year 
consolidated file 
 Rounds and number of subjects  





20,868        
 
43,469 




12,935       
 
26,618 




10,440      
 
21,577 




13,963     
 
28,141 




10,855    
 
21,988 




21,959   
 
44,660 



















subtotal 22,601 34,551 24,072 24,618 25,096 33,556 39,165 34,215 34,403 272,277
Response 
Rate 70.7% 66.8% 67.4% 66.0% 65.8% 66.3% 64.7% 64.5% 63.1%  
R1 =the first interview (round 1), R2 =the second interview (round 2), etc;  
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The sampling frames of the IC include employers or insurance companies 
identified by participants, a list of private insurance providers from the Bureau of the 
Census, and the public insurance programs.  The IC provides information on health 
insurance plans in both public and private sectors.  The NHC samples are obtained 
separately and serve as a supplement to the other components.227F228  The NHC provides 
information on nursing home residents regarding demographic characteristics, residence 
history, health and functional status, utilization and expenditures for healthcare services 
and prescriptions. The HC data are integrated with related data from other components 
and presented as free public-access HC datasets by calendar years.  For example, the 
1998 HC, MPC and IC data are integrated and aggregated from Round 4 to Round 5 of 
Panel 2 and Round 1 to Round 2 of Panel 3, as indicated in Table 3.1.   
 
3.1.2.3 Weighted Estimates 
The MEPS datasets provide year-specific personal weights and variance estimates 
of variables for each MEPS subject in each year.  The personal weights involve the 
household probability of selection for the NHIS, an adjustment for nonresponse and 
poststratification to related estimates from the Current Population Survey (CPS).  These 
variables were used to form weighted statistics and correct standard errors that reflect 
national estimates for the U.S. civilian non-institutionalized population.  To obtain 
overall weighted statistics from 1996 to 2004, data from each year are manipulated 
separately in most cases.  This is because year-specific personal weights and variance 
estimates of variables are derived from year-specific data that were separately reported in 
different years.   
                                                 
228 Cohen, S. B. (2000). Sample design of the 1997 Medical Expenditure Panel Survey Household 
Component. AHRQ Pub. No. 01-0001: MEPS Methodology Report 11:1-18. 
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For example, if a subject who was recruited in Panel 3 (January 1998-December 
1999), received alendronate from September 1998 to June 1999, a unique identification 
number (RXRECIDX) for each prescription of this prescribed medicine is assigned.  
Alendronate should be reported by this subject in 1998 (Round 2 of panel 3), and in 1999 
(Round 3 and Round 4 of panel 3).  Data associated with these alendronate prescriptions 
are reported separately in each round.  For alendronate prescriptions reported in 1998, 
for example, the weighted results for this subject should be calculated based on the 
personal weight and variance variables listed in 1998 PUFs; similarly, 1999 weighted 
estimates are based on variables listed in 1999 files.  The weighted estimate in each year 
files accounts for the portion of total national estimate that the subject represents in each 
year.   
Another example is that an osteoporotic fracture that occurred across two years 
for the same subject should be treated differently.  It is because costs, events and 
medical utilization associated with this fracture were reported separately in each year’s 
files.  Additionally, the incidence of fracture is represented differently in different years 
because the personal weights are different in each year for the same person.  Therefore, 
such a fracture accounts for one incidence in year one and another incidence in year two 
in calculations of weighted annual incidence rates of osteoporotic fractures.   
 
3.1.2.4 MEPS Public Used Data Files (PUFs) 
Data collected for MEPS in one calendar year were reported in that year’s public 
use data files (PUFs).  MEPS PUFs can be downloaded without any charge through the 
AHRQ web site (http://www.meps.ahrq.gov/) and are currently available from 1996 to 
2004.  The MEPS public use data files (PUFs) for each calendar year include (1) one 
 93
full-year consolidated data file; (2) one medical conditions file; (3) eight medical events 
files; and (4) two link files which were used to connect the above files.  Each personal 
identity is replaced by a computer-generated identification number (DUPERSID), and 
sensitive codes are collapsed for privacy and confidentiality.  Additionally, only the first 
three digits of ICD-9-CM condition codes and the first two digits of ICD-9-CM 
procedure codes are displayed in the public-access files.  Figure 3.1 uses 1998 datasets 
as an example to demonstrate relationships among year-specific MEPS public use data 
files (PUFs) and variables used for file linkage.  Some important variables in each 
year-specific public use data files are highlighted as follows.   
(1) Each record in the full-year consolidated files contains personal information 
and a summary of selected person-level statistics for the whole year.  This file is located 
on the left in Figure 3.1.  This person-level file contains information including 
demographic characteristics, insurance coverage, health status, measures of satisfaction 
with care, total expenditures and utilization summaries which are associated with each 
person within that particular year.   
(2) Each record in the medical conditions files represents a personal-level health 
condition.  A specific condition identification number (CONDIDX) is assigned to each 
condition, with which a corresponding event identification number (EVNTIDX) can be 
linked by the year-specific condition-event link file.  The file includes information on 
the start date of the condition, the round(s) during which the respondent saw doctors for 
this condition, whether a further treatment was recommended (yes/no), whether the 
respondent received follow-ups for the condition (yes/no), whether the condition was due 
to a fall, a flag associated with missed work/school days or bed days (yes/no), an 
ICD-9-CM condition code associated with the condition, an ICD-9-CM procedure code 
associated with the condition, and the numbers of visits (separated for prescriptions, 
 94
inpatient visits, outpatient visits, emergency room visits, office-based visits or home 




Figure 3.1 Relationships among MEPS 1998 public use data files and variables used for 
file linkage 
 
(3) Each record in the medical event files represents a unique medical event, such 
as a prescription, an inpatient stay, etc., and information associated with that event.  
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There are eight types of medical events in MEPS PUFs.  Selected variables in each 
medical event file are briefly described as follows:   
(A) The prescribed medicines file contains a specific identification number 
(RXRECIDX) for each prescription, a specific identification number for linking to 
corresponding event (LINKIDX) and information on the date when the medicine was 
obtained, the round during which the medicine was reported, imputed drug name, 
national drug code (NDC), imputed quantity, dosage form, strength, whether obtained as 
a free sample (yes/no), up to three 3-digit ICD-9-CM condition codes associated with this 
prescribed medicine, type of pharmacy, and the amount paid (imputed/edited).  The 
associated event can be identified via the year-specific event-link file;  
(B) The dental visits file is not used for this study;  
(C) The other medical expenses file contains a specific identification number for 
each event (EVNTIDX) and information on other medical type variables (such as glasses, 
insulin, medical equipment, disposable supplies, ambulance services, orthopedic items, 
hearing devices and bathroom aids), total number of other medical visits, flat fee 
variables and the amount paid;  
(D) The hospital inpatient stays file contains a specific identification number for 
each event (EVNTIDX), a specific link identification number (ERHEVIDX) if the 
subject was admitted after an emergency visit, and information on admission date, 
discharge date, total number of nights for stays, the reason for admission, any operations 
or surgeries performed (yes/no), up to four 3-digit ICD-9-CM condition codes, up to two 
2-digit ICD-9-CM procedure codes, total expenditures associated with this event, total 
charges, total facility charges, the actual amount paid for facility charges, total doctor fee 
charged and actual amount paid for total doctor fees;  
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(E) The emergency room visits file contains a specific identification number for 
each event (EVNTIDX), a specific ID corresponding to inpatient stays (ERHEVIDX) if 
the patient was admitted to a hospital after the emergency room visit, and information on 
the event date, any X-rays received (yes/no), any surgeries performed (yes/no), any 
medication prescribed (yes/no), up to three 3-digit ICD-9-CM condition codes, up to two 
2-digit ICD-9-CM procedure codes, total expenditure for this event, total charges, total 
facility charges, the amount paid for facility charges, total doctor fee charged and the 
amount paid for total doctor fee;  
(F) The outpatient department visits file contains a specific identification 
number for each event (EVNTIDX) and information on the event date, physician 
specialty, any X-rays received (yes/no), any medicine prescribed (yes/no), up to four 
3-digit ICD-9-CM condition codes, up to three 2-digit ICD-9-CM procedure codes, total 
number of visits, total expenditure for this event, total charges, total facility charges, the 
amount paid for total facility charges, total doctor fee charged and the amount paid for 
total doctor fee;  
(G) The office-based medical provider visits file contains a specific 
identification number for each event (EVNTIDX) and information on the event date, 
physician specialty, any X-rays received (yes/no), any medicine prescribed (yes/no), up 
to four 3-digit ICD-9-CM condition codes, up to three 2-digit ICD-9-CM procedure 
codes, total number of visits and the amount paid; and  
(H) The home health care file contains a specific identification number for each 
event (EVNTIDX) and information on the event date, the event type, the type of health 
care worker, any home health service due to hospitalization (yes/no) or due to health 
condition (yes/no), any medical treatment received (yes/no), the number of days in the 
facility or time spent in each visit and the amount paid.   
 97
(4) Each record in two specified link files (IF1 and IF2) contains a set of specific 
identification numbers by which condition and medical events files can be linked with 
each other.   
Study variables from each PUF are retained, files from the same year are linked 
and files of the same type from different years are merged.  The next step is to identify 
study samples.  In the next section, the study inclusion and exclusion criteria are 
described in detail.   
 
3.2 INCLUSION AND EXCLUSION CRITERIA 
This study focused on comparisons of outcomes among different anti-osteoporotic 
treatments in users of oral glucocorticoid steroid tablets, so each piece of information 
needs to be carefully defined.  This section lists inclusion and exclusion criteria for 
study samples and definitions of anti-osteoporotic treatments, clinical and economic 
outcomes and comparators for analyses.   
 
3.2.1 Target Population   
The target population for this study is oral glucocorticoid tablet users in the U.S. 
civilian non-institutionalized population.  MEPS datasets are the primary data source for 
this study and the target population of MEPS is the U.S. civilian non-institutionalized 
population, so the study population is limited accordingly.  Glucocorticoid users are 
limited to MEPS subjects who reported use of oral glucocorticoid tablets.  The 
definitions of study subjects are described below.   
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3.2.1.1 Limits to Oral Glucocorticoid Tablets 
Only glucocorticoid forms which have systemic effects on bone mass loss are 
considered for this study.  There are five reasons to include oral dosage forms and to 
exclude other forms of glucocorticoid steroids.  First, the spray/inhaler and topical forms 
(such as ophthalmic drops, creams, lotions and ointments) are excluded.  Next, the 
injections are also excluded because an injectable form is unlikely to be used by patients 
for long-term glucocorticoid therapy, and because many injectable glucocorticoid steroids 
are discontinued for safety reasons.  Third, the solutions and suspensions are also 
excluded because topical solutions and suspensions cannot be differentiated from oral 
solutions and suspensions, respectively, in MEPS data.  Fourth, the syrups are also 
excluded because this form is likely used by children who have the lowest chance to 
develop osteoporosis and osteoporotic fractures.  Finally, the tablet form is retained 
because it is used for the majority of glucocorticoid users in the target population.  
Moreover, focusing on oral tablets makes future interpretations easier.   
 
3.1.2.2 Study Samples 
The 2001 American College of Rheumatology (ACR) Recommendation for 
Glucocorticoid-Induced Osteoporosis 228F229 and the physician’s guideline from the National 
Osteoporosis Foundation (NOF)229F230 defined long-term glucocorticoid users as users of 
prednisone (or its equivalent) at a minimal daily dosage of 5 mg for at least three months.  
However, the cumulative glucocorticoid dose is a more important indicator for bone loss 
                                                 
229 ACR (2001). Recommendations for the prevention and treatment of glucocorticoid-induced 
osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on 
glucocoritcoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503.  
230 NOF. (2003). Physician's guide to prevent and treatment of osteoporosis. National Osteoporosis 
Foundation; Washington, D.C. 1-37.  
 99
than the daily glucocorticoid dosage or the duration of glucocorticoid therapy.230F 231  
Nonetheless, all patients on glucocorticoid therapy at any dose for any length of treatment 
ought to monitor possible glucocorticoid-induced bone loss, so both a broader and a 
restricted definition for glucocorticoid users are considered for this study: long-term 
glucocorticoid users (LTGS) and high-risk glucocorticoid users (HRGS).  
Glucocorticoid use is defined in detail in Section 3.2.2.2.  It is noted that the criteria for 
glucocorticoid users may not cover all glucocorticoid tablets such as cases where subjects 
had previously received glucocorticoid therapy which was not recorded during the 
periods of data collection.   
This study focused on subjects who have received oral glucocorticoid tablets for 
at least three months (long-term glucocorticoid users) and those who have received 
prednisone (or equivalent) tablets at a minimal cumulative dose of 450 mg (high-risk 
glucocorticoid users).  Based on previous estimates of prevalence rates, approximately 
0.7% to 0.9% of the general population received oral glucocorticoid steroids.231F232, 232F233  
Given a total unweighted number of 272,277 subjects in 1996-2004 MEPS datasets (see 
Table 3.1), the unweighted number of glucocorticoid tablet users in these data files is 
estimated to range from 1,906 to 2,450 subjects, which represents approximately 2.03 to 
2.62 million glucocorticoid users in the U.S.233F234   
 
                                                 
231 van Staa, T. P. et al. (2000). Oral corticosteroids and fracture risk: relationship to daily and cumulative 
doses. Rheumatology 39(12): 1383-1389.  
232 Gudbjornsson, B. et al. (2002). Prevalence of long term steroid treatment and the frequency of 
decision making to prevent steroid induced osteoporosis in daily clinical practice. Annals of the Rheumatic 
Diseases 61(1): 32-36.  
233 van Staa, T. P. et al. (2000). Use of oral corticosteroids in the United Kingdom. QJM 93(2): 105-111.  
234 The estimated U.S. civilian non-institutionalized population is 290,850,005 in 2003, according to the 
data from the U.S. Census Bureau (2005). National and state dataset in comma separated values file. The 
U.S.Census Bureau and Population Division, The U.S. Department of Commerce. Washington, DC. 
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3.2.2 Medication Use 
The use of medications for this study includes the use of oral glucocorticoid 
tablets and the use of anti-osteoporotic agents.  Each medication is described and 
defined.  Some common definitions are listed before the definitions of medications.   
 
3.2.2.1 General Definitions for All Medications 
The MEPS prescribed medicines files include three variables (RXBEGDD, 
RXBEGMM and RXBEGYRX) which indicate the start date of the medication; however, 
some data points for these variables are missing.  To estimate the start date for a 
prescribed medicine, the start date of the round when the prescribed medicine was 
reported serves as a proxy of the start date of the prescribed medicine.  The variables for 
these reference dates include BEGRFD31, BEGRFM31, BEGRFY31, BEGRFD42, 
BEGRFM42, BEGRFY42, BEGRFD53, BEGRFM53 and BEGRFY53.  The index date 
of a medication is defined as the earliest start date reported by the subject in MEPS data 
between 1996 and 2004.  The index date for a medication is important in determining a 
prior experience related to osteoporosis and/or osteoporotic fractures.   
The length of a treatment needs to be defined.  To estimate the length of a 
treatment, the quantity of a medication (RXQUANTY) serves as a proxy.  This 
definition assumes continuous use of a medication without considering compliance and 
possible gaps.  Except for weekly use of bisphosphonates and dosage regimens for 
HRT, most anti-osteoporotic agents are administered once daily (i.e., the label use 
approved by the FDA).  Therefore, the length of a treatment can be estimated by the 
quantity of a medication.  Proper adjustments are implemented for non-once-per-day 
dose regimen for bisphosphonates and HRT.   
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The names of prescribed medicines (RXNAME) in MEPS prescribed medicines 
files are imputed and presented as the generic names or the most common brand names.  
The following names of prescribed medicines were used in this study for identifying 
users of glucocorticoid steroids and users of anti-osteoporotic agents.  Some 
anti-osteoporotic agents are also used to treat conditions other than osteoporosis or 
fractures, so the exclusion criteria for each anti-osteoporotic agent are described.   
 
3.2.2.2 Glucocorticoid Therapy (GS) 
The use of oral glucocorticoid tablets is defined as any use of oral prednisone (or 
its equivalent) tablets.  The glucocorticoid steroids include cortisone (cortisone acetate), 
betamethasone (Celestone®), dexamethasone (Decadron®, Dexameth®, Dexone® or 
Hexadrol®), hydrocortisone (Cortef® or Hydrocortone®), methylprednisolone (Medrol®), 
prednisone (Meticorten®, Orasone®, Panasol-s®, Deltasone®, Prednicen-m®, Sterapred® 
or Sterapred DS®), prednisolone and triamcinolone (Aristocort®).  Glucocorticoid use is 
characterized by three indicators: cumulative glucocorticoid dose, a cumulative quantity 
of glucocorticoid tablets and average daily glucocorticoid dose.  The strengths of 
different glucocorticoid steroids are converted to equivalent dosage of prednisone.  
Long-term glucocorticoid use (LTGS) for this study is defined as the use of oral 
glucocorticoid tablets for a total period of 90 days or more.  High-risk glucocorticoid 
use (HRGS) for this study is defined as the use of prednisone (or its equivalent) at a 
cumulative dose of at least 450 mg (which is calculated by multiplying 5 mg of 
prednisone by 90 days).  Table 3.2 lists the equivalent dosage of various glucocorticoid 
steroids to prednisone, and their corresponding 90-day accumulated dosage.   
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The cumulative glucocorticoid dose for each subject was calculated by summmg 
up the product of the glucocorticoid dose multiplied by the number of tablets for each 
qualified glucocorticoid prescription reported by the subject.  Qualified glucocorticoid 
prescriptions refer to prescriptions of oral prednisone (or equivalent) tablets.  The 
cumulative quantity of glucocorticoid tablets for each subject was calculated by summing 
up the the number of tablets for each qualified glucocorticoid prescription reported by the 
subject.   
 


















Betamethasone 0.75 67.5 Methylprednisolone 4 360 
Cortisone 25   2,250  Prednisolone 5 450 
Dexamethasone 0.75 67.5 Prednisone 5 450 




3.2.2.3 Bisphosphonates (BP) 
Bisphosphonates used for this study include alendronate (alendronate sodium or 
Fosamax®) and risedronate (risedronate sodium or Actonel®), because the U.S. Food and 
Drug Administration (FDA) only approved these two products for the management of 
glucocorticoid-induced osteoporosis (5 mg/day or 10 mg/day for alendronate, 5 mg/day 
for risedronate, etc. see Table 2.1).  If a dosage of 40 mg of alendronate or 30 mg of 
risedronate was reported, these subjects were excluded.  Bisphosphonates at those doses 
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probably were used for Paget’s disease (an ICD-9-CM code of 731).  If an ICD-9-CM 
code of 731 was reported in any one of three variables for ICD-9-CM codes, these 
subjects were excluded.  Adverse drug events for bisphosphonates are defined as a 
diagnosis of any of the following ICD-9-CM codes: 530 (disease of esophagus), 531 
(gastric ulcer), 532 (duodenal ulcer), 533 (peptic ulcer, site unspecified), 535 (gastritis 
and duodenitis), 536 (disorders of function of stomach), 578 (Gastrointestinal 
hemorrhage), 787 (Symptoms involving digestive system), and 789 (Other symptoms 
involving abdomen and pelvis).234F235, 235F236  
A study used a large claims database to investigate the medication costs of 
alendronate, risedronate and nasal calcitonin in the first year after a fracture. 236F237  The 
average annual direct medical costs for non-vertebral fractures were $320, $110 and $512 
for alendronate, risedronate and calcitonin, respectively.237F 238  The average costs for 
gastrointestinal (GI) adverse reaction were $72 for alendronate and $26 for risedronate 
(2002 dollars).238F239 
 
3.2.2.4 Calcium and Vitamin D Preparations (CA) 
The MEPS datasets do not include information regarding over-the-counter (OTC) 
use of calcium and vitamin D products.  The inclusion of calcium and vitamin D 
                                                 
235 Miller, R. et al. (2004). Incidence of gastrointestinal events among bisphosphonate patients in an 
observational study. The American Journal of Managed Care, 10(7): S207-S215. 
236 Kane, S. et al. (2004). Pharmacoeocnomic evaluation of gastrointestinal tract events during treatment 
with risedronate or alendronate: a retrospective cohort study. The American Journal of Managed Care, 
10(7): S216-S226. 
237 Brixner, D. (2006). Assessment of the prevalence and costs of osteoporosis treatment options in a 
real-world setting. The American Journal of Managed Care, 12(7 Supple.): S191-S198. 
238 Ibid. 
239 Kane, S. et al. (2004). Pharmacoeocnomic evaluation of gastrointestinal tract events during treatment 
with risedronate or alendronate: a retrospective cohort study. The American Journal of Managed Care, 
10(7): S216-S226. 
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preparations may lead to inaccurate estimations, so calcium and vitamin D preparations 
are excluded as one comparison group for this study.  Additionally, as mentioned in 
Section 2.4.1, calcium and vitamin D are frequently recommended for interventions 
associated with bone loss, and are frequently included in both study and control groups.  
It is assumed that all study subjects used calcium and vitamin D preparations daily, and 
that the effects of calcium and vitamin D products on fracture rates are equal.  
Therefore, the effects of calcium and/or vitamin D products on osteoporosis or 
osteoporotic fractures are not specifically considered in this study.   
 
3.2.2.5 Calcitonin (CN)  
Calcitonin is available as nasal spray (200 IU/spray) and injection (200 IU/ml).  
Calcitonin salmon (Miacalcin®) was approved by the FDA before 1995, so Miacalcin® 
users were included in this study.  Calcitonin salmon recombinant (Fortical®) was 
approved by the FDA on Aug 12, 2005, which is beyond the study period (1996-2004), 
so Fortical® is not included in this study.  Miacalcin® nasal spray (2200 IU/mL 
calcitonin-salmon in a 3.7-ml glass bottle) is usually used one spray (200 IU or 0.09 mL 
per spray) in one nostril each day alternating nostrils daily, so the quantity of calcitonin 
sprays could be the proxy for duration of therapy.  A bottle of Miacalcin® provides at 
least 1-month supply of nasal sprays.  Calcitonin can also be used for Paget’s disease.  
If an ICD-9-CM code of 731 is reported in any of three variables for ICD-9-CM 
diagnosis, the subjects will be excluded.  Adverse drug events for calcitonin are defined 
as a diagnosis of any of the following ICD-9-CM codes: 782 (symptoms involving skin 
and other integumentary tissue, including skin flushing) and 787 (symptoms involving 
digestive system, including nausea and vomiting).   
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3.2.2.6 Hormone Replacement Therapy (HT) 
Hormone replacement therapy for this study refers to the use of estrogen-and 
progestin-containing drug products, including estrogen, estradiol (Alora®, Angeliq®, 
Climara®, Climara Pro®, Combipatch®, Esclim®, Estraderm®, Estrasorb®, Femring®, 
Fempatch®, Vivelle® or Vivelle-dot®), gynodiol (Estrace®), conjugated estrogen 
(Premarin® or Enjuvia®), esterified estrogen (Estratab® or Menest®), estropipate 
(Ortho-estm® or Ogen®), or estrogen and progestin combined (Activella®, femhrt®, 
Ortho-prefest®, Prefest®, Prempro® or Premphase®) in forms of tablets, transdermal 
systems (patches), emulsion/gels and vaginal rings.239F240  Although the Women’s Health 
Initiative (WHI) trial indicated that conjugated estrogens plus medroxyprogesterone 
increased the risks of invasive breast cancer in postmenopausal women, hormone 
replacement therapy is still included in this study.  This is because hormone replacement 
therapy is believed to be frequently used during the period of 1996 and 2004 in which 
study data were obtained.  Even if hormone replacement therapy was originally 
prescribed for treating postmenopausal symptoms, the effects of hormone replacement 
therapy on preventing osteoporotic fractures remain.  However, hormone replacement 
therapy is not expected to be used by men for this study, so male subjects were excluded 
for hormone replacement therapy.  Adverse drug events for hormone replacement 
therapy are defined as a diagnosis of any of the following ICD-9-CM codes: 174 
(malignant neoplasm of female breast), 179 (malignant neoplasm of uterus, part 
unspecified), 182 (malignant neoplasm of body of uterus), 410-414 (ischemic heart 
disease), 430-438 (cerebrovascular disease), 444 (arterial embolism and thrombosis), 445 
                                                 
240 Drug Facts and Comparisons 57th ed. (2003). Wolters Kluwer Company; St. Louis, Missouri, Pages 
251-266.  
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(atheroembolism), 451 (phlebitis and thrombophlebitis) and 453 (other venous embolism 
and thrombosis).240F241, 241F242, 242F243, 243F244, 244F245   
 
3.2.2.7 Combination of Hormone Replacement and Bisphosphonate Therapy (HB)   
Eleven combinations are possible: [BP-HT], [BP-raloxifene (RF)], [BP-CN], 
[HT-RF], [HT-CN], [RF-CN], [BP-HT-RF], [BP-HT-CN], [BP-RF-CN], [HT-RF-CN] 
and [BP-HT-RF-CN].  However, as mentioned in Section 2.4.7, combination therapy is 
currently not recommended because the small additive protective effects of using 
combination therapy may not outweigh increased chances of potential adverse reactions.  
Only the combination of hormone replacement and bisphosphonate therapy (HB) is 
included in this study because: (1) this combination is more popular than other 
combinations; and (2) this combination has demonstrated risk reduction of osteoporotic 
fractures compared to monotherapy of bisphosphonates or hormone replacement therapy 
in an observational study.245F246  The observation window for the HB combination is 
unclear, so the inclusion criterion for length of HB therapy also depends on the inclusion 
                                                 
241 Rossouw, J. E. et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal 
women: principal results from the Women's Health Initiative randomized controlled trial. The Journal of 
the American Medical Association, 288(3): 321-333. 
242 Pentti, K. et al. (2006). Hormone replacement therapy and mortality in 52-to 70-year-old women: the 
Kuopio Osteoporosis Risk Factor and Prevention Study. European Journal of Endocrinology, 154(1): 
101-107. 
243 Daly, E. et al. (1996). Hormone replacement therapy in a risk-benefit perspective. Maturitas, 23(2): 
247-259. 
244 Armstrong, K. et al. (2001). Cost-effectiveness of raloxifene and hormone replacement therapy in 
postmenopausal women: impact of breast cancer risk. Obstetrics & Gynecology, 98(6): 996-1003. 
245 Yu, Y. F. et al. (2004). Cost-effectiveness analysis of long-term hormone replacement therapy 
(estrogen plus progestin) in healthy postmenopausal women for osteoporosis prevention. Value in Health, 
7(3): 296-296. 
246 Tiller, W. (2004). Alendronate and hormone replacement therapy in the prevention of osteoporotic 
fracture: A pharmacoeconomic analysis employing a net-benefit regression method of cost-effectiveness. 
Dissertation. The University of Texas at Austin, Austin, TX. 325 Pages. 
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criteria for bisphosphonates in order to facilitate comparisons.  Adverse drug events for 
this combination therapy include all ICD-9-CM codes identified as adverse drug 
reactions for bisphosphonates and hormone replacement therapy described previously.   
 
3.2.2.8 Raloxifene (RF)  
Raloxifene (raloxifene hydrochloride, RF) is the only FDA-approved prescribed 
medicine among selective estrogen receptor modulators (SERMs) for treatment of 
post-menopausal osteoporosis.  No indication of raloxifene is for men, so male subjects 
are excluded.  The brand name of raloxifene is Evista® which is available as 60 mg 
tablets.  Adverse drug events for raloxifene include the same set of ICD-9-CM codes as 
adverse drug reactions for hormone replacement therapy.   
 
3.2.2.9 Teriparatide (PT) 
The parathyroid hormone for treating osteoporosis is teriparatide (Forteo® or 
PTH).  The BMD reduction and the anti-fracture effect of teriparatide may be observed 
after one year of teriparatide therapy.246F 247 , 247F 248   Because Forteo® was approved in 
November 2002, and the publicly available MEPS datasets contain data up to 2004, the 
anti-fracture effects of teriparatide are likely not reported in the 1996-2004 MEPS 
datasets.  Therefore, teriparatide is excluded in this study.   
 
                                                 
247 Lane, N. E. et al. (2000). Bone mass continues to increase at the hip after parathyroid hormone 
treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled 
clinical trial. Journal of Bone and Mineral Research 15(5): 944-951.  
248 Lane, N. E. et al. (2000). Short-term increases in bone turnover markers predict parathyroid 
hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced 
osteoporosis. Osteoporosis International 11(5): 434-442.  
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3.2.3 Subgroups for Comparisons 
MEPS subjects are classified into subgroups by some confounding factors in 
order to partially control the contributions of these factors to the outcomes of interests.  
Important confounding factors include gender, glucocorticoid use, length of 
anti-osteoporotic treatments, age and the underlying conditions.  However, not all of 
these factors are controlled in the analyses.  In order to generate nationally 
representative estimates from MEPS data, it generally requires at least 15 subjects with 
positive personal weights in each subgroup.248F249  If the subgroup classification does not 
yield a sufficient number of subjects in each subgroup, information from different levels 
of a factor may be used.  Figure 3.2 shows a conceptual diagram of relations associated 
with gender, glucocorticoid use and use of anti-osteoporotic agents to overall 
osteoporosis and osteoporotic fractures.   
It is known that men and women have different risks of osteoporosis or 
osteoporotic fractures, so male and female subjects should be considered separately.  
Subjects are also categorized into three types of glucocorticoid use: (1) high-risk 
glucocorticoid use (HRGS); (2) long-term glucocorticoid use (LTGS); and (3) all MEPS 
subjects regardless of glucocorticoid use.  It is noted that these categories of 
glucocorticoid use are not mutually exclusive: HRGS users are usually included in LTGS 
users, which are included in all MEPS subjects.  Among either HRGS, LTGS or MEPS 
subjects, there are six groups of anti-osteoporotic treatments, of which three of them were 
used for females only.  Therefore, a total of three subgroups for men and six subgroups 
for women exist for each type of glucocorticoid use.   
                                                 
249 Personal communications with experienced members of the AHRQ's question & discussion group 
regarding MEPS.  
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A minimal period of 90 days for anti-osteoporotic treatments was used for all 
subjects who reported anti-osteoporotic medications.  Two reasons support this 
restriction: (1) it reflects the shortest time for observing a possible incidence of 
osteoporotic fractures after the use of anti-osteoporotic medications; and (2) it matches a 
minimal period of 90 days for glucocorticoid therapy.  The minimal period of 
observation needed to determine the anti-fracture effects of each anti-osteoporotic agent 
is not certain.  Reports indicate that the shortest period of effective bisphosphonate 
therapy for preventing osteoporotic fractures is three months and for raloxifene is 12 
months.  A significant reduction (P =0.044) for multiple symptomatic vertebral fractures 
could be found as early as three months after alendronate therapy.249F250  The Multiple 
Outcomes of Raloxifene Evaluation (MORE) study indicates that the anti-fracture effect 
of raloxifene could be found as early as one year after the therapy is initiated.250F251, 251F252  
There is no report in the literature about the observation period needed for other 
anti-osteoporotic treatments to be effective in preventing osteoporotic fractures.   
The categories regarding anti-osteoporotic treatments are explained in detail 
below:  
(1) control (CT) group includes subjects who may or may not report 
calcium/vitamin D preparations but did not report any use of other anti-osteoporotic 
medications in MEPS data between 1996 and 2004;  
                                                 
250 Levis, S. et al. (2002). Alendronate reduces the risk of multiple symptomatic fractures: results from 
the Fracture Intervention Trial. Journal of the American Geriatrics Society 50(3): 409-415.  
251 Ettinger, B. et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with 
osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Journal of the 
American Medical Association 282(7): 637-645. 
252 Seeman, E. et al. (2006). Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis 
International 17(2): 313-316.  
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(2) bisphosphonate group (BP) includes subjects who reported bisphosphonates 
(i.e., Actonel®, alendronate, Fosamax® or risedronate) with or without reporting 
calcium/vitamin D preparations but who did not report any use of other anti-osteoporotic 
medications in MEPS data between 1996 and 2004;  
(3) calcitonin group (CN) includes subjects who reported calcitonin (or 
Miacalcin®) with or without reporting calcium/vitamin D preparations but who did not 
report any use of other anti-osteoporotic medications in MEPS data between 1996 and 
2004;  
(4) hormone replacement therapy group (HT) includes female subjects who 
reported medications listed previously for hormone replacement therapy with or without 
reporting calcium/vitamin D preparations but who did not report any use of other 
anti-osteoporotic medications in MEPS data between 1996 and 2004;  
(5) The group of hormone replacement and bisphosphonate combination 
therapy (HB) includes female subjects who reported the use of both bisphosphonates and 
medications for hormone replacement therapy, but who did not report any use of other 
anti-osteoporotic medications in MEPS data between 1996 and 2004;  
(6) raloxifene group (RF) includes female subjects who reported raloxifene (or 
Evista®) with or without reporting calcium/vitamin D preparations but who did not report 
any use of other anti-osteoporotic medications in MEPS data between 1996 and 2004; 
Subjects with different ages have different risks of osteoporosis and osteoporotic 
fractures; the effects due to senile osteoporosis (Type 2) should be separated from 
glucocorticoid-induced osteoporosis.  The incidence rates of osteoporosis and 
osteoporotic fractures are calculated separately for the following four age groups: (1) 
subjects aged 11 to 30 years old; (2) subjects aged 31 to 50 years old; (3) subjects aged 
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51 to 70 years old; and (4) subjects aged 71 to 90 years old.  Therefore, effects of age 
should be partially controlled.   
 
 
Figure 3.2 Conceptual diagram of relations associated with gender, glucocorticoid use 
and use of anti-osteoporotic agents to osteoporosis and osteoporotic 
fractures 
However, the confounding effects of underlying conditions are not measurable, 
nor controllable in this study.  However, the expected impacts of underlying conditions 
should be relatively lower than those from the key factors that described earlier.  
Moreover, if subjects were categorized in groups based on some major underlying 
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conditions, as mentioned in Section 2.2.2, the sample size of each subgroup would be too 
small to have enough statistical power for analyses.   
 
3.2.4 Clinical Outcomes   
The major clinical outcomes for this study are prevalence and incidence of 
glucocorticoid-induced osteoporosis and glucocorticoid-induced osteoporotic fractures.  
The clinical outcomes for this study are carefully defined in considerations of four factors 
regarding MEPS.  A few assumptions are also made accordingly.   
First, as mentioned in Section 3.1.2, MEPS public use files provide 3-digit ICD-9 
codes.  The use of 3-digit ICD-9 codes is not sufficient to precisely identify 
glucocorticoid-induced osteoporosis and glucocorticoid-induced osteoporotic fractures.  
Nevertheless, glucocorticoid-induced osteoporosis for this study is defined as the use of 
glucocorticoid steroids and the diagnosis of osteoporosis (Clinical Classification Code 
[CCC] =206 or ICD-9-CM code =733).  Glucocorticoid-induced fractures are defined 
for this study as the use of glucocorticoid steroids and a diagnosis of: (1) pathological 
fractures (CCC =207); (2) vertebral fracture without spinal cord injury (ICD-9-CM code 
=805); (3) fracture of rib(s), sternum, larynx and trachea (ICD-9-CM code =807); (4) 
fracture of pelvis (ICD-9-CM code =808); (5) fracture of clavicle (ICD-9-CM code 
=810); (6) fracture of humerus (ICD-9-CM code =812); (7) fracture of radius and ulna 
(ICD-9-CM code =813); (8) fracture of neck of femur (ICD-9-CM code =820) or fracture 
of other unspecified parts of femur (ICD-9-CM code =821); and (9) fracture of tiba and 
fibula (ICD-9-CM code =823).  Both close-and open-type fractures will be included 
because these two types can only be differentiated by the fourth digit of ICD-9-CM 
codes, which is not available in the MEPS public use data files (PUFs).  Therefore, it is 
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likely that the rates of osteoporotic fractures will be over-estimated in this study.  On the 
other side, the definitions of osteoporotic fractures for this study are relatively 
conservative in a comparison to a range of diagnoses for osteoporotic fractures in some 
studies.252F253, 253F254, 254F255, 255F256, 256F257  
Second, MEPS does not capture information about the causal relationship 
between the use of medications and the incidence of osteoporosis and osteoporotic 
fractures.  A few assumptions of causal relations are made for this study in order to 
reasonably define a new incidence of glucocorticoid-induced osteoporosis and 
osteoporotic fractures in MEPS.  Specifically, it is assumed that when an incidence of 
osteoporosis or fracture occurred after use of glucocorticoid steroids, it is a 
“glucocorticoid-induced” event.  All study subjects are glucocorticoid users, and 
glucocorticoid use is an important factor associated with the development of osteoporosis 
and osteoporotic fractures.  Even if osteoporosis (or fractures) occurred before the use of 
glucocorticoid steroids and were caused by another factor, there is an increased risk that 
the glucocorticoid users with prior osteoporosis (or fractures) will remain osteoporotic (or 
develop another fracture).  It is also assumed that when an incidence of fractures 
occurred after an anti-osteoporotic treatment, it is considered as “osteoporotic.”  The 
                                                 
253 Brixner, D. (2006). Assessment of the prevalence and costs of osteoporosis treatment options in a 
real-world setting. The American Journal of Managed Care, 12(7 Supple.): S191-S198. 
254 Lesile, W. D. et al. (1997). Effectiveness of bone density measurement for predicting osteoporotic 
fractures in clinical practice. The Journal of Clinical Endocrinology and Metabolism, 92(1): 77-81. 
255 Steinbuch, M. et al. (2004). Oral glucocorticoid use is associated with an increased risk of fracture. 
Osteoporosis International, 15(4): 323-328. 
256 van den Boogaard, C. H. A. et al. (2006). Persistent bisphosphonates use and the risk of osteoporotic 
fractures in clinical practice: a database analysis Study. Current Medical Research and Opinions, 22(9): 
1757-1764. 
257 Johnell, O. et al. (2005). The burden of hospitalised fractures in Sweden. Osteoporosis International 
16(2): 222-228. 
 114
fracture is “osteoporotic” because the major indication of these anti-osteoporotic agents, 
except HRT, is osteoporosis.   
Third, MEPS does not collect the beginning date of a condition unless it is on the 
priority list.  Osteoporosis and fractures are not on the priority list.  However, the index 
date of osteoporosis or osteoporotic fractures is a key to the determination of prior 
experience in osteoporosis and/or osteoporotic fractures.  It is problematic to determine 
the exact date of an incidence of osteoporosis or osteoporotic fractures.  A proxy must 
be used.  Similar to the estimation of a missing start date of a medication, the estimation 
of the missing condition date of osteoporosis or osteoporotic fractures can be achieved by 
assigning the start date of the round when the condition was reported.   Again, the 
variables for these reference dates are BEGRFD31, BEGRFM31, BEGRFY31, 
BEGRFD42, BEGRFM42, BEGRFY42, BEGRFD53, BEGRFM53 and BEGRFY53.  
Therefore, the index date of an incidence of osteoporosis or osteoporotic fractures is 
defined as the earliest start date reported by the subject in MEPS data between 1996 and 
2004.  One record in the MEPS medical condition files is treated as one incidence of 
osteoporosis or osteoporotic fractures. It is also assumed that a reported fracture is a 
subject’s first fracture, unless more than one fracture was reported.   
Fourth, MEPS does not capture events that are beyond the period of data 
collection. MEPS followed subjects for two years, so the MEPS data do not contain 
complete information regarding the medical history associated with medication use, 
medical conditions and events.  For example, it may take more than two years for a 
subject to develop osteoporosis or osteoporotic fractures after glucocorticoid use.  
Similarly, glucocorticoid or medication use before the period of MEPS data collection 
was not reported in MEPS.  Previous use of these medications may contribute to 
osteoporosis or osteoporotic fractures which were reported in MEPS later.  
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Additionally, a subject may only report recent use of medications because of possible 
recall bias.  Therefore, precise determination of glucocorticoid-induced osteoporosis 
and osteoporotic fractures in MEPS is not feasible.   
 
3.2.5 Economic Outcomes   
The perspective of this study focuses on the payers.  Direct medical costs are the 
major interest and will be included in this study.  Direct medical costs for medical 
events in MEPS include costs for medications and pharmacy services (RXXPYRX), costs 
for other medical expenses (OMXPYRX), costs for hospital inpatient stays (IPXPYRX), 
costs for emergency room visits (ERXPYRX), costs for outpatient visits (OPXPYRX), 
costs for office-based medical provider visits (OBXPYRX) and costs for home health 
(HHXPYRX).  Economic outcomes for this study include total costs for evaluation of 
osteoporosis, costs for treatment of osteoporotic fractures, costs for anti-osteoporotic 
medications and total costs for anti-osteoporotic treatments.  Each of these four types of 
costs is defined as follows. 
 
3.2.5.1 Costs for Evaluation of Osteoporosis 
Costs for evaluation of osteoporosis for each subject in this study are defined as 
the summation of total costs for outpatient visits and office-based medical provider 
visits related to osteoporosis reported by the subject.  Although MEPS does not 
explicitly specify costs of BMD tests, costs of laboratory tests, X-ray examinations, 
screenings and alike were included in total costs of outpatient visits and office-based 
medical provider visits, as indicated in the documentation of the MEPS data files.  
Osteoporosis-related outpatient visits and office-based medical provider visits were 
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identified by linking the specific condition identification number (CONDIDX) of 
osteoporosis to specific event identification numbers (EVNTIDX) via condition-event 
link files.  Costs for outpatient visits (OPXPYRX) and office-based medical provider 
visits (OBXPYRX) related to osteoporosis for a subject were added.  Because each 
subject was followed for two years in MEPS, the summation was divided by eight to 
yield the three-month average cost for evaluation of osteoporosis for each subject.   
 
3.2.5.2 Costs for Treatment of Osteoporotic Fractures 
Costs for treatment of osteoporotic fractures for each incidence in this study are 
defined as the summation of total costs for prescribed medicines and all type of MEPS 
events (RXXPYRX to HHXPYRX) which were linked to the specific condition 
identification number (CONDIDX) for an incidence of osteoporotic fractures  via 
condition-link files.  New incidences of osteoporotic fractures were differentiated by the 
first-time eisode or repeated episode for a subject.  Costs were added and then divided 
by the total number of fracture incidences to yield an average of total costs for treatment 
of osteoporotic fractures per incidence.   
 
3.2.5.3 Costs for Anti-osteoporotic Medications 
Costs for each group of anti-osteoporotic medications (i.e., BP, CN, HB, HT and 
RF) are defined as the summation of total costs for medications and pharmacy services 
(RXXPYRX) listed in MEPS prescribed medicines files.  Costs for the same treatment 
group were added, and then divided by total number of subjects in the treatment group 
and then divided by eight to yield the three-month average cost for the anti-osteoporotic 
medications per person   
 117
 
3.2.5.4 Costs for Anti-Osteoporotic Treatments 
Total costs for anti-osteoporotic treatments are defined as the summation of costs 
for anti-osteoporotic medications, costs for outpatient visits and office-based medical 
provider visits linked to anti-osteoporotic medications, and costs for adverse drug events 
linked to anti-osteoporotic medications.  (1) Costs for anti-osteoporotic medications 
have been described in Section 3.2.5.3.  (2) Osteoporosis-related outpatient visits and 
office-based medical provider visits were identified by linking the specific prescription 
identification number (LINKIDX) via prescribed medicines-event link files.  Total costs 
were added and then divided by eight to yield the three-month average for each subject.  
(3) Total costs for adverse reactions of an anti-osteoporotic treatment include total costs 
of all events associated with adverse conditions and total costs of prescribed medications 
associated with adverse conditions.  Possible adverse drug reactions are defined in 
Section 3.2.2 for each anti-osteoporotic medication.  These conditions with specific 
identification numbers (CONDIDX) were identified by ICD-9-CM codes; however, these 
conditions were not necessarily associated with adverse drug reactions.  These 
CONDIDX were linked to events to obtain specific event identification numbers 
(EVNTIDX) via condition-event files.  Events related to adverse drug reactions for a 
group of anti-osteoporotic medications were identified by linking the specific prescription 
identification number (RXRECIDX) via prescribed medicines-event link files.  By 
linking these EVNTIDX, associated medical events (such as emergency room visits, etc.) 
and prescribed medicines other than the anti-osteoporotic medication were identified.  
Costs for events and prescribed medicines (other than anti-osteoporotic medications) 
were added and divided by eight to yield the three-month average cost for a subject.   
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3.2.5.5 Costs That Are Excluded 
Direct medical costs associated with glucocorticoid therapy, including costs for 
glucocorticoid steroids and treatments of the underlying conditions, are not considered 
because the use of anti-osteoporotic agents is the main focus in this study.  Indirect costs 
(e.g., work loss) and direct non-medical costs (e.g., travel, hotel, meals) were excluded 
because related data in MEPS are neither complete nor accurate.  Although MEPS 
provides detailed information which could differentiate costs among different sources of 
insurance, cost analyses of insurance sources are beyond the study scope.  Costs 
associated with death were not included. 
 
3.2.5.6 Examples 
An example is provided to demonstrate the identification of direct medical costs 
in MEPS data.  Figure 3.3 illustrates relations among MEPS public use files for 
identification of costs associated with bisphosphonates (BP) for a subject (Z) and 
identification of costs for osteoporotic fracture (FX).  The steps are:  
 
(A) Costs of bisphosphonates:  
(1) Identification and costs of bisphosphonates:  Qualified bisphosphonates 
(e.g., BP1=alendronate prescription A, BP2=alendronate prescription B, BP3= alendronate 
prescription C) were identified based on appropriate criteria (e.g., ICD-9 codes ≠731 to 
exclude Paget’s disease, length of therapy  90 days) from the prescribed medicine files.  ≧
Each prescription (BP1 to BP3) had a specific linkage identification number (LINKIDX1, 
LINKIDX2 and LINKIDX3, respectively) for subject Z with a personal weight (wt).  
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The costs for a bisphosphonate prescription were found accordingly (RXXPYRX=C1, C2 
and C3, respectively).  Total medication cost for bisphosphonates was the summation of 
C1, C2 and C3 for subject Z.  The three-month cost for subject Z was calculated by 
dividing the sum by eight.  The average cost for all subjects in the bisphosphonate 
treatment group is one of the costs identified in Section 3.2.5.3;  
(2) Identification of medical events associated with bisphosphonates:  The 
corresponding medical events (e.g., office-based medical provide visits and outpatient 
visits) with specific event identification numbers (EVNTIDX) were identified for subject 
Z by using the LINKIDX via a prescribed medicine-event link file;  
(3) Identification and calculation of total costs for medical events associated 
with bisphosphonates:  The total cost of each medical event (EVNTIDX) was found 
for subject Z.  This step was repeated for identifying costs for office-based medical 
provider visits and outpatient visits (i.e., C4 and C7) in the related medical event file.  
Total costs are the summation of C4 and C7 for subject Z by using DUPERSID.  The 
three-month cost for office-based medical provide visits and outpatient visits was 
calculated by dividing the sum by eight.  The average cost for all subjects in the 
bisphosphonate treatment group is the second type of costs identified in Section 3.2.5.4; 
(4) Identification and calculation of total costs for adverse drug reactions 
associated with bisphosphonates:  Specific condition identification numbers (e.g., 
CONDIDX4) were identified by selecting ICD-9 codes for possible adverse drug 
reactions related to bisphosphosnate treatments.  The corresponding event identification 
numbers (e.g., EVNTIDX2 to EVNTIDX5) were identified by using CONDIDX via a 
condition-event link file.  Only those events (e.g., EVNTIDX6) linked to bisphosphonate 
prescriptions (linking LINKIDX1, LINKIDX2, etc. via prescribed medicine-event files) 
were adverse drug events and costs of these events were added.  Next, these adverse 
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drug events were linked to prescriptions other than anti-osteoporotic medications via 
prescribed medicine-event files (EVNTIDX6-LINKIDX); these prescriptions were 
associated with treatments of adverse drug reactions.  Costs of these prescriptions were 
added.  The summation of costs of adverse drug events and prescriptions (other than 
anti-osteoporotic medications) was the total cost for adverse drug reactions associated 
with bisphospohonate treatment for subject Z.  The three-month cost for adverse drug 
reactions related to bisphosphonate treatments was calculated by dividing the sum by 
eight.  The average cost for all subjects in the bisphosphonate treatment group is the 
third type of costs identified in Section 3.2.5.4. 
 
 (B) Costs of osteoporotic fracture (FX):  
(1) Identification of fractures (FX):  Specific condition identification numbers 
(e.g., CONDIDX3) were identified by selecting ICD-9 codes for osteoporotic fractures;  
(2) Identification of medical events associated with fractures (FX):  The 
corresponding event identification numbers (e.g., EVNTIDX2 to EVNTIDX5) were 
identified by using CONDIDX via a condition-event link file.  In this example, 
EVNTIDX2 was an emergency room visit and EVNTIDX3 was a hospitalization.  
ERHEVIDX links EVNTIDX2 and EVNTIDX3, so the hospital admission was based on 
an emergency room visit resulting from an osteoporotic fracture (CONDIDX2).  
EVNTIDX4 was an outpatient visit for follow-up after the hospitalization for the fracture.  
EVNTIDX5 was for home health care after the hospitalization for the fracture;  
(3) Identification of costs for bisphosphonate treatments associated with 
fractures (FX):  Bisphosphonates associated with osteoporotic fractures were identified 
by linking EVNTIDX to LINKIDX via prescribed medicine-event link files.  Costs of 
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bisphosphonates (C1 to C3) were obtained accordingly.  Total costs for bisphosphonates 





Figure 3.3 An example of identification of costs associated with an anti-osteoporotic 
agent (BP) and osteoporotic fracture (FX) for a subject (Z) in MEPS data 
Other Medical Expenses file 
Subject Z: no associated cost. 
Prescribed Medicines file 
Subject Z: ICD-9≠731 
BP1: date1, LINKIDX1, C1, wt. 
BP2: date2, LINKIDX2, C2, wt. 
BP3: date3, LINKIDX3, C3, wt. 
Outpatient Visits file 
Subject Z:  
EVNTIDX4, C7, wt.
Home Health file 
Subject Z: EVNTIDX5, C8, wt. 
Office-Based Medical 
Provider Visits file 
Subject Z:  















Medical Conditions file 
Subject Z: CONDIDX1, 
CONDIDX2 by ICD-9 
Full Year Consolidated 
Data file 
Subject Z: gender, age, 
reference dates for round, 








Hospital Inpatient Stays file 
Subject Z: 
EVNTIDX3, ERHEVIDX, C6, wt. 
Emergency Room Visits file 
Subject Z: 
EVNTIDX2, ERHEVIDX, C5, wt. 
EVNTIDX1 to 7
Link Files Event Files 
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(4) Calculation of costs associated with fractures (FX):  Total costs for 
treatment of osteoporotic fractures were the summation of the above total costs for 
medical events and bisphosphonates in this example.   
 
3.2.5.7 Weights and Discount on Costs 
Costs previously described are original values without weighting to reflect the 
national estimates.  MEPS provides sampling weights which reflect adjustments for 
survey non-response and to the Current Population Survey conducted by the U.S. Bureau 
of the Census.  Each individual has different personal weights in different years.  In a 
traditional approach with simple random sampling (SRS), the weighted values can be 
calculated by simply multiplying the value by the corresponding personal weight in that 
specific year, as shown in the following equation.  All related weighted values can be 
summed up or averaged to yield a weighted total or a weighted mean.  
 











= 1  
Where iY  =weighted value in year i; iW  =personal weight in year i; iX  =Value in 
year i; iY =average weighted value. 
 
However, MEPS employed a complex multistage sampling design, including 
stratification, clustering, multiple stages of selection and disproportionate sampling.  
The approach with simple random sampling (SRS), as described in previous paragraph 
could not be used to yield accurate national estimates of variance.  To obtain accurate 
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estimates of variance from the MEPS data, standard errors associated with the weighted 
estimates can be derived by an appropriate technique;257F258 the most commonly cited and 
used approach is the Taylor-series linearization method.258F 259  One of the statistical 
software packages applying the Taylor approach to estimate weight-associated standard 
errors is SAS (version 8.2 or higher).259F260  SAS version 9.1.3 with the Service Pack 4 
(SP4) updates was used for this study.  SAS/STAT provides the SURVEYMEANS 
procedure for producing weighted means and total costs, and the SURVEYFREQ 
procedure for computing national estimates of weighted frequencies and percentages.   
All costs are presented as 2005 dollars based on discount rates derived from the 
Consumer Price Index (CPI).260F261  Table 3.4 lists annual U.S. CPIs based on city average 
costs for medical care services from 1996 to 2005, and calculated annual discount rates.  
The CPI for medical care services was selected based on the best estimate for matching 
expenditures in MEPS.  For example, the discount rate of costs for yr1 is calculated as 
the difference in annual U.S. city average costs for medical care services between yr1 and 
yr2 divided by the annual U.S. city average cost for medical care in yr1.  The converted 
value in yr2 dollars is calculated by multiplying the original value in yr1 by (one plus the 










                                                 
258 AHRQ (2003). Computing Standard Errors for MEPS Estimates Agency for Healthcare Research and 
Quality; Rockville, MD. URL: http://www.meps.ahrq.gov/factsheets/FS_StandardErrors.htm  (Accessed 
July 31, 2006).  
259 Woodruff, R. (1971). A simple method for approximating the variance of a complicated estimate. 
Journal of the American Statistical Association 66: 411-414.  
260 Intelligent property by SAS Institute Inc., Cary, NC, USA.  
261 Consumer Price Index (not seasonally adjusted), Bureau o f Labor statistics, U.S. Department of 
Labor. Washington, DC. Available online from URL: http://data.bls.gov/cgi-bin/surveymost?cu or 
http://data.bls.gov/cgi-bin/surveymost/ (Accessed Aug. 14, 2006).   
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Costyr2 =Costyr1 * (1 + discount rateyr1) 
 
Table 3.3 Annual U.S. Consumer Price Index (for medical care services) and calculated 
discount rates (1996 to 2005) 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
CPI§ 232.4 239.1 246.8 255.1 266.0 278.8 292.9 306.0 321.3 336.7
Multiplier 
of the year 
to 2005† 





2.8830 3.2204 3.3630 4.2728 4.8120 5.0574 4.4725 5.0000 4.7930 0
§ Consumer Price Index (not seasonally adjusted) based on Annual U.S. city average costs for medical care services, Bureau of Labor 
statistics, U.S. Department of Labor., See reference 260. 
† For conversion of values to 2006 U.S. dollars; 
‡ For conversion of values to U.S. dollars in previous year 
 
3.3 CROSS-SECTIONAL ANALYSES OF MEPS DATA 
The third section describes cross-sectional analyses of MEPS data.  The analyses 
aim to obtain descriptive statistics for this study.  Specifically, this analysis will yield 
the following descriptive statistics:  
(1) Characteristics of study subjects (i.e., number of subjects in each subgroup, 
average age, percentages in gender and percentages in race), glucocorticoid use (i.e., 
average cumulative dose of glucocorticoid tablets, cumulative quantity of glucocorticoid 
tablets and average daily glucocorticoid dose).  These characteristics are further 
summarized for subjects in different subgroups classified by gender, type of 
glucocorticoid use (i.e., MEPS, LTGS or HRGS) and type of anti-osteoporotic treatments 
(i.e., BP, CN, CT, HB, HT and RF).  These results address the first study objective;  
(2) National estimates of prevalence and incidence rates of 
glucocorticoid-induced osteoporosis and osteoporotic fractures in glucocorticoid users.  
These rates are calculated separately in subgroups classified by gender, four age groups 
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(i.e., four ranges of ages between 11-30, 31-50, 51-70 or 71-90), type of anti-osteoporotic 
treatments  (i.e., BP, CN, CT, HB, HT and RF) and type of glucocorticoid use (MEPS, 
LTGS or HRGS).  These results address the second study objective;  
(3) National estimates of average direct medical costs associated with evaluation 
of osteoporosis and treatment of osteoporotic fractures in glucocorticoid users.  The 
results help address the third study objective; and (4) national estimates of average direct 
medical costs associated with anti-osteoporotic agents and treatments in glucocorticoid 
users.  The results address the fourth study objective.  As mentioned in Section 3.2.5.7, 
the SURVEYMEANS procedure was used to compute averages and standard error of the 
means, and the SURVEYFREQ procedure was used to produce national estimates of 
weighted numbers and percentages.  These descriptive statistics were used as model 
inputs to estimate long-term outcomes in the Markov modeling (which will be explained 
in Section 3.5.3).   
Analyses of variance (ANOVAs) were used for testing study hypotheses for 
objectives one, three and four.  The SAS SURVEYMEANS procedure was used for 
comparing weighted means by ANOVA models.  An alpha level of 0.05 was used for 
the ANOVAs.   
Logistic regression analyses were performed to investigate relative risks of 
osteoporotic fractures between long-term glucocorticoid users and non-glucocorticoid 
users in MEPS subjects.  The SAS SURVEYLOGISTIC procedure was used.  The 
dependent variable is incidence of osteoporotic fractures; the independent variables are 
age, gender (male/female), glucocorticoid use (yes/no), BP treatment (yes/no), CN 
treatment (yes/no), HT treatment (yes/no), HB treatment (yes/no) and RF treatment 
(yes/no).  The results were used to estimate incidence rates of osteoporotic fractures in 
some subgroups with small sample sizes.  Because incidence rates of osteoporotic 
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fractures are calculated separately in subgroups classified by different ranges of age, 
gender and type of anti-osteoporotic treatments, the sample size of some subgroups was 
too small (or zero) to generate national estimates for incidence rates of osteoporotic 
fractures.   
 
3.4 THEORETICAL FRAMEWORK OF ECONOMIC EVALUATIONS 
In situations involving scarce resources, decisions are often needed to allocate 
those resources.  In the healthcare sector, this frequently refers to allocating a payer’s 
budget for optimal medical utilization.  For this study, the decision is translated to how 
much extra money payers should pay to avoid one episode of glucocorticoid-induced 
osteoporosis or fractures.  Many economic evaluation approaches have been proposed in 
the past few decades.  Cost-effectiveness analysis is probably the most frequently used 
technique for decision analyses.  This section briefly outlines the theoretical framework 
of decision analysis, especially for cost-effectiveness analysis. 
 
3.4.1 Basic Concepts in Decision Analysis 
Welfare economics is used as the theoretical foundation for many economic 
evaluations.  It is assumed that each individual pursues his or her maximal utility or 
benefits, and the social welfare is the summation of utilities across all individuals.  
However, because of limited resources and possible conflicts among individuals, 
allocation of resources is usually needed to reach the maximal overall social welfare.  
An economic model is built upon equilibrium of the competitions.261F262  An example is 
                                                 
262 McGuire, A. (2001). Theoretical concepts in the economic evaluation of health care. In: Drummond, 
M. F.; McGuire, A. (editors) Economic Evaluation in Health Care-Merging Theory with Practice. Oxford 
University Press: New York; Pages 1-21.  
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that a pharmaceutical manufacturer wants maximal profits by re-allocating outputs of all 
productions of various pharmaceutical products given a budget.  Another example is 
that a re-allocation of a pharmacist’s counseling time is needed to reach maximal benefits 
for patients receiving pharmaceutical interventions (e.g., education on prevention of 
fractures due to falls).   
Paretian Welfare Economics is the conceptual basis of classic welfare analysis.  
The core is Pareto optimality, which includes two concepts: Pareto improvement and 
Pareto efficiency.  Pareto improvement refers to the scenario that ALL individuals 
GAIN from the re-allocation of resources. Pareto efficiency occurs when AT LEAST one 
individual GAINS from the re-allocation and NO individual LOSES.262F263  Given the 
pharmaceutical manufacturer as an example, optimality of pharmaceutical production 
occurs when a re-allocation increases outputs of a pharmaceutical product without 
decreasing outputs of other pharmaceutical products.  Another example is that, given a 
contracted insurance premium, optimality of member care is achieved when the health 
insurance plan defines what health care services should be covered and what are not.  
When the decision of coverage is made, the majority of members should benefit from the 
plan and no member should be harmed.   
In most “real-world” cases, some people gain (from an intervention) and others 
lose; Pareto optimality could never be reached.  From the perspective of social welfare, 
when a public policy is considered, a better re-allocation of resources is to yield maximal 
benefits to most individuals but minor losses to a few individuals in comparison with the 
baseline.  A solution is that potential gainers of one resource compensate potential losers 
with another resource for exchange, so ideally there is no absolute loser after all in 
                                                 
263 McGuire, A. (2001). Ibid.  
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theory.263F 264   An example is the negotiation of insurance premiums for covered 
prescriptions in formularies between health insurance companies and payers.  Health 
insurance companies will get a rebate or discount from a pharmaceutical manufacturer for 
listing preferred pharmaceutical products in formularies; plan sponsors and members 
experiences formulary restrictions but pay lower insurance premiums.  Another example 
is that a patient decides whether s/he should pay more money (a loss) in exchange for 
better patient care (a gain).   
However, individuals value resources differently, so benefits enjoyed by gainers 
may be different than those by losers.  Insurance companies and plan sponsors/members 
may have different values of gains and losses for formulary restrictions, for example.  
Different patients have different values for patient care.  A practical approach is to value 
resources in terms of monetary values.  The no-loser constraint with hypotheticalal 
compensation and monetary valuation in outcomes serves the theoretical foundation of 
cost-benefit analysis (CBA).  Cost-benefit analysis is a technique to test whether the 
sum of the monetary values of all gainers exceeds the sum of monetary values of all 
losers.264F 265   Cost-effectiveness analysis (CEA) can be viewed as a special case of 
cost-benefit analysis, where utility is measured and compared as a natural unit instead of 
transforming it to a monetary value.   
 
                                                 
264 Tsuchiya, A. & Williams, A. (2001). Welfare economics and economic evaluation. In: Drummond, M. 
F.; McGuire, A. (editors) Economic Evaluation in Health Care. Oxford University Press; New York. Pages 
22-45.  
265 Tsuchiya, A. & Williams, A. (2001). Welfare economics and economic evaluation. In: Drummond, M. 
F.; McGuire, A. (editors) Economic Evaluation in Health Care: Oxford University Press; New York. Pages 
22-45. 
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3.4.2 Basic Concepts of Cost-Effectiveness Analyses   
Cost-effectiveness analyses can be performed with a decision tree to aid decision 
making.  A traditional decision tree has one decision node (shown as a square) at the 
root, several branches off the decision node to represent competing alternatives, a chance 
node (shown as a circle) with branches to represent different outcomes/events and a 
terminal node (shown as a triangle) at the end of each branch to represent final outcomes.   
The expected value (EV) of the utility (such as costs and effectiveness) for each 
alternative is calculated as the probability-weighted summation of utilities in branches 
related to the corresponding alternative.   
 





 Ui Pi  
where Pi is the probability of selecting branch i; Ui is the utility in branch i,  branches 
are numbered from 1 to n. 
 
Comparisons of both costs and effectiveness of one alternative with those of 
another option (that is usually the standard option) lead to a selection of the preferred 
alternative with a lower cost-effectiveness ratio.  Any alternative with both a higher cost 
and lower effectiveness than the reference is dominated and can always be rejected for 
strategy selection.  Similarly, any alternative with both a lower cost and higher 
effectiveness than the reference dominates.  The null hypothesis of cost-effectiveness 
analysis is that the mean cost-effectiveness of one alternative equals that of another 








where Ca (Cb) is total costs of alternative a (b); Ea (Eb) is total effectiveness of 
alternative a (b). 
 
However, when an alternative has both higher costs and effectiveness, or both 
lower costs and effectiveness than the relevant alternative, the selection is not clearly 
made.  A solution is to calculate the incremental cost-effectiveness ratio (ICER), which 
means the incremental cost per additional unit of outcome.  If the ICER of an alternative 
is less than the maximum acceptable cost-effectiveness ratio (or ceiling ratio, Rc), this 
alternative is preferable.  Frequently, the ceiling ratio (Rc) is set arbitrarily based on 
budget constraints, willingness-to-pay (WTP), and similar considerations.  The null 
hypothesis could be formulated as the incremental cost-effectiveness ratio (ICER) equals 














where Ca (Cb) is total costs of alternative a; Ea (Eb) is total effectiveness of alternative a 
(b); EΔ  is incremental effects between alternatives a and b; and CΔ  is the incremental 
costs between alternatives a and b. 
 
A major problem with this approach is that ICER approaches infinity as the 
denominator approaches zero.  A new method to overcome this problem is the 
net-benefit approach.265F266, 266F267 
                                                 
266 Stinnet, A. & Mullahy, J. (1998). Net health benefits: a new framework for the analysis of uncertainty 




Net monetary benefit: CERcNMB Δ−Δ=  
Net health benefit: 
Rc
CENHB Δ−Δ=  
where Rc  is a threshold ICER in cost-effectiveness analyses; EΔ  is the average of 
incremental effects between alternatives and the reference; and CΔ  is the average of 
incremental costs between alternatives and the reference.   
 
Other advantages of using the net benefit method include: (1) the variance for the 
net-benefit statistic can be calculated by using standard methods of calculations for 
statistics (e.g., confidence intervals, normal distributions); (2) cost-effectiveness 
acceptability curves can be produced; and (3) the regression-type framework allows the 
addition of more explanatory variables in the model to directly examine the impact of 
these variables on cost-effectiveness.267F 268   Net benefit framework is useful when 
confidence intervals are desired.  The issue of confidence intervals for ICERs will be 
discussed in Section 3.5.4.   
 
3.5 LONGITUDINAL PROJECTION 
The fifth section highlights the theoretical concepts associated with techniques of 
modeling, and describes specifications of parameters in the Markov model for this study.  
                                                                                                                                                 
267 Briggs, A. H. (2001). Handling uncertainty in economic evaluation and presenting the results. In: 
Drummond, M. F.; McGuire, A. (editors) Economic Evaluation in Health Care; Oxford University Press, 
New York. Pages 172-214.  
268 Hock, J. S. et al. (2002) Something old, something new, something borrowed, something blue: a 
framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econimics 
11(5): 415-430.   
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Many patients with chronic conditions receive glucocorticoid therapy for a long period of 
time.  Given the empirical sources of short-term data, modeling is needed to project the 
long-term estimates of costs and effectiveness related to glucocorticoid-induced 
osteoporosis and fractures.   
 
3.5.1 Techniques of Modeling 
Collecting longitudinal data from a large population-based randomized clinical 
trial of prolonged glucocorticoid therapy is unlikely to be feasible in terms of time, 
money, effort and ethics.  Available clinical data are usually limited to criteria-restricted 
samples, relatively small sample sizes and short-term outcomes, but economic evaluation 
considers outcomes over the lifetime of individuals.  Likewise, observational data are 
subject to many confounding issues, and tend to provide information only on surrogate 
endpoints, so a synthesis of existing evidence is necessary.  Mathematical techniques are 
often required to synthesize data from different sources and extrapolate from available, 
short-term data to long-term or lifetime estimates for decision analyses.   
Deterministic and probabilistic models are two common types of mathematical 
decision models.  A model is called deterministic when parameters and variables are 
well defined and do not randomly vary; in this case, the system always generates the 
same results and same prediction over time when all subjects start with the same initial 
conditions.  When the values of parameters and variables depend on chance, the model 
is probabilistic.  In “real-world” health models, neither pure deterministic nor 
probabilistic models exist.  The selection of model types mainly depends on the nature 
of disease, model structure, assumptions which simplify the model and information 
requested.   
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Stochastic processes, a class of probabilistic models, are the most common 
approach in time-dependent health decision analyses.  Stochastic processes are popular 
because they can be applied to time-series analyses.  Basically, a stochastic process is a 
sequence of variables governed by probability.  Time could be divided into sequential 
pieces (treated as either discrete or continuous) and (probabilistic) variables within each 
piece could be analyzed separately.  In statistics, a stochastic process is also known as a 
time series.   
Markov models are frequently used in health economic evaluation.  A Markov 
process is one class of stochastic processes and could be discrete or continuous with 
respect to time and/or states.  For example, in a discrete-time Markov chain, all 
parameters and variables are fixed in each state during one cycle, and (probabilistic) 
changes occur only at the end of each cycle.  Next, the technique of Markov modeling is 
briefly outlined, followed by the simulations and handling of uncertainty.   
 
3.5.2 Basic Concepts of Markov Modeling 
Markov decision models have a relative advantage over traditional decision 
analyses.  Traditional decision analyses sometimes require a bulky structure of trees 
(possibly with endless branches) in order to fully describe a disease with repeated events 
over time, such as cancer recurrence and osteoporotic fractures.  Furthermore, the 
simple decision tree cannot specify the point of time when the event occurs.  A Markov 
decision model can be a time-dependent model, and is ideal for modeling the natural 
progress of a disease and the recurring events.  Unlike other stochastic processes, 
Markov models are characterized by six components: structure, cycle, initial and 
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transition probabilities, Markov property, termination condition and rewards.  Each of 
these components is discussed below.   
 
3.5.2.1 Model Structure and Markov Cycle 
A Markov model contains mutually exclusive and collectively exhaustive states, 
which are referred to as Markov states.  In health-related models, the states should 
reflect the disease progression including recurring event(s).  Each subject must be 
assigned to only one health state at any one time.  The length of residence is the Markov 
cycle, which depends on the nature of the disease.  A disease with quick progression or 
fast recurrences needs a short Markov cycle to represent the nature of the condition.  A 
temporary state could represent a short-term effect of an event, in which subjects stay for 
only one cycle and must leave at the end of the cycle.  A tunnel state is a series of 
temporary states and it restricts all subjects to follow a fixed path.  Temporary or tunnel 
states are useful to describe special events, such as an adverse drug event and its 
treatments which do not have any impact on other states.   
 
3.5.2.2 Initial and Transition Probabilities 
At the very beginning of the Markov cycle, subjects are distributed to states based 
on initial probabilities.  At the end of each Markov cycle, each subject is allowed to 
either stay in the same state (except for temporary states), or move to another state 
(except for the absorbing state, such as death, where no subject can exit).  The net 
probabilities of re-distributing subjects from one state to another during a cycle are called 
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transition probabilities.268F269, 269F270, 270F271  It is noted that transition probabilities for a specific 
state can be temporarily adjusted by adding a temporary or tunnel state.271F272   
In the literature, rates are frequently reported instead of probabilities; each 
represents a different meaning.  The rate is instantaneous and expresses the occurrence 
of an event per unit time.  It can be directly converted to different time intervals; for 
example, the monthly rate equals to the annual rate divided by 12.  The probability is the 
overall likelihood that an event will occur.  Unlike a rate, a probability must range from 
zero to one, and the conversion between time intervals is not intuitive.   
Given a constant or average rate (r) during a specified time (t), the probability (P) 
can be calculated by the following equation:272F273, 273F274 
rteP −−= 1  
 
3.5.2.3 Markov Property and Termination Condition 
Generally, transition probabilities in a Markov process may vary over time.  This 
variability is commonly found in health models; for example, mortality rates increase 
with an increased age.  If transition probabilities remain constant over time, it is called a 
Markov chain, which is a special case of Markov processes.  Markov models treat 
                                                 
269 Beck, J. R. & Pauker, S. G. (1983). The Markov process in medical prognosis. Medical Decision 
Making 3(4): 419-458.  
270 Sonnenberg, F. A. & Beck, J. R. (1993). Markov models in medical decision making: a practical 
guide. Medical Decision Making 13(4): 322-338.  
271 Briggs, A. H. & Sculpher, M. J. (1998). An introduction to Markov modeling for economic evaluation. 
Pharmacoeconomics 13(4): 397-409.  
272 Hunink, M. G. M. et al. (2001). Recurring events. In: Hunink, M. G. M.; Glasziou, P. P. (editors) 
Decision Making in Health and Medicine. The Press Syndicate of the University of Cambridge; 
Cambridge, Pages 305-338.  
273 Beck, J. R.; Pauker, S. G. (1983). The Markov process in medical prognosis. Medical Decision 
Making 3(4): 419-458.  
274 Sonnenberg, F. A. & Beck, J. R. (1993). Markov models in medical decision making: a practical 
guide. Medical Decision Making 13(4): 322-338.  
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everyone in the same state as equal (i.e., they have the same expected values of 
outcomes, same transition probabilities, etc.) during that state residence.  In other words, 
all subjects in the same state during any cycle have equal probabilities and utilities 
without considering individual past experiences.  Therefore, Markov processes have no 
memory for previous cycles, so transition probabilities depend only on the current state, 
not on past states.  This is referred as the Markovian assumption or Markov property.  
In order to model disease progression with a reasonable, finite number of health states, 
the Markovian assumption and a termination condition are needed.  In time-dependent 
models, the Markov process is terminated when an arbitrary number of cycles is reached 
or all subjects enter an absorbing state (such as death).   
 
3.5.2.4 Rewards 
The calculation of Markov rewards is very similar to the calculation of expected 







 Ui* Ti  
where Ti is the average cycle time in state i; Ui is the utility in state I; and states are 
numbered from 1 to n. 
 
The rewards can be obtained in three ways: (1) matrix algebraic solutions; (2) the 
Markov cohort simulation; and (3) the first-order Monte Carlo simulation.  In a model 
                                                 
275 Sonnenberg, F. A. & Beck, J. R. (1993). Markov models in medical decision making: a practical 
guide. Medical Decision Making 13(4): 322-338.  
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with time-independent Markov chains, all transition probabilities are fixed so the 
expected length of time for an individual can be calculated by using simple matrix 
algebra.  In a model with a time-dependent Markov process, the Markov cohort 
simulation is a deterministic approach and the first-order Monte-Carlo simulation is a 
probabilistic approach.   
 
3.5.2.5 Simulations 
In the Markov cohort simulation, all hypothetical subjects are distributed to states 
based on initial transition probabilities at the first cycle.  Subjects in each state (cohort) 
are relocated to states based on the transition probabilities at the second cycle.  The 
process is repeated until it reaches the point of termination.  The rewards are the sum of 
the number of cohort members in each state multiplied by the incremental utility for that 
state.  Given the same inputs, a Markov cohort simulation always yields the same 
outputs, so it is deterministic.  A Markov cohort simulation targets overall outcomes 
among states, while the first-order Monte Carlo simulation focuses on outcomes at the 
individual level.   
The first-order Monte Carlo simulation models a subject’s lifetime progression of 
disease (as a trial) based on probabilistic transition probabilities.275F 276   It is like a 
longitudinal study that follows each participant for his/her whole lifetime.  It is 
commonly used in health analyses when a subject’s historical experiences need to be 
included in the model.  (Remember that Markov processes have no memory for previous 
cycles.)  The rewards are calculated as the average time that all subjects spent at each 
state multiplied by the utility (effectiveness) of each state.  Even given the same inputs, 
                                                 
276 Briggs, A. H. (2000). Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5): 
479-500.  
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this method may generate different outputs for each trial/simulation because of the 
randomization at chance nodes.  Only if the number of simulations is large enough (at 
least thousands) will the average outputs from the first-order Monte Carlo simulation and 
outputs from the Markov cohort simulation reach similar results.  Unlike the 
deterministic Markov cohort simulation, the probabilistic first-order Monte Carlo 
simulation can easily calculate statistics (such as the means, variance of error and 
confidence intervals) and handle uncertainty.276F277   
 
3.5.2.6 Features of Markov Modeling 
The advantages of using the Markov model include: (1) appropriate modeling of 
the state progression for conditions of glucocorticoid-induced osteoporosis and 
osteoporotic fractures; (2) Markov modeling can project long-term costs and clinical 
outcomes, and compare both outcomes at the same time for the cost-effectiveness study; 
and (3) uncertainty may be adequately addressed by performing probabilistic sensitivity 
analyses.  Therefore, Markov modeling is the preferred method for this study.  There 
are at least four components that must be explicitly described for a Markov model: (1) 
states and allowable transitions; (2) cycle length; (3) transition probabilities; and (4) 
method of simulations.   
 
3.5.3 Specifications of the Study Model 
A Markov model can model sequences of fractures where the probability of a 
fracture occurring depends upon the occurrence of a preceding fracture.  A Markov 
                                                 
277 Hunink, M. G. M. et al. (2001). Variability and uncertainty. In: Hunink, M. G. M.; Glasziou, P. P. 
(editors) Decision Making in Health and Medicine. The Press Syndicate of the University of Cambridge; 
Cambridge. Pages 339-363.  
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model with a Monte Carlo approach was used for generating long-term estimates of costs 
and effectiveness (osteoporotic fracture avoided), which were used in the decision 
analyses explained in Section 3.6.  Deterministic analyses allow the projection of 
long-term estimates for the base cases.  The first-order Monte Carlo simulation provides 
person-level estimates, and yields estimates of variance for averaged long-term estimates.  
The average costs from long-term estimations were compared.  The hypotheses for the 
fifth study objective were tested by comparisons of the average costs among different 
treatment options.  The second-order Monte Carlo simulations incorporate long-term 
estimates with variance in parameters and were used as a tool for probabilistic sensitivity 
analysis.  The model specifications are explicitly stated in the following sections.   
 
3.5.3.1 Model States, Allowable Transitions and Cycle Length 
The Markov (state-transition) model will simulate the natural course of 
glucocorticoid-induced osteoporosis in glucocorticoid users at the initiation of 
glucocorticoid therapy through two-years, 10 years, lifetime (defined as the age of 99 
years), a limited number of episodes of osteoporotic fracture (two episodes for two-year 
or 10-year estimations, three episodes for lifetime estimations) or death.  The Markov 
health states for glucocorticoid users and allowable state transitions are illustrated in 
Figure 3.4.  Five health states are proposed: (1) the “WELL” state where subjects have 
no symptoms; no prior experience with fractures and osteoporosis; (2) the “GIOP” state 
where subjects are diagnosed with glucocorticoid-induced osteoporosis without any prior 
fracture; (3) the “FX” state where glucocorticoid-induced osteoporotic fracture is 
diagnosed and subjects are being treated; (4) the “GIFX” state where subjects recover 
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from fractures and remain osteoporotic with a prior experience of fractures; and (5) the 
“DEAD” state.   
All allowable transitions are not reversible (i.e., they are one-way), except 
between the “FX” and “GIFX” states.  It means that once glucocorticoid-induced 
osteoporosis (or osteoporotic fracture) is developed and diagnosed, subjects cannot go 
back to the “WELL” state, which indicates no experience with osteoporosis and fractures.  
Basically, subjects in the “GIOP” and “GIFX” states are considered to have osteoporosis.  
The major difference is that subjects in the “GIOP” state have no prior experience in 
fractures, while those in the “GIFx” state experienced at least one episode of osteoporotic 
fractures.  The “FX” state is treated as a tunnel state, and viewed as a process of fracture 
treatments.  It is assumed that subjects will stay in the “FX” state for only one cycle 
(i.e., three months, see Section 3.5.3.2) and must enter to the “GIFX” state in the next 
cycle.  Subjects in this state were treated for osteoporotic fractures.  It is assumed that 
subjects receiving treatments for osteoporotic fractures will be recovered after one 
Markov cycle (i.e., three months).   
The cycle length of a Markov model usually depends upon the speed, progression 
and the nature of the condition/disease.  The cycle length of Markov modeling for this 
study is three months, because glucocorticoid-induced bone loss occurs as early as three 
months after the initiation of glucocorticoid therapy.  It is assumed that osteoporotic 
fractures occur at the end of the model cycle, so that half-cycle correction (HCC) is not 
used.  At the end of model cycle: (1) subjects who entered the absorbed (“DEAD”) state 
remain in the “Dead” state; (2) those who enter the “FX” state must enter the “GIFX” 
state; (3) those who are in the “WELL,” “GIOP,” or “GIFX” state may either stay in the 
same state or transit to another state based on transition probabilities which were obtained 
from descriptive statistics described in Section 3.2.3.   
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3.5.3.2 Transition Probabilities 
As shown in Figure 3.4, a total of eight transition probabilities are needed for each 
treatment option in this Markov model.  The descriptive analyses in Section 3.3 yield 
national estimates of age-specific annual incidence rates of osteoporosis and osteoporotic 
fractures.  The annual rates (r) are converted to three-month transition probabilities (t 
=4) by the equation described in Section 3.5.2.2.   
Therefore, the following transition probabilities can be obtained: (1) pO (from 
“WELL” state to “GIOP” state); (2) pFw (from “WELL” state to “FX” state); (3) pFp 
(from “GIOP” state to “FX” state); and (4) pFr (from “GIFX” state to “FX” state).  In 
theory, osteoporotic fractures result from osteoporosis.  When subjects in the “WELL” 
state develop osteoporotic fractures, they should go through the “GIOP” state, and reach 
“FX” state.  In practice, glucocorticoid-induced osteoporosis may be under-diagnosed 
and/or the development of osteoporotic fractures is within three months (a model cycle).  
Subjects in the “WELL” state may skip the “GIOP” state and directly enter the “FX” 
state within one cycle.   








WELL =subjects without prior osteoporosis and fracture. GIOP =subjects with prior osteoporosis but no prior fracture. 
FX =subjects experiencing any one of osteoporotic fractures. GIFX =subjects recovered from prior fracture. 
DEAD =subjects are dead.  
pFw =Probability of osteoporotic fractures from the WELL state pM_w =Probability of deaths from the WELL state 
pO =Probability of osteoporosis from the WELL state pM_x =Probability of deaths from the FX state 
pFp =Probability of osteoporotic fractures from the GIOP state pM_p =Probability of deaths from the GIOP state 
pFr =Probability of osteoporotic fractures from the GIFX state pM_x2 =Probability of deaths from the GIFX state 
Figure 3.4 Markov health states for glucocorticoid tablet users 
 
A totally different approach was used to estimate the other four mortality-related 
transition probabilities, pM_w, pM_p, pM_x and pM_x2.  MEPS data do not yield 
information on mortality rates, so transition probabilities to the “DEAD” state need to be 















the literature review on mortality due to osteoporosis and osteoporotic fractures in 
glucocorticoid users (Section 2.3.3).  Because there is no information on differences in 
mortality among different anti-osteoporotic treatments in glucocorticoid users, the 
mortality rates are assumed to be the same.  Table 3.5 summarizes three-month 
transition probabilities for mortality which were converted from the annual rates.   
The pM_w (WELL-to-DEAD) in the control group is estimated by using the 
crude mortality rate of low-dose glucocorticoid users with rheumatoid arthritis (RA).  
The pM_w in the treatment groups were estimated by multiplying the pM_w in control 
group by 0.34 which is the odds ratios of mortality rates in osteoporosis-treated patients 
to untreated patients.277F278  The same estimation applies to other probabilities of mortality 
(pM_p, pM_x and pM_x2) between the control group and the treatment groups (as 
indicated by “f” in note column of Table 3.5).  These mortality rates were obtained from 
previous studies including different target populations (e.g., different underlying 
conditions and different glucocorticoid use), so sensitivity analysis was performed to vary 
transition probabilities of mortality.   
 
                                                 
278 Cree, M. W. et al. (2003). Mortality and morbidity associated with osteoporosis drug treatment 
following hip fracture. Osteoporosis International 14(9): 722-727. 
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Table 3.5 Three-month mortality rates for the base case in female glucocorticoid users 
State* WELL to DEAD FX to DEAD GIOP to DEAD GIFX to DEAD 
Option** Age 3-m 
Prob. 
Note Age 3-m 
Prob. 
Note Age 3-m 
Prob. 
Note Age 3-m 
Prob. 
Note
Female             


















BP, CN, HT, 
HB, RF 


















Male             


















BP, CN, HT, 
HB, RF 


















*WELL state: subjects without any prior osteoporosis and osteoporotic fractures; GIOP state: subjects with 
prior osteoporosis but without prior osteoporotic fractures; GIFX state: subject with prior osteoporotic 
fractures; 
**BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone 
replacement therapy; Index=average age multiplied by four; RF=raloxifene group; 
a. The crude mortality rate of RA patients with glucocorticoid use less than 10 years is 12.3% or 60.5% for 
more than 10-year glucocorticoid therapy, Sihvonen et al. (2006) J Rheumatology 33(9): 1740-1746. 
b. Age-adjusted mortality rates (converted to 3-month probabilities) within one year after fractures in the 
general population in Sweden; Johnell et al. (2004) Osteoporosis Int 15: 38-42. 
c. The hazard risk of deaths after one-year glucocorticoid treatment in RA patients is 1.14 (95% CI 
0.98-1.27); for 10-year GS treatment it is 1.69 (95% CI 1.12-2.56); Sihvonen et al. (2006) J Rheumatology 
33(9): 1740-1746. 
d. Compared to no glucocorticoid use, the adjusted relative risk of mortality in severe COPD patients with 
10 mg glucocorticoid use is 2.34 (95% CI 1.24-4.43); Schds et al. (2001) Eur Respir Journal 17: 337-342. 
e. The crude mortality rate in post menopausal women with BMD t-score < -1.5 is 4.7/1,000 person-years, 
or 27.89/1,000 person-years in women with prior fracture; Causley et al. (2000) Osteoporosis Int 11: 
556-561.  
f. The odds ratio of long-term mortality is 0.34 (95% CI 0.17-0.70) for some osteoporosis treatment after 
hip fracture; Cree et al. (2003) Osteoporosis Int 14:722-727 
g. No data are available in men for estimation. Assume a 50% decrease from those in the FX state. 
h. No data are available in men for estimation.  Assume the same as those in the FX state. 
 
 
Age-specific mortality rates within one year after fractures in the general 
population were reported by Johnell et al.278F279  Mortality rates after osteoporotic fractures 
were also reported in men by Center et al.279F280  The hazard risk of deaths after one year of 
                                                 
279 Johnell, O. et al. (2004). Mortality after osteoporotic fractures. Osteoporosis International 15(1): 
38-42. 
280 Center, J. R. et al. (1999). Mortality after all major types of osteoporotic fracture in men and women: 
an observational study. The Lancet 353(9156): 878-882. 
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glucocorticoid treatment in RA patients is 1.69 (95% CI 1.12-2.56) for 10-year 
glucocorticoid treatment.280F 281   The pM_x (FX-to-DEAD) in the control group was 
estimated by multiplying age-specific mortality rates by 1.69.   
The crude mortality rate in post menopausal women with BMD t-score < -1.5 is 
4.7 per 1,000 person-years or 27.89 per 1,000 person-years in women with prior 
fractures.281F282  Compared to no glucocorticoid use, the adjusted relative risk of mortality 
in COPD patients who received daily 10 mg oral prednisone equivalents for at least six 
months is 2.34 (95% CI 1.24-4.43).282F283  The pM_p and pM_x2 (GIOP-to-DEAD and 
GIFX-to-DEAD) in women were estimated by multiplying the crude mortality rates by 
2.34.  For pM_p in men, no data were available for estimates, so a 50% decrease in 
mortality rates after fractures in men are assumed (as indicated by “g” in note column of 
Table 3.5).  For pM_x2 in men, no data were available for estimates, so the same 
mortality rates as men in the FX state are assumed (as indicated by “h” in note column of 
Table 3.5). 
 
3.5.3.3 Example of Decision Tree and Markov Information 
The decision-tree of the Markov model for bisphosphonates as an example is 
illustrated in Figure 3.5.  Other therapeutic options include calcitonin (CN), control 
group (CT), combination of hormone replacement and bisphosphonate therapy (HB), 
hormone replacement therapy (HT), and raloxifene (RF).  All share a structure similar to 
                                                 
281 Sihvohen, S. et al. (2006). Mortality in patients with rheumatoid arthritis treated with low-dose oral 
glucocorticoids. a population-based cohort study. Journal of Rheumatology, 33(9): 1740-1746. 
 
282 Cauley, J. A. et al. (2000). Risk of mortality following clinical fractures. Osteoporosis International 
11(7): 556-561. 
283 Schols, A. M. W. J. et al. (2001). Dose dependent increased mortality risk in COPD patients treated 
with oral glucocorticoids. European Respiratory Journal, 17(3): 337-342. 
 146
the bisphosphonate option, but have different transition probabilities and outcomes in the 
decision tree.  Decision analyses with Markov modeling allows long-tern projections 
and yields rewards for all options simultaneously.   
A set of parameters in Markov modeling is described below as an example of base 
cases for a cohort of female glucocorticoid users aged 50 years old who receive 
bisphosphonate (BP) treatment.  Figure 3.6 illustrates parameter settings for all options 
in the decision tree by using this cohort as an example.  The inputs of costs are obtained 
from results of descriptive analyses described in Section 5.3.  A randomly generated 
probability based on the normal distribution [DistSamp (1), mean=0, standard 
deviation=1] was used to introduce variance for the average costs.  Figure 3.7 and 
Figure 3.8 illustrate an example of Markov information (i.e., parameter settings in 
Markov modeling), including initial status, criterion for termination of Markov cycles, 
reference for transition probabilities and assignment of rewards (i.e., costs and 
effectiveness gained after each cycle), for the bisphosphonate (BP) branch of the decision 
tree.  A randomly generated probability based on the triangular distribution [DistSamp 
(2), min.=0.7, likeliest=1, max.=1.3] was used to introduce variance for the transition 






BP =bisphosphonate; CN =calcitonin; CT =controls; HT =hormone replacement therapy; RF =raloxifene;  
HB =combined use of BP & HT; y/o =years old; 5%=annual discount rate of 5% 
pWELL, pGIOP, pFX, pGIFX=initial distribution of subjects in each state; 
WELL =subjects without prior osteoporosis and fracture. GIOP =subjects with prior osteoporosis but no prior fracture. 
FX =subjects experiencing any one of osteoporotic fractures. GIFX =subjects recovered from prior fracture. 
DEAD =subjects are dead.  
pFw =Probability of osteoporotic fractures from the WELL state pM_w =Probability of deaths from the WELL state 
pO =Probability of osteoporosis from the WELL state pM_x =Probability of deaths from the FX state 
pFp =Probability of osteoporotic fractures from the GIOP state pM_p =Probability of deaths from the GIOP state 
pFr =Probability of osteoporotic fractures from the GIFX state pM_x2 =Probability of deaths from the GIFX state 
Figure 3.5 Decision tree with Markov modeling by showing the bisphosphonate subtree 





y/o =years old; 5%=annual discount rate of 5% Age= initial age, converted to number of Markov cycles 
Cost =average costs± multiplier times standard deviation Eff =effectiveness (fracture avoided) 
DistSamp(1)= a random value based on a normal distribution. 
cBP=3-month costs for bisphosphonate treatment cHB=3-month costs for combined use of BP and HRT 
cCN=3-month costs for calcitonin treatment cHT=3-month costs for hormone replacement therapy 
cRF=3-month costs for raloxifene treatment cOP=3-month costs for monitoring osteoporosis 
{T}Fx=cumulative number of osteoporotic fractures {T}OP=cumulative number of osteoporosis 
 





BP =bisphosphonate; y/o =years old; 5%=annual discount rate of 
5% 
pWELL, pGIOP, pFX, pGIFX=initial distribution of subjects; 
DistSamp(2)= a triangular distribution: ± 30% of variance, minimum=0.7, likeliest=1, maximum=1.3 
WELL =subjects without prior osteoporosis and fracture. GIOP =subjects with prior osteoporosis but no prior fracture. 
FX =subjects experiencing any one of osteoporotic fractures. GIFX =subjects recovered from prior fracture. 
Cost =total costs Eff =effectiveness (fracture avoided) 
cBP=3-month costs for bisphosphonate treatment cOP=3-month costs for monitoring osteoporosis 
pFw =Probability of osteoporotic fractures from the WELL state pM_w =Probability of deaths from the WELL state 
pO =Probability of osteoporosis from the WELL state pM_x =Probability of deaths from the FX state 
pFp =Probability of osteoporotic fractures from the GIOP state pM_p =Probability of deaths from the GIOP state 
pFr =Probability of osteoporotic fractures from the GIFX state pM_x2 =Probability of deaths from the GIFX state 
 
Figure 3.7 Markov information for the WELL and GIOP states for the bisphosphonate 





BP =bisphosphonate; y/o =years old; 5%=annual discount rate pWELL, pGIOP, pFX, pGIFX=initial distribution of subjects 
DistSamp(2)= a triangular distribution: ± 30% of variance, minimum=0.7, likeliest=1, maximum=1.3 
WELL =subjects without prior osteoporosis and fracture. GIOP =subjects with prior osteoporosis but no prior fracture. 
FX =subjects experiencing any one of osteoporotic fractures. GIFX =subjects recovered from prior fracture. 
Cost =total costs Eff =effectiveness (fracture avoided) 
cBP=3-month costs for bisphosphonate treatment cOP=3-month costs for monitoring osteoporosis 
pFw =Probability of osteoporotic fractures from the WELL state pM_w =Probability of deaths from the WELL state 
pO =Probability of osteoporosis from the WELL state pM_x =Probability of deaths from the FX state 
pFp =Probability of osteoporotic fractures from the GIOP state pM_p =Probability of deaths from the GIOP state 
pFr =Probability of osteoporotic fractures from the GIFX state pM_x2 =Probability of deaths from the GIFX state 
 
Figure 3.8 Markov information for the FX, GIFX and DEAD states for the 
bisphosphonate option in the decision tree 
 
 151
3.5.3.4 Monte Carlo Simulations 
A simulation method must be used for a Markov model to project long-term 
estimates.  The Markov cohort analysis and Monte Carlo simulations are two commonly 
used approaches which were briefly described earlier in Section 3.5.2.5.  There are two 
important features of the Monte Carlo method which makes it the preferred approach for 
this study.  The first-order Monte Carlo simulation can yield the estimation of variance 
(which will be presented as confidence intervals) of expected values/rewards for each 
state so uncertainty of sampling variation could be evaluated (see Section 3.5.4).  The 
first-order simulation helps address uncertainty at the individual level.   
The first-order Monte Carlo simulations were performed for the cohort of 10,000 
hypothetical glucocorticoid users.  All hypothetical patients start from the “WELL” state 
at the beginning of the first cycle.  Results of analyses for base cases (also called 
“reference cases”) were reported because it has been suggested by the U.S. Panel on 
Cost-effectiveness in Health and Medicine.283F284, 284F285, 285F286  The base cases for this study 
were hypothetical male or female cohorts at ages of 30 years old, 50 years old and 65 
years old.  Model inputs of costs and effectiveness were derived from results of 
descriptive analyses without introducing estimation of variance.  Rewards (means of 
costs and effectiveness) and standard deviations were calculated based on 10,000-sample 
simulations.  These rewards were treated as long-term estimates for costs and 
effectiveness.  Rewards were compared among different anti-osteoporotic treatments, 
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and hypotheses for the fifth study objective were tested.  Information on rewards is also 
presented as cost-effectiveness ratios (C/E) or an incremental cost-effectiveness ratio 
(ICER), which means the cost to prevent an additional fracture (e.g., the cost per avoided 
fracture).  These pieces of information were used in the cost-effectiveness analyses in 
Section 3.6.   
The second-order Monte Carlo simulation introduces estimation of variance at the 
parameter level.  Additionally, the variables that potentially influence the transition 
probabilities can be varied simultaneously.  Probabilistic/stochastic sensitivity analyses 
on these variables can be performed at the same time by using the second-order Monte 
Carlo simulation.  Therefore, parameter uncertainty can be evaluated.  The next section 
highlights the basic concepts and theories about uncertainty related to cost-effectiveness 
analyses.  
 
3.5.4 Handling Uncertainty   
There are four sources of uncertainty in cost-effectiveness analytical models. (1) 
Methodological uncertainty comes from the disagreement among analysts who used 
different analytical methods in terms of definition, inclusion, measurements and valuation 
of outcomes in the analysis, so the study results may not be directly comparable.  (2) 
Parameter uncertainty refers to uncertainty of model inputs (parameters).  Sampling 
variation from different inclusion/exclusion criteria and sample characteristics is also 
classified as parameter uncertainty.  (3) Modeling uncertainty includes uncertainty due 
to model structure and the whole modeling process.  (4) Generalizability implies the 
uncertainty of extrapolating study results to the target population in general. 286F287, 287F288  
                                                 
287 Briggs, A. H. (2000). Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5): 
479-500.  
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Basically, model analysts must explicitly describe study methods in detail so that the 
above sources of uncertainty can be identified accordingly.  The use of a “reference 
case” of core methods is advocated for handling methodological uncertainty, and makes 
possible comparisons of results among studies using different analytical methods.  Some 
statistical methods are highlighted as follows to estimate uncertainty for stochastic 
analyses. 
 
3.5.4.1 Confidence Intervals 
Confidence intervals (CIs) for ICERs are frequently reported to indicate 
uncertainty.  There are five common methods.  The first method is the confidence 
box, where the upper and lower limits of the confidence intervals on cost and 
effectiveness are based on standard parametric statistics.  For example, when α =0.05, 








96.196.1.. +×±Δ=×±Δ=  
where UΔ  is the incremental difference between two alternatives, Se  is the standard 
error of the difference, 2s  is the estimated variance from the sample, and n  is the 
sample size.   
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289 Briggs, A. H. (2001). Handling uncertainty in economic evaluation and presenting the results. In: 
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+Δ ), respectively.  
However, the chance of simultaneously considering both cost and effectiveness CI 
is 2)1( α− , when cost is independent of effectiveness.  If α =0.05, the two limits of 
ICERs actually represent the 90.25% CI, instead of the 95% CI.  Using this method to 
represent uncertainty is misleading.   
The second method is the Delta method or the Taylor series approximation of the 
variance.  One assumption of this method requires normally distributed data.  The 
Taylor approximation incorporates the covariance between the cost and effectiveness of 
the ICER.  However, given the highly skewed data of health care costs in most health 
analyses, the Taylor approximation should be used cautiously.   
The third method is the confidence ellipse.  It was proposed that the costs and 
effectiveness follow a joint normal distribution.  The locus of points of the “joint 
density” is assumed to be elliptical in shape.  The confidence ellipse method accounts 
for covariance between cost and effectiveness, but the correlation of cost and 
effectiveness has a big impact on the elliptical contour lines, which may result in 
incorrect confidence limits.   
The fourth method is the Fieller’s theorem.  The advantage of this method is that 
it accounts for the potentially skewed distribution of ratio statistics.  Therefore, the 
confidence ellipse may not be symmetric.  However, the Fieller’s theorem assumes 





= ) is normally distributed around zero; the skewness of 
health care costs may still violate the assumption.   
The fifth method is non-parametric bootstrapping.  Instead of assuming a normal 
distribution, the sample distribution of the ICER statistic is created by re-sampling from 
the original data.  The confidence limits are derived by using a straightforward 
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percentile method: (α/2)100 and (1-α/2)100 percentiles.  However, if the two extreme 
ends of the distribution have relatively high frequency (for example, the ICER is close to 
zero when costs are similar and the ICER is close to infinity when effectiveness is 
similar), the bootstrap method is misleading.  Of these five methods, Fieller’s method 
and the bootstrap method are often recommended, and Taylor series approximation is 
frequently used.289F290  This study used the SAS SURVEYMEANS procedure, which uses 
the Taylor series approximation to calculate the variance of weighted means.  
 
3.5.4.2 Sensitivity Analyses 
In addition to confidence intervals, sensitivity analysis is another useful tool to 
provide possible results by varying factors (parameters, process, criteria, etc.) associated 
with uncertainty, so decision makers have more information on strategy selection.  
Sensitivity analyses may also be classified as either deterministic or probabilistic.  The 
deterministic n-way sensitivity analysis assesses the robustness of model outcomes by 
varying values of n parameters.  However, when the parameters are more than two, the 
use of this deterministic sensitivity analysis becomes burdensome.  Uncertainty exists in 
estimates of costs and transition probabilities in the study model.  To handle uncertainty 
for these parameters simultaneously, probabilistic sensitivity analysis was selected for 
this study. 
Second-order Monte Carlo simulation is a tool for a probabilistic sensitivity 
analysis.  Second-order Monte Carlo simulation assesses the impact on model outcomes 
by varying values of multiple parameters simultaneously and can be used in the Markov 
                                                 
290 Briggs, A. H. (2001). Handling uncertainty in economic evaluation and presenting the results. In: 
Drummond, M. F.; McGuire, A. (editors) Economic Evaluation in Health Care; Oxford University Press, 
New York. Page 191.  
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cohort analysis or the first-order Monte Carlo simulation.290F 291   The probabilistic 
second-order Monte Carlo simulation addresses the issue of parameter uncertainty, and 
simultaneously considers different types of probability distributions for different 
parameters.291F 292  For example, a gamma (log-normal) distribution could be used to 
describe positively skewed health care cost data; a triangular or beta distribution could be 
used to represent probabilities which are bounded between zero and one.  When 
probabilities are obtained directly from original data, Bayesian methods could be used.   
A Bayesian approach to stochastic (probabilistic) sensitivity analysis were used 
for selected variables to assess uncertainty on the levels of sampling and parameters.292F293, 
293F
294, 294F295, 295F296, 296F297  The variables include, but are not limited to, sampling variance, rewards 
and transition probabilities.  Because descriptive analyses yield means and standard 
deviations for cost estimates, a normal distribution was used to describe uncertainty of 
cost estimates.  A triangular distribution (± 30% of variance, minimum=0.7, likeliest=1, 
maximum=1.3) was used to represent transition probabilities which are bounded between 
zero and one.   
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3.6 COST-EFFECTIVENESS ANALYSES 
This section covers cost-effectiveness analysis which addresses the sixth study 
objective.  The long-term estimates of costs and effectiveness were obtained from the 
results of Markov modeling with the first-order Monte Carlo simulations for each option 
of anti-osteoporotic treatments, including the control group.  The incremental 
cost-effectiveness ratios (ICERs) of these long-term estimates were calculated for each 
option of the anti-osteoporotic agents compared with glucocorticoid users who did not 
use any anti-osteoporotic agent (the control option).  The second-order Monte Carlo 
simulation yielded estimates for probabilistic sensitivity analyses.   
The confidence levels of the ICER can be interpreted by the cost-effectiveness 
acceptability curve which facilitates decision making.297F 298   The cost-effectiveness 
acceptability curve provides an estimate of the probabilities that the true ICER is less 
than the value of the ceiling ratio (i.e., willingness-to-pay, WTP).298F299, 299F300, 300F301 This allows 
a simultaneous comparison of all possible alternatives in one plot.  It also allows checks 
of hypotheses for the sixth study objective where ICER of each option is compared to the 
ceiling ratios (i.e., WTP).  By using the cost-effectiveness acceptability curve, different 
decision makers may find the corresponding range of probabilities that remain 
cost-effective based on personalized willingness-to-pay.   
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3.7 OTHER CONSIDERATIONS 
3.7.1 General Assumptions 
In addition to assumptions mentioned in previous sections, several general 
assumptions are made for this study.  The study results should still reflect actual patient 
experience given these assumptions.  Some assumptions are made because of limitations 
of data.  There are a total of nine general assumptions.  Some assumptions which 
specifically relate to Markov modeling are described in Section 3.5 (Longitudinal 
Projection).   
(1) Diagnosis.  It is assumed that glucocorticoid-induced osteopenia, 
osteoporosis and osteoporotic fractures were fully identified in MEPS subjects during the 
data collection, and that these conditions are fully detected in hypothetical subjects for 
the modeling.  There is no information available to estimate the degree of 
non-diagnosis.  Even though osteoporosis is under-diagnosed, the ICD-9-CM codes 
reported in MEPS will still be used to estimate incidence of osteoporosis.  The study 
results may still reflect the reality of under-diagnosis. 
(2) Label and off-labeled use.  It is assumed that all study subjects used 
bisphosphonates based on the FDA-approved regimens for glucocorticoid-induced 
osteoporosis, and used other anti-osteoporotic agents by following regimens for 
postmenopausal osteoporosis.  Only FDA-approved agents for osteoporosis are 
considered for this study.   
(3) Switches, combination use and prior use of medications.  Switches 
between anti-osteoporotic agents are possible but switches are not considered in this 
study.  Except for the bisphosphonate-HRT combination, subjects who reported more 
than one anti-osteoporotic agent are excluded in this study.  The main reason is that it is 
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difficult to compare and interpret the “pure” cost-effectiveness of an anti-osteoporotic 
medication to another if medication switches and combination use were included.  
However, no information is available for switches and combination use beyond the 
periods of data collections for MEPS.  The protective effects of anti-osteoporotic agents 
on bone loss may continue if subjects used any of the anti-osteoporotic agents before, but 
this study excludes subjects who reported use of anti-osteoporotic agents for less than 
three months.  The carry-over effects are unlikely to be present for qualified study 
subjects.  Nevertheless, it is assumed that there is no carry-over effect for qualified 
study subjects.   
(4) Adherence.  The issues of compliance for use of anti-osteoporotic agents 
have been discussed in the literature; however, compliance with and duration of each 
therapy were not explicitly stated in most studies.301F 302 , 302F 303    Evidence shows that 
compliance with therapy has an impact on cost-effectiveness.  For example, a study 
reported that 20% improvement in persistence with bisphosphonates decreases fractures 
by 6 percent.303F304   Even though the issue of compliance is important to evaluation of 
cost-effectiveness of anti-osteoporotic treatments, this study reflects the reality based on 
the study data.  It is assumed that the pattern of imperfect compliance in the use of 
anti-osteoporotic agents remains the same for study subjects if they continue to use the 
same anti-osteoporotic agent beyond the period of data collection.  This assumption 
allows projections of long-term estimates by the Markov modeling for hypothetical 
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subjects with “imperfect” compliance.  Therefore, the results of long-term projections 
reflect the “real-world” situations that patients may not totally comply with prescribed 
dosing regimens of anti-osteoporosis therapy.  Additionally, because intermittent use of 
glucocorticoid steroids does not reduce bone loss and because the cumulative 
glucocorticoid dose is more important than lengths of glucocorticoid therapy, the impact 
of non-adherence with glucocorticoid therapy on risk of osteoporotic fractures is ignored.   
(5) Adverse drug reactions.  The adverse drug reactions due to use of 
anti-osteoporotic agents were included in calculations of total costs for anti-osteoporotic 
treatments in this study.  However, to simplify the structure of the decision tree in 
Markov modeling, it was assumed that the adverse drug reactions do not alter the 
transition probabilities among Markov states in the study model.  Besides the bone loss, 
other adverse reactions of glucocorticoid use were assumed to be equally distributed 
among users so they could be ignored.   
(6) Underlying conditions.  The impact of the underlying diseases on 
osteoporotic fractures was assumed to be equal between glucocorticoid users who used 
anti-osteoporotic agents and those who did not (the controls).  Although different 
underlying diseases may have different impacts on the fracture rates as described in 
Chapter Two, it is not feasible to include all underlying diseases and categorize them into 
appropriate groups.  Even if categories could be formed and study samples could be 
grouped into these categories, the sample size in each group (for each disease state) 
would be too small to generate meaningful national estimates for statistical analyses, 
which is an important study objective.   
(7) Causal relations.  It is assumed that all osteoporosis and osteoporotic 
fractures which occurred after the use of glucocorticoids are glucocorticoid-induced.  
Even though many other confounding factors (such as age, underlying diseases, etc.) may 
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have impacts on osteoporosis and osteoporotic fractures, glucocorticoid use is the most 
important factor for the study outcomes.  Even though study outcomes may be 
influenced by many confounding factors, the effects from anti-osteoporotic treatments 
play a most cost-effective role on the overall study outcomes.   
(8) Limited number of episodes for osteoporotic fractures.  For the simplicity 
of the study models, each individual is limited to a maximum of two episodes of 
osteoporotic fractures in two-year or 10-year simulations, and a maximum of three 
episodes of osteoporotic fractures in lifetime simulations.  This information was 
included in the criteria for Markov termination.  The probability of having four or more 
osteoporotic fractures is believed to be relatively low in the general population; therefore, 
these rates were ignored in the study model.  It is also assumed that any reported 
fracture in MEPS data is the subject’s first fracture, unless more than one fracture was 
reported. 
(9) Longitudinal projection.  Using glucocorticoid steroids at a cumulative 
dose of 450 mg of prednisone or its equivalent is defined as high-risk glucocorticoid use.  
Once an individual starts long-term glucocorticoid therapy or anti-osteoporosis treatment, 
he or she is assumed to use it continuously by following the same pattern for the rest of 
his or her lifetime.  This assumption allows for the projection of long-term outcomes 
(costs and fracture rates) from the short-term data.   
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3.7.3 Ethical Consideration 
The study was approved by the University of Texas Institutional Review Board 
(IRB) on February 8th, 2007.  The IRB protocol number is #2007-01-0094.  This study 
has minimal risk regarding privacy and confidentiality.  The letter of approval is 
included in Appendix A.   
This project involves the collection of existing datasets (MEPS) which are publicly 
available and governed by the Agency for Healthcare Research and Quality (AHRQ).  
Because personal identifiers have been removed from the public-access datasets in MEPS 
by the AHRQ, subjects cannot be identified directly or indirectly through identifiers linked 
to the subjects.  Additionally, this study is a retrospective database analysis.  Study 
subjects were not physically involved in the research project and there was no interaction 
between the researcher and survey participants.  This study has no impact on therapies 
that has been received or will be received by the study subjects.  Therefore, no informed 
consent can be obtained or applied to this project.   
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3.8 SUMMARY OF CHAPTER THREE 
The use of “real-world” data is one of the important keys to this study, so the 
study datasets were described at the beginning of this chapter.  A retrospective analysis 
of data from the 1996-2004 MEPS was conducted to yield nationally representative, 
“real-world” estimates of clinical and economic outcomes for this study.  Analysis of 
variance was used to compare means of these estimates among anti-osteoporotic 
treatment groups.  Logistic regression analysis was used to to estimate relative risks of 
osteoporotic fractures in long-term glucocorticoid users in comparison to 
non-glucocorticoid users.  Markov modeling with Monte Carlo simulations was used to 
yield long-term estimates of cost-effectiveness for each anti-ostoeporotic treatment.  
Cost-effectiveness analysis was used to compare long-term estimates of 
cost-effectiveness of anti-osteoporotic treatments.  A brief review of therories and 
concepts was provided for cost-effectiveness analyses and the Markov modeling 
technique. 
There were a total of six groups of anti-osteoporotic treatments: bisphosphonate 
therapy (BP), calcitonin therapy (CN), hormone replacement therapy (HT), the combined 
use of HRT and bisphosphonates (HB), raloxifene therapy (RF) and the control group 
(CT).  Calcium and vitamin D products were excluded as a comparison group because 
they were assumed to be provided to all study subjects.  Teriparatide has been available 
since 2003.  Because teriparatide was not used by any glucocorticoid user who was 





This chapter consists of five sections which present study results according to 
study objectives.  Section 4.1 summarizes and compares average ages and 
glucocorticoid use of study subjects among different treatment groups.  Section 4.2 
shows national estimates of incidence rates of osteoporosis and osteoporotic fractures in 
subjects categorized by gender and different types of glucocorticoid use.  Section 4.3 
shows national estimates of average direct medical costs associated with osteoporosis, 
osteoporotic fractures and different treatments.  Because these estimates of costs and 
fracture rates are based on 2-year follow-ups for each individual in the Medical 
Expenditure Panel Survey (MEPS), they are treated as “short-term” outcomes.  Section 
4.4 describes inputs of Markov modeling, and demonstrates estimated “long-term” 
outcomes for cohorts with different characteristics.  Section 4.5 compares “short-term” 
and “long-term” cost-effectiveness across different treatment options, and suggests the 
best option for patients in different cohorts.  
 
4.1 STUDY SUBJECTS 
The first section describes study subjects by providing descriptive statistics of 
important characteristics which may have an impact on study outcomes.  These 
characteristics include gender, age, glucocorticoid use and the underlying conditions for 
which glucocorticoid tablets were prescribed.  They are compared among subjects 
categorized by duration and amount of glucocorticoid use.  These characteristics are 
further compared among subjects with different treatments.  When a significant 
difference in any of these important characteristics is found, it indicates the characteristic 
evaluated has an impact on costs and effectiveness of anti-osteoporotic treatments.  
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Study outcomes should be compared among anti-osteoporotic treatments with caution in 
this chapter.  The results from this section address the first study objective.  
 
4.1.1 Glucocorticoid Users 
First of all, subjects in the Medical Expenditure Panel Survey (MEPS) from 1996 
to 2004 are summarized in Table 4.1.1, which shows unweighted and weighted number 
and average ages of subjects by year and gender.  The average unweighted numbers of 
subjects is 30,253 per year, the weighted average age is 35.6 years old and 51.1% of them 
are female.  Female subjects are older than male subjects (weighted average age of 
women: 36.7 years old, men: 34.5 years old; df=1, F=627.38, p<0.0001).  It is estimated 
that 4.5% (12,663,459/280,566,064) of the non-institutional U.S. population are oral 
glucocorticoid tablet users at any dose and length of therapy; the percentages are 3.7% 
(5,075,366/137,088,576) in men and 5.3% (7,588,093/143,477,487) in women (data not 
shown in tables).   
Because the target population for this study is glucocorticoid users, important 
characteristics are compared in long-term glucocorticoid tablet (LTGS) users, who 
reported use of glucocorticoid tablets at a cumulative quantity of more than 90 days, and 
high-risk glucocorticoid (HRGS) users, who reported use of glucocorticoid tablets at a 
minimal cumulative dose of 450mg prednisone (or its equivalent).  Of all glucocorticoid 
tablet users, 49.6% (6,280,061/12,663,459) are LTGS users and 37.6% 
(4,754,998/12,663,459) are HRGS users.  Of male glucocorticoid tablet users, 47.7% 
(2,421,374/5,075,366) are LTGS users and 37.4% (1,896,290/5,075,366) are HRGS 
users.  Of female glucocorticoid tablet users, 50.9% (3,858,687/7,588,093) are LTGS 
users, and 37.7% (2,858,707/7,588,093) are HRGS users.  Table 4.1.2 and Table 4.1.3 
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show the number, average age, average cumulative quantity of glucocorticoid tablets and 
average glucocorticoid dose per tablet in LTGS users and HRGS users, respectively.   
 
Table 4.1.1 Number and average age of MEPS subjects by gender and year 
MEPS Unweighted Weighted§ 
Year N % Ave Age SD N % 
Ave 
Age SE 
95% CI for 
Mean 
All 272,277         
1996 22,601  33.8 22.1 268,905,492  34.9 0.28 34.4 35.5
1997 34,551  33.8 22.3 271,278,585  35.1 0.25 34.6 35.6
1998 24,072  33.7 22.4 273,533,688  35.3 0.27 34.7 35.8
1999 24,618  34.1 22.3 276,410,763  35.4 0.29 34.8 35.9
2000 25,096  34.2 22.4 278,405,514  35.5 0.29 34.9 36.0
2001 33,556  34.4 22.2 284,247,324  35.9 0.24 35.4 36.3
2002 39,165  34.0 22.2 288,181,764  36.1 0.20 35.7 36.5
2003 34,215  33.5 22.3 290,604,438  36.2 0.21 35.8 36.7
2004 34,403  33.7 22.3 293,526,999  36.3 0.24 35.9 36.8
Ave. 30,253  33.9  280,566,064  35.6 0.16 35.3 36.0
          
Male 129,916         
1996 10,833 47.9 32.6 21.5 131,526,594 48.9 33.7 0.30 33.1 34.3
1997 16,414 47.5 32.4 21.7 132,605,208 48.9 33.9 0.27 33.4 34.5
1998 11,443 47.5 32.2 21.8 133,614,279 48.8 34.1 0.31 33.5 34.7
1999 11,801 47.9 33.0 22.0 134,602,641 48.7 34.3 0.30 33.7 34.8
2000 12,057 48.0 33.1 22.1 135,881,865 48.8 34.4 0.29 33.8 35.0
2001 16,107 48.0 33.2 21.9 138,630,933 48.8 34.7 0.24 34.3 35.2
2002 18,702 47.8 32.6 21.8 140,801,931 48.9 35.0 0.21 34.6 35.4
2003 16,216 47.4 31.9 21.8 142,264,593 49.0 35.2 0.21 34.7 35.7
2004 16,343 47.5 32.2 21.8 143,869,149 49.0 35.3 0.24 34.8 35.8
Ave. 14,435 47.7 32.6  137,088,576 48.9 34.5 0.16 34.2 34.8
          
Female 142,361         
1996 11,768 52.1 35.0 22.6 137,378,898 51.1 36.0 0.34 35.4 36.7
1997 18,137 52.5 35.1 22.8 138,673,377 51.1 36.2 0.29 35.6 36.8
1998 12,629 52.5 35.1 22.7 139,919,409 51.2 36.4 0.32 35.8 37.1
1999 12,817 52.1 35.2 22.5 141,808,131 51.3 36.4 0.35 35.7 37.1
2000 13,039 52.0 35.1 22.7 142,523,658 51.2 36.5 0.34 35.8 37.2
2001 17,449 52.0 35.5 22.6 145,616,391 51.2 36.9 0.28 36.4 37.5
2002 20,463 52.2 35.3 22.5 147,379,833 51.1 37.1 0.24 36.6 37.6
2003 17,999 52.6 34.9 22.7 148,339,836 51.0 37.3 0.27 36.7 37.8
2004 18,060 52.5 35.1 22.7 149,657,859 51.0 37.4 0.30 36.8 38.0
Ave. 15,818 52.3 35.1  143,477,487 51.1 36.7 0.18 36.4 37.1
Ave. =average; CI=confidence interval; MEPS=Medical Expenditure Panel Survey; N=number of subjects; 
SD=standard deviation; SE=standard error of the mean. 
§Each subject has different year-specific personal weights. . 
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An estimated 2.2% (6,280,061/280,566,064) of the non-institutional U.S. 
population are LTGS users; the percentages are 1.8% (2,421,374/137,088,576) in men 
and 2.7% (3,858,687/143,477,487) in women.  The unweighted average number of 
LTGS users per year in the sample is 607, and the weighted average age is 49.7 years old.  
Of these LTGS users, 61.4% are female and women are older than men (50.7 versus 48.1 
years old; df=1, F=18.66, p<0.0001).  No significant difference was found in 
cumulative glucocorticoid dose (df=1, F=1.54, p=0.2141) and cumulative quantity of 
glucocorticoid tablets (df=1, F=0.10, p=0.7494) and average glucocorticoid dose per 
tablet (df=1, F=3.70, p=0.0545) between men and women.   
An estimated 1.7% (4,754,998/280,566,064) of the non-institutional U.S. 
population are HRGS users; the percentages are 1.4% (1,896,290/137,088,576) in men 
and 2.0% (2,858,707/143,477,487) in women.  The average unweighted number of 
HRGS users is 462 per year and the weighted average age is 50.8 years old.  
Approximately 60.1% of HRGS users are female and women are older than men (52.0 
versus 49.2 years old; df=1, F=17.26, p<0.0001).  No significant difference was found 
in cumulative glucocorticoid dose (df=1, F=0.14, p=0.7114), cumulative quantity of 
glucocorticoid tablets (df=1, F=1.03, p=0.3091) and average glucocorticoid dose (df=1, 
F=3.00, p=0.0836) between female and male HRGS users.  Subjects who were 
classified as both LTGS and HRGS users account for 53.7% of LTGS users and 71.0% of 
HRGS users (Table 4.1.4).   
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Table 4.1.2 Number, average age and glucocorticoid tablet use of long-term 
glucocorticoid tablet users in MEPS by gender and year 
LTGS Unwtd Weighted§ 
Gender Age Cum. quantity of  GS tablets 
GS dose per 
tablet* (mg) 
Year 
N N % 
Ave. SE Ave. SE Ave. SE 
All 5,461 56,520,549   
1996 464 6,122,964 49.9 1.18 255.3 20.80 10.4 0.46
1997 735 6,190,499 49.0 1.07 268.5 19.10 10.4 0.40
1998 463 5,411,734 48.7 1.23 280.4 30.19 10.3 0.42
1999 457 5,897,846 49.6 4.05 250.2 23.40 11.1 0.35
2000 502 6,546,429 49.7 1.21 225.7 17.40 11.0 0.35
2001 717 6,759,368 50.7 0.87 225.8 15.43 11.1 0.33
2002 854 7,219,940 48.9 0.96 216.0 13.87 11.3 0.30
2003 740 7,237,723 48.1 1.00 205.8 15.71 11.4 0.31
2004 529 5,134,046 52.3 0.92 220.9 17.63 11.4 0.41
Ave. 607 6,280,061 49.7 0.53 237.2 8.93 11.0 0.17
     
Male 2,064 21,792,370 38.6   
1996 171 2,216,329 36.2 48.2 1.86 285.2 44.16 10.6 0.88
1997 285 2,402,616 38.8 49.8 1.58 274.1 39.04 10.5 0.71
1998 196 2,230,429 41.2 50.0 1.93 277.5 48.52 10.5 0.63
1999 187 2,416,358 41.0 49.0 1.93 248.5 31.92 11.3 0.49
2000 202 2,632,011 40.2 47.1 2.12 228.3 27.89 11.3 0.56
2001 259 2,431,258 36.0 47.6 1.49 237.8 22.45 11.6 0.53
2002 292 2,534,994 35.1 46.3 1.69 213.7 19.16 11.9 0.47
2003 272 2,842,067 39.3 46.4 1.86 195.9 19.71 11.4 0.45
2004 200 2,086,308 40.6 49.6 1.73 207.3 23.74 11.5 0.63
Ave. 229 2,421,374 38.6 48.1 0.90 239.6 14.91 11.2 0.29
      
Female 3,397 34,728,179 61.4   
1996 293 3,906,635 63.8 50.9 1.37 238.3 23.34 10.2 0.57
1997 450 3,787,883 61.2 48.4 1.22 265.0 22.60 10.3 0.47
1998 267 3,181,305 58.8 47.8 1.37 282.5 37.43 10.2 0.58
1999 270 3,481,489 59.0 50.0 1.30 251.3 31.82 11.0 0.45
2000 300 3,914,418 59.8 51.4 1.53 223.9 21.52 10.8 0.47
2001 458 4,328,110 64.0 52.5 1.00 219.0 19.93 10.7 0.39
2002 562 4,684,946 64.9 50.2 0.98 217.2 16.89 11.0 0.36
2003 468 4,395,656 60.7 50.8 1.03 212.2 20.79 11.5 0.43
2004 329 3,047,739 59.4 54.1 1.04 230.2 23.72 11.3 0.53
Ave. 377 3,858,687 61.4 50.7 0.60 235.7 10.65 10.8 0.19
Ave. =average; Cum. =cumulative; GS=glucocorticoid steroid tablets; LTGS=long-term users of 
glucocorticoid tablets for at least three months; N=number of subjects; MEPS=Medical Expenditure Panel 
Survey; SE=standard error of the mean; Unwtd=Unweighted. 
§Each subject has different year-specific personal weights.  
*Doses of various glucocorticoid steroids are converted to prednisone equivalents. 
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 Table 4.1.3 Number, average age and glucocorticoid tablet use of high-risk 
glucocorticoid tablet users in MEPS by gender and year 
HRGS Unwtd Weighted§ 
Gender Age Cum. quantity of  GS tablets 
GS dose per 
tablet * (mg) 
Year 
N N % 
Ave. SE Ave. SE Ave. SE 
All 4,162 42,794,978   
1996 351 4,636,824 51.2 1.33 297.8 24.37 11.2 0.55
1997 565 4,735,050 50.0 1.21 292.9 19.74 11.2 0.46
1998 349 3,986,716 49.9 1.44 315.4 33.36 10.9 0.49
1999 366 4,680,070 50.4 1.22 293.5 28.15 11.8 0.40
2000 401 5,217,007 50.7 1.33 268.5 20.75 11.8 0.42
2001 523 4,901,090 52.4 1.01 296.9 20.22 11.9 0.37
2002 639 5,336,783 50.1 1.12 281.3 17.04 11.8 0.33
2003 557 5,342,591 49.9 1.12 267.7 19.35 11.8 0.34
2004 411 3,958,846 53.7 1.03 275.2 21.00 11.9 0.50
Ave. 462 4,754,998 50.8 0.60 286.8 10.34 11.6 0.21
     
Male 1,612 17,066,606  39.9   
1996 133 1,765,152 38.1 49.4 2.23 308.5 50.59 11.4 1.02
1997 223 1,902,355 40.2 50.0 1.81 275.9 34.45 11.4 0.82
1998 150 1,686,292 42.3 51.2 2.29 290.5 38.00 11.2 0.76
1999 156 2,024,372 43.3 49.6 2.09 286.4 31.01 12.1 0.55
2000 164 2,146,482 41.1 47.7 2.31 267.2 25.30 12.3 0.64
2001 191 1,800,003 36.7 49.7 1.67 307.1 28.92 12.8 0.63
2002 226 1,937,562 36.3 47.6 1.90 270.4 23.33 12.3 0.52
2003 213 2,183,037 40.9 47.1 2.10 246.9 22.67 11.4 0.49
2004 156 1,621,350 41.0 51.2 1.99 256.3 27.19 11.8 0.75
Ave. 179 1,896,290 39.9 49.2 1.11 278.0 14.94 11.9 0.32
      
Female 2,550 25,728,372 60.1   
1996 218 2,871,672 61.9 52.3 1.69 291.2 28.61 11.1 0.68
1997 342 2,832,696 59.8 50.0 1.41 304.3 25.18 11.0 0.52
1998 199 2,300,424 57.7 48.9 1.71 333.7 48.52 10.7 0.68
1999 210 2,655,698 56.7 51.0 1.61 298.9 31.17 11.7 0.53
2000 237 3,070,525 58.9 52.7 1.68 269.4 26.27 11.5 0.51
2001 332 3,101,087 63.3 53.9 1.21 291.0 27.20 11.5 0.42
2002 413 3,399,220 63.7 51.5 1.09 287.5 21.24 11.6 0.39
2003 344 3,159,554 59.1 51.9 1.19 282.1 26.30 12.0 0.46
2004 255 2,337,496 59.0 55.3 1.16 288.4 28.28 11.9 0.64
Ave. 209 2,858,707 60.1 52.0 0.68 292.7 13.31 11.4 0.23
Ave. =average; Cum. =cumulative; GS=glucocorticoid steroid tablets; HRGS=high-risk users of 
glucocorticoid tablets at a cumulative prednisone-equivalent dose of 450 mg or more; MEPS=Medical 
Expenditure Panel Survey; N=number of subjects; SE=standard error of the mean; Unwtd=Unweighted. 
§Each subject has different year-specific personal weights. . 
*Doses of various glucocorticoid steroids are converted to prednisone equivalents. 
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Table 4.1.4 Percentage of subjects classified as LTGS and HRGS users by gender 

















Male 2,098 21,792,370 53.2 1,120 11,591,271 67.9 1,641 17,066,606
Female 3,454 34,728,179 54.1 1,927 18,774,288 73.0 2,597 25,728,372
Total 5,552 56,520,549 53.7 3,047 30,365,559 71.0 4,238 42,794,978
LTGS=long-term users of glucocorticoid tablets for at least three months; HRGS=high-risk users of 
glucocorticoid tablets at a cumulative prednisone-equivalent dose of 450 mg or more; N=number of 
subjects; Unwtd=Unweighted; Wtd=weighted. 
 
4.1.2 Treatment Groups 
In addition to glucocorticoid use, study subjects are further classified by type of 
treatments.  Subjects are classified in one of the following groups: the control group 
(CT) who did not report any anti-osteoporotic agent; the bisphosphonate group (BP) 
who reported use of bisphosphonate only; the calcitonin group (CN) who reported use 
of calcitonin only; the HB group who reported use of both hormone replacement therapy 
and bisphosphonate; the HT group who reported use of hormone replacement therapy 
only; the raloxifene group (RF) who reported use of raloxifene only; and the OTHER 
group who reported use of two or more anti-osteoporotic agents, but excluding subjects 
in the HB group.  The ELSE group was used for showing descriptive statistics in this 
section and is not used for other analyses for this study.   
Table 4.1.5 shows the weighted numbers and percentages of subjects who 
received anti-osteoporotic treatments by gender, type of glucocorticoid use and 
treatment.  It is noted that treatments are reported for both primary and secondary 
prevention in Table 4.1.5.  Overall, 12.0% of MEPS subjects, 22.4% of LTGS users, 
and 22.8% of HRGS users reported use of any anti-osteoporotic agent.  In women, 
21.4% of MEPS subjects, 34.8% of LTGS users, and 35.9% of HRGS users reported use 
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of any anti-osteoporotic agent.  In men, only 0.3% of MEPS subjects, 2.5% of LTGS 
users, and 2.9% of HRGS users reported use of any anti-osteoporotic agent.  More 
women received anti-osteoporotic treatments than men.  However, the percentages of 
glucocorticoid users who received anti-osteoporotic treatments are relatively low.  The 
most frequently used type among all anti-osteoporotic agents is hormone replacement 
therapy in women or use of both bisphosphonates and calcitonin for men.  The next 
frequently used type is bisphosphonates. 
 
Table 4.1.5 Total weighted number and percentage of subjects by gender, type of 
glucocorticoid use and treatment, MEPS 1996-2004 
GS type MEPS LTGS HRGS 
Treatment* Total N§ % Total N§ % Total N§ % 
Women       
BP 13,547,167 1.30 1,199,572 3.42 1,015,601 3.91
CN 2,742,785 0.26 281,275 0.80 281,275 1.08
HB 4,355,743 0.42 395,564 1.13 277,374 1.07
HT 151,153,832 14.53 7,518,676 21.41 5,677,935 21.83
RF 4,583,888 0.44 83,345 0.24 85,345 0.33
ELSE 46,535,244 4.47 2,719,903 7.74 1,991,436 7.66
CT 817,546,517 78.58 22,923,408 65.26 16,676,780 64.13
Total 1,040,465,176 100.00 35,123,743 100.0 26,005,746 100.01a
Men  
BP 695,000 0.08 215,809 0.99 170,580 1.00
CN 414,926 0.05 76,222 0.35 76,222 0.45
ELSE 1,401,205 0.17 244,399 1.12 244,399 1.43
CT 838,164,761 99.70 21,255,940 97.54 14,439,076 97.12
Total 840,675,892 100.0 21,792,370 100.00 17,066,606 100.00
GS=glucocorticoid steroids; HRGS=high-risk users of glucocorticoid tablets at an accumulated 
prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of glucocorticoid tablets for at least 
three months; MEPS=Medical Expenditure Panel Survey. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group; ELSE=any use of anti-osteoporotic agent(s) other 
than treatments (BP only, CN only, HB, HT only, RF only) previously identified. 
§N=total number of subjects from 1996 to 2004.  
a Sum of percentages does not equal to 100% because of rounding. 
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Average ages and glucocorticoid use (average cumulative glucocorticoid doses, 
average cumulative quantities of glucocorticoid tablets and average daily doses per 
glucocorticoid tablet) were compared across treatment groups.  Table 4.1.6 shows the 
total numbers, average ages, average cumulative quantities of glucocorticoid tablets and 
average doses per glucocorticoid tablet in subjects with different treatments (data of 
average cumulative glucocorticoid doses not shown).   
 
 Age 
Table 4.1.6 shows that average ages are different among treatment groups in 
female glucocorticoid users (for LTGS users: df=5, F=50.82, p<0.0001; for HRGS 
users: df=5, F=36.78, p<0.0001).  Post hoc analysis indicated that female 
glucocorticoid users in the control (CT, both LTGS and HRGS users, P<0.0001) and 
hormone replacement therapy (HT, both LTGS and HRGS users, P<0.0001) groups are 
younger than those in other treatment groups.  Similarly, average ages are different 
among treatment groups in male glucocorticoid users (for LTGS users: df=2, F=7.83, 
p=0.0004; for HRGS users: df=2, F=4.51, p=0.0112).  Post hoc analysis indicated that 
male glucocorticoids users in the bisphosphonate (BP) groups are older than those in the 
control group (both LTGS and HRGS users, P<0.0001).  Because of significant 
differences in age among treatment groups, the effect of age on fractures was partially 
controlled by categorizing study subjects into four age groups (as shown in Tables of 
Appendix B). 
 
 Glucocorticoid use 
An overall difference in average cumulative glucocorticoid doses was found 
among treatment groups in females (for LTGS users: df=5, F=3.70, p=0.0024, for 
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HRGS users: df=5, F=2.32, p=0.0412).  Post hoc analysis indicated that female LTGS 
users in the bisphosphonate (BP) group had a higher average cumulative glucocorticoid 
dose than those in the HRT (HT, p=0.0364) and control (CT, p=0.0015) groups.  
Female HRGS users in bisphosphonate groups had a higher average cumulative 
glucocorticoid dose than those in the calcitonin (CN, p=0.0319) and in the control (CT, 
p=0.0039) group.  Overall differences in average cumulative glucocorticoid doses were 
found among treatment groups in male glucocorticoid users (for LTGS users: df=2, 
F=11.80, p<0.0001; for HRGS users: df=2, F=8.46, p=0.0002).  Male glucocorticoid 
users in the bisphosphonate group had higher average cumulative glucocorticoid doses 
than those in the control (CT, for LTGS users p=0.0030, for HRGS users p=0.0056) 
groups (results not shown in Table 4.1.6). 
Upon further investigation, the cumulative glucocorticoid dose was decomposed 
to the cumulative quantity of glucocorticoid tablets, which represents the length of 
glucocorticoid therapy, and the average dose per tablet (results shown in Table 4.1.6).  
Significant differences in average cumulative quantity of glucocorticoid tablets were 
found among treatment groups in female glucocorticoid users (for LTGS users: df=5, 
F=9.72, p<0.0001; for HRGS users: df=5, F=7.87, p<0.0001).  Post hoc analysis 
indicated that female LTGS glucocorticoid users in bisphosphante (BP) group had a 
longer average period of treatments than those in the HRT (HT, p=0.0364) and the 
control (CT, p=0.0015) groups.  Female LTGS users in the raloxifene group had a 
shorter average period of treatments than those in the control group (CT, p=0.0138).  
Female HRGS users in the bisphosphonate group had a longer period of treatments than 
those in the calcitonin group (CN, p=0.0319).  With regard to male glucocorticoid 
users, significant differences in average cumulative quantity of glucocorticoid tablets 
were found among treatment groups (for LTGS users: df=2, F=89.94, p<0.0001; for 
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HRGS users: df=2, F=21.95, p<0.0001).  Post hoc analysis indicated that male 
glucocorticoid users in the bisphosphonate (BP) group had longer average periods of 
treatments than the control groups (for LTGS user: p=0.0377; for HRGS users: 
p=0.0331).   
Significant differences in average glucocorticoid dose per tablet were found 
among treatment groups in female LTGS glucocorticoid users (df=5, F=2.89, 
p=0.0131), but not in female HRGS users (df=5, F=2.21, p=0.0506).  Post hoc analysis 
indicated that female glucocorticoid users in bisphosphonate (BP) group, control (CT) 
group and hormone replacement therapy (HT) group had higher average glucocorticoid 
doses per tablet than those in raloxifene (RF vs. BP p=0.0093, CT p=0.0015; HT 
p=0.0007) and HB (for BP p=0.0384, CT p=0.0027, HT p=0.013) groups.  In male 
glucocorticoid users, significant differences in average glucocorticoid dose per tablet 
were found among treatment groups (for LTGS users: df=2, F=3.15, p=0.0431; for 
HRGS users: df=2, F=3.91, p=0.0203).  Post hoc analysis indicated that subjects in the 
calcitonin (CN) groups had a lower average glucocorticoid doses per tablet than those in 
the control groups (both LTGS and HRGS users p<0.0001). 
Even though an overall statistically significant difference in average 
glucocorticoid dose per tablet was not found in female HRGS users (df=5, F=2.21, 
p=0.0506), the trends are similar to significant differences found for female LTGS 
users.  It was noted that sample size in the raloxifene groups is relatively small which 
may not have enough statistical power to detect the differences that may exist.  The 
unweighted sample size of The RF group is 11 and the number was too small to detect 
the real differences.  Based on a personal communication with the staff of MEPS, a 
sample size of 25 is generally acceptable to yield nationally representative statistics; 
however, it depends on variance of estimates and also varies by research topics.   
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Table 4.1.6 Average age and GS use in subjects receiving at least three months of 
treatment by gender, treatment type and GS type, MEPS 1996-2004 
 Unwtd Weighted§ 
Treatment* Age Cum. quantity of GS tablets 




Ave. SE Ave. SE Ave. SE 
Female    
BP 1,275 13,547,167 70.1 0.52 336.1  54.07 11.3  0.78 
LTGS 125 1,199,572 67.3a d 2.53 437.7a 64.19 11.1c e 0.91 
HRGS 111 1,015,601 65.3a d 2.86 488.6a 73.26 11.0 0.66 
CN 236 2,742,785 72.4 0.82 239.5  69.40  8.8  0.21 
LTGS 24 281,275 64.7a d 2.34 312.8  86.86  8.8 0.09 
HRGS 24 281,275 64.7a d 2.34 312.8  86.86  8.8  0.09 
HB 402 4,355,743 64.7 0.71 205.6  55.89  9.4  0.74 
LTGS 42 395,564 61.2a e 2.69 318.1  59.68  7.9a d f 0.31 
HRGS 32 277,374 65.9a d - 433.3  -  9.2  - 
HT 13,749 151,153,832 50.8 0.28 140.8  17.46 10.7  0.32 
LTGS 699 7,518,676 55.6a b e f 0.76 237.4  30.84 11.4c e 0.48 
HRGS 523 5,677,935 57.0a b c e f 0.81 303.5  38.54 11.9 0.56 
RF 419 4,583,888 65.7 0.64 152.7  85.20  7.2  0.21 
LTGS 11 85,345 74.1a c d - 609.5  -  6.9a d f - 
HRGS 11 85,345 74.1a d - 609.5  -  6.9 - 
CT 85,810 817,546,517 35.6 0.20 112.8  6.06 10.7  0.19 
LTGS 2,269 22,923,408 47.2b c d e f 0.74 208.4f  10.84 10.8c e 0.24 
HRGS 1,682 16,676,780 48.4b c d e f 0.88 255.6f  14.00 11.5 0.28 
Male        
BP 67 695,000 65.0 0.01  1,120.9  -  8.2  - 
LTGS 26 215,809 67.1a -  1,390.9a -  8.4  - 
HRGS 22 170,580 64.7a - 870.7a -  8.6  - 
CN 40 414,926 77.2  1.11 545.7  255.01  8.2  0.62 
LTGS 10 76,222 61.8  6.26 668.0  343.75  5.4a 0.11 
HRGS 10 76,222 61.8  6.26 668.0  343.75  5.4a 0.11 
CT 81.287 838,164,761 37.0  0.20 113.5  6.28 10.9  0.20 
LTGS 2,003 21255,940 47.7f 0.91 213.6f 11.53 11.3b 0.29 
HRGS 1,555 16,575,405 48.7f 1.12 254.4f 12.73 12.0b 0.32 
Ave. =average; Cum. =cumulative; GS=glucocorticoid steroid tablets; GS doses of various glucocorticoid 
steroids are converted to as prednisone equivalents; HRGS=high-risk users of glucocorticoid tablets at an 
accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of glucocorticoid 
tablets for at least three months; MEPS=Medical Expenditure Panel Survey. SE=standard error of the 
mean; Unwtd=unweighted 
§Each subject has different year-specific personal weights. . 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group;  
**Doses of various glucocorticoid steroids are converted to prednisone equivalents. 
a p<0.05 compared to CT; b p<0.05 compared to CN; c p<0.05 compared to HB; d p<0.05 compared to HT;  
e p<0.05 compared to RF, f p<0.05 compared to BP. 
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 Summary of Results for Study Objective One 
There was no significant difference in average cumulative glucocorticoid doses 
among female high-risk glucocorticoid users (HRGS) who received different 
anti-osteoporotic treatments, so hypothesis Ho1B3 was not rejected.  However, all other 
hypotheses for the first study objective were rejected because statistically significant 
differences were found in average ages and glucocorticoid use among different treatment 
groups.  These differences are briefly summarized as follows.  
Female groups are older than male groups regardless of glucocorticoid use.  
Female glucocorticoid users in the hormone replacement threpay (HT) and the control 
(CT) groups were younger than those in other treatment groups.  Compared to male 
glucocorticoid users in the calcitonin (CN) group, those in the control (CT) group are 
younger and those in the bisphosphonate (BP) group are older.  The effect of age on 
fracture rates was partially controlled by dividing subjects into four age groups, which are 
11-30, 31-50, 51-70 and 71-90 years old..   
Female glucocorticoid users in the bisphosphonate (BP) group, hormone 
replacement therapy (HT) and the control (CT) groups had significantly higher average 
glucocorticoid doses per tablet than those in other groups, but those in the HT and CT 
groups are younger than those in other group.  The overall impact of glucocorticoid use 
and age on fracture rates for female glucocorticoid users in the HT and CT groups were 
unclear.  However, it is likely that more glucocorticoid use in female glucocorticoid 
users of the bisphosphonate (BP) and raloxifene (RF) groups will have a negative 
impact on osteoporotic fractures.  Similarly, male glucocorticoid users in the control 
group had higher average glucocorticoid doses per tablet and are younger than the 
bisphosphonate and the control groups.  The overall impact of glucocorticoid use and 
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age on fracture rates for male glucocorticoid users in the CT groups were unclear.  
These findings suggested a selection bias.  Readers should be aware of these 
differences when interpreting economic and clinical outcomes among different 
treatment groups throughout this chapter.   
 
4.1.3 Race Groups 
In MEPS data from 1996 to 2004, 81.7% of subjects are white, 12.8% are black or 
African American, 4.0% are Asian, Hawaiian or Pacific Islanders, 0.9% are American 
Indian or Alaska Native, and 0.6% reported no race or multiple race groups or other type 
of race group.  The majority of glucocorticoid users (86.2% of LTGS and 86.3% of 
HRGS) are white, followed by black (10.0% of LTGS and 10.3% of HRGS) and Asian or 
Pacific Islanders (2.4% of LTGS and 2.4% of HRGS).  Table 4.1.7 shows national 
estimates of percentages of subjects by race group.   
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Table 4.1.7 Weighted Percentages of subjects by racial group and glucocorticoid type 
GS type MEPS LTGS HRGS 
Racial group (%) All Male Female All Male Female All Male Female
White 81.67 82.29 81.08 86.21 86.98 85.72 86.26 87.37 85.53 
Black 12.84 12.26 13.39 10.02 9.39 10.41 10.29 9.22 11.00 
Asian / Pacific Islander 4.03 4.02 4.05 2.42 2.16 2.58 2.44 2.34 2.52 
American Indian / Alaska Native 0.91 0.91 0.90 0.85 0.99 0.77 0.69 0.80 0.63 
Other 0.55 0.52 0.58 0.51 0.49 0.51 0.31 0.28 0.33 
Total 100.00 100.00 100.00 100.01a 100.01a 99.99a 99.99a 100.01a 100.01a
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of 
glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey. 
a Sum of percentages does not equal to 100% because of rounding. 
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Next, percentages of subjects in racial groups within each type of treatment are 
listed in Table 4.1.8 and Table 4.1.9.  Approximately 90% of female glucocorticoid 
users in the BP, CN, HB or HT groups are white.  Almost all male subjects who 
received anti-osteoporotic therapy are white.  Among female subjects in the same racial 
group, hormone replacement therapy (HT) was most frequently used anti-osteoporotic 
treatment; it is followed by bisphosphonate treatments except for MEPS female subjects 
in the American Indian/Alaska Native group.  More bisphosphonates were used in male 
subjects of the same racial group, except MEPS male subjects in the American Indian/ 
Alaska Native group.   
In each racial group, the majority of women received hormone replacement 
therapy (HT) for management of osteoporosis (Table 4.1.8).  The next most popular 
anti-osteoporotic treatment was bisphosphonates within most racial groups.  It is noted 
that the unweighted number of female glucocorticoid users in the RF group is 11, that 
fewer than 30 male glucocorticoid users were identified in the BP group, and that there 
were 10 male glucocorticoid users in the CN group, so these percentages in race groups 
may not be representative.   
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Table 4.1.8 Weighted percentages of female subjects by treatment and racial group 
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Total column % 100.00  100.00 100.00 100.00 100.00 99.99 a 
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Total column % 100.00  100.00 100.00 100.00 100.00 100.00  
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey. 
† not included The CT group.   
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone 
replacement therapy; RF=raloxifene group.  
a Sum of percentages does not equal to 100% because of rounding. 
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Table 4.1.9 Weighted percentages of male subjects by treatment and racial group 




















































































































Total column % 100.00 100.00 99.99 a
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey. 
 not included The CT group. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
a Sum of percentages does not equal to 100% because of rounding. 
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4.1.4 Underlying Conditions 
Another important factor, which may have an impact on fracture rates, is the 
underlying disease for which glucocorticoid steroids were used.  Table 4.1.10 lists 
some common conditions in MEPS subjects, LTGS or HRGS users identified by 
International Classification of Disease, the ninth edition, Clinical Modification 
(ICD-9-CM) codes and Clinical Classification Code (CCC) codes.  Based on the list, at 
least 25.3% of LTGS users reported respiratory diseases, including asthma (CCC=128), 
chronic obstructive pulmonary diseases (CCC=127), lower and upper respiratory 
problems (CCC=126, 133, 134), followed by joint problems (21.9%), including 
non-traumatic joint disorders (CCC=204), rheumatoid arthritis (CCC=202) and 
connective tissue diseases (CCC=211).  By following the same calculation, 
approximately 24.1% of HRGS users reported respiratory diseases, and 23.3% reported 
joint problems.  The percentages of conditions for LTGS and HRGS users are similar. 
When LTGS users are categorized by type of anti-osteoporotic treatments, 
percentages of some conditions are listed in Table 4.1.11.  Joint problems remain the 
top ranked underlying condition, followed by respiratory diseases in LTGS users with 
most types of anti-osteoporotic treatments.  Table 4.1.11 does not indicate a potential 
difference in preference of anti-osteoporotic treatments in LTGS users with the same 
condition.  This issue is beyond the scope of this study and, furthermore, the sample 
size in some treatment groups is too small to have sufficient statistical power to draw 
any conclusion.   
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Table 4.1.10 Percentages of selected conditions for which glucocorticoid steroids were 
prescribed by glucocorticoid type, MEPS 1996-2004 
Unwtd % Code Condition GS LTGS HRGS 
ICD-9-CM§   
493 Asthma 11.60 12.85 12.68 
716 Arthropathies, nec 5.88 9.35 10.17 
714 Rheumatoid arthritis/ inflammatory polyarthropathies 4.89 8.01 8.51 
710 Diffuse diseases of connective tissue 2.34 3.74 4.06 
492 Emphysema 2.26 3.55 3.84 
692 Contact dermatitis 6.92 2.98 2.57 
725 Polymyalgia rheumatica 1.23 2.10 2.19 
255 Adrenal gland disorders 1.00 1.62 1.80 
555 Regional enteritis 0.99 1.34 1.73 
496 Chronic airway obstruction, nec 0.89 1.42 1.36 
401 Essential hypertension 1.57 1.22 1.31 
782 Skin and other integument symptoms 4.84 1.70 1.30 
518 Other lung diseases 0.73 1.12 1.18 
135 Sarcoidosis 0.63 1.09 1.18 
490 Bronchitis, nos 1.98 1.40 1.16 
477 Allergic rhinitis 2.08 1.39 0.99 
696 Psoriasis/like disorders 1.19 0.78 0.76 
473 Chronic sinusitis 1.12 1.02 0.58 
     
CCC§    
128 Asthma 11.60 12.85 12.68 
204 Other non-traumatic joint disorders 6.46 10.04 10.88 
202 Rheumatoid arthritis and related disorders 4.97 8.09 8.61 
127 Chronic obstructive pulmonary diseases 5.29 6.56 6.49 
210 Systemic lupus erythematosus and conditions 2.34 3.74 4.06 
211 Other connective tissue diseases 2.73 3.74 3.78 
253 Allergic reactions   8.30 3.74 3.23 
133 Other lower respiratory disorders 2.24 2.67 2.66 
144 Regional enteritis and ulcerative colitis 1.44 2.20 2.38 
051 Other endocrine disorders 1.49 2.19 2.23 
200 Other skin disorders 6.73 2.19 1.74 
134 Other upper respiratory diseases   2.53 1.65 1.18 
126 Other upper respiratory infections 2.71 1.61 1.05 
GS=glucocorticoid steroid tablets; HRGS=high-risk users of glucocorticoid tablets at an accumulated 
prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of glucocorticoid tablets for at least 
three months; MEPS=Medical Expenditure Panel Survey; nec=not elsewhere classified; nos=not specified 
as acute or chronic, Unwtd=unweighted. 
§ICD-9-CM=International Classification of Disease, the ninth edition, Clinical Modification, CCC=Clinical 
Classification Code. 
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Table 4.1.11 Percentages of selected conditions for which glucocorticoid steroids were 
prescribed by type of treatment, MEPS 1996-2004 
Treatment* (% unwtd LTGS users) 
Male Female Code Condition 
BP CN BP CN HB HT RF 
ICD-9-CM§   
493 Asthma 4.88 4.83  10.05  
716 Arthropathies, nec 22.76 11.98 13.92 18.13 12.30 50.70 
714 Rheumatoid arthritis/ inflammatory 
polyarthropathies 
25.20 10.53 15.64 30.38 27.50 8.98  
710 Diffuse diseases of connective tissue 4.16 7.59 7.50 5.03  
492 Emphysema 13.82 3.99  1.02  
692 Contact dermatitis 2.53 1.25 2.14  
725 Polymyalgia rheumatica 5.32  2.35  
255 Adrenal gland disorders  2.78  
555 Regional enteritis 21.05 2.66  1.28  
496 Chronic airway obstruction, nec 0.33 10.13  0.80  
401 Essential hypertension 0.50  0.59 4.00 
518 Other lung diseases 12.20 0.17 10.13 1.25 1.55  
135 Sarcoidosis 8.77 3.83  0.80  
490 Bronchitis, nos 1.16 2.53  1.18  
477 Allergic rhinitis 4.07 5.06 2.50 1.50 1.33 
696 Psoriasis/like disorders 6.88 1.07  
473 Chronic sinusitis 4.38 2.51  
CCC§    
128 Asthma 4.88 4.83  10.05  
204 Other non-traumatic joint disorders 22.76 12.48 13.92 18.13 13.58 50.70 
202 Rheumatoid arthritis & related disorders 34.96 10.53 15.64 30.38 27.50 8.98  
127 Chronic obstructive pulmonary diseases 14.63 5.82 12.66 1.88 3.42  
210 Systemic lupus erythematosus 4.16 7.59 7.50 5.03  
211 Other connective tissue diseases 0.81 5.32  3.80 17.30 
253 Allergic reactions   1.16 2.53 1.25 2.99  
133 Other lower respiratory disorders 12.20 0.50 10.13 3.75 3.21  
144 Regional enteritis and ulcerative colitis 21.05 2.66  1.28  
051 Other endocrine disorders 0.17 5.63 4.01  
200 Other skin disorders 3.00  2.41  
134 Other upper respiratory diseases   4.07 5.06 2.50 1.66 1.33 
126 Other upper respiratory infections 0.17 2.53 4.38 3.32  
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure 
Panel Survey; nec=not elsewhere classified; nos=not specified as acute or chronic; Unwtd=unweighted. 
§ICD-9-CM=International Classification of Disease, the ninth edition, Clinical Modification, CCC=Clinical 
Classification Code. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; HB=simultaneously use of hormone 
replacement therapy and bisphosphonates; HT=hormone replacement therapy; RF=raloxifene group. 
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4.2 CLINICAL OUTCOMES 
This section describes national estimates of prevalence and incidence rates for 
glucocorticoid-induced osteoporosis and glucocorticoid-induced osteoporotic fractures in 
the U.S.  These estimates are obtained from the cross-sectional analyses of MEPS data 
from 1996 to 2004.  Prevalence rates are calculated regardless of the start date of 
anti-osteoporotic treatment.  To better estimate the causal relations between incidence of 
osteoporosis (or osteoporotic fractures) and use of anti-osteoporotic agents, incidences 
which were reported 90 days after the initiation of anti-osteoporotic therapy (the index 
date) are included in calculations for incidence rates.  The results from this section 
address the second study objective.   
 
4.2.1 Prevalence 
National estimates of average annual prevalence rates of osteoporosis and 
osteoporotic fractures in the U.S. from 1996 to 2004 are summarized in Table 4.2.1 by 
gender and age groups.  It is noted that the number of male LTGS users, for example, is 
larger than the sum of male LTGS users in four age groups; this can be explained by two 
reasons.  First, subjects younger than 11 or older than 90 years of age are not included in 
the four age groups, but are included in the total number of subjects.  Second, subjects 
with invalid age values (including missing) were not included in the calculation within 
age groups.   
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Table 4.2.1 Average annual prevalence of osteoporosis and osteoporotic fractures in 
subjects by glucocorticoid type and age group, MEPS 1996-2004 
Subject* N§ Osteoporosis Osteoporotic fractures 
Age Unwtd Wtd Unwtd Wtd P (/106) Unwtd Wtd P(/106)
MEPS 183,333 1,833,687,259 2,344 24,595,274 13,413 3,091 33,410,396 18,220
Male 81,442 839,757,327 142 1,381,956 1,646 1,416  15,525,076 18,488 
11-30 18,844 194,850,218 4 5,209 27 319  3,571,355 18,329 
31-50 21,954 242,561,578 17 147,636 609 426  4,704,402 19,395 
51-70 16,511 175,489,396 60 605,396 3,450 282  2,906,371 16,562 
71-90 7,071 75,801,560 60 567,963 7,493 186  2,233,042 29,459 
Female 101,891 993,929,932 2,202 23,213,318 23,355 1,675  17,885,320 17,995 
11-30 24,899 244,530,244 9 73,910 302 230  2,555,949 10,452 
31-50 30,562 303,822,624 159 1,350,446 4,445 367  3,844,127 12,653 
51-70 2,022 197,491,690 1,014 10,391,432 52,617 369  3,645,001 18,456 
71-90 10,499 106,602,271 990 11,006,812 103,251 568  6,305,504 59,150 
LTGS 5,209 53,951,811 237 2,400,065 44,485 146 1,612,532 29,888
Male 2,039 21,547,971 23 210,478 9,768 52  641,347 29,764 
11-30 336 3,340,638 0 0 0 5  41,649 12,467 
31-50 470 5,270,509 6 38,173 7,243 12  163,371 30,997 
51-70 622 6,444,968 9 73,374 11,385 21  265,465 41,189 
71-90 365 4,116,138 8 98,930 24,035 11  122,831 29,841 
Female 3,170 32,403,840 214 2,189,587 67,572 94  971,185 29,971 
11-30 363 3,752,320 4 22,213 5,920 4  56,953 15,178 
31-50 1,038 11,106,726 25 206,954 18,633 23  203,340 18,308 
51-70 1,051 10,445,885 84 881,200 84,359 25  217,418 20,814 
71-90 547 5,464,289 93 982,412 179,788 35  398,558 72,939 
HRGS 3,970 40,836,518 204 1,998,212 48,932 118 1,295,881 31,733
Male 1,587 16,822,207 19 155,297 9,232 43  552,088 32,819 
11-30 251 2,567,643 0 0 0 4  31,412 12,234 
31-50 368 4,059,678 4 17,615 4,339 8  131,442 32,377 
51-70 492 5,085,343 9 73,374 14,429 18  235,405 46,291 
71-90 297 3,365,873 6 64,308 19,106 11  122,831 36,493 
Female 2,383 24,014,311 185 1,842,915 76,742 75  743,793 30,973 
11-30 253 2,582,540 4 22,213 8,601 2  31,354 12,141 
31-50 737 7,768,111 20 161,816 20,831 16  116,166 14,954 
51-70 805 7,919,931 77 766,169 96,739 21  179,008 22,602 
71-90 463 4,541,641 78 820,044 180,561 30  326,826 71,962 
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey. 
Wtd=weighted; Unwtd=Unweighted. 
*Total number of subjects includes those records with the missing value of age, so may be larger than sum of subjects 
in age groups. 
§N=total number of subjects from 1996 to 2004. 
P=prevalence per 1,000,000 person-years. 
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Gender is another factor; women generally have higher prevalence rates of 
osteoporosis than men in groups of the same range of age.  Glucocorticoid use also 
plays an important role.  Glucocorticoid users have higher prevalence rates of 
osteoporosis than overall MEPS subjects within the same range of age and same gender.  
The prevalence rates of osteoporotic fractures between LTGS and HRGS users are 
similar within the same range of age and same gender. 
For most cases, prevalence rates of osteoporosis and osteoporotic fractures 
increase with increased age.  Prevalence rates of osteoporosis and osteoporotic fractures 
for subjects aged 50 years old or older are reported as follows.  Overall, the prevalence 
rate of osteoporosis and osteoporotic fractures in MEPS subjects aged 50 years old or 
older for this study are 40,641/106 person-years (22,571,603/555,384,917) and 
27,170/106 person-years (15,089,918/555,384,917), respectively.  In all men aged 50 
years old and over, the average annual prevalence rates are 4,669/106 person-years for 
osteoporosis and 20,452/106 person-years for osteoporotic fracture.  In all women aged 
50 years old and over, the average annual prevalence rates are 70,367/106 person-years 
for osteoporosis and 32,722/106 person-years for osteoporotic fracture.   
Overall, the prevalence rate of osteoporosis and osteoporotic fractures in LTGS 
users aged 50 years old or older for this study are 76,910/106 person-years and 37,938/106 
person-year, respectively.  In male LTGS users aged 50 years old and over, the average 
annual prevalence rates are 16,315/106 person-years for osteoporosis and 36,767/106 
person-years for osteoporotic fracture.  In female LTGS users aged 50 years old and 
over, the average annual prevalence rates are 117,133/106 person-years for osteoporosis 
and 38,716/106 person-years for osteoporotic fracture.   
Overall, the prevalence rates of osteoporosis and osteoporotic fractures in HRGS 
users aged 50 years old or older for this study are 82,433/106 person-years and 41,318/106 
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person-year, respectively.  In male HRGS users aged 50 years old and over, the average 
annual prevalence rates are 16,291/106 person-years for osteoporosis and 42,389/106 
person-years for osteoporotic fracture.  Finally, in female HRGS users aged 50 years old 
and over, the average annual prevalence rates are 127,288/106 person-years for 
osteoporosis and 40,592/106 person-years for osteoporotic fracture.   
 
4.2.2 Incidence Rates of Osteoporosis 
The incidence of osteoporosis (or osteoporotic fractures) for a subject is an 
episode reported by the control group during the data collection period of MEPS or a new 
episode reported by subjects receiving an anti-osteoporotic agent after 90 days of 
initiation of therapy.  Incidence rates are often different among subjects with different 
experiences in prior exposure to osteoporosis and/or osteoporotic fractures; therefore, 
these rates are summarized and reported in groups based on different prior exposure.  A 
prior exposure in osteoporosis (or osteoporotic fractures) is defined for this study when a 
subject had an episode of osteoporosis or osteoporotic fractures before the index date of 
anti-osteoporotic treatment or within 90 days of initiation of therapy.  Furthermore, 
these rates were used in Markov modeling in Section 4.4.  Therefore, subjects are 
classified into one of the following three states: the WELL, GIOP or GIFX state.  
Subjects without prior osteoporosis and osteoporotic fractures are grouped in the WELL 
state; those with prior osteoporosis without any prior osteoporotic fracture are in the; and 
those with prior osteoporotic fracture(s) are in the GIFX state.  Table 4.2.2 shows the 
weighted number and percentage of subjects in each state. 
Table 4.2.3 shows incidence rates of osteoporosis for women in the WELL state.  
Glucocorticoid users in the CN and HB groups have relatively higher incidence rates of 
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osteoporosis than those in other treatment groups.  In addition to protective effects from 
the treatment, a possible explanation is that the sample size in the CN and HB groups 
may be too small to reach the statistical power needed to detect osteoporosis.  On the 
other side, subjects in the control (CT) and hormone replacement therapy (HT) groups 
have relatively lower incidence rates of osteoporosis than those in other groups 
(chi-square test, p<0.0001).   
In general, incidence rates of osteoporosis in female glucocorticoid tablet users 
are higher than those rates in MEPS female subjects, except for subjects in 
bisphosphonate and raloxifene groups.  The rates between LTGS and HRGS users are 
similar.  This phenomenon may indicate the negative effect of glucocorticoid use on 
incidence of osteoporosis, and that glucocorticoid use for over three months or high 
cumulative glucocorticoid dose may have a similar effect on incidence of osteoporosis.   
However, BP users of the MEPS group have a relatively higher incidence rate 
than those with glucocorticoid use.  One possible explanation for this phenomenon is 
selection bias.  It has been discussed in the literature that osteoporosis and vertebral 
fractures are often under-diagnosed.  Increasing the chance of screening may increase 
the probability of early detection of osteoporosis and osteoporotic fractures.  Subjects in 
some treatment groups, for example, the BP and HB groups, may be proactive to 
screening which increases the probability of detecting a new incidence of osteoporosis.  
Additionally, the younger average age of glucocorticoid users in the BP group than those 
of MEPS may be another factor (see Table 4.1.6).   
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Table 4.2.2 Weighted number and percentage of subjects in each state by gender and 
treatment group, MEPS 1996-2004 
 Weighted 
State WELL GIOP GIFX  
Treatment* N§ % N§ % N§ % Total§ 
Women        
MEPS   
BP 7,547,768  55.05 5,402,484 39.41 759,690 5.54 13,709,942 
CN 1,328,204  48.12 1,097,498 39.76 334,481 12.12 2,760,183 
HB 2,577,252  58.75 1,680,494 38.31 129,162 2.94 4,386,908 
HT 149,478,066  98.79 1,185,942 0.78 638,454 0.42 151,302,462 
RF 3,839,675  83.76 678,515 14.80 65,699 1.43 4,583,889 
CT 817,546,517  97.83 5,363,149 0.64 12,806,558 1.53 835,716,224 
LTGS   
BP 573,947  47.85 492,065 41.02 133,560 11.13 1,199,572 
CN 162,800  57.88 72,069 25.62 46,406 16.50 281,275 
HB 286,900  72.53 101,944 25.77 6,719 1.70 395,563 
HT 7,291,654  96.78 216,683 2.88 26,143 0.35 7,534,480 
RF 47,065  55.15 38,280 44.85 0 0 85,345 
CT 22,923,408  95.09 570,481 2.37 613,730 2.55 24,107,619 
HRGS   
BP 504,664  49.69 409,344 40.31 101,593 10.00 1,015,601 
CN 162,800  57.88 72,069 25.62 46,406 16.50 281,275 
HB 239,512  86.35 31,143 11.23 6,719 2.42 277,374 
HT 5,474,244  96.41 193,353 3.41 10,338 0.18 5,677,935 
RF 47,065  55.15 38,280 44.85 0 0 85,345 
CT 16,676,780  94.66 501,987 2.85 439,593 2.50 17,618,360 
Men   
MEPS   
BP 449,008  63.69 232,678 33.00 23,320 3.31 705,006 
CN 248,773  59.96 83,718 20.18 82,435 19.87 414,926 
CT 838,164,761  98.10 818,787 0.10 15,399,002 1.80 854,382,550 
LTGS   
BP 124,087  57.50 91,723 42.50 0 0 215,810 
CN 64,842  85.07 11,380 14.93 0 0 76,222 
CT 21,255,940  96.81 67,977 0.31 631,608 2.88 21,955,525 
HRGS   
BP 113,480  66.53 57,101 33.47 0 0 170,581 
CN 64,842  85.07 11,380 14.93 0 0 76,222 
CT 16,575,405  96.56 47,419 0.28 542,349 3.16 17,165,173 
WELL state: subjects without any prior osteoporosis and osteoporotic fractures; GIOP state: subjects with 
prior osteoporosis but without prior osteoporotic fractures; GIFX state: subject with prior osteoporotic 
fractures; MEPS=Medical Expenditure Panel Survey. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group;  
§ N=total number of subjects from 1996 to 2004. 
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Table 4.2.3 Incidence of osteoporosis in women without prior osteoporosis and fracture 
by type of glucocorticoid use and treatment group, MEPS 1996-2004 











MEPS female 100,818  982,317,482 1,224 12,538,043 12,764 
 BP 722 7,547,768 246 2,535,696 71.5 335,953 97,287 
 CN 122 1,328,204 30 349,905 70.8 263,442 73,593 
 HB 245 2,577,252 74 763,565 68.3 296,271 84,093 
 HT 13,575 149,478,066 254 2,769,737 64.4 18,529 4,665 
 RF 344 3,839,675 66 755,991 66.3 196,889 53,340 
 CT 85,810 817,546,517 554 5,363,149 69.0 6,560 1,644 
LTGS female 3,064 31,285,774 116 1,128,856 36,082 
 BP 69 573,947 21 153,306 61.8 267,108 74,748 
 CN 16 162,800 8 89,179 58.6 547,783 179,957 
 HB 32 286,900 14 113,925 75.5 397,090 118,823 
 HT 671 7,291,654 17 201,965 67.0 27,698 6,998 
 RF 7 47,065 0 - - - -
 CT 2,269 22,923,408 56 570,481 67.7 24,886 6,281 
HRGS female 2,293 23,105,065 101 959,036 41,508 
 BP 63 504,664 19 135,388 61.0 268,274 75,116 
 CN 16 162,800 8 89,179 58.6 547,783 179,957 
 HB 26 239,512 14 113,925 75.5 475,655 149,049 
 HT 499 5,474,244 11 118,557 70.1 21,657 5,459 
 RF 7 47,065 0 - - - -
 CT 1,682 16,676,780 49 501,987 66.5 30,101 7,612 
Ave.=average; HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent 
dose of 450 mg or more; LTGS=long-term users of glucocorticoid tablets for at least three months; 
MEPS=Medical Expenditure Panel Survey; Osteoporosis=new events of osteoporosis occurred after the 
treatment; WELL state: subjects without any prior osteoporosis and osteoporotic fractures; Wtd=weighted; 
Unwtd=unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group;  
**Rates per 1,000,000 person-years. 
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Table 4.2.4 shows the incidence rates of osteoporosis in men.  The issue of lack 
of statistical power due to small sample size is observed.  The information provided in 
Table 4.2.4 is insufficient to draw any conclusion. 
 
Table 4.2.4 Incidence of osteoporosis in men without prior osteoporosis and fracture by 
type of glucocorticoid use and treatment group, MEPS 1996-2004 











MEPS male 81,359 838,862,542 109 1,032,044 1,230 
 BP 44 449,008 17 195,496 65.0 435,395 133,166 
 CN 28 248,773 2 17,761 90.0 71,394 18,347 
 CT 81,287 838,164,761 90 818,787 63.2 977 244 
LTGS male 2,029 21,444,869 13 107,375 5,007 
 BP 18 124,087 6 39,398 63.7 317,503 91,081 
 CN 8 64,842 0 - - - -
 CT 2,003 21,255,940 7 67,977 59.0 3,198 800 
HRGS male 1,579 16,753,727 11 86,817 5,182 
 BP 16 113,480 6 39,398 63.7 347,180 101,127 
 CN 8 64,842 0 - - - -
 CT 1,555 16,575,405 5 47,419 64.4 2,861 716 
Ave.=average; HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent 
dose of 450 mg or more; LTGS=long-term users of glucocorticoid tablets for at least three months; 
MEPS=Medical Expenditure Panel Survey; Osteoporosis=new events of osteoporosis occurred after the 
treatment; WELL state: subjects without any prior osteoporosis and osteoporotic fractures; Wtd=weighted; 
Unwtd=Unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
 
4.2.3 Incidence Rates of Osteoporotic Fractures 
Table 4.2.5 to Table 4.2.10 show incidence rates of osteoporotic fractures in 
women and men with different prior exposure to osteoporosis and osteoporotic fractures.  
It is estimated that the overall annual incidence rates of osteoporotic fractures are 16,306 
per 106 person-years (PY) (29,866,357/1,831,575,101) for all MEPS subjects, 17,175 per 
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106 PY (14,413,308/839,212,686) for male MEPS subjects, and 15,572 per 106 PY 
(15,453,049/992,362,415) for female MEPS subjects.  The estimated annual incidence 
rates of osteoporotic fractures in LTGS users are 24,116 per 106 PY for all LTGS users, 
27,199 per 106 PY for male LTGS users and 22,054 per 106 PY for female LTGS users.  
In HRGS users, the estimated annual incidence rates of osteoporotic fractures are 26,543 
per 106 PY for all HRGS users, 32,063 per 106 PY for male HRGS users and 22,649 per 
106 PY for female HRGS users.  
The use of glucocorticoid steroids increases the incidence of osteoporotic 
fractures. Overall, higher annual incidence rates of osteoporotic fractures increase are 
observed when comparing rates in glucocorticoid users to those in all MEPS subjects.  
Annual incidence rates of osteoporotic fractures in HRGS users are slightly higher than 
those in LTGS users, but they are close.   
Compared to subjects in the WELL state, those in the GIFX state have the highest 
incidence rates of osteoporotic fractures within the same treatment, followed by those in 
the GIOP state.  The effect of glucocorticoid use on the incidence of osteoporotic 
fractures is unclear.  The effects of anti-osteoporotic treatments on the incidence rates of 
osteoporotic fractures are inconclusive because of limited information in the tables. 
No incidence of osteoporotic fractures was observed in some cases in these tables.  
Possible explanations are that treatments may reduce the risks of osteoporotic fractures, 
and that the period of data collection for a MEPS subject is two years which may be too 
short to detect all osteoporotic fractures.  Another probable explanation, as described 
earlier, is that a small sample size may not have enough statistical power to detect 
incidence of osteoporotic fractures.   
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Table 4.2.5 Incidence of first osteoporotic fracture in women without prior osteoporosis 
and fracture by type of glucocorticoid use and treatment group, MEPS 
1996-2004 











MEPS female 100,264  976,954,333 1,366 14,606,992 14,952 
 BP 722 7,547,768 22 272,851 75.5 36,150 9,163 
 CN 122 1,328,204 16 160,630 74.7 120,938 31,711 
 HB 245 2,577,252 8 65,645 60.1 25,471 6,429 
 HT 13,575 149,478,066 242 2,588,126 57.8 17,314 4,357 
 RF 344 3,839,675 6 65,666 63.6 17,102 4,303 
 CT 85,256 812,183,368 1,072 11,454,074 49.9 14,103 3,545 
LTGS female 3,008 30,715,293 61 615,782 20,048 
 BP 69 573,947 0 - - - -
 CN 16 162,800 0 - - - -
 HB 32 286,900 0 - - - -
 HT 671 7,291,654 18 160,431 66.5 22,002 5,546 
 RF 7 47,065 0 - - - -
 CT 2,213 22,352,927 43 455,351 57.0 20,371 5,132 
HRGS female 2,244 22,603,078 46 445,661 19,717 
 BP 63 504,664 0 - - - -
 CN 16 162,800 0 - - - -
 HB 26 239,512 0 - - - -
 HT 499 5,474,244 15 139,144 68.5 25,418 6,416 
 RF 7 47,065 0 - - - -
 CT 1,633 16,174,793 31 306,517 60.8 18,950 4,772 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg 
or more; LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical 
Expenditure Panel Survey; WELL state: subjects without any prior osteoporosis and osteoporotic fractures; 
Wtd=weighted; Unwtd=unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group;  
**Rates per 1,000,000 person-years. 
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Table 4.2.6 Incidence of first osteoporotic fracture in women with prior osteoporosis by 
type of glucocorticoid use and treatment group, MEPS 1996-2004 












MEPS female 1,480 15,408,082 74 846,057 54,910 
 BP 497 5,402,484 19 240,751 79.1 44,563 11,332 
 CN 87 1,097,498 0 - - - -
 HB 146 1,680,494 6 78,904 62.5 46,953 11,951 
 HT 128 1,185,942 2 16,124 71.3 13,596 3,416 
 RF 68 678,515 2 22,569 76.4 33,262 8,421 
 CT 554 5,363,149 45 487,709 72.7 90,937 23,553 
LTGS female 141 1,491,522 6 94,505 63,361 
 BP 43 492,065 0 - - - -
 CN 4 72,069 0 - - - -
 HB 8 101,944 0 - - - -
 HT 26 216,683 0 - - - -
 RF 4 38,280 0 - - - -
 CT 56 570,481 6 94,505 59.1 165,658 44,268 
HRGS female 120 1,246,176 6 94,505 75,836 
 BP 37 409,344 0 - - - -
 CN 4 72,069 0 - - - -
 HB 4 31,143 0 - - - -
 HT 22 193,353 0 - - - -
 RF 4 38,280 0 - - - -
 CT 49 501,987 6 94,505 59.1 188,262 50,808 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
GIOP state: subjects with prior osteoporosis but without prior osteoporotic fractures; HRGS=high-risk 
users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure 
Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group;  
**Rates per 1,000,000 person-years. 
 
 196
Table 4.2.7 Incidence of repeated osteoporotic fracture in women with prior fracture by 
type of glucocorticoid use and treatment group, MEPS 1996-2004 












MEPS female 1,388 14,734,044 140 1,393,347 94,567 
 BP 70 759,690 20 238,788 74.5 314,323 90,024 
 CN 29 334,481 4 29,314 75.5 87,640 22,669 
 HB 13 129,162 6 60,746 61.2 470,309 146,889 
 HT 64 638,454 20 172,093 52.9 269,546 75,519 
 RF 7 65,699 2 27,651 79.5 420,874 127,645 
 CT 1,205 12,806,558 88 864,755 62.8 67,524 17,326 
LTGS female 78 826,558 14 143,055 173,073 
 BP 13 133,560 4 56,656 78.7 424,199 128,900 
 CN 4 46,406 0 - - - -
 HB 2 6,719 2 6,719 56.5 1,000,000 -
 HT 4 26,143 2 15,806 50.5 604,598 207,024 
 RF 0 - 0 - - - -
 CT 55 613,730 6 63,874 70.2 104,075 27,101 
HRGS female 60 604,649 8 69,979 115,735 
 BP 11 101,593 2 24,689 70.5 243,019 67,237 
 CN 4 46,406 0 - - - -
 HB 2 6,719 2 6,719 56.5 1,000,000 -
 HT 2 10,338 0 - - - -
 RF 0 - 0 - - - -
 CT 41 439,593 4 38,571 78.4 87,743 22,697 
Ave.=average; GIFX state: subject with prior osteoporotic fractures;HRGS=high-risk users of 
glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term 
users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey; 
Repeated fracture=the second new events of osteoporotic fractures occurred after the treatment; 
Wtd=weighted; Unwtd=Unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table 4.2.8 Incidence of first osteoporotic fracture in men without prior osteoporosis and 
fracture by type of glucocorticoid use and treatment group, MEPS 
1996-2004 











MEPS male 81,270 838,077,503 1,309 14,393,420 17,174 
 BP 45 482,756 2 10,005 69.6 20,725 5,222 
 CN 28 248,773 2 9,739 70.5 39,148 9,934 
 CT 81,197 837,345,974 1,305 14,373,676 39.7 17,166 4,319 
LTGS male 2,022 21,376,891 46 586,081 27,417 
 BP 18 124,087 0 - - - -
 CN 8 64,842 0 - - - -
 CT 1,996 21,187,962 46 586,081 55.5 27,661 6,988 
HRGS male 1,574 16,706,308 41 539,374 32,286 
 BP 16 113,480 0 - - - -
 CN 8 64,842 2 9,739 70.5 150,196 39,871 
 CT 1,550 16,527,986 39 529,635 56.6 32,045 8,109 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg 
or more; LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical 
Expenditure Panel Survey; WELL state: subjects without any prior osteoporosis and osteoporotic fractures; 
Wtd=weighted; Unwtd=Unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table 4.2.9 Incidence of first osteoporotic fracture in men with prior osteoporosis by type 
of glucocorticoid use and treatment group, MEPS 1996-2004 












MEPS male 119 1,135,183 4 19,888 17,520 
 BP 21 232,678 0 - - - -
 CN 8 83,718 2 10,580 78.5 126,377 33,212 
 CT 90 818,787 2 9,308 80.6 11,368 2,854 
LTGS male 17 171,080  
 BP 8 91,723 0 - - - -
 CN 2 11,380 0 - - - -
 CT 7 67,977 0 - - - -
HRGS male 13 115,900  
 BP 6 57,101 0 - - - -
 CN 2 11,380 0 - - - -
 CT 5 47,419 0 - - - -
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
GIOP state: subjects with prior osteoporosis but without prior osteoporotic fractures; HRGS=high-risk 
users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure 
Panel Survey; Wtd=weighted; Unwtd=Unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table 4.2.10 Incidence of repeated osteoporotic fracture in men with prior fracture by 
type of glucocorticoid use and treatment group, MEPS 1996-2004 











MEPS male 1,412 15,504,757 99 1,026,024 66,175 
 BP 4 23,320 2 10,005 69.6 429,031 130,733 
 CN 4 82,435 0 - - - -
 CT 1,404 15,399,002 97 1,016,019 49.9 65,980 16,919 
LTGS male   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 50 631,608 4 45,527 52.9 72,081 18,529 
HRGS male   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 41 542,349 2 12,714 65.3 23,442 5,913 
Ave.=average; GIFX state: subject with prior osteoporotic fractures;HRGS=high-risk users of 
glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term 
users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey; 
Repeated fracture=the second new events of osteoporotic fractures occurred after the treatment; 
Wtd=weighted; Unwtd=Unweighted. 
§ total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
 
 
Age plays an important role with respect to incidence rates of osteoporosis and 
osteoporotic fractures.  Appendix B lists 24 tables which provide a further breakdown of 
incidence rates by four age groups: 11 to 30 years old, 31 to 50 years old, 51 to 70 years 
old and 71 to 90 years old.  Generally speaking, incidence rates of osteoporosis in 
groups of older ages are likely larger than those in groups of younger ages; however, it is 
not absolute.  A similar trend is not observed for incidence rates of osteoporotic 
fractures.  In some cases, subjects in groups of 51 to 70 years old have relatively higher 
incidence rates of osteoporotic fractures.  It appears that the patterns are inconsistent.  
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To further investigate the relationships between incidence of osteoporotic fracture and 
potential factors, such as age, gender and use of glucocorticoid steroids and use of 
anti-osteoporotic agents, a logistic regression analysis was performed.  The next section 
demonstrates the analysis and results. 
 
4.2.4 Relative Risks of Osteoporotic Fractures 
In logistic regression models for this study, all independent variables, except age, 
are coded by dichotomous values (FX=1 when incidence of osteoporotic fracture was 
found, otherwise, FX=0; sex=0 for men and sex=1 for women; GS=1 for use of 
glucocorticoid tablets and GS=0 for non-GS users; BP=1 if use of bisphosphonate and 
BP=0 for non-users, etc.).  Age is treated as continuous variable.   
The logistic regression analyses indicated that the use of oral glucocorticoid 
tablets does not significantly change the odds of osteoporotic fractures in study subjects 
(relative risk (RR)= 1.146, 95% confidence interval (CI) 0.901-1.458 for subjects in the 
WELL state; RR=0.55, 95% CI 0.188-1.621 for subjects in the GIOP state; RR=1.241, 
95% CI 0.532-2.893 for subjects in GIFX state).  Women in the WELL states had 
significantly lower odds of osteoporotic fractures than men in the same state (RR=0.823, 
95% CI 0.723-0.936), whereas the impact of gender on the odds ratio was not significant 
for subjects in the GIOP and GIFX states (RR=3.266 95% CI 0.638-16.709 for the GIOP 
state, RR=0.870 95% CI 0.552-1.373 for the GIFX state).  The positive coefficient for 
age indicates that the odds of osteoporotic fractures increase with an increased age 
(RR=1.016 95% CI 1.013-1.019 for subjects in the WELL state; RR=1.052, 95% CI 
1.019-1.087 for subjects in the GIOP state; RR=1.018, 95% CI 1.009-1.028 for subjects 
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in the GIFX state).  Table 4.2.11 shows the logistic regression models, estimates of 
coefficients for each variable and statistics.   
 
Table 4.2.11 Logistic regression analysis of odds of osteoporotic fractures for state 
Odds Ratio State* 
Variable** Coefficient P
† Estimate 95% Confidence Interval 
WELL Model fit (% correct): 61.1%   
Intercept -4.7063 <.0001 - - - 
GS 0.1364 0.2674 1.146 0.901 1.458 
BP 0.4947 0.1378 1.640 0.853 3.152 
CN 1.5636 0.0001 4.776 2.158 10.569 
HB 0.2128 0.7025 1.237 0.415 3.687 
HT 0.0171 0.8811 1.017 0.813 1.273 
RF -0.1592 0.7903 0.853 0.264 2.756 
Gender -0.1950 0.0031 0.823 0.723 0.936 
Age 0.0156 <.0001 1.016 1.013 1.019 
GIOP Model fit (% correct): 70.1%   
Intercept -7.2640 <.0001 - - - 
GS -0.5935 0.2800 0.552 0.188 1.621 
BP -0.6523 0.1428 0.521 0.218 1.246 
CN -2.3492 0.0327 0.095 0.011 0.824 
HB -0.2770 0.7081 0.758 0.178 3.232 
HT -1.4908 0.1582 0.225 0.028 1.785 
RF -0.7888 0.4608 0.454 0.056 3.696 
Gender 1.1835 0.1553 3.266 0.638 16.709 
Age 0.0510 0.0021 1.052 1.019 1.087 
GIFX Model fit (% correct): 61.1%   
Intercept -3.5530 <.0001 - - - 
GS 0.2158 0.6172 1.241 0.532 2.893 
BP 1.5250 0.0006 4.595 1.918 11.007 
CN -0.4224 0.5378 0.655 0.171 2.513 
HB 2.4245 0.0090 11.296 1.834 69.585 
HT 1.7343 0.0031 5.665 1.795 17.877 
RF 2.0400 0.0728 7.690 0.828 71.438 
Gender -0.1388 0.5507 0.870 0.552 1.373 
Age 0.0180 0.0002 1.018 1.009 1.028 
Estimation of logit using maximum likelihood method. 
Incidence of osteoporotic fractures (yes=1, no=0); gender (male=0, female=1). 
*WELL state: subjects without any prior osteoporosis and osteoporotic fractures; GIOP state: subjects with 
prior osteoporosis but without prior osteoporotic fractures; GIFX state: subject with prior osteoporotic 
fractures. 
**variable (yes=1, no=0): BP=bisphosphonate group; CN=calcitonin group; CT=control group without 
using any anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and 
bisphosphonates; HT=hormone replacement therapy; RF=raloxifene group. 
† Probability (Wald’s Chi-Square). 
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The impact of glucocorticoid use on osteoporotic fractures for subjects in the 
GIOP state (RR=0.55, 95% CI 0.188-1.621) does not match the findings in the literature 
that glucocorticoid use increases fracture risks.  Table 4.2.12 shows weighted number 
and charactieristics of subjects by glucocorticoid use and Markov state.  The average 
age of subjects in the GIOP state was 68.7 years old.  Therefore, a possible reason for 
the low odds ratio is that subjects in the GIOP state tend to be aware of osteoporosis and 
be receiving pharmacologic or non-pharmacologic strategies that prevent the occurance 
of osteoporotic fractures.  Further investigation on confounding factors is needed. 
 
Table 4.2.12 Weighted number and age of subjects by state 
State/ Unwtd. Weighted Weighted averages 
GS use/ 




of GS tablets 
Daily 
GS dose 
WELL 181,581 1,815,341,765 37.7    
GS 10,126 106,748,184 45.1 900.7 118.1 10.8 
Male 4,166 45,048,318     
Female 5,960 61,699,866     
No GS 171,442 1,708,593,581 37.2 - - - 
 Male 77,146 793,423,785     
 Female 94,296 915,169,796     
GIOP 1,597 16,522,541 68.7    
GS 210 2,186,312 67.8 1,602.5 333.0 10.6 
Male 19 190,149     
Female 191 1,996,163     
No GS 1,387 14,336,229 68.9 - - - 
 Male 100 945,034     
 Female 1,287 13,391,195     
GIFX 2,798 30,218,056 46.8    
GS 200 2,346,937 53.6 1,521.5 202.0 10.3 
Male 90 1,149,352     
Female 110 1,197,585     
No GS 2,598 27,871,119 46.3 - - - 
 Male 1,322 14,355,405     
 Female 1,276 13,515,714     
Cum.=cumulative; GS=glucocorticoid steroids; Unwtd.=unweighted. 
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Although no significant impact of glucocorticoid use on osteoporotic fractures 
was found, relative risks of osteoporotic fractures for subjects in MEPS were used to 
estimate missing values of incidence rates of osteoporotic fractures in Section 4.2.3.  
Information derived from the MEPS data provided the best estimate for the missing 
values.  Table 4.2.13 shows expected probabilities of osteoporotic fractures for subjects 
with different sets of independent variables.  By comparing probabilities in 
non-glucocorticoid users to those in glucocorticoid users for the same set of other 
independent variables, relative risks of osteoporotic fractures in glucocorticoid use are 
calculated.  The relative risks are listed in Table 4.2.14.  The relative risks are 
consistent across different treatments for subjects in the same state, and demonstrate the 
overall harmful effects of glucocorticoid use on osteoporotic fractures for subjects in the 
WELL and GIFX states and protective effects for subjects in the GIOP state.   
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Table 4.2.13 Predicted one-year probability of osteoporotic fractures for subjects based 
on logistic regression by gender, type of treatment, subject’s state and age 
  1-Year probability (/106) 
State*  Treatment for women** Treatment for men** 
Age GS use BP CN HB HT RF CT BP CN CT 
WELL           
30 No 13525 38394 10237 8432 7079 8291 16389 46278 10058
 Yes 15471 43760 11715 9653 8105 9491 18740 52685 11511
     
50 No 14606 41380 11058 9110 7649 8957 17695 49845 10865
 Yes 16705 47142 12653 10428 8757 10253 20229 56717 12433
     
70 No 15772 44587 11944 9842 8264 9677 19103 53672 11736
 Yes 18036 50772 13666 11264 9461 11075 21834 61037 13428
     
90 No 16389 46278 12413 10229 8590 10058 19848 55688 12197
 Yes 18740 52685 14202 11707 9833 11511 22683 63311 13955
GIOP     
30 No 1743 320 2535 754 1521 3341 534 98 1026
 Yes 964 177 1402 417 841 1849 295 54 567
     
50 No 2248 413 3269 973 1962 4308 690 126 1323
 Yes 1243 228 1808 538 1085 2384 381 70 731
     
70 No 2900 533 4215 1256 2531 5552 890 163 1707
 Yes 1604 294 2332 694 1399 3075 492 90 943
     
90 No 3293 605 4785 1426 2874 6302 1010 185 1938
 Yes 1821 334 2649 788 1589 3491 558 102 1072
GIFX     
30 No 115904 18357 243737 139134 179933 27739 130903 21033 31738
 Yes 139915 22678 285672 167047 213997 34191 157467 25967 39083
      
50 No 125450 20051 260706 150268 193598 30272 141486 22968 34623
 Yes 151100 24761 304386 179948 229524 37291 169778 28344 42607
      
70 No 135662 21898 278423 162125 208037 33028 152775 25077 37760
 Yes 163010 27030 323770 193613 245826 40660 182844 30930 46433
      
90 No 141025 22883 287553 168331 215548 34496 158691 26201 39430
 Yes 169243 28239 333699 200736 254264 42452 189663 32308 48467
† per 1,000,000 person-years. 
*WELL state: subjects without any prior osteoporosis and osteoporotic fractures; GIOP state: subjects with 
prior osteoporosis but without prior osteoporotic fractures; GIFX state: subject with prior osteoporotic 
fractures. 
**Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using 
any anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
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Table 4.2.14 Relative risks of osteoporotic fractures within one year in glucocorticoid 
users versus non-glucocorticoid users by gender, type of treatment, subject’s 
state and age 
 Relative risk of osteoporotic fractures within one year 
State* Treatment for women** Treatment for men** 
Age BP CN HB HT RF CT BP CN CT 
WELL          
30 1.1439 1.1397 1.1444 1.1447 1.1450 1.1448 1.1434 1.1384 1.1455
50 1.1437 1.1393 1.1443 1.1446 1.1449 1.1446 1.1432 1.1379 1.1443
70 1.1435 1.1387 1.1441 1.1445 1.1448 1.1445 1.1429 1.1372 1.1442
90 1.1434 1.1384 1.1441 1.1444 1.1447 1.1445 1.1428 1.1369 1.1441
GIOP          
30 0.5528 0.5525 0.5530 0.5526 0.5528 0.5532 0.5525 0.5524 0.5526
50 0.5529 0.5525 0.5532 0.5526 0.5529 0.5535 0.5526 0.5524 0.5527
70 0.5531 0.5525 0.5534 0.5527 0.5530 0.5538 0.5526 0.5524 0.5528
90 0.5532 0.5525 0.5536 0.5527 0.5531 0.5540 0.5526 0.5524 0.5529
GIFX          
30 1.2072 1.2354 1.1720 1.2006 1.1893 1.2326 1.2029 1.2346 1.2314
50 1.2145 1.2349 1.1675 1.1975 1.1856 1.2319 1.2000 1.2340 1.2306
70 1.2016 1.2343 1.1629 1.1942 1.1816 1.2311 1.1968 1.2334 1.2297
90 1.2001 1.2341 1.1605 1.1925 1.1796 1.2306 1.1952 1.2335 1.2292
*WELL state: subjects without any prior osteoporosis and osteoporotic fractures; GIOP state: subjects with 
prior osteoporosis but without prior osteoporotic fractures; GIFX state: subject with prior osteoporotic 
fractures. 
**Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using 
any anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
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4.3 ECONOMIC OUTCOMES 
This section shows national estimates of average direct medical costs associated 
with osteoporosis, osteoporotic fractures and treatments according to MEPS data from 
1996 to 2004.  Detailed definitions of costs are described in Chapter 3.  The unadjusted 
costs represent original values reported in MEPS.  All costs have been adjusted to 2005 
U.S. dollars based on the medical component of the Consumer Price Index (CPI) for 
comparisons.  The results of this section address the third and fourth study objectives.   
Table 4.3.1 shows average total direct medical costs associated with 
anti-osteoporosis treatments in MEPS data from 1996 to 2004.  The total costs of 
anti-osteoporotic treatments include expenses for prescribed medicines, expenses for 
medical events associated with new osteoporosis and osteoporotic fractures, expenses for 
outpatient visits and office-based medical provider visits associated with the 
anti-osteoporotic treatment, and expenses of medical events and prescribed medicines 
associated with treatments of adverse drug events.  Because each subject was followed 
for two years, these costs likely reflect total costs of an anti-osteoporotic treatment for 
two years.  These costs were used to calculate the short-term (two-year) 
cost-effectiveness ratio for anti-osteoporotic treatments in Section 4.5.   
Among women in the BP, CN and HT groups, glucocorticoid users have higher 
average total direct medical costs than all female MEPS subjects.  Men in the BP groups 
have similar average total direct medical costs.  Female glucocorticoid users in the HB 
and RF groups and male glucocorticoid users in the CN group have relatively lower 
average total direct medical costs.  This phenomenon may be explained by a relatively 
large variance due to small sample size in these groups.   
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Table 4.3.1 Average total costs of anti-osteoporosis treatments per subject by gender and type of subject 
Gender All Men Women 
 Cost* Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ 
Type† Subject** N Mean SE Mean SE N Mean SE Mean SE N Mean SE Mean SE 
BP MEPS 1,072 701.2 42.5 816.2 50.8 67 409.7 30.5 488.5 35.6 1,005 721.3 45.5 838.8 54.3 
 LTGS 126 733.9 37.7 850.0 44.1 23 395.7 25.8 475.5 33.9 103 804.7 43.3 928.4 50.2 
 HRGS 107 803.0 35.8 926.5 41.9 21 394.0 28.5 466.8 37.2 86 899.8 38.1 1,035.2 44.3 
CN MEPS 148 548.2 63.7 671.0 75.6 21 910.2 24.8 1,086.6 30.5 127 499.6 37.1 615.3 48.4 
 LTGS 18 696.8 71.8 882.4 81.7 5 629.3 126.3 819.7 167.6 13 771.6 64.1 896.1 67.0 
 HRGS 18 696.8 71.8 882.4 81.7 5 629.3 126.3 819.7 167.6 13 771.6 64.1 896.1 67.0 
HB MEPS   330 767.5 143.9 915.2 181.4 
 LTGS   32 773.2 25.5 875.5 31.1 
 HRGS   25 715.8 809.7 
HT MEPS   8,654 414.3 7.8 516.7 9.8 
 LTGS   404 504.3 47.5 631.0 59.4 
 HRGS   299 434.4 20.7 549.3 26.5 
RF MEPS   303 878.9 44.5 1,010.3 49.6 
 LTGS   11 861.4 96.9 963.9 114.0 
 HRGS   10 889.5 101.2 994.2 119.0 
*Total costs include expenses for prescribed medicines, expenses for medical events linked to new osteoporosis and osteoporotic fractures, expenses for 
outpatient visits and office-based medical provider visits linked to prescriptions but not linked to osteoporosis and osteoporotic fractures, and expenses 
of medical events and prescribed medicines linked to treatments of adverse drug events. 
§Costs are adjusted to 2005 dollars based on the medical component of the Consumer Price Index (CPI). 
†Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent; HB=simultaneous 
use of hormone replacement therapy and bisphosphonates; HT=hormone replacement therapy; RF=raloxifene group. 
**HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of 
glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey. SE=standard error of the mean; Unwtd=unweighted. 
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Table 4.3.2 shows the average total costs per incidence of osteoporotic fracture, 
and the average total three-month costs of medical events per subject with osteoporosis.  
The total costs include expenses for medical events linked to an episode of osteoporosis 
or osteoporotic fracture, and expenses for prescribed medicines linked to the episode, but 
exclude expenses for medical events linked to anti-osteoporotic treatments.  It is noted 
that the unit for osteoporosis is per subject per three months and that the unit for 
osteoporotic fractures is per episode.  Average costs of osteoporosis are higher in both 
male and female glucocorticoid users than in all MEPS subjects.  Compared to values in 
corresponding MEPS subjects, costs per osteoporotic fracture in glucocorticoid users are 
not significantly different.  The extreme costs of repeated fractures may not be 
representative because of small sample sizes.   
Table 4.3.3 shows the average three-month costs per subject of anti-osteoporotic 
treatments.  The total costs include expenses for prescribed medicines, expenses for 
outpatient visits and office-based medical provider visits linked to prescriptions, and 
expenses of all medical events for treatments for adverse drug events.  It is noted that 
the unit for anti-osteoporotic treatments is per subject per three months.  Analysis of 
variance (ANOVA) of these costs indicates significant differences in average direct 
medical costs of preventive anti-osteoporotic treatments for glucocorticoid users among 
treatments (for men and women, df=5, F=43.55, p< 0.0001, specifically, p=0.0021 for 
BP, p< 0.0001 for CN, p=0.0014 for HB, p<0.0001 for HT) when comparing to costs of 
the RF group.  Therefore, all hypotheses for the fourth study objective were rejected.   
Table 4.3.4 shows the average prescription costs per subject for a three-month 
supply of anti-osteoporotic agents.  Cost information in Table 4.3.2 and Table 4.3.3 
were used in Markov modeling to estimate long-term costs associated with an episode of 
osteoporotic fracture and monitoring costs for osteoporosis in Section 4.5.   
 209
Table 4.3.2 Average total costs per episode of osteoporotic fracture and average total three-month costs per subject with 
osteoporosis by gender and type of subject 
Gender All Men Women 
 Cost* Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ 
Type† Subject** N Mean SE Mean SE N Mean SE Mean SE N Mean SE Mean SE 
Per subject per 3 months  
OP MEPS 392 150.4 18.7 183.2 22.3 14 398.7 530.4 378 142.6 19.0 172.2 22.0 
 LTGS 47 295.7 21.0 347.9 24.3 5 530.9 705.6 42 273.8 22.5 314.6 26.2 
 HRGS 37 377.7 29.5 441.1 34.6 4 818.8 1,086.0 33 341.4 31.5 388.0 36.9 
Per fracture episode  
FS MEPS 1,591 4,369.5 417.6 5,299.8 522.7 745 3,654.6 524.6 4,363.2 608.7 846 5,018.3 637.9 6,149.8 827.2 
 LTGS 74 4,053.7 382.5 4,933.4 443.4 29 4,483.1 131.9 5,704.0 167.5 45 3,781.3 620.0 4,444.5 709.9 
 HRGS 59 4,139.1 476.7 5,033.0 552.2 24 4,233.5 155.7 5,325.7 185.1 35 4,074.3 805.3 4,832.0 924.9 
FR MEPS 29 8,184.3 1,203.6 9,100.1 1,332.6 1 39.0 49.4 28 8,366.2 1,235.3 9,302.2 1,367.8 
 LTGS 5 6,710.3 7,653.6 0  5 6,710.3 7,653.6 
 HRGS 2 19,158.0 21,661.0 0  2 19,158.0 21,661.0 
§Costs are adjusted to 2005 dollars based on the medical component of the Consumer Price Index (CPI). 
*Total costs include expenses for medical events linked to an episode of osteoporosis or osteoporotic fracture, and expenses for prescribed medicines 
linked to the episode, but exclude expenses for medical events linked to anti-osteoporotic treatments. 
†FS=new episode of first-time osteoporotic fractures; FR=new episode of repeated osteoporotic fractures; OP=new episode of osteoporosis. 
**HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of 




Table 4.3.3 Average three-month costs of anti-osteoporotic treatments by gender and type of subject 
Gender All Men Women 
3-Month Tx* Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ 
Type† Subject** N Mean SE Mean SE N Mean SE Mean SE N Mean SE Mean SE
BP MEPS 1072 83.3 3.3 97.0 4.1 67 51.7 3.4 61.9 3.9 1005 85.6 3.6 99.5 4.4 
 LTGS 126 71.2 4.1 84.8 4.8 23 51.7 3.4 62.9 4.5 103 75.2 4.9 89.4 5.7 
 HRGS 107 75.7 3.5 90.1 4.2 21 51.8 3.8 62.2 4.9 86 81.4 4.2 96.8 4.9 
CN MEPS 148 60.6 4.4 74.7 5.7 21 53.7 2.5 66.5 3.4 127 61.6 4.9 75.9 6.4 
 LTGS 18 92.6 8.4 117.2 9.4 5 85.1 9.1 111.0 12.0 13 94.2 9.0 118.5 9.5 
 HRGS 18 92.6 8.4 117.2 9.4 5 85.1 9.1 111.0 12.0 13 94.2 9.0 118.5 9.5 
HB MEPS  330 78.5 3.5 92.3 3.8 
 LTGS  32 96.6 3.2 109.4 3.9 
 HRGS  25 89.5 101.2 
HT MEPS  8652 51.6 0.9 64.3 1.2 
 LTGS  404 63.1 6.0 78.9 7.5 
 HRGS  299 54.0 2.5 68.2 3.2 
RF MEPS  303 107.1 5.4 123.1 6.0
 LTGS  11 106.8 12.2 119.7 14.4 
 HRGS  10 110.6 12.8 123.7 15.1 
§Costs are adjusted to 2005 dollars based on the medical component of the Consumer Price Index (CPI). 
* The total costs include expenses for prescribed medicines, expenses for outpatient visits and office-based medical provider visits linked to 
prescriptions, expenses for medical events linked to new osteoporosis and osteoporotic fractures, and expenses of all medical events for treatments for 
adverse drug events. 
**HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of 
glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey. SE=standard error of the mean; Unwtd=unweighted. 
†Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent; HB=simultaneous 




Table 4.3.4 Average prescription costs for three-month supply of anti-osteoporotic agents by gender and type of subject 
Gender All Men Women 
3-Month Rx* Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ Unwtd Un-adjusted 2005 $§ 2005 dollar§
Type† Subject** N Mean SE Mean SE N Mean SE Mean SE N Mean SE Mean SE
BP MEPS 1,072 69.7 2.3 81.1 2.8 65 42.6 3.4 50.8 3.8 1,007 71.6 2.5 83.2 3.0 
 LTGS 126 62.4 3.7 74.6 4.4 23 35.4 2.8 43.7 3.8 103 68.1 4.3 81.1 5.1 
 HRGS 107 65.5 3.3 78.3 3.9 21 35.2 3.1 43.2 4.2 86 72.8 3.7 86.8 4.4 
CN MEPS 148 50.3 4.0 61.8 4.9 21 44.5 2.8 55.5 3.8 127 51.1 4.3 62.8 5.5 
 LTGS 18 73.2 7.3 92.0 8.1 5 77.0 11.3 99.9 15.1 13 72.4 6.2 90.3 6.1 
 HRGS 18 73.2 7.3 92.0 8.1 5 77.0 11.3 99.9 15.1 13 72.4 6.2 90.3 6.1 
HB MEPS  330 59.5 2.5 69.8 2.8 
 LTGS  32 62.5 2.1 71.8 2.7 
 HRGS  25 46.3 53.7 
HT MEPS  8,654 39.7 0.5 49.3 0.6 
 LTGS  404 45.5 2.2 56.7 2.7 
 HRGS  299 44.0 2.2 55.6 2.9 
RF MEPS  303 95.0 5.0 109.1 5.6 
 LTGS  11 97.1 12.0 109.3 14.1 
 HRGS  10 100.5 12.6 112.9 14.7 
§Costs are adjusted to 2005 dollars based on the medical component of the Consumer Price Index (CPI). 
*Average total costs of prescriptions per subject per three months; costs include expenses of prescriptions only. 
**HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg or more; LTGS=long-term users of 
glucocorticoid tablets for at least three months; MEPS=Medical Expenditure Panel Survey. SE=standard error of the mean; Unwtd=unweighted. 
†Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent; HB=simultaneous 




4.4 LONG-TERM ESTIMATES OF COSTS AND EFFECTIVENESS 
This section shows estimates of long-term costs and incidence rates of 
osteoporosis and osteoporotic fractures in glucocorticoid tablet users in each of the 
following groups: bisphosphonates (BP), calcitonin (CN), control (CT), 
HRT-bisphosphonate combination (HB), hormone replacement therapy (HT) and 
raloxifene (RF).  The long-term estimates are obtained from Markov modeling with 
model inputs derived from Section 4.1 to Section 4.3.  It is noted that annual incidence 
rates of osteoporosis and osteoporotic fractures must be converted to three-month 
transition probabilities to fit the need of Markov modeling.  The following paragraphs 
describe the transformation and model inputs.   
 
4.4.1 Model inputs 
Model inputs for costs are listed in Table 4.3.2 and Table 4.3.3.  Based on Tables 
A.1 to A.24 in Appendix B, annual incidence rates of osteoporosis and osteoporotic rates 
are converted to three-month transition probabilities for subjects in different states and 
age groups.  The results are shown in Table 4.4.1, and data sources are marked for each 
entry.  In order to directly apply the transition probabilities in Markov modeling, the 
average age of subjects for that transition probability is multiplied by four to get an index 
used in tables of transition probabilities in the modeling.  In other words, four Markov 
cycles match one year of age.  Information from Appendix B is marked as source a, b 
and c when sources are based on HRGS users, LTGS users and all MEPS subjects, 
respectively.  However, these sources do not provide direct information on some 
transition probabilities among Markov states; therefore, information on relative risks 
described in Section 4.2.4 was used.  
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Compared to female non-glucocorticoid users in the WELL state, the relative risk 
(RR) of any osteoporotic fracture in female glucocorticoid users is approximately 1.14.  
Similarly, relative risks for subjects in the GIOP and GIFX states and for men are found 
in Table 4.2.14.  Each entry marked as “c, d” “c, f” and “c, g” in Table 4.4.1 and Table 
4.4.3 is carefully matched with the corresponding age (i.e., index), treatment group and 
state in the logistic regression models demonstrated in Section 4.2.4; therefore,  the 
actual value of relative risks for calculations may be more or less than 1.14.   
Some expected values of probabilities obtained from logistic regression models 
were used for the lower limits (i.e., age=30 or index=120) because the study model used 
interpolation in tables of transition probabilities to estimate proper values for model 
simulations.  These estimates are marked as “e” in Tables 4.4.1 and 4.4.3.  For 
transition probabilities in the CN group from the GIOP to the FX state, no information is 
available for females in Appendix B.  To estimate this transition probability for the 
female CN group, relative risks of osteoporotic fractures between men and women were 
evaluated.  The logistic regression models demonstrate that the relative risks of 
osteoporotic fractures for female glucocorticoid users in the GIOP state are 
approximately 0.31 when males at the same age and GIOP state are the comparator.  
Accordingly, three-month transition probabilities for the female CN group were obtained, 
which was marked as an “h” in Table 4.4.1.  Bolded values in Tables 4.4.1 and 4.4.2 
were used in model simulations.   
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Table 4.4.1 Three-month transition probabilities among Markov states for the base case 
in female glucocorticoid users 
State* WELL To GIOP WELL To FX GIOP To FX GIFX To FX 





































































































































































































































































































































































* Bolded values were used in modeling; WELL state: subjects without any prior osteoporosis and osteoporotic fractures; GIOP state: 
subjects with prior osteoporosis but without prior osteoporotic fractures; GIFX state: subject with prior osteoporotic fractures. 
†BP=bisphosphonate; CN=calcitonin; CT=controls without using any anti-osteoporotic agent; HB=use of hormone replacement 
therapy and bisphosphonates; HT=hormone replacement therapy; Index=average age multiplied by four; RF=raloxifene. 
a. From MEPS data (1996-2004) related to subjects who used glucocorticoid tablets at accumulated dose of 450 mg or more. 
b. From MEPS data (1996-2004) related to subjects who used glucocorticoid tablets for at least three months. 
c. From MEPS data (1996-2004) related to subjects who used anti-resorptive agents for at least three months. 
d. Compared to non-glucocorticoid female users in the WELL state, the relative risk of any fracture in glucocorticoid users is 1.14. 
e. Expected 3-month probabilities calculated based on the logistic regression equation and conversion. 
f. Compared to non-glucocorticoid female users in the GIOP state, the relative risk of any fracture in glucocorticoid users is 0.55. 
g. Compared to non-glucocorticoid female users in the GIFX state, the relative risk of any fracture in glucocorticoid users is 1.23. 
h. Data is not available for women. Compared to male oral glucocorticoid users in the GIOP state at the same age, the relative risk of 
any fracture in females is 0.31. 
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Table 4.4.2 Three-month transition probabilities among Markov states for the base case 
in male glucocorticoid users 
State* WELL To GIOP WELL To FX GIOP To FX GIFX To FX 



















































































































Bolded values were used in modeling. 
*WELL state: subjects without any prior osteoporosis and osteoporotic fractures; GIOP state: subjects with prior 
osteoporosis but without prior osteoporotic fractures; GIFX state: subject with prior osteoporotic fractures. 
†BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent; 
Index=average age multiplied by four. 
a. From MEPS data (1996-2004) related to subjects who used glucocorticoid tablets at cumulative dose≧ 450 mg.  
b. From MEPS data (1996-2004) related to subjects who used glucocorticoid tablets for at least three months. 
c. From MEPS data (1996-2004) related to subjects who used anti-resorptive agents for at least three months. 
d. Compared to non-glucocorticoid users, the relative risk (RR) of any fracture in female oral glucocorticoid users from 
the WELL state is 1.14; the expected RR match with rx type, age and gender. 
e. Expected 3-month probabilities calculated based on the logistic regression equation and conversion. 
f. Compared to non-glucocorticoid users, the relative risk (RR) of any fracture in female oral glucocorticoid users from 
the GIOP state is 0.55; the expected RR match with rx type, age and gender. 
g. Compared to persons with normal BMD, the risk of any osteoporotic fracture is increased 2.5-fold in men with BMD 
t-score < -2.5; Kanis et al. (2001) Osteoporosis Int 12: 989-995. 
 
4.4.2 Estimates of Long-Term Outcomes 
Long-term costs and effectiveness are estimated based on the Markov model for 
six hypothetical cohorts: male or female glucocorticoid users at an age of 30, 50 or 65 
years old.  Estimates are generated by the first-order and second-order Monte Carlo 
simulations for 10,000 samples at three different lengths of anti-osteoporotic treatment: 
two years, 10 years and life time.  Prior exposure to osteoporosis and/or osteoporotic 
fractures are introduced by assigning subjects of each hypothetical cohort to different 
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Markov states based on percentages listed in Table 4.2.2.  Costs are adjusted to 2005 
dollars based on an annual discount rate of 5% for all base cases.  Effectiveness 
represents percentage of osteoporotic fractures avoided (full protective effect=1, no 
protective effect=0) and is not discounted by time.  Tables 4.4.3 to 4.4.8 list average 
cost and average effectiveness for each of six hypothetical cohorts by length of treatment.  
Significant differences tested by Tukey’s method at an alpha level of 0.001 are indicated.   
Table 4.4.3, Table 4.4.4 and Table 4.4.5 list long-term estimates for hypothetical 
cohorts of female glucocorticoid users.  Common findings for these female cohorts are 
described as follows.  Within the same age cohort, the longer the length of treatment, the 
more the total costs, the less the overall effectiveness of the treatment.  Bisphosphonate 
(BP) therapy is the most costly treatment in women with two-year or 10-year simulations, 
but is not the most expensive treatment for 65-year-old women in the lifetime 
estimations.  Hormone replacement therapy (HT), except for the control group, is the 
least costly anti-osteoporotic treatments in women for all three lengths of simulations.   
Not all long-term costs increase with increased ages.  The two-year costs are 
similar among three female cohorts with ages of 30, 50 and 65 years old, and the same 
pattern applies to the 10-year estimates of costs among these cohorts.  The pattern for 
lifetime estimates of costs is unclear with respect to age.  The long-term effectiveness 
does not decrease with increased ages.  Apparently, the 30-year-old female cohort has 
relatively lower estimates of lifetime effectiveness than other age cohorts.  
Theoretically, younger subjects may go through more cycles than older ones, and an 
increased number of cycles may increase the chance of osteoporotic fractures.   
Significant differences in average costs and effectiveness among anti-osteoporotic 
treatments are indicated in each table.  Specifically, Table 4.4.3 shows estimates of 
long-term costs and effectiveness for 30-year-old female glucocorticoid users.  
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Significant differences in average costs were found for 10-year and lifetime simulations.  
Significant differences in average effectiveness were found for lifetime simulations.  
Therefore, study hypotheses Ho5A1, Ho5B1and Ho5D1 were rejected.   
 
Table 4.4.3 Estimates of long-term costs and effectiveness for 30-year-old women 
Length of estimation 
Treatment Cost
§ SD Eff.† SD 
2 years  
BP $4,541       $527 0.9603        0.0041 
CN $4,249       $408 0.9885        0.0011 
HB $2,782       $299 0.9701        0.0047 
HT $1,188       $117 0.9823        0.0025 
RF $3,048       $328 0.9906        0.0012 
CT $534       $86 0.7542        0.0261
10 years  
BP $18,500a b c d e f $2,124 0.9241a b c d e f 0.0077 
CN $16,246a b c d e f $1,542 0.9567a b c d e f 0.0052 
HB $15,442a b c d e f $1,857 0.8987a b c d e f 0.0159 
HT $6,646a b c d e f $857 0.9320a b c d e f 0.0100 
RF $12,103a b c d e f $1,339 0.9590a b c d e f 0.0054 
CT $2,217a b c d e f $318 0.3266a b c d e f 0.0396 
Lifetime  
BP $43,618a b c d e f $4,941 0.4310a b c d e f 0.0629 
CN $38,137a b c d e f $3,779 0.4172a b c d e f 0.0618 
HB $40,505a b c d e f $4,743 0.1702a b c d e f 0.0564 
HT $25,783a b c d e f $3,387 0.3061a b c d e f 0.0617 
RF $36,359a b c d e f $4,434 0.3161a b c d e f 0.0696 
CT $4,822a b c d e f $649 0.0050a b c d e f 0.0033 
Results of second-order Monte-Carlo simulations, N=10,000. 
BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone 
replacement therapy; RF=raloxifene group. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate; C/E=cost-effectiveness ratio; 
SD=standard deviation. 
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures. 
a p<0.05 compared to BP; b p<0.05 compared to CN; c p<0.05 compared to HB; d p<0.05 compared to HT;  
e p<0.05 compared to RF, f p<0.05 compared to CT. 
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Table 4.4.4 shows estimates of long-term costs and effectiveness for 50-year-old 
female glucocorticoid users.  Significant differences in average costs and effectiveness 
were found for two-year and 10-year simulations.  No significant differences in average 
costs and effectiveness were found for lifetime simulations.  Therefore, study 
hypotheses Ho5A1 and Ho5C1 were rejected. 
 
Table 4.4.4 Estimates of long-term costs and effectiveness for 50-year-old women 
Length of estimation 
Treatment Cost
§ SD Eff.† SD 
2 years  
BP $5,752a b c d e f $772 0.9297a b c d e f 0.0076 
CN $4,495a b c d e f $472 0.9804a b c d e f 0.0021 
HB $3,522a b c d e f $438 0.9637a b c d e f 0.0047 
HT $1,049a b c d e f $88 0.9863a b c d e f 0.0019 
RF $3,275a b c d e f $369 0.9846a b c d e f 0.0022 
CT $545a b c d e f $90 0.7538a b c d e f 0.0260 
10 years  
BP $22,664a b c d e f $2,959 0.8815a b c d e f 0.0133 
CN $17,167a b c d e f $1,748 0.9390a b c d e f 0.0084 
HB $15,469a b c d e f $1,730 0.9196a b c d e f 0.0125 
HT $6,356a b c d e f $811 0.9249a b c d e f 0.0111 
RF $14,530a b c d e f $1,776 0.9330a b c d e f 0.0108 
CT $2,968a b c d e f $480 0.3297a b c d e f 0.0406 
Lifetime  
BP $46,263       $5,659 0.4287        0.0621 
CN $37,090       $3,794 0.4657        0.0604 
HB $39,080       $4,386 0.3630        0.0690 
HT $27,282       $3,605 0.3439        0.0613 
RF $40,050       $5,104 0.3688        0.0696 
CT $5,851       $802 0.0181        0.0097 
Results of second-order Monte-Carlo simulations, N=10,000. 
BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent; 
HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone replacement therapy; 
RF=raloxifene group. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate; C/E=cost-effectiveness ratio; SD=standard 
deviation. 
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures. 
a p<0.05 compared to BP; b p<0.05 compared to CN; c p<0.05 compared to HB; d p<0.05 compared to HT;  e p<0.05 
compared to RF. 
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The patterns of significant differences in costs and effectiveness for 65-year-old 
female glucocorticoid users are different from those for the 50-year-old cohort.  Table 
4.4.5 shows estimates of long-term costs and effectiveness for 65-year-old female 
glucocorticoid users.  No significant differences in average costs and effectiveness were 
found for two-year and 10-year simulations.  Significant differences in average costs 
and effectiveness were found for lifetime simulations.  Therefore, study hypotheses 
Ho5B1 and Ho5D1 were rejected.   
 
Table 4.4.5 Estimates of long-term costs and effectiveness for 65-year-old women 
Length of estimation 
Treatment 
Cost§ SD Eff.† SD 
2 years  
BP $6,346       $879 0.9125         0.0100 
CN $4,602       $516 0.9685         0.0036 
HB $2,890       $282 0.9785         0.0031 
HT $2,004       $295 0.9561         0.0070
RF $4,437       $583 0.9548         0.0067 
CT $697       $116 0.7546         0.0263 
10 years  
BP $21,165       $2,664 0.8614         0.0197 
CN $17,563       $1,901 0.8873         0.0165 
HB $15,927       $1,675 0.8979         0.0178 
HT $13,523       $2,209 0.8107         0.0312 
RF $20,240       $2,798 0.8335         0.0260 
CT $3,850       $554 0.3590         0.0399 
Lifetime  
BP $39,643a b c d e f $4,982 0.4557a b c d e f 0.0626 
CN $33,345a b c d e f $3,640 0.5414a b c d e f 0.0561 
HB $35,832a b c d e f $4,079 0.5099a b c d e f 0.0677 
HT $32,502a b c d e f $4,734 0.3829a b c d e f 0.0634 
RF $41,236a b c d e f $5,745 0.4199a b c d e f 0.0662 
CT $6,971a b c d e f $909 0.0711a b c d e f 0.0247 
Results of second-order Monte-Carlo simulations, N=10,000. 
BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent; HB=simultaneously 
use of hormone replacement therapy and bisphosphonates; HT=hormone replacement therapy; RF=raloxifene group. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate; C/E=cost-effectiveness ratio; SD=standard deviation. 
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures. 
a p<0.05 compared to BP; b p<0.05 compared to CN; c p<0.05 compared to HB; d p<0.05 compared to HT;  e p<0.05 compared to RF. 
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Tables 4.4.6 to 4.4.8 shows estimates of long-term costs and effectiveness in male 
glucocorticoid users.  The patterns for male glucocorticoid users are much clearer.  
Bisphosphonate (BP) appears relatively more expensive than calcitonin (CN) treatment in 
two-year and 10-year estimations, but CN is more expensive in the lifetime estimation.  
Bisphosphonate treatment has less effectiveness on men than calcitonin treatment 
regardless of age and length of treatment.  According to results from Tables 4.4.3 to 
4.4.8, at least one statistically significant difference was found in long-term estimates of 
costs and effectiveness for female and male glucocorticoid users in different lengths of 
estimations.  All hypotheses for the fifth study objective were rejected.   
 
Table 4.4.6 Estimates of long-term costs and effectiveness for 30-year-old men 
Length of estimation 
Treatment Cost
§ SD Eff.† SD 
2 years  
BP $3,686* $300 0.9582* 0.0060 
CN $2,722* $247 0.9696* 0.0039 
CT $449* $43 0.9473* 0.0068 
10 years  
BP $14,030* $1,109 0.7645* 0.0265 
CN $12,620* $1,116 0.8452* 0.0210 
CT $2,270* $195 0.7117* 0.0359 
Lifetime  
BP $23,855* $2,049 0.0058* 0.0027 
CN $28,737* $2,342 0.1985* 0.0347 
CT $4,125* $239 0.0218* 0.0109 
Results of second-order Monte-Carlo simulations, N=10,000. 
BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate; C/E=cost-effectiveness ratio; 
SD=standard deviation. 
†Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures. 
* An overall significant difference, p<0.05. 
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Table 4.4.7 Estimates of long-term costs and effectiveness for 50-year-old men 
Length of estimation 
Treatment 
Cost§ SD Eff.† SD 
2 years  
BP $3,680* $294 0.9295* 0.0102 
CN $2,908* $263 0.9537* 0.0064 
CT $680* $69 0.9180* 0.0113 
10 years   
BP $13,130* $1,040 0.6436* 0.0371 
CN $13,098* $1,119 0.7926* 0.0254 
CT $2,552* $192 0.5853* 0.0443 
Lifetime   
BP $19,023* $1,696 0.0094* 0.0042 
CN $26,633* $2,128 0.2492* 0.0356 
CT $3,700* $204 0.0554* 0.0204 
Results of second-order Monte-Carlo simulations, N=10,000. 
BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate; C/E=cost-effectiveness ratio; SD=standard deviation. 
†Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures. 
* An overall significant difference, p<0.05. 
Table 4.4.8 Estimates of long-term costs and effectiveness for 65-year-old men 
Length of estimation 
Treatment Cost
§ SD Eff.† SD 
2 years  
BP $3,754* $294 0.8612* 0.0194 
CN $3,001* $270 0.9269* 0.0106 
CT $663* $65 0.8994* 0.0136 
10 years   
BP $10,985* $923 0.3604* 0.0473 
CN $13,096* $1,002 0.6461* 0.0347 
CT $2,182* $157 0.5595* 0.0432 
Lifetime   
BP $13,281* $1,350 0.0140* 0.0063 
CN $22,712* $1,854 0.2929* 0.0394 
CT $3,055* $167 0.1333* 0.0339 
Results of second-order Monte-Carlo simulations, N=10,000. 
BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic agent. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate; C/E=cost-effectiveness ratio; SD=standard deviation. 
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures. 
* An overall significant difference, p<0.05. 
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4.5 COST-EFFECTIVENESS ANALYSIS 
This section compares estimates of long-term costs and effectiveness for male and 
female glucocorticoid users, and interprets the results of comparisons.  Sensitivity 
analyses are performed for variables with uncertainty.  Based on the comparisons, 
cost-effective options are recommended for the prevention and management of 
glucocorticoid-induced fractures in glucocorticoid tablet users.   
 
4.5.1 Cost-Effectiveness 
Markov cohort analyses generate estimates for base cases by using the model 
inputs which represent the most likely scenario.  An annual discount rate of 5% and 
values described in Section 4.4.1 were used as model inputs of the base cases for Markov 
cohort analyses.  Tables 4.5.1 to 4.5.6 list model outputs of costs and effectiveness for 
six hypothetical cohorts by length of treatment.  Compared to estimates for the control 
group, cost-effectiveness ratios (C/E), incremental cost, incremental effectiveness and 
incremental cost-effectiveness ratio (ICER) are also listed for comparisons in the 
cost-effectiveness analyses.   
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Based on information listed in Table 4.5.1, the most cost-effective option is 
hormone replacement therapy (HT) for 30-year-old female glucocorticoid users in 
two-year, 10-year and lifetime simulations.  Other options that follower are HT-BP 
combination (HB) and raloxifene therapy (RF) for two-year simulations, raloxifene 
therapy (RF) for 10-year simulations and calcitonin therapy (CN) and bisphosphonate 
therapy (BP) for lifetime simulations.   
 
Table 4.5.1 Long-term estimates of cost-effectiveness for 30-year-old women 
Length 
Treatment* Cost
§ Incremental Cost Effectiveness
Incremental 
Effectiveness C/E ICER 
2 years   
BP $4,541 $4,007 0.9603 0.2061 $4,730 $19,437
CN $4,249 $3,714 0.9885 0.2344 $4,298 $15,848
HB $2,782 $2,248 0.9701 0.2159 $2,869 $10,412
HT $1,188 $654 0.9823 0.2281 $1,210 $2,868
RF $3,048 $2,513 0.9906 0.2364 $3,077 $10,630
CT $534 reference 0.7542 reference $711 -
10 years   
BP $18,500 $16,283 0.9241 0.5975 $20,025 $27,253
CN $16,246 $14,029 0.9567 0.6300 $16,984 $22,269
HB $15,442 $13,225 0.8987 0.5721 $17,205 $23,118
HT $6,646 $4,429 0.9320 0.6053 $7,137 $7,316
RF $12,103 $9,886 0.9590 0.6324 $12,622 $15,633
CT $2,217 reference 0.3266 reference $6,924 -
Lifetime   
BP $43,618 $38,795 0.4310 0.4260 $103,516 $91,075
CN $38,137 $33,315 0.4172 0.4122 $93,384 $80,821
HB $40,505 $35,682 0.1702 0.1651 $267,380 $216,089
HT $25,783 $20,961 0.3061 0.3011 $88,629 $69,610
RF $36,359 $31,536 0.3161 0.3111 $121,283 $101,366
CT $4,822 reference 0.0050 reference $1,416,526 -
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures; 
C/E=cost-effectiveness ratio; ICER=incremental cost-effectiveness ratio. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate. 
*BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone 
replacement therapy; Index=average age multiplied by four; RF=raloxifene group. 
 224
The most cost-effective option remains hormone replacement therapy (HT) for 
50-year-old female glucocorticoid users at two-year, 10-year and lifetime simulations, as 
shown in Table 4.5.2.  Other options that follow are raloxifene therapy (RF) and HT-BP 
combination (HB) for two-year simulations, raloxifene therapy (RF) for 10-year 
simulations and calcitonin therapy (CN) for lifetime simulations.  The patterns for 
30-year-old and 50-year-old female glucocorticoid users are similar.   
 
Table 4.5.2 Long-term estimates of cost-effectiveness for 50-year-old women 
Length 
Treatment* Cost
§ Incremental Cost Effectiveness
Incremental 
Effectiveness C/E ICER 
2 years   
BP $5,752 $5,207 0.9297 0.1760 $6,189 $29,586
CN $4,495 $3,950 0.9804 0.2267 $4,585 $17,428
HB $3,522 $2,977 0.9637 0.2100 $3,656 $14,179
HT $1,049 $504 0.9863 0.2325 $1,064 $2,168
RF $3,275 $2,730 0.9846 0.2308 $3,326 $11,825
CT $545 reference 0.7538 reference $726 -
10 years   
BP $22,664 $19,696 0.8815 0.5518 $25,730 $35,692
CN $17,167 $14,199 0.9390 0.6094 $18,285 $23,301
HB $15,469 $12,501 0.9196 0.5900 $16,834 $21,188
HT $6,356 $3,388 0.9249 0.5953 $6,880 $5,692
RF $14,530 $11,562 0.9330 0.6033 $15,583 $19,165
CT $2,968 reference 0.3297 reference $9,222 -
Lifetime   
BP $46,263 $40,412 0.4287 0.4106 $110,422 $98,418
CN $37,090 $31,239 0.4657 0.4476 $80,976 $69,791
HB $39,080 $33,228 0.3630 0.3449 $112,037 $96,333
HT $27,282 $21,431 0.3439 0.3258 $82,435 $65,775
RF $40,050 $34,199 0.3688 0.3507 $112,979 $97,519
CT $5,851 reference 0.0181 reference $427,670 -
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures; 
C/E=cost-effectiveness ratio; ICER=incremental cost-effectiveness ratio. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate. 
*BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone 
replacement therapy; Index=average age multiplied by four; RF=raloxifene group. 
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However, the pattern for 65-year-old female glucocorticoid users is different from 
previous cohorts with younger ages.  Table 4.5.3 shows that, for 65-year-old female 
glucocorticoid users, the most cost-effective option remains hormone replacement 
therapy (HT) for two-year and 10-year simulations, and that calcitonin therapy (CN) 
dominates for lifetime simulations.  Other options that follow are HT-BP combination 
(HB) in two-year, 10-year and lifetime simulations.  
 
Table 4.5.3 Long-term estimates of cost-effectiveness for 65-year-old women 
Length 
Treatment* Cost
§ Incremental Cost Effectiveness
Incremental 
Effectiveness C/E ICER 
2 years   
BP $6,346 $5,649 0.9125 0.1578 $6,959 $35,789
CN $4,602 $3,905 0.9685 0.2138 $4,753 $18,262
HB $2,890 $2,193 0.9785 0.2239 $2,954 $9,793
HT $2,004 $1,306 0.9561 0.2015 $2,097 $6,483
RF $4,437 $3,739 0.9548 0.2002 $4,648 $18,681
CT $697 reference 0.7546 reference $928 -
10 years   
BP $21,165 $17,315 0.8614 0.5024 $24,598 $34,462
CN $17,563 $13,713 0.8873 0.5283 $19,806 $25,957
HB $15,927 $12,077 0.8979 0.5389 $17,757 $22,411
HT $13,523 $9,673 0.8107 0.4518 $16,760 $21,412
RF $20,240 $16,390 0.8335 0.4745 $24,335 $34,538
CT $3,850 reference 0.3590 reference $10,919 -
Lifetime   
BP $39,643 $32,672 0.4557 0.3846 $88,790 $84,942
CN $33,345 $26,375 0.5414 0.4702 $62,257 $56,087
HB $35,832 $28,861 0.5099 0.4388 $71,696 $65,775
HT $32,502 $25,532 0.3829 0.3117 $87,733 $81,899
RF $41,236 $34,266 0.4199 0.3488 $100,920 $98,237
CT $6,971 reference 0.0711 reference $109,810 -
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures; 
C/E=cost-effectiveness ratio; ICER=incremental cost-effectiveness ratio. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate. 
*BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone 
replacement therapy; Index=average age multiplied by four; RF=raloxifene group. 
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Table 4.5.4, Table 4.5.5 and Table 4.5.6 show estimates of long-term costs and 
effectiveness for male glucocorticoid users in hypothetical cohorts at different ages.  
The patterns in all tables are similar.  Calcitonin therapy (CN) is the most cost-effective 
option for all cohorts in either two-year, 10-year or lifetime simulations.   
 
Table 4.5.4 Long-term estimates of cost-effectiveness for 30-year-old men 
Length 
Treatment* 
Cost§ Incremental Cost Effectiveness
Incremental 
Effectiveness C/E ICER 
2 years   
BP $3,686 $3,237 0.9582 0.0108 $3,848 $298,343
CN $2,722 $2,272 0.9696 0.0223 $2,807 $102,114
CT $449 reference 0.9473 reference $475 -
10 years   
BP $14,030 $11,760 0.7645 0.0527 $18,372 $222,999
CN $12,620 $10,350 0.8452 0.1335 $14,952 $77,533
CT $2,270 reference 0.7117 reference $3,208 -
Lifetime   
BP $23,855 $19,731 0.0058 -0.0161 $4,959,694 Dominated
CN $28,737 $24,612 0.1985 0.1766 $149,122 $139,326
CT $4,125 reference 0.0218 reference $240,886 -
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures; 
C/E=cost-effectiveness ratio; ICER=incremental cost-effectiveness ratio. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate. 




Table 4.5.5 Long-term estimates of cost-effectiveness for 50-year-old men 
Length 
Treatment* 
Cost§ Incremental Cost Effectiveness
Incremental 
Effectiveness C/E ICER 
2 years   
BP $3,680 $3,001 0.9295 0.0116 $3,961 $259,485
CN $2,908 $2,228 0.9537 0.0357 $3,050 $62,354
CT $680 reference 0.9180 reference $741 -
10 years   
BP $13,130 $10,578 0.6436 0.0583 $20,452 $181,387
CN $13,098 $10,546 0.7926 0.2073 $16,559 $50,873
CT $2,552 reference 0.5853 reference $4,403 -
Lifetime   
BP $19,023 $15,323 0.0094 -0.0460 $2,374,513 Dominated
CN $26,633 $22,932 0.2492 0.1937 $109,040 $118,364
CT $3,700 reference 0.0554 reference $76,637 -
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures; 
C/E=cost-effectiveness ratio; ICER=incremental cost-effectiveness ratio. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate. 
*BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent. 
 






Effectiveness C/E ICER 
2 years   
BP $3,754 $3,091 0.8612 -0.0382 $4,362 Dominated
CN $3,001 $2,338 0.9269 0.0275 $3,240 $85,082
CT $663 reference 0.8994 reference $738 -
10 years   
BP $10,985 $8,803 0.3604 -0.1991 $30,872 Dominated
CN $13,096 $10,914 0.6461 0.0866 $20,344 $126,052
CT $2,182 reference 0.5595 reference $3,940 -
Lifetime   
BP $13,281 $10,226 0.0140 -0.1192 $1,107,952 Dominated
CN $22,712 $19,658 0.2929 0.1596 $78,743 $123,191
CT $3,055 reference 0.1333 reference $24,579 -
Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures; 
C/E=cost-effectiveness ratio; ICER=incremental cost-effectiveness ratio. 
§Costs are adjusted to 2005 dollars based on 5% annual discount rate. 
*BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent. 
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Figures 4.5.1 to 4.5.6 illustrate comparisons of cost-effectiveness among different 
treatment options with the same length of simulations based on information listed in 
Tables 4.5.1 to 4.5.6.  Specifically, Figure 4.5.1 shows cost-effectiveness plots of base 
cases with two-year simulations for female glucocorticoid users.  In female 
glucocorticoid users with a two-year period of treatments, hormone replacement therapy 
(HT) is the most cost-effective option at ages of 30, 50 and 65 years old, and 
bisphosphonate (BP) therapy is dominated by all treatments.  The second recommended 
option for female glucocorticoid users is raloxifene (RF) for the 30-year-old cohort or 
HT-BP combination (HB) for the 65-year-old cohort.   
Figure 4.5.2 shows cost-effectiveness plots of base cases with two-year 
simulations for male glucocorticoid users.  In male glucocorticoid users with a two-year 
period of treatments, bisphosphonate (BP) therapy is dominated by calcitonin (CN) 
therapy at ages of 30, 50 and 65 years old.  However, two-year BP therapy has a worse 




Figure 4.5.1 Costs and fractures avoided for female cohorts at different ages from 2-year estimations of base cases 
 
Figure 4.5.2 Costs and fractures avoided for male cohorts at different ages from 2-year estimations of base cases 
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Figure 4.5.3 shows cost-effectiveness plots of base cases with 10-year simulations 
for female glucocorticoid users.  In female glucocorticoid users with a 10-year period of 
treatments, hormone replacement therapy (HT) is still the most cost-effective option at 
ages of 30, 50 and 65 years old.  The second recommended option for female 
glucocorticoid users remains raloxifene (RF) for the 30-year-old cohort or HT-BP 
combination (HB) for the 65-year-old cohort.  HB therapy is the second worse option 
for the 30-year-old cohort.  Bisphosphonate (BP) therapy is dominated by most of the 
rest options.  The patterns for recommended options for female glucocorticoid users for 
the two-year and 10-year simulations are similar.   
Figure 4.5.4 shows cost-effectiveness plots of base cases with 10-year simulations 
for male glucocorticoid users.  In male glucocorticoid users with a 10-year period of 
treatments, bisphosphonate (BP) therapy is dominated by calcitonin (CN) therapy at ages 
of 30, 50 and 65 years old.  10-year BP therapy has a worse effectiveness than the 
control treatment (CT); the patterns for male glucocorticoid users for the two-year and 





Figure 4.5.3 Costs and fractures avoided for female cohorts at different ages from 10-year estimations of base cases 
 
Figure 4.5.4 Costs and fractures avoided for male cohorts at different ages from 10-year estimations of base cases 
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Figure 4.5.5 shows cost-effectiveness plots of base cases with lifetime simulations 
for female glucocorticoid users.  In female glucocorticoid users with lifetime estimates, 
hormone replacement therapy (HT) and calcitonin therapy (CN) are the most 
cost-effective options at ages of 30 and 50, but only CN therapy remains most 
cost-effective at 65 years of age.  The HRT-BP combination (HB) is dominated by other 
treatments for the 30-year-old cohort, but is the next recommended option for the 
65-year-old cohort.     
Figure 4.5.6 shows cost-effectiveness plots of base cases with lifetime simulations 
for male glucocorticoid users.  In male glucocorticoid users with lifetime estimates, 
bisphosphonate (BP) therapy is dominated by calcitonin (CN) therapy at ages of 30, 50 
and 65 years old.  Actually, BP therapy has the worse lifetime effectiveness in male 
glucocorticoid users than the control treatment (CT).   
Based on the above analyses of base cases, the following options are 
recommended.  For two-year and 10-year treatments, hormone replacement therapy 
(HT) works better for women at younger ages, followed by raloxifene therapy (RF); 
while HB treatment works better for women at age of 65 years old.  For lifetime use of 
anti-osteoporotic treatment in female glucocorticoid users, calcitonin (CN) is the choice 
for women at any age, and hormone replacement therapy (HT) works better for women at 
younger ages.  Bisphosphonate treatment (BP) is the least-favored option for most cases.  
In male glucocorticoid users, calcitonin therapy (CN) is superior to bisphosphonate (BP) 
and control treatments (CT) for any length of treatments and at any age.  Nonetheless, 
the base-case analyses do not address uncertainty of model inputs, and the average 
estimates may not apply to all individuals.  Therefore, sensitivity analyses were 
performed to check the robustness of the recommendations based on the base-case 
analyses.   
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Figure 4.5.5 Costs and fractures avoided for female cohorts at different ages from lifetime estimations of base cases 
 
Figure 4.5.6 Costs and fractures avoided for male cohorts at different ages from lifetime estimations of base cases 
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4.5.2 Sensitivity Analyses 
The analyses of base cases are based on most likely scenarios of costs and fracture 
rates; however, these estimates bear a certain degree of uncertainty.  For example, the 
standard error of the average costs of the first-time fractures ($4,832) among HRGS users 
is $924.9.  A few transition probabilities are derived based on indirect sources and 
logistic regression models.  The “variable” uncertainty from these estimates may have a 
significant impact on long-term estimates of outcomes in the modeling.  Traditional 
one-way or two-way sensitivity analyses cannot address the uncertainty of these model 
inputs simultaneously.  A second-order Monte-Carlo simulation serves as a tool to 
address uncertainties at the level of variables simultaneously, so it was performed for 
each Markov model cohort.   
 
4.5.2.1 Monte Carlo Simulations 
In each hypothetical cohort, a total of 10,000 samples were simulated by 
second-order Monte Carlo simulations based on a set of transition probabilities and costs 
with variance introduced.  The variance was assigned based on proper statistical 
distributions which account for hypothetical measurement error by chance.  Figure 4.5.7 
illustrates the results of costs and effectiveness drawn from 1,000 of 10,000 samples in 
each female cohort; results are presented by different ages and lengths of treatment 
periods.  Among female cohorts, with an increased age or increased lengths of 
treatment, the best or better option among treatments is less clear.  Additional sensitivity 
analysis is required for female glucocorticoid users to further facilitate the 





Figure 4.5.7 Monte Carlo simulations on variable uncertainty for female cohorts
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Figure 4.5.8 illustrates the results of cost and effectiveness, drawn from 1,000 of 
10,000 samples in each male cohort; results are presented by different ages and lengths of 
treatment periods.  The decisions should be relatively clear for male glucocorticoid 
users.  Therefore, no further sensitivity analysis is performed for male glucocorticoid 
users. 
 
4.5.2.2 Annual Discount Rates 
The variety of annual discount rates is not included in the Monte-Carlo 
simulations, so a separate sensitivity analysis was performed to check the robustness of 
recommendations.  The analyses of base cases used an annual discount rate of 5%; 
another analysis was performed by using annual discount rate of 3%.  A cohort of 
50-year-old female glucocorticoid users was used as an example. 
Table 4.5.7 shows estimates of long-term costs and effectiveness for 50-year-old 
female glucocorticoid users based on the annual discount rate of 3% (see Table 4.5.2 for 
the estimates using the rate of 5%).  The estimates of effectiveness between these two 
tables are identical.  Figures 4.5.9 illustrates cost-effectiveness plots based on Table 
4.4.5 and Table 4.5.1.  For the two-year simulation, the difference in estimates is subtle 
because of the short period of time.  The patterns among treatments are similar between 
estimates from annual discount rate of either 3% or 5%.  Therefore, the 
recommendations for 50-year-old female glucocorticoid users are robust between annual 
discount rates of 3% and 5%.  A similar pattern was found between annual discount 
rates of 3% and 5% within the same cohort.  Data and figures are not shown.  It 





Figure 4.5.8 Monte Carlo simulations on variable uncertainty for male cohorts 
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Table 4.5.7 Estimates of long-term costs and effectiveness for 50-year-old women, 
annual discount rate 3% 
Length 
Treatment* Cost





2 years   
BP 5,840 $5,287 0.9297 0.1759 $4,730 $30,057
CN 4,568 $4,015 0.9804 0.2266 $4,298 $17,718
HB 1,066 $513 0.9637 0.2099 $2,869 $2,444
HT 3,326 $2,773 0.9863 0.2325 $1,210 $11,927
RF 3,577 $3,024 0.9846 0.2308 $3,077 $13,102
CT 553 reference 0.7538 reference $711 -
10 years      
BP 24,868 $21,580 0.8815 0.5518 $20,025 $39,108
CN 18,830 $15,542 0.9390 0.6093 $16,984 $25,508
HB 7,076 $3,788 0.9196 0.5899 $17,205 $6,421
HT 16,027 $12,739 0.9249 0.5952 $7,137 $21,403
RF 17,037 $13,749 0.9330 0.6033 $12,622 $22,790
CT 3,288 reference 0.3297 reference $6,924 -
Lifetime      
BP 62,390 $54,875 0.4287 0.4106 $103,516 $133,646
CN 50,573 $43,058 0.4657 0.4476 $93,384 $96,197
HB 41,231 $33,716 0.3630 0.3449 $267,380 $97,756
HT 57,078 $49,563 0.3439 0.3258 $88,629 $152,127
RF 55,022 $47,507 0.3688 0.3507 $121,283 $135,463
CT 7,515 reference 0.0181 reference $1,416,526 -
§Costs are adjusted to 2005 dollars based on 3% annual discount rate. 
†Effectiveness: 1=no osteoporotic fractures at all; 0=100% chance of osteoporotic fractures. 
*BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any anti-osteoporotic 
agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; HT=hormone 




   
 
 
Figure 4.5.9 Costs and fractures avoided for 50-year-old female glucocorticoid users at 
different annual discount rates 
 240
4.5.2.3 Willingness-To-Pay 
Compared to the baseline option (i.e., The CT group for this study), second-order 
Monte Carlo simulations also yield information on probabilities of cost-effective samples 
for a treatment based on a threshold incremental cost-effectiveness ratio (ICER), which 
usually equals the willingness-to-pay (WTP) value.  Figure 4.5.10 shows the scatterplot 
of incremental cost and effectiveness in 1,000 of 10,000 samples in simulations for 
30-year-old female glucocorticoid users who use 10-year calcitonin treatment when it is 
compared to control group.  A ceiling ratio of $22,500 was developed to establish a 
break-even point; it was not a pre-established WTP value.  The control group (baseline 
option) is on the origin so it is not visible in the Figure.  Samples below the dashed line, 
which represents WTP, are cost-effective.  This scatterplot indicates that if a 30-year-old 
female glucocorticoid user is willing to pay a total of $22,500 more for a 10-year 
calcitonin treatment in addition to a strategy of “screening for osteoporosis” (control 
treatment), the probability to reach cost-effective results is 52.65%.  
 
----dashed line indicates WTP=$22,500 
*1,000 points of 10,000 subjects shown 
Figure 4.5.10 Scatterplot of incremental cost and effectiveness for 30-year-old female 
glucocorticoid users with 10-year calcitonin treatment compared to control 
group 
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The same analysis was performed for 30-year-old female glucocorticoid users 
who want to pay 10-year calcitonin treatment at different amounts of WTP.  Table 4.5.8 
shows percentages of cost-effective samples of 30-year-old female glucocorticoid users 
for a 10-year calcitonin treatment based on different WTP values.  Based on information 
shown in Table 4.5.8, Figure 4.5.11 illustrates the acceptability curve of calcitonin 
treatment for 30-year-old female glucocorticoid users by different WTP values.   
 
Table 4.5.8 Percentages of cost-effective samples of 30-year-old female glucocorticoid 
users for a 10-year calcitonin treatment by WTP 
Willingness-to-pay (*$1,000) 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 
% Cost-effective 0.0 7.1 15.7 52.7 86.4 97.4 99.7 100.0







15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5












Figure 4.5.11 Acceptability curve of 10-year calcitonin treatment compared to control 
group in 30-year-old female glucocorticoid users 
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The same analysis was performed for all treatment options and by different values 
of WTP.  Table 4.5.9 shows percentages of cost-effective samples of 30-year-old female 
glucocorticoid users for a 10-year treatment based on different WTP values.  Based on 
information shown in Table 4.5.9, Figure 4.5.12 illustrates the acceptability curve of each 
treatment option by WTP values.  In Figure 4.5.3, which was illustrated earlier, HT is 
the most cost-effective option, followed by RF.  If a payer can afford $30,000 for a 
10-year treatment to avoid an incidence of osteoporotic fracture, of HT, RF, CN or HB 
has almost a 100% probability of reaching the goal.  If the payer can tolerate 20% 
failure in treatment, BP treatment may be one of the options, too.  Decisions on the 
selection of treatments may also depend on WTP.  Similarly, Figures 4.5.13 to 4.5.17 
illustrate acceptability curves for female cohorts with different ages and length of 
treatment periods.  The acceptability curve on the far left usually implies that treatment 
is the most cost-effective option for the cohort.   
 
Table 4.5.9 Percentage of cost-effective samples by willingness to pay and treatment 
WTP* 5.0  7.5 10.0  12.5  15.0 17.5 20.0 22.5 25.0 27.5 30.0  32.5  35.0 40.0 
Treatment % cost-effective 
BP       0.8 6.3 22.2 51.6 80.6 94.3 99.0 100.0
CN     0.0 7.1 15.7 52.7 86.4 97.4 99.7 100.0   
HB     0.0 0.9 9.2 39.2 77.3 96.4 99.7 100.0   
HT 0.0 61.1 100.0            
RF   0.0 3.2 34.0 85.3 98.7 100.0 100.0      
*WTP=willingness to pay in a unit of US $1,000. 
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Figure 4.5.12 Acceptability curves of 10-year anti-osteoporotic treatments compared to 
control group in 30-year-old female glucocorticoid users  
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Figure 4.5.13 Acceptability curves of 10-year anti-osteoporotic treatments compared to 
control group in 50-year-old female glucocorticoid users  
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Figure 4.5.14 Acceptability curves of 10-year anti-osteoporotic treatments compared to 
control group in 65-year-old female glucocorticoid users  
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Figure 4.5.15 Acceptability curves of lifetime anti-osteoporotic treatments compared to 
control group in 30-year-old female glucocorticoid users  
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Figure 4.5.16 Acceptability curves of lifetime anti-osteoporotic treatments compared to 
control group in 50-year-old female glucocorticoid users  
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Figure 4.5.17 Acceptability curves of lifetime anti-osteoporotic treatments compared to 
control group in 65-year-old female glucocorticoid users  
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These figures may also serve as informal tests for the sixth study hypotheses by 
drawing a line on x-axls of WTP and checking whether the percentage of cost-effective 
for each treatment option reaches at least 95% (or any alpha level determined by the 
decision makers).  The the ceiling costs (Rc) or WTP values were assumed as $1,000, 
$10,000 and $100,000 per fracture avoided (see Section 2.9.6).  No treatment option is 
cost-effective based on a WTP of $1,000 per fracture avoided.  Hormone replacement 
therapy is the most cost-effective option based on a WTP of $10,000 per fracture 
avoided.  Most treatment options are accepted based on a WTP of $100,000 per fracture 
avoided.  With regard to the selection of a preferred opton, the acceptability curves 
provide useful information which assists decision-making processes based on different 
needs.   
The acceptability curves implied that there were significant differences in ICERs 
among different treatment groups.  Therefore, all hypotheses for the sixth study 
objective were rejected.  Table 4.5.10 summaries all study hypoetheses and results of 
hypothesis testing.   
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Table 4.5.10 Summary of study hypotheses and test results 
 Description of hypothesis Rejected or Not rejected 
Average age  
Ho1A1 There is no significant difference in average ages among female long-term glucocorticoid users (LTGS) who received 
different anti-osteoporotic treatments. 
Rejected 
(page 172) 
Ho1A2 There is no significant difference in average ages among male long-term glucocorticoid users (LTGS) who received 
different anti-osteoporotic treatments. 
Rejected 
(page 172) 
Ho1A3 There is no significant difference in average ages among female high-risk glucocorticoid users (HRGS) who received 
different anti-osteoporotic treatments. 
Rejected 
(page 172) 
Ho1A4 There is no significant difference in average ages among male high-risk glucocorticoid users (HRGS) who received 
different anti-osteoporotic treatments. 
Rejected 
(page 172) 
Average cumulative glucocorticoid dose  
Ho1B1 There is no significant difference in average cumulative glucocorticoid doses among female long-term glucocorticoid 
users (LTGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 172-173)
Ho1B2 There is no significant difference in average cumulative glucocorticoid doses among male long-term glucocorticoid 
users (LTGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 172-173)
Ho1B3 There is no significant difference in average cumulative glucocorticoid doses among female high-risk glucocorticoid 
users (HRGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 172-173)
Ho1B4 There is no significant difference in average cumulative glucocorticoid doses among male high-risk glucocorticoid users 
(HRGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 172-173)
Average cumulative quantity of oral glucocorticoid tablets  
Ho1C1 There is no significant difference in average cumulative quantity of oral glucocorticoid tablets among female long-term 
glucocorticoid users (LTGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 173-174)
Ho1C2 There is no significant difference in average cumulative quantity of oral glucocorticoid tablets among male long-term 
glucocorticoid users (LTGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 173-174)
Ho1C3 There is no significant difference in average cumulative quantity of oral glucocorticoid tablets among female high-risk 
glucocorticoid users (HRGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 173-174)
Ho1C4 There is no significant difference in average cumulative quantity of oral glucocorticoid tablets among male high-risk 





Table 4.5.10 Summary of study hypotheses and test results (continued) 
 Description of hypothesis Rejected or Not rejected 
Average glucocorticoid dose per tablet  
Ho1D1 There is no significant difference in average glucocorticoid dose per tablet among female long-term glucocorticoid users 
(LTGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 174) 
Ho1D2 There is no significant difference in average glucocorticoid dose per tablet among male long-term glucocorticoid users 
(LTGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 174) 
Ho1D3 There is no significant difference in average glucocorticoid dose per tablet among female high-risk glucocorticoid users 
(HRGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 174) 
Ho1D4 There is no significant difference in average glucocorticoid dose per tablet among male high-risk glucocorticoid users 
(HRGS) who received different anti-osteoporotic treatments. 
Rejected 
(page 174) 
Average direct medical costs of preventive anti-osteoporotic treatments  
Ho4A1 There is no significant difference in average direct medical costs of preventive anti-osteoporotic treatments for female 
long-term glucocorticoid users (LTGS). 
Rejected 
(page 206) 
Ho4A2 There is no significant difference in average direct medical costs of preventive anti-osteoporotic treatments for male 
long-term glucocorticoid users (LTGS). 
Rejected 
(page 206) 
Ho4B1 There is no significant difference in average direct medical costs of preventive anti-osteoporotic treatments for female 
high-risk glucocorticoid users (HRGS). 
Rejected 
(page 206) 
Ho4B2 There is no significant difference in average direct medical costs of preventive anti-osteoporotic treatments for male 
high-risk glucocorticoid users (HRGS). 
Rejected 
(page 206) 
Average long-term costs of anti-osteoporotic treatments  
Ho5A1 There is no significant difference in average direct medical costs of 10-year anti-osteoporotic treatments for female 
glucocorticoid tablet users. 
Rejected 
(page 217-8) 
Ho5A2 There is no significant difference in average direct medical costs of 10-year anti-osteoporotic treatments for male 
glucocorticoid tablet users. 
Rejected 
(page 220) 
Ho5B1 There is no significant difference in average direct medical costs of lifetime anti-osteoporotic treatments for female 
glucocorticoid tablet users. 
Rejected 
(page 217, 219)
Ho5B2: There is no significant difference in average direct medical costs of lifetime anti-osteoporotic treatments for male 





Table 4.5.10 Summary of study hypotheses and test results (continued) 
 Description of hypothesis Rejected or Not rejected 
Average long-term effectiveness of anti-osteoporotic treatments  
Ho5C1 There is no significant difference in average effectiveness of 10-year anti-osteoporotic treatments for female 
glucocorticoid tablet users. 
Rejected 
(page 218) 
Ho5C2 There is no significant difference in average effectiveness of 10-year anti-osteoporotic treatments for male 
glucocorticoid tablet users. 
Rejected 
(page 220) 
Ho5D1 There is no significant difference in average effectiveness of lifetime anti-osteoporotic treatments for female 
glucocorticoid tablet users. 
Rejected 
(page 217, 219)
Ho5D2 There is no significant difference in average effectiveness of lifetime anti-osteoporotic treatments for male 
glucocorticoid tablet users. 
Rejected 
(page 220) 
Incremental long-term cost-effectiveness ratio (ICER)  
Ho6A1 The incremental cost-effectiveness ratios (ICERs) of a 10-year anti-osteoporotic treatment for female glucocorticoid 
tablet users, compared to those who do not use any anti-osteoporotic agent, equals the ceiling cost (Rc). 
Rejected 
(page 246) 
Ho6A2 The incremental cost-effectiveness ratios (ICERs) of a 10-year anti-osteoporotic treatment for male glucocorticoid tablet 
users, compared to those who do not use any anti-osteoporotic agent, equals the ceiling cost (Rc). 
Rejected 
(page 246) 
Ho6B1 The incremental cost-effectiveness ratios (ICERs) of a lifetime anti-osteoporotic treatment for female glucocorticoid 
tablet users, compared to those who do not use any anti-osteoporotic agent, equals the ceiling cost (Rc). 
Rejected 
(page 246) 
Ho6B2 The incremental cost-effectiveness ratios (ICERs) of a lifetime anti-osteoporotic treatment for male glucocorticoid tablet 






4.6 SUMMARY OF CHAPTER FOUR 
In combined data from the 1996 to 2004 Medical Expenditure Panel Survey 
(MEPS), an average number of 30,235 subjects per year represent an estimated average 
of 280,566,064 non-institutionalized people in the U.S.  Of these MEPS subjects, the 
weighted average age is 35.6 years old [Standard error of the mean (SE) =0.16], 52.3% 
are female, 81.7% are white and 12.8% are black or Africa American.  Study results for 
high-risk glucocorticoid (HRGS) users are similar to those for long-term glucocorticoid 
(LTGS) users, so results for LTGS users were summarized for simplicity.  
A total of 5,461 subjects met the study criteria for long-term glucocorticoid users 
(LTGS).  Overall, 2.2% of non-institutionalized U.S. population are LTGS users (1.8% 
of males and 2.7% of females).  Of these LTGS users, the weighted average age is 49.7 
years old (SE=0.53); 61.4% are female, 86.2% are white, 10.0% are black or African 
American, the average length of glucocorticoid therapy is 237.2 days (weighted, SE=8.93 
days) and the weighted average daily dose (prednisone equivalent) is 11.0 mg (SE=0.17 
mg).  In LTGS users, at least 25.3% of glucocorticoid prescriptions were prescribed for 
respiratory diseases, followed by joint problems (21.9%).   
Overall, 12.0% of MEPS subjects or 22.4% of LTGS users reported use of any 
anti-osteoporotic agent.  The most frequently used type among all anti-osteoporotic 
agents is hormone replacement therapy (HT) in women or use of both bisphosphonates 
and calcitonin for men.  The next most frequently used type is bisphosphonates.  
Analysis of variance (ANOVA) indicates that LTGS users in the control and the HT 
groups are significantly younger (df=5, F=36.17, p<0.0001) than those in other treatment 
groups.  ANOVA also indicates that the control group in LTGS users has a lower 
average cumulative glucocorticoid dose (p=0.0122).  The majority of LTGS users in 
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each treatment group is white (77.6% to 100.0%).  The differences in background of 
LTGS users among different treatment groups may imply a selection bias.   
LTGS users had higher prevalence rates of osteoporosis and osteoporotic fractures 
than the general population in the U.S.  Women had higher prevalence rates of 
osteoporosis than men in both groups, but the prevalence rates of osteoporotic fractures 
were similar.  From 1996 to 2004, it is estimated that the average annual prevalence of 
osteoporosis is 1,646 per 1,000,000 person-years (PY) for men, 23,355 per 1,000,000 PY 
for women, 9,768 per 1,000,000 PY for male LTGS users and 67,572 per 1,000,000 PY 
for female LTGS users in the U.S.  During the same period of time, it is also estimated 
that that the estimated average annual prevalence of osteoporotic fractures is 18,488 per 
1,000,000 PY for men, 17,995 per 1,000,000 PY for women, 29,764 per 1,000,000 PY 
for male LTGS users and 29,971 per 1,000,000 PY for female LTGS users in the U.S.   
The incidence rates of osteoporosis and osteoporotic fractures differ by gender, 
age, prior exposure to osteoporosis or fractures, type of glucocorticoid use and type of 
treatment received.  In general, incidence rates of osteoporosis in female glucocorticoid 
users are higher than those rates in MEPS female subjects, and those rates in groups of 
older age groups are likely larger than those in younger groups; however, it is not 
absolute.  A similar trend was not observed for incidence rates of osteoporotic fractures.  
In some cases, subjects in the 51 to 70 year-old age groups had relatively higher 
incidence rates of osteoporotic fractures.  It appears that the patterns are inconsistent.  
The logistic regression analyses indicated that the use of oral glucocorticoid tablets does 
not significantly change the odds of osteoporotic fractures in study subjects (relative risk 
(RR)= 1.146, 95% confidence interval (CI) 0.901-1.458 for subjects in the WELL state; 
RR=0.55, 95% CI 0.188-1.621 for subjects in the GIOP state; RR=1.241, 95% CI 
0.532-2.893 for subjects in GIFX state).  
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It is estimated that the average direct medical cost for evaluation of osteoporosis 
is $347.9 (SE=$24.3, 2005 dollars) per three months in LTGS users.  The average direct 
medical costs for osteoporotic fractures in LTGS users are $4,933 (SE=$443, 2005 
dollars) for first-time osteoporotic fractures and $6,710 for repeated osteoporotic 
fractures.  For LTGS users, the average total direct medical costs of anti-osteoporotic 
treatments for two years are $850 (SE=$44.1) for bisphosphonate therapy, $882.4 
(SE=$81.7) for calcitonin therapy, $631 (SE=$59.4) for hormone replacement therapy, 
$875.5 (SE=$31.1) for combined use of hormone-replacement and bisphosphonate 
therapy and $963.9 (SE=114) for raloxifene therapy. 
Long-term estimates of costs and effectiveness were generated for hypothetical 
male and female cohorts with different ages in each group of anti-osteoporotic treatments 
by using Markov modeling and Monte Carlo simulations.  Analyses of long-term costs 
and effectiveness among treatment groups indicate that the 30-year-old and 50-year-old 
female cohorts have a similar pattern of comparisons, while the pattern for the 
65-year-old female cohorts is different.  Comparisons of acceptability curves of 
different anti-osteoporotic treatments indicate that hormone replacement therapy is the 
most cost-effective option for hypothetical female cohorts for either two-year, 10-year or 
lifetime estimations except that calcitonin therapy is the most cost-effective option for 
65-year-old female cohorts for lifetime estimations.  The cost-effectiveness patterns 
among bisphosphonate, calcitonin and control groups for hypothetical male cohorts are 
similar.  Calcitonin therapy is the most cost-effective option for hypothetical male 
cohorts at any age and any length of simulations.  One-way sensitivity analysis on 
annual discount rates indicates the patterns of study results are robust in comparisons 
among different groups of anti-osteoporotic treatments.   
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CHAPTER FIVE-DISCUSSION AND CONCLUSIONS 
 
This chapter interprets and discusses the study results, and provides 
recommendations for treatment of glucocorticoid-induced osteoporosis and fractures.  
The first section discusses important study findings and compares some of these findings 
to those from other studies in the literature.  The next section discusses study 
limitations.  The third section brings up some possible topics for future research.  The 
last section makes recommendations for the management of glucocorticoid-induced 
osteoporosis and related fractures.   
 
5.1 DISCUSSION 
There have been a few studies investigating the cost-effectiveness of 
anti-osteoporotic treatments for osteoporosis, especially for post-menopausal 
osteoporosis in the literature.  Little has been published about the long-term 
cost-effectiveness of anti-osteoporotic treatments for glucocorticoid-induced 
osteoporosis.  This section compares the study findings to what was found in the 
literature.   
 
5.1.1 Study Subjects 
Previous studies estimated that about 0.7% of the general population in Iceland 
are long-term glucocorticoid (LTGS) users, and 0.9% of the general population in the 
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U.K. had received oral glucocorticoid therapy.304F 305, 305F 306  In this study, 2.2% of the 
non-institutionalized U.S. population are LTGS users while 4.5% reported use of oral 
glucocorticoid tablets.  These percentages cannot be directly compared because: (1) the 
data of subjects in previous studies were obtained in 1996 while this study covers MEPS 
data from 1996 to 2004; and (2) different countries may have different prevalence rates.  
However, these percentages still provide useful information showing that a relatively low 
percent of the general population are glucocorticoid users.   
Long-term glucocorticoid therapies were most frequently used for 
musculoskeletal and respiratory conditions.  Previous research indicates that 
musculoskeletal and pulmonary diseases are two major categories of underlying 
conditions.306F307, 307F308  This study shows similar results; for example, respiratory diseases 
(25.3%) and joint problems (21.9%) rank as the top two categories in LTGS users.  
Therefore, RCTs or observational studies for glucocorticoid-induced osteoporosis should 
not exclude subjects with the comobidities listed above.  
The majority of glucocorticoid users were categorized into the racial group of 
white.  In this study, 92.7% of MEPS subjects who used bisphosphonates were white 
while in a previous study 93.7% of those subjects were white.308F309  In the white group of 
this study, the majority of MEPS female subjects used hormone replacement therapy, 
                                                 
305 Gudbjornsson, B. et al. (2002). Prevalence of long term steroid treatment and the frequency of 
decision making to prevent steroid induced osteoporosis in daily clinical practice. Annals of the Rheumatic 
Diseases 61(1): 32-36.  
306 van Staa, T. P. et al. (2000). Use of oral corticosteroids in the United Kingdom. QJM 93(2): 105-111.  
307 Boling, E. P. (2004). Secondary osteoporosis: underlying disease and the risk for 
glucocorticoid-induced osteoporosis. Clinical Therapeutics 26(1): 1-14.  
308 van Staa, T. P. et al. (2002). The epidemiology of corticosteroid-induced osteoporosis: a 
meta-analysis. Osteoporosis International 13(10): 777-787.  
309 Farley, J. F. et al. (2006) Racial variations in antiresorptive medication use: results from the 2000 
Medical Expenditure Panel Survey (MEPS). Osteoporosis International 17(1): 395-404.  
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followed by bisphosphonates.  The same pattern was observed in Farley’s study.309F310  
This finding also echoes recommended use of HRT for postmenopausal women by many 
guidelines and consensus reports, as described in Chapter One.   
 
5.1.2 Medication Use 
A previous cohort study showed that 46.4% of female high-risk glucocorticoid 
users (≧90 days, ≧ 5 mg prednisone, aged 18 years old and over) received HRT and 
18.3% received other anti-osteoporotic medications, while 8.9% of male glucocorticoid 
users received any osteoporotic medication. 310F311  In this study, 21.8% of female high-risk 
glucocorticoid (HRGS) users received HRT and 14.0% received other anti-osteoporotic 
medications; 2.2% of male glucocorticoid users received any osteoporotic medication.  
In both of these two studies, HRGS users were evaluated, about 90% of the study 
subjects are white and the period of data collection is two years.  However, the Feldstein 
et al. study collected data from 2000 to 2001, a total of 575 subjects were excluded 
because of ineligibility of the HMO plan, and it used no weighted adjustments.   
In the current study, significant differences in average ages and average 
glucocorticoid doses were found among treatment groups.  For example, subjects in the 
bisphosphonate, HRT and control groups have a significantly higher average 
glucocorticoid dose than those in the calcitonin, raloxifene and HRT-bisphosphonate 
combination groups, but those in the HRT and control groups were younger than those in 
other groups (Table 4.1.6).  The combined effects of younger age and more 
glucocorticoid use on fractures are unknown, but the effect of age on fractures was 
                                                 
310 Ibid 
311 Feldstein, A. C. et al. (2005). Practice patterns in patients at risk for glucocorticoid-induced 
osteoporosis. Osteoporosis International 16(12): 2168-2174. 
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partially controlled by categorizing study subjects into four age groups (as shown in 
Tables of Appendix B).  However, the higher average glucocorticoid dose for subjects 
in bisphosphonate group likely implies a bias.  Overall, it suggests that a potential 
selection bias should exist among treatment groups.   
 
5.1.3 Prevalence and Incidence 
According to the National Osteoporosis Foundation (NOF), an estimated 12.5% 
(10 million) of Americans aged 55 years old or more already have osteoporosis.311F312  It 
was estimated in this study that the overall annual prevalence rate of osteoporosis and 
osteoporotic fractures are about 4.1% and 2.7%, respectively, in MEPS subjects aged 50 
years old or older.  The discrepancy in prevalence may be due to different sources of 
data, different methods of estimation, different reference periods (1996-2004 for this 
study) or different ranges of prevalence (e.g., annual vs. 10-year prevalence).   
It was estimated by a previous two-year cross-sectional survey that 20% of 
long-term steroid (LTGS) users had osteoporosis or osteopenia, and 26% had fragility 
fractures.312F313  In this study, the weighted annual prevalence rates in LTGS users are 
about 7.7% for osteoporosis and 3.8% for osteoporotic fractures.  This study included 
more LTGS users (unweighted N=5,209) than those (N=191) in the previous study by 
Gudbjornsson et al.  Additionally, the estimates in this study are weighted to represent 
nationally representative estimates.  Moreover, this study does not include osteopenia 
and has more a restricted criterion for osteoporotic fractures, so the total numbers of 
                                                 
312 National Osteoporosis Foundation (2004). America's bone health: the state of osteoporosis and low 
bone mass. 2002. National Osteoporosis Foundation. Washington, D. C. 22 pages. 
313 Gudbjornsson, B. et al. (2002). Prevalence of long term steroid treatment and the frequency of 
decision making to prevent steroid induced osteoporosis in daily clinical practice. Annals of the Rheumatic 
Diseases 61(1): 32-36.  
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osteoporosis and osteoporotic fractures are lower than those in the study by Gudbjornsson 
et al.   
It was estimated from a hospital database that the incidence rates of osteoporotic 
fractures during 2001 in France were 2,312 and 7,567 per one million men and women 
aged over 45 years, respectively.313F314  It is estimated in this study that the average annual 
incidence rates of osteoporotic fractures between 1996 and 2004 in the U.S. are 17,175 
and 15,572 per 106 person-years (PY) for the non-institutionalized men and women, 
respectively.  With respect to the impact of glucocorticoid use on fracture rates, it was 
estimated from a population-based cross-sectional study in the U.K. that the incidence 
rates of osteoporotic fractures is about 26,000 per 106 PY in glucocorticoid users with a 
daily dose of at least 7.5 mg.314F315  In this study, the estimated annual incidence rates of 
osteoporotic fractures in the U.S. are 26,543 per 106 PY for all HRGS users.  These two 
estimates are similar.   
Previous studies have shown the relationship between incidence of fractures and 
glucocorticoid use.  Compared to non-glucocorticoid users, it was reported in the 
literature that the relative risk (RR) of any osteoporotic fractures in oral glucocorticoid 
users is 1.75 (95% confidence interval [CI] 1.6-1.9),315F316 1.59 (95% CI 1.49-1.70)316F317 or 
1.33 (95% CI 1.29-1.38).317F318  In this study, the RR of osteoporotic fractures is 1.15 (95% 
CI= 0.90-1.45) for LTGS users without prior exposure to osteoporosis and osteoporotic 
                                                 
314 Maravic, M. et al. (2005). Incidence and cost of osteoporotic fractures in France during 2001. a 
methodological approach by the national hospital database. Osteoporosis International 16(12): 1475-1480.  
315 van Staa, T. P. et al. (2000). Use of oral corticosteroids and risk of fractures. Journal of Bone and 
Mineral Research 15(6): 993-1000.  
316 Steinbuch, M. et al. (2004). Oral glucocorticoid use is associated with an increased risk of fracture. 
Osteoporosis International, 15(4): 323-328. 
317 Vestergaard, P. et al. (2003). Corticosteroid use and risk of hip fracture: a population-based 
case-control study in Denmark. Journal of Internal Medcine 254: 486-493. 
318 van Staa, T. P. et al. (2000). Use of oral corticosteroids and risk of fractures. Journal of Bone and 
Mineral Research 15(6): 993-1000.  
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fractures.  As indicated by van Staa et al.,318F319 different findings may be due to: (1) 
different sample sizes; (2) various definitions of glucocorticoid exposure, imprecise 
measurement of glucocorticoid doses or incomplete information on compliance; (3) 
different locations (femoral neck, spine, etc.) or methods (dual x-ray absorptiometry 
(DXA), quantitative computed tomography (QCT), etc.) of bone density measurement; 
and (4) inappropriate control group.  In addition to these comments, there are different 
inclusion criteria for osteoporotic fractures.  This study uses relatively restricted 
definitions of osteoporotic fractures, targets LTGS users which are different from those in 
previous studies, and, most importantly, involves effects from anti-osteoporotic 
treatments while other studies may not.  A direct comparison among RRs is 
inappropriate, but the trend shows that use of glucocorticoid steroids increases the risks 
of osteoporotic fractures with or without use of anti-osteoporotic treatments.   
Based on the logistic regression analyses, men in the WELL and GIFX states had 
higher odds of osteoporotic fractures than women in the same state, whereas women in 
the GIOP state have higher odds of osteoporotic fractures than men in the GIOP state.  
A possible explanation is that the prevalence rate of osteoporosis in women is relatively 
higher than in men so that women in the GIOP state may be proactive to any intervention 
which prevents osteoporotic fractures.  For example, women are generally aware of 
consuming diary food for prevention of osteoporosis; these actions were not recorded in 
the MEPS data.  The possibility that glucocorticoid users with osteoporosis may be 
proactive regarding anti-osteoporotic treatment can also explain why glucocorticoid users 
in the GIOP state have a relatively lower RR than those in other states.   
                                                 
319 Ibid. 
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The protective effects of bisphosphonates on bone mineral density (BMD) 
increases are significant in most RCTs, but the effects of bisphosphonates on osteoporotic 
fractures are inconsistent in the literature.  For example, a one-year RCT showed that no 
significant differences in both prevalence and incidence rates of vertebral fractures were 
found between the alendronate and placebo groups (prevalence: 54% in the alendronate 
group and 39% in the placebo group, incidence: 13% in alendronate group and 4% in the 
placebo group).319F 320   Although the differences are not significant, both rates for 
alendronate group are higher than those for the placebo group.  This is similar to the 
current study findings in that bisphosphonate groups have higher prevalence and 
incidence rates than the control groups.   
 
5.1.4 Costs 
The estimates of direct medical costs of osteoporotic fractures vary by population 
at risk, affected sites, year of estimates and countries in the literature.  The estimated 
hospital costs of hip fractures ranged from U.S. $8,977 to $10,314 plus $752 to $7,897 
per additional year320F321, 321F322 or an overall estimate of $19,800.322F323  The estimated hospital 
costs of vertebral and wrist fractures range from $790 to $1,255 and from $772 to $1,496, 
respectively323F324, 324F325  In this study, the estimated average direct medical costs of all 
                                                 
320 Lems, W. F. et al. (2006). Positive effect of alendronate on bone minieal density and makers of bone 
turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a 
randomized, double-blind, placebo-controlled trial. Osteoporosis International 17: 716-723. 
321 Reginster, J.-Y. et al. (1999). Direct costs of hip fractures in patients over 60 years of age in Belgium. 
Pharmacoeconomics 15(5): 507-514.  
322 $1 USD =0.84219 Euro, as of Jan. 4, 1999.  URL: 
http://www.geocities.com/eureka/concourse/8751/tabl-er2.htm  Accessed July 12, 2007.  
323  1₤=$1.6120-1.7255 in 1998, URL: http://www.taxfreegold.co.uk/1998forexrates.html  Accessed 
July 12, 2007. 
324 Dolan, P. & Torgerson, D. J. (1998). The cost of treating osteoporosis fractures in the United 
Kingdom female population. Osteoporosis International 8(6): 611-617.  
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osteoporotic fractures in the U.S. non-institutional population are $5,300 for the first-time 
episode and $9,100 for a repeated episode (Table 4.3.2).  The disparity in cost 
estimations may arise because this study calculates overall average costs of osteoporotic 
fractures at different sites and includes costs from sources other than hospital stays.   
The average wholesale prices (AWP) for one-year supplies of risedronate (5 
mg/day), alendronate (5-and 10-mg/day) and conjugated estrogen (0.625 mg/day) are 
$668,325F326 $762 and $75,326F 327 respectively.  The AWP of a prescribed medication is 
usually the “list price” of the medication, and has been used in calculations for pricing or 
reimbursements.327F 328  However, AWP does not reflect the actual market price of a 
medication because actual prices involve various discounts for reimbursement.  The use 
of “real-world” costs in cost analyses is becoming notable in the literature.  For 
example, recent studies reported that the medication costs in the first year after a 
non-vertebral fracture are $320, $110 and $512 for alendronate, risedronate and 
calcitonin, respectively,328F329 and that the average costs for GI-related adverse reactions are 
$72 for alendronate and $26 for risedronate.329F330   
The estimated costs of anti-osteoporotic treatments in this study are different from 
those reported in previous studies.  It is estimated in this study that the average costs 
                                                                                                                                                 
325 Gabriel, S. E. et al. (2002). Direct medical costs attributable to osteoporosis fractures. Osteoporosis 
International 13(4): 323-330.  
326 Wyman, M. (2000). Pharmacotherapy Update 3(3) Cleveland Clinic Foundation. 
http://clevelandclinicmeded.com/medical_info/pharmacy/aug2000/pharm.htm 
327 Buckley, L. M. & Hillner, B. E. (2003). A cost effectiveness analysis of calcium and vitamin D 
supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with 
glucocorticoids. Journal of Rheumatology 2003 30(1): 132-138. 
328 Gencarelli, D. M. (2002). Average wholesale price for prescription drugs: is there a more appropriate 
pricing mechanism? National Health Policy Forum Issue Brief 775:1-19.  
329 Brixner, D. (2006). Assessment of the prevalence and costs of osteoporosis treatment options in a 
real-world setting. The American Journal of Managed Care, 12(7 Supple.): S191-S198. 
330 Kane, S. et al. (2004). Pharmacoeocnomic evaluation of gastrointestinal tract events during treatment 
with risedronate or alendronate: a retrospective cohort study. The American Journal of Managed Care, 
10(7): S216-S226. 
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(including costs for treatments of GI-related adverse reactions) per MEPS subject for 
prevention of osteoporotic fractures are $388 in the bisphosphonate group and $299 in 
the calcitonin group.  Table 4.3.4 also shows that the average annual prescription costs 
per MEPS subject are $324 for bisphosphonates and $247 for calcitonin.  If costs for 
treatments of existing osteoporotic fractures are included, the annual average total 
fracture-related costs per MEPS subject are $816 in the bisphosphonate group and $617 
in the calcitonin group.  The “real-world” costs are lower than AWP likely due to 
discounts and free samples received in study subjects.  The reasons for disparity in 
estimated costs between this and previous studies include different inclusion criteria for 
costs, inflation in later years and different sampling frames (e.g., regions, hospitals, etc.).   
 
5.1.5 Long-Term Cost-Effectiveness 
No significant difference in long-term effectiveness of anti-osteoporotic 
treatments was found for the 30-year-old and 65-year-old female cohorts with two-year 
or 10-year simulations and for 50-year-old female cohorts with lifetime simulations.  
Significant differences in long-term effectiveness of anti-osteoporotic treatments were 
found for the 30-year-old and 65-year-old female cohorts with lifetime simulations and 
for the 50-year-old female cohorts with two-year or 10-year simulations.  If costs of 
anti-osteoporotic treatments are not considered at this moment, the current study 
suggested that 50-year-old female glucocorticoid users should selecte a preferred 
treatment based on short-term effectiveness and 30-year-old and 65-year-old female 
glucocorticoid users select a preferred treatment based on lifetime effectiveness.   
Explanations for these findings are discussed as follows.  The younger 
(30-year-old) women have relatively healthy bones overall and the older (65-year-old) 
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women have a relatively low bone mass overall, so the differences between 
anti-osteoporotic treatments in osteoporotic fractures were too small to be detected in a 
short perioid of time (two years or 10 years).  The differences in osteoporotic fractures 
for 50-year-old women may be due to menopausal status, and anti-osteoporotic 
treatments have a protective effect on vertebral fractures, which are frequently observed 
in post-menopausal women.  Anti-osteoporotic treatments likely show differences in 
effectiveness for 50-year-old women in a short period of time.   
Compared with no treatment, Homik et al. estimated that the 10-year incremental 
costs per vertebral fracture avoided were $9,000 in bisphosphonate treatment for 
hypothetical young female glucocorticoid users;330F331 Buckley and Hillner estimated that 
the 10-year and lifetime incremental costs per vertebral fracture avoided were 
$7,883-$121,125 (10-year) or $4,122-$7,883 (lifetime) in alendronate treatments for 
hypothetical Caucasian female glucocorticoid users with different ages and BMD 
measurements.331F332  In this study, the estimated 10-year and lifetime incremental cost per 
osteoporotic fracture avoided are $27,253 to $35,692 (10-year) and $84,942 to $91,075 
(lifetime) in hypothetical female glucocorticoid users with different ages.  In 
comparison to these two studies., this study has at least three differences: (1) this study 
used higher annual costs of bisphosphonate treatments ($1,035 in Table 4.3.1 vs. $780 in 
the Homik et al. study vs. $762 in Buckley and Hillner’s study) because this study 
includes costs for all medical events in addition to pharmacy costs; (2) this study 
estimates cost-effectiveness for all osteoporotic fractures while the other two studies 
                                                 
331 Homik, J. E. et al. (1998). Cost-effectiveness of bisphosphonates in the prevention of 
corticosteroid-induced osteoporosis. Arthritis and Rheumatism 4(Suppl. 9): S303.  
332 Buckley, L. M. & Hillner, B. E. (2003). A cost effectiveness analysis of calcium and vitamin D 
supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with 
glucocorticoids. Journal of Rheumatology 2003 30(1): 132-138.  
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addressed vertebral fractures only; and (3) three studies used different Markov models 
and specifications for osteoporosis and osteoporotic fractures.   
This comparison indicates that different methodologies and models yield different 
estimates of long-term cost-effectiveness of bisphosphonate treatment in female 
glucocorticoid users.  It is relatively difficult to directly compare study findings with 
each other.  This situation echoes with the need for model transparency based on 
principles of good practice for modeling suggested by the International Society for 
Pharmacoeconomics and Outcomes and Research (ISPOR) Task Force Panel.332F333, 333F334  
Cost-effectiveness analyses involving modeling techniques should explicitly describe the 
methodology and model specifications, so that study findings are comparable with each 
other.   
The current study projected that HRT was the most cost-effective option for 
female glucocorticoid users in most long-term estimations.  The findings about hormone 
replacement therapy (HRT) in this study were based on MEPS data from 1996 to 2004 
when HRT was still a recommended option for osteoporosis.  However, HRT is 
currently not recommended for post-menopausal women for prevention of vertebral 
fractures in general based on the findings of Women Health Initiative (WHI) study.334F335, 
335F
336  The study included insufficient information about the adverse drug events resulting 
from HRT, so it is questionable to apply the long-term estimates of HRT in this study to 
                                                 
333 Garrison, L. P. (2003) The ISPOR good practice modeling principles-a sensible approach: be 
transparent, be reasonable. Value in Health 6(1): 6-8. 
334 Weinstein, M. C. et al. (2003). Principles of good practice for decision analytic modeling in 
health-care evaluation: report of the ISPOR Task Force on good research practice-modeling studies. Value 
in Health 6(1): 9-17.  
335 Kleerekoper, M. (2002). Lessons from the skeleton: was the Women's Health Initiative (WHI) a 
primary prevention trial? Osteoporosis International 13(9): 685-687.  
336 Majumdar, S. R. et al. (2004). Promotion and prescribing of hormone therapy after report of harm by 
the Women's Health Initiative. Journal of the American Medical Association 292(16): 1983-1988.  
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current clinical practices.  If HRT will be used in female glucocorticoid users, adverse 
drug reactions should be cautiously monitored.336F337   
When HRT is not considered, based on study findings, raloxifene is the most 
cost-effective option for prevention of glucocorticoid-induced fractures in young 
(30-year-old or 50-year-old) women who receive glucocorticoid therapy for less than 10 
years, while calcitonin is the most cost-effective option in older (65-year-old) women 
who receive glucocorticoid therapy for less than 10 years.  Nasal calcitonin is the 
cost-effective option for prevention of glucocorticoid-induced fractures in women at any 
age who receive glucocorticoid therapy over 10 years.   
 
5.1.6 Managed Care 
From the perspective of managed care, the incremental cost-effectiveness ratios 
(ICERs) can be translated to an average additional expense to avoid one episode of 
osteoporotic fracture in 10,000 long-term glucocorticoid users.  For example, compared 
to the strategy of regular monitoring for osteoporosis, the total osteoporosis-related 
expenditures for 50-year-old female glucocorticoid users receiving bisphosphonate 
therapy to avoid one episode of osteoporotic fracture were $29,586 for two years and 
$35,692 for 10 years, respectively (Table 4.5.2).  As Barrington et al. pointed out, an 
explanation based on return on investment (ROI) is more relavent to payers in settings of 
managed care.337F338  By using the same example, the average annual costs related to 
osteoporosis for female glucocorticoid users receiving bisphosphonate therapy were 
                                                 
337 American College of Rheumatology (ACR) (2001). Recommendations for the prevention and 
treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad 
Hoc Committee on glucocoritcoid-induced osteoporosis. Arthritis and Rheumatism 44(7): 1496-1503.  
338 Barrington, C. et al. (2006). Managing osteoporosis in a managed care population. The f 12(7) 
S199-202.   
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$14,793 (two years) and $3,569 (10 years), respectively; the saving is $11,224 in the 10th 
years.  In other words, compared to the current annual total osteoporosis-related 
expenditures for female glucocorticoid users to avoid an osteoporosis fracture, payers 
will pay less ($11,224) after 10 years.  Therefore, for every dollar invested within two 
years, payers will receive an ROI of $0.76 ($11,224/$14,793) after 10 years.   
 
5.2 STUDY LIMITATIONS 
Due to the study design and the nature of the data sources, some study limitations 
are presented.  Limitations restrict the applications of study results or methodology for 
other uses.  Acknowledging these limitations helps with the interpretation of study 
results and drawing reasonable conclusions.   
 
(1) Assignment of dates for events in MEPS.  A notable source of uncertainty 
in this study is the assignment of dates for events of osteoporosis, fractures and 
prescriptions if the data are missing.  These dates are critical in this study because they 
were used to determine the incidence of osteoporosis and osteoporotic fractures (i.e., new 
episodes after the use of anti-osteoporotic treatment) and prior exposure to osteoporosis 
and osteoporotic fractures which determine the percentage of subjects in the initial 
Markov states.  The use of a proxy (i.e., the reference date of the corresponding round 
that events occurred) solved the problem of missing data, but uncertainty remains.  The 
sensitivity analyses did not address this issue.  
 
(2) Selection bias.  Potential selection biases were found in this study, especially 
for subjects receiving bisphosphonate therapy.  The current study indicates that 
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glucocorticoid users receiving bisphosphonate therapy had relatively higher average daily 
glucocorticoid doses than those in other groups.  It is uncertain whether or not 
glucocorticoid users receiving bisphosphonate therapy have more severe comorbid 
conditions and/or worse bone health at the baseline.  The potential selection bias has 
important implications for both the internal validity and the generalizability of the study 
findings.   
 
(3) Costs.  The estimation of weighted costs does not reflect the actual costs.  
The costs for treating the underlying conditions are not considered for this study.  
Utilization of medical services for the underlying diseases may vary among 
glucocorticoid users with different disease states and conditions.  The costs for 
laboratory tests were not considered separately but have been included in costs for events.   
 
(4) Osteoporotic fractures.  Because osteoporosis and non-symptomatic 
vertebral fractures are believed to be under-diagnosed, their true incidence is likely to be 
under-estimated.  All estimates are based on retrospective data (1996-2004), so the 
study results may not represent current status.  In addition, both the underlying diseases 
and the use of glucocorticoid steroids contribute to the risks of fractures; it is difficult to 
isolate the portion solely due to glucocorticoid therapy, or the protective effects due to 
the use of anti-osteoporotic agents.   
Another challenge in this study was to estimate incidence rates as model inputs 
because of small sample sizes for estimation in some cases.  These estimates were 
indirectly derivated from relative risks which were calculated based on study data, so 
there is still some uncertainty for estimations.  Sensitivity analyses address part of this 
issue by varying 30% above and below averages in transition probabilities.  
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Nonetheless, this study provides “real-world” up-to-date information about prevalence 
and incidence of osteoporosis and osteoporotic fractures.   
 
(5) Confounding factors.  The control of all confounding factors is limited.  
Age is a confounding factor for osteoporotic fractures, but it has been partially controlled 
by dividing study subjects into four age groups. The incidence rates of osteoporotic 
fractures were calculated for each age group.  The underlying conditions, use of 
glucocorticoid steroids,and prior use of anti-osteoporotic treatments, were not controlled 
in this study.  Other potential confounding factors, such as psycho-social factors and 
other medications (e.g., anti-convulsants) that have an impact on fractures, were not 
considered in this study.   
 
(6) Secondary database.  Because MEPS datasets are secondary databases, they 
are subject to limitations recognized for secondary databases.  Some articles have 
discussed possible limitations for retrospective databases.338F339, 339F340, 340F341  There is little 
control over the existing data in terms of selection of survey samples, information 
collected, data quality, input errors and possible selection bias.  For example, values of 
lab tests desired for this study are not available in the MEPS data.  Additionally, there is 
no way to trace information needed for unclear or missing values in MEPS.  For 
example, participant-reported disease conditions may be incorrectly coded based on the 
3-digit ICD-9-CM in the MEPS datasets, and that cannot be validated.  There is no 
                                                 
339 Arnold, R. G. et al. (1999). Panel 3: Methodological issues in conducting pharmacoeconomic 
evaluations-retrospective and claims database studies. Value in Health 2(2): 82-87.  
340 Motheral, B. et al. (2003). A checklist for retrospective database studies-report of the ISPOR task 
force on retrospective databases. Value in Health 6(2): 90-97.  
341 Brixner, D. (2006). Assessment of the prevalence and costs of osteoporosis treatment options in a 
real-world setting. The American Journal of Managed Care, 12(7 Supple.): S191-S198. 
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control over some variables of interest, such as records for calcium and vitamin D which 
may be incomplete in MEPS.  However, MEPS attempts to clean and validate much of 
its data.  The overall MEPS data is relatively reliable and accurate.   
 
(7) Generalizability.  Because some non-responses occurred in the MEPS 
surveys, limitations in generalizability apply to the MEPS data.  Even though MEPS is 
designed to generate national estimates for the U.S. civilian non-institutionalized 
population, the MEPS samples may be not representative of the target population.  
Furthermore, the ability to generalize the study results to populations other than the U.S. 
civilian non-institutionalized population is limited.   
 
5.3 DIRECTIONS OF FUTURE RESEARCH 
The sample size of some subgroups in this study was too small to have enough 
statistical power to detect differences in osteoporotic fractures among treatment groups.  
A database with a larger sample size may achieve sufficient statistical power.  
Additionally, databases with clear records for dates of events (episodes of osteoporosis, 
fractures and prescriptions) and detailed diagnosis codes are preferable.  Also, databases 
should cover a timeframe that is long enough (for example, at least three years for each 
individual) to detect differences in osteoporotic fractures.  Furthermore, adverse drug 
reactions should be carefully studied again by using up-to-date data since HRT and 
bisphosphonates have received more attention recently.  Considerations of selection bias 
and the inclusion of more confounding factors will clarify uncertainty and facilitate 
comparisons of cost-effectiveness among treatment groups.   
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5.4 RECOMMENDATIONS AND CONCLUSIONS 
This study provides up-to-date epidemiological information on prevalence and 
incidence rates of osteoporosis and osteoporotic fractures in the U.S.  A relatively low 
percentage of long-term glucocorticoid users received anti-osteoporotic treatments for 
prevention of glucocorticoid-induced osteoporosis and osteoporotic fractures.  This 
study is the first research using “real-world” nationally representative information to 
estimate long-term costs and effectiveness of anti-osteoporotic treatments for 
glucocorticoid-induced osteoporosis and osteoporotic fractures.  Most inputs for the 
Markov model were derived from “real-world” data so the study results should reflect 
realilties of treatments.  Cost-effectiveness analyses compared long-term estimates of 
costs and effectiveness for hypothetical cohorts with different ages and length of 
treatments, and the following anti-osteoporotic treatements are recommended. 
It is recommended that hormone replacement therapy may still be used in 
pre-menopausal women receiving long-term glucocorticoid therapy with careful 
monitoring adverse drug reactions, but the evidence of safety needs further investigation.  
Raloxifene could be recommended as an alternative to HRT, but evidence in 
glucocorticoid users is needed.  Calcitonin is cost-effective in post-menopausal women 
and men of all ages who receive long-term glucocorticoid therapy.  Bisphosphonates are 
less cost-effective in most cases which may be due to selection bias.  Overall, use of 
anti-osteoporotic treatments is recommended for long-term glucocorticoid users in 
comparison to the controls.  The final decision of treatment selection depends on age, 
length of glucocorticoid therapy and maximal allowance of payments.   
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APPENDIX B-Incidence Rates of Osteoporosis and Osteoporotic 
Fractures by Gender, Type of Subject, Age Groups and Treatments 
Table B.1 Incidence of osteoporosis in MEPS female subjects without prior osteoporosis 
and fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 6 101,101 0 - - - -
 CN 0 0 0 - - - -
 HB 2 21,148 0 - - - -
 HT 1,825 23,026,192 0 - - - -
 RF 0 0 0 - - - -
 CT 23,059 221,261,906 9 73,910 24.4 334 84 
31-50   
 BP 50 520,540 16 112,096 46.6 215,346 58,827 
 CN 10 118,669 2 28,222 40.6 237,821 65,640 
 HB 20 204,077 2 23,514 48.6 115,221 30,141 
 HT 3,655 39,885,186 18 171,219 45.3 4,293 1,075 
 RF 20 166,356 1 9,565 48.0 57,497 14,695 
 CT 26,744 262,308,892 69 486,035 44.3 1,853 464 
51-70   
 BP 293 2,997,543 92 911,586 62.9 304,111 86,655 
 CN 37 461,249 10 97,693 64.7 211,801 57,766 
 HB 140 1,438,736 40 393,339 63.0 273,392 76,738 
 HT 6,732 71,818,172 168 1,818,805 61.4 25,325 6,392 
 RF 198 2,261,730 40 442,311 62.6 195,563 52,950 
 CT 12,131 113,479,390 197 1,920,893 62.2 16,927 4,259 
71-90   
 BP 363 3,812,364 134 1,465,216 78.7 384,333 114,198 
 CN 73 725,946 18 223,989 77.3 308,548 88,114 
 HB 82 902,154 31 346,713 75.7 384,317 114,193 
 HT 1,304 14,024,126 65 763,320 75.8 54,429 13,894 
 RF 121 1,291,312 23 256,099 75.5 198,325 53,764 
 CT 8,053 80,115,975 265 2,696,664 79.6 33,660 8,523 
Ave.=average; MEPS=Medical Expenditure Panel Survey; Osteoporosis=new events of osteoporosis 
occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.2 Incidence of the first osteoporotic fracture in MEPS female subjects without 
prior osteoporosis and fracture by age and treatment group, MEPS 
1996-2004 

















11-30   
 BP 6 101,101 0 - - - -
 CN 0 - 0 - - - -
 HB 2 21,148 0 - - - -
 HT 1,825 23,026,192 20 210,463 24.5 9,140 2,293 
 RF 0 - 0 - - - -
 CT 23,050 221,187,996 197 2,170,695 20.8 9,814 2,463 
31-50   
 BP 50 520,540 0 - - - -
 CN 10 118,669 0 - - - -
 HB 20 204,077 2 23,514 48.6 115,221 30,141 
 HT 3,655 39,885,186 55 581,344 45.4 14,575 3,664 
 RF 20 166,356 0 - - - -
 CT 26,675 261,822,856 266 2,784,405 41.2 10,635 2,669 
51-70   
 BP 293 2,997,543 8 93,369 66.3 31,149 7,880 
 CN 37 461,249 5 59,490 69.6 128,976 33,932 
 HB 140 1,438,736 4 29,069 59.0 20,205 5,090 
 HT 6,732 71,818,172 106 1,073,713 57.7 14,950 3,759 
 RF 198 2,261,730 4 39,464 57.6 17,449 4,391 
 CT 11,934 111,558,497 180 1,776,554 60.0 15,925 4,005 
71-90   
 BP 363 3,812,364 14 179,481 80.4 47,079 11,983 
 CN 73 725,946 10 89,874 78.1 123,803 32,501 
 HB 82 902,154 2 13,062 83.4 14,479 3,639 
 HT 1,304 14,024,126 58 691,242 78.5 49,289 12,557 
 RF 121 1,291,312 2 26,202 72.6 20,291 5,112 
 CT 7,788 77,419,310 308 3,386,429 81.8 43,741 11,119 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.3 Incidence of the first osteoporotic fracture in MEPS female subjects with prior 
osteoporosis by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 9 73,910 0 - - - -
31-50   
 BP 11 120,807 0 - - - -
 CN 8 88,141 0 - - - -
 HB 12 141,035 2 31,164 49.5 220,966 60,517 
 HT 12 72,071 0 - - - -
 RF 0 - 0 - - - -
 CT 69 486,035 4 28,468 40.4 58,572 14,976 
51-70   
 BP 212 2,215,563 2 15,002 64.5 6,771 1,697 
 CN 34 386,268 0 - - - -
 HB 95 1,010,987 2 14,173 53.5 14,019 3,523 
 HT 80 742,190 0 - - - -
 RF 33 320,264 0 - - - -
 CT 197 1,920,893 10 98,642 61.0 51,352 13,093 
71-90   
 BP 271 3,024,983 17 225,749 80.1 74,628 19,203 
 CN 44 620,016 0 - - - -
 HB 39 528,471 2 33,567 78.4 63,517 16,272 
 HT 34 329,750 2 16,124 71.3 48,898 12,455 
 RF 34 350,523 2 22,569 76.4 64,387 16,501 
 CT 265 2,696,664 29 314,654 79.3 116,683 30,542 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.4 Incidence of repeated osteoporotic fracture in MEPS female subjects with prior 
fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 7 119,897 0 - - - -
 RF 0 - 0 - - - -
 CT 203 2,225,590 6 54,895 19.8 24,665 6,224 
31-50   
 BP 4 55,393 0 - - - -
 CN 2 16,859 0 - - - -
 HB 2 31,164 2 31,164 49.5 - -
 HT 24 202,537 10 77,938 44.7 384,809 114,370 
 RF 0 - 0 - - - -
 CT 288 3,011,254 18 198,381 38.6 65,880 16,893 
51-70   
 BP 16 137,511 9 97,985 65.9 712,561 267,789 
 CN 2 38,096 0 - - - -
 HB 6 47,759 2 6,719 56.5 140,686 37,196 
 HT 21 244,078 4 54,799 52.1 224,514 61,588 
 RF 2 12,321 0 - - - -
 CT 201 1,961,124 11 85,928 61.1 43,816 11,139 
71-90   
 BP 50 566,786 11 140,804 80.4 248,425 68,907 
 CN 25 279,526 4 29,314 75.5 104,870 27,317 
 HB 5 50,239 2 22,863 78.6 455,085 140,824 
 HT 10 57,420 5 27,530 78.2 479,450 150,593 
 RF 5 53,377 2 27,651 79.5 518,032 166,790 
 CT 372 4,130,982 41 429,899 84.3 104,067 27,098 
Ave.=average; MEPS=Medical Expenditure Panel Survey; Repeated fracture=the second new events of 
osteoporotic fractures occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.5 Incidence of osteoporosis in long-term glucocorticoid female users without 
prior osteoporosis and fracture by age and treatment group, MEPS 
1996-2004 

















11-30   
 BP 2 53,175 0 - - - -
 CN 0 0 0 - - - -
 HB 2 21,148 0 - - - -
 HT 36 539,762 0 - - - -
 RF 0 0 0 - - - -
 CT 323 3,138,236 4 22,213 15.9 7,078 1,774 
31-50   
 BP 12 70,028 4 24,976 41.1 356,657 104,407 
 CN 3 38,095 2 28,222 40.6 740,832 286,498 
 HB 2 18,999 0 - - - -
 HT 139 1,506,334 0 - - - -
 RF 0 0 0 - - - -
 CT 871 9,371,402 10 62,227 39.1 6,640 1,664 
51-70   
 BP 22 187,146 10 93,832 64.0 501,384 159,686 
 CN 9 68,463 4 38,217 64.1 558,214 184,727 
 HB 15 138,181 4 24,442 64.4 176,884 47,499 
 HT 385 4,152,260 9 127,423 63.5 30,688 7,762 
 RF 2 15,563 0 - - - -
 CT 570 5,394,771 11 114,504 64.2 21,225 5,349 
71-90   
 BP 28 225,394 5 22,852 75.3 101,387 26,372 
 CN 4 56,241 2 22,740 71.5 404,331 121,481 
 HB 13 108,572 10 89,483 78.5 824,181 352,460 
 HT 102 990,721 7 68,762 73.5 69,406 17,822 
 RF 5 31,502 0 - - - -
 CT 349 3,544,572 27 311,566 78.4 87,899 22,739 
Ave.=average; LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical 
Expenditure Panel Survey; Osteoporosis=new events of osteoporosis occurred after the treatment; 
Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.6 Incidence of the first osteoporotic fracture in long-term glucocorticoid female 
users without prior osteoporosis and fracture by age and treatment group, 
MEPS 1996-2004 

















11-30   
 BP 2 53,175 0 - - - -
 CN 0 - 0 - - - -
 HB 2 21,148 0 - - - -
 HT 36 539,762 0 - - - -
 RF 0 - 0 - - - -
 CT 319 3,116,023 4 56,953 16.1 18,277 4,601 
31-50   
 BP 12 70,028 0 - - - -
 CN 3 38,095 0 - - - -
 HB 2 18,999 0 - - - -
 HT 139 1,506,334 3 27,030 44.0 17,944 4,517 
 RF 0 - 0 - - - -
 CT 861 9,309,175 14 128,733 42.3 13,829 3,475 
51-70   
 BP 22 187,146 0 - - - -
 CN 9 68,463 0 - - - -
 HB 15 138,181 0 - - - -
 HT 385 4,152,260 4 32,599 53.4 7,851 1,969 
 RF 2 15,563 0 - - - -
 CT 559 5,280,267 8 58,823 63.6 11,140 2,797 
71-90   
 BP 28 225,394 0 - - - -
 CN 4 56,241 0 - - - -
 HB 13 108,572 0 - - - -
 HT 102 990,721 11 100,801 76.7 101,745 26,469 
 RF 5 31,502 0 - - - -
 CT 322 3,233,006 12 159,618 81.1 49,371 12,578 
Ave.=average;  1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure 
Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.7 Incidence of the first osteoporotic fracture in long-term glucocorticoid female 
users with prior osteoporosis by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 4 22,213 0 - - - -
31-50   
 BP 3 26,358 0 - - - -
 CN 0 - 0 - - - -
 HB 3 40,898 0 - - - -
 HT 1 7,758 0 - - - -
 RF 0 - 0 - - - -
 CT 10 62,227 2 20,724 41.5 333,039 96,298 
51-70   
 BP 14 146,977 0 - - - -
 CN 4 72,069 0 - - - -
 HB 3 49,961 0 - - - -
 HT 18 144,031 0 - - - -
 RF 2 11,493 0 - - - -
 CT 11 114,504 2 19,374 59.4 169,199 45,284 
71-90   
 BP 25 299,319 0 - - - -
 CN 0 - 0 - - - -
 HB 2 11,085 0 - - - -
 HT 7 64,895 0 - - - -
 RF 2 26,787 0 - - - -
 CT 27 311,566 1 18,906 78.0 60,681 15,528 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure 
Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.8 Incidence of repeated osteoporotic fracture in long-term glucocorticoid female 
users with prior fracture by age and treatment group, MEPS 1996-2004 












11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 4 56,953 0 - - - -
31-50   
 BP 2 16,515 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 3 18,519 1 8,182 50.0 441,817 135,641 
 RF 0 - 0 - - - -
 CT 16 149,456 0 - - - -
51-70   
 BP 3 20,154 1 13,258 70.0 657,835 235,180 
 CN 2 38,096 0 - - - -
 HB 2 6,719 2 6,719 56.5 1,000,000 -
 HT 1 7,624 1 7,624 51.0 1,000,000 -
 RF 0 - 0 - - - -
 CT 14 119,848 4 41,651 63.5 347,532 101,248 
71-90   
 BP 8 96,891 3 43,398 81.3 447,905 138,008 
 CN 2 8,310 0 - - - -
 HB 0 - - - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 14 192,556 1 14,032 90.0 72,872 18,738 
Ave.=average; LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical 
Expenditure Panel Survey; Repeated fracture=the second new events of osteoporotic fractures occurred 
after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group.  
**Rates per 1,000,000 person-years. 
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Table B.9 Incidence of osteoporosis in high-risk glucocorticoid female users without 
prior osteoporosis and fracture by age and treatment group, MEPS 
1996-2004 

















11-30   
 BP 2 53,175 0 - - - -
 CN 0 - 0 - - - -
 HB 0 0 0 - - - -
 HT 21 283,084 0 - - - -
 RF 0 0 0 - - - -
 CT 230 2,246,282 4 22,213 15.9 9,889 2,481 
31-50   
 BP 12 70,028 4 24,976 41.1 356,657 104,407 
 CN 3 38,095 2 28,222 40.6 740,832 286,498 
 HB 2 18,999 0 - - - -
 HT 94 1,092,124 0 - - - -
 RF 0 0 0 - - - -
 CT 618 6,490,378 8 60,469 39.1 9,317 2,337 
51-70   
 BP 22 187,146 10 93,832 64.0 501,384 159,686 
 CN 9 68,463 4 38,217 64.1 558,214 184,727 
 HB 13 121,274 4 24,442 64.4 201,544 54,715 
 HT 286 3,152,208 5 53,769 66.2 17,058 4,292 
 RF 2 15,563 0 - - - -
 CT 428 3,927,152 11 114,504 64.2 29,157 7,370 
71-90   
 BP 23 165,013 4 13,835 76.8 83,842 21,654 
 CN 4 56,241 2 22,740 71.5 404,331 121,481 
 HB 11 99,239 10 89,483 78.5 901,692 440,052 
 HT 92 894,474 5 59,008 73.7 65,969 16,917 
 RF 5 31,502 0 - - - -
 CT 292 2,912,949 23 260,065 78.2 89,279 23,108 
Ave.=average; HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent 
dose of 450 mg or more; MEPS=Medical Expenditure Panel Survey; Osteoporosis=new events of 
osteoporosis occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.10 Incidence of the first osteoporotic fracture in high-risk glucocorticoid female 
users without prior osteoporosis and fracture by age and treatment group, 
MEPS 1996-2004 

















11-30   
 BP 2 53,175 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 21 283,084 0 - - - -
 RF 0 - 0 - - - -
 CT 226 2,224,069 2 34,354 12.5 15,446 3,884 
31-50   
 BP 12 70,028 0 - - - -
 CN 3 38,095 0 - - - -
 HB 2 18,999 0 - - - -
 HT 94 1,092,124 2 18,848 41.4 17,258 4,343 
 RF 0 - 0 - - - -
 CT 610 6,429,910 8 49,741 46.0 7,736 1,940 
51-70   
 BP 22 187,146 0 - - - -
 CN 9 68,463 0 - - - -
 HB 13 121,274 0 - - - -
 HT 286 3,152,208 2 19,494 52.5 6,184 1,550 
 RF 2 15,563 0 - - - -
 CT 417 3,812,648 8 58,823 63.6 15,428 3,880 
71-90   
 BP 23 165,013 0 - - - -
 CN 4 56,241 0 - - - -
 HB 11 99,239 0 - - - -
 HT 92 894,474 11 100,801 76.7 112,693 29,449 
 RF 5 31,502 0 - - - -
 CT 269 2,652,884 9 119,853 79.4 45,178 11,491 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg 
or more; MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.11 Incidence of the first osteoporotic fracture in high-risk glucocorticoid female 
users with prior osteoporosis by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 4 22,213 0 - - - -
31-50   
 BP 3 26,358 0 - - - -
 CN 0 - 0 - - - -
 HB 1 5,275 0 - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 8 60,469 2 20,724 41.5 342,721 99,596 
51-70   
 BP 14 146,977 0 - - - -
 CN 4 72,069 0 - - - -
 HB 1 14,782 0 - - - -
 HT 17 137,833 0 - - - -
 RF 2 11,493 0 - - - -
 CT 11 114,504 2 19,374 59.4 169,199 45,284 
71-90   
 BP 19 216,598 0 - - - -
 CN 0 - 0 - - - -
 HB 2 11,085 0 - - - -
 HT 5 55,520 0 - - - -
 RF 2 26,787 0 - - - -
 CT 23 260,065 1 18,906 78.0 72,697 18,692 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg 
or more; MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HT=hormone replacement therapy; RF=raloxifene group; HB=simultaneously use 
of hormone replacement therapy and bisphosphonates. 
**Rates per 1,000,000 person-years. 
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Table B.12 Incidence of repeated osteoporotic fracture in high-risk glucocorticoid female 
users with prior fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 2 34,354 0 - - - -
31-50   
 BP 2 16,515 0 - - - -
 CN 0 - 0 - - - -
 HB 0 - 0 - - - -
 HT 2 10,338 0 - - - -
 RF 0 - 0 - - - -
 CT 10 70,464 0 - - - -
51-70   
 BP 3 20,154 1 13,258 70.0 657,835 235,180 
 CN 2 38,096 0 - - - -
 HB 2 6,719 2 6,719 - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 12 94,545 2 16,348 68.4 172,912 46,352 
71-90   
 BP 6 64,923 1 11,430 71.0 176,055 47,260 
 CN 2 8,310 0 - - - -
 HB 0 - 0 - - - -
 HT 0 - 0 - - - -
 RF 0 - 0 - - - -
 CT 11 152,791 1 14,032 90.0 91,838 23,795 
Ave.=average;  HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent 
dose of 450 mg or more; MEPS=Medical Expenditure Panel Survey; Repeated fracture=the second new 
events of osteoporotic fractures occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent; HB=simultaneously use of hormone replacement therapy and bisphosphonates; 
HT=hormone replacement therapy; RF=raloxifene group. 
**Rates per 1,000,000 person-years. 
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Table B.13 Incidence of osteoporosis in MEPS male subjects without prior osteoporosis 
and fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 0 0 - - - -
 CN 0 0 0 - - - -
 CT 18,836 194,768,392 3 18,260 16.0 94 23 
31-50   
 BP 5 57,222 0 - - - -
 CN 0 0 0 - - - -
 CT 21,928 242,313,124 11 120,701 42.2 498 125 
51-70   
 BP 23 252,159 12 150,917 61.9 598,499 203,984 
 CN 10 76,889 0 - - - -
 CT 16,456 174,961,092 42 409,088 61.6 2,338 585 
71-90   
 BP 15 130,674 4 35,627 78.1 272,640 76,499 
 CN 16 144,585 2 17,761 90.0 122,841 32,236 
 CT 7,011 75,156,326 34 270,738 78.2 3,602 902 
Ave.=average; MEPS=Medical Expenditure Panel Survey; Osteoporosis=new events of osteoporosis 
occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.14 Incidence of the first osteoporotic fracture in MEPS male subjects without 
prior osteoporosis and fracture by age and treatment group, MEPS 
1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 18,833 194,750,132 306 3,455,070 19.6 17,741 4,465 
31-50   
 BP 5 57,222 0 - - - -
 CN 0 - 0 - - - -
 CT 21,917 242,192,423 395 4,376,472 40.5 18,070 4,548 
51-70   
 BP 23 252,159 2 10,005 69.6 39,677 10,070 
 CN 10 76,889 1 4,653 70.0 60,516 15,485 
 CT 16,414 174,552,004 252 2,679,960 58.4 15,353 3,861 
71-90   
 BP 15 130,674 0 - - - -
 CN 16 144,585 1 5,087 71.0 35,183 8,914 
 CT 6,977 74,885,587 160 1,905,389 78.0 25,444 6,423 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.15 Incidence of the first osteoporotic fracture in MEPS male subjects with prior 
osteoporosis by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 1 33,749 0 - - - -
 CN 0 - 0 - - - -
 CT 3 18,260 0 - - - -
31-50   
 BP 4 15,555 0 - - - -
 CN 2 11,380 0 - - - -
 CT 11 120,701 0 - - - -
51-70   
 BP 2 17,164 0 - - - -
 CN 2 14,913 0 - - - -
 CT 42 409,088 0 - - - -
71-90   
 BP 14 166,210 0 - - - -
 CN 4 57,426 2 10,580 78.5 184,237 49,634
 CT 34 270,738 2 9,308 80.6 34,380 8,708
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.16 Incidence of repeated osteoporotic fracture in MEPS male subjects with prior 
fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 319 3,571,355 13 116,285 20.8 32,560 8,241 
31-50   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 426 4,704,402 31 327,930 40.9 69,707 17,902 
51-70   
 BP 4 23,320 2 10,005 69.6 429,031 130,733 
 CN 0 - 0 - - - -
 CT 277 2,878,399 25 198,439 60.0 68,941 17,700 
71-90   
 BP 0 - 0 - - - -
 CN 4 82,435 0 - - - -
 CT 179 2,134,940 17 220,244 81.1 103,162 26,853 
Ave.=average; MEPS=Medical Expenditure Panel Survey; Repeated fracture=the second new events of 
osteoporotic fractures occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.17 Incidence of osteoporosis in long-term glucocorticoid male users without 
prior osteoporosis and fracture by age and treatment group, MEPS 
1996-2004 

















11-30   
 BP 0 0 0 - - - -
 CN 0 0 0 - - - -
 CT 336 3,340,638 0 - - - -
31-50   
 BP 2 27,848 0 - - - -
 CN 0 0 0 - - - -
 CT 464 5,225,046 2 20,558 46.4 3,935 985 
51-70   
 BP 8 49,820 4 32,773 61.9 657,828 235,177 
 CN 3 20,689 0 - - - -
 CT 609 6,357,296 3 23,438 57.2 3,687 923 
71-90   
 BP 8 46,418 2 6,626 72.5 142,746 37,773 
 CN 3 16,854 0 - - - -
 CT 350 3,984,542 2 23,981 71.5 6,019 1,508 
Ave.=average; LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical 
Expenditure Panel Survey; Osteoporosis=new events of osteoporosis occurred after the treatment; 
Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.18 Incidence of the first osteoporotic fracture in long-term glucocorticoid male 
users without prior osteoporosis and fracture by age and treatment group, 
MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 336 3,340,638 5 41,649 23.8 12,467 3,132 
31-50   
 BP 2 27,848 0 - - - -
 CN 0 - 0 - - - -
 CT 462 5,204,488 11 147,590 38.9 28,358 7,166 
51-70   
 BP 8 49,820 0 - - - -
 CN 3 20,689 1 4,653 70.0 224,902 61,706 
 CT 606 6,333,858 18 248,099 59.3 39,170 9,940 
71-90   
 BP 8 46,418 0 - - - -
 CN 3 16,854 1 5,087 71.0 301,827 85,906 
 CT 348 3,960,561 10 117,745 79.6 29,729 7,517 
Ave.=average;  1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure 
Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.19 Incidence of the first osteoporotic fracture in long-term glucocorticoid male 
users with prior osteoporosis by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - - - - - -
 CT 0 - 0 - - - -
31-50   
 BP 2 6,236 0 - - - -
 CN 2 11,380 - - - - -
 CT 2 20,558 0 - - - -
51-70   
 BP 2 17,164 0 - - - -
 CN 0 - - - - - -
 CT 3 23,438 0 - - - -
71-90   
 BP 4 68,323 0 - - - -
 CN 0 - - - - - -
 CT 2 23,981 0 - - - -
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical Expenditure 
Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
 
 292
Table B.20 Incidence of repeated osteoporotic fracture in long-term glucocorticoid male 
users with prior fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - - - - - -
 CT 5 41,649 0 - - - -
31-50   
 BP 0 - 0 - - - -
 CN 0 - - - - - -
 CT 12 163,371 1 15,781 43.0 96,596 25,077 
51-70   
 BP 0 - 0 - - - -
 CN 0 - - - - - -
 CT 20 260,813 2 12,714 65.3 48,748 12,416 
71-90   
 BP 0 - 0 - - - -
 CN 0 - - - - - -
 CT 10 117,745 0 - - - -
Ave.=average; LTGS=long-term users of glucocorticoid tablets for at least three months; MEPS=Medical 
Expenditure Panel Survey; Repeated fracture=the second new events of osteoporotic fractures occurred 
after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.21 Incidence of osteoporosis in high-risk glucocorticoid male users without prior 
osteoporosis and fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 0 0 - - - - 
 CN 0 0 0 - - - - 
 CT 251 2,567,643 0 - - - - 
31-50    
 BP 2 27,848 0 - - - - 
 CN 0 - 0 - - - - 
 CT 362 4,014,215 0 - - - - 
51-70    
 BP 8 49,820 4 32,773 62.9 657,828 235,177 
 CN 3 20,689 - - - - - 
 CT 479 4,997,670 3 23,438 57.2 4,690 1,175 
71-90    
 BP 6 35,811 2 6,626 72.5 185,027 49,864 
 CN 3 16,854 0 - - - - 
 CT 286 3,279,505 2 23,981 71.5 7,312 1,833 
Ave.=average; HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent 
dose of 450 mg or more; MEPS=Medical Expenditure Panel Survey; Osteoporosis=new events of 
osteoporosis occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.22 Incidence of the first osteoporotic fracture in high-risk glucocorticoid male 
users without prior osteoporosis and fracture by age and treatment group, 
MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 251 2,567,643 4 31,412 26.6 12,234 3,073 
31-50   
 BP 2 27,848 0 - - - -
 CN 0 - 0 - - - -
 CT 362 4,014,215 8 131,442 38.2 32,744 8,289 
51-70   
 BP 8 49,820 0 - - - -
 CN 3 20,689 1 4,653 70.0 224,902 61,706 
 CT 476 4,974,232 15 218,038 59.5 43,834 11,143 
71-90   
 BP 6 35,811 0 - - - -
 CN 3 16,854 1 5,087 71.0 301,827 85,906 
 CT 284 3,255,524 10 117,745 79.6 36,168 9,167 
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg 
or more; MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.23 Incidence of the first osteoporotic fracture in high-risk glucocorticoid male 
users with prior osteoporosis by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 0 - 0 - - - -
31-50   
 BP 2 6,236 0 - - - -
 CN 2 11,380 - - - - -
 CT 0 - 0 - - - -
51-70   
 BP 2 17,164 0 - - - -
 CN 0 - 0 - - - -
 CT 3 23,438 0 - - - -
71-90   
 BP 2 33,701 0 - - - -
 CN 0 - 0 - - - -
 CT 2 23,981 0 - - - -
Ave.=average; 1st Fracture=the first new events of osteoporotic fractures occurred after the treatment; 
HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent dose of 450 mg 
or more; MEPS=Medical Expenditure Panel Survey; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
**Rates per 1,000,000 person-years. 
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Table B.24 Incidence of repeated osteoporotic fracture in high-risk glucocorticoid male 
users with prior fracture by age and treatment group, MEPS 1996-2004 

















11-30   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 4 31,412 0 - - - -
31-50   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 8 131,442 0 - - - -
51-70   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 17 230,752 2 12,714 65.3 55,098 14,069
71-90   
 BP 0 - 0 - - - -
 CN 0 - 0 - - - -
 CT 10 117,745 0 - - - -
Ave.=average;  HRGS=high-risk users of glucocorticoid tablets at an accumulated prednisone-equivalent 
dose of 450 mg or more; MEPS=Medical Expenditure Panel Survey; Repeated fracture=the second new 
events of osteoporotic fractures occurred after the treatment; Wtd=weighted; Unwtd=unweighted. 
§N=total number of subjects from 1996 to 2004. 
*Treatment groups: BP=bisphosphonate group; CN=calcitonin group; CT=control group without using any 
anti-osteoporotic agent. 
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